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Abstract 
Over the past decade, deep brain stimulation (DBS) has emerged as an alternative, reversible, 
and non-ablative neuromodulatory method to help individuals with treatment resistant 
depression (TRD). TRD patients typically fail to attain adequate benefits from traditional 
treatments, including several courses of pharmacotherapy, psychotherapy and 
electroconvulsive therapy. A proportion of these patients (~60%), however, reported 
therapeutic improvements in small scale clinical DBS trials. Unfortunately, the critical gap in our 
knowledgebase on the mechanisms of DBS may be delaying effective implementation of this 
promising therapy in a systematic manner. At this juncture, it is imperative to take a step back 
and study the antidepressant properties of DBS preclinically, so that these translational findings 
can shed light on the factors mediating treatment responsivity.  
Investigations into the underlying effects of clinically relevant DBS targets included the nucleus 
accumbens (NAc), lateral habenula (LHb) and infralimbic cortex (IL; homologous to the human 
subgenual cingulate target) in an animal model of antidepressant resistance. To achieve this, 
male Wistar or Sprague Dawley rats received chronic administrations of adrenocorticotropic 
hormone (ACTH) for the induction of tricyclic resistance. The antidepressant-like effects of DBS 
were characterized through well-validated behavioral assay –the forced swim test (FST). The 
neurobiological alterations were quantified using immunoblotting, gene expression and 
mitochondrial function techniques in regions implicated in the pathophysiology of depression. 
Additionally, stimulation-evoked transient dopamine neurotransmission were explored as a 
potential common mechanism of NAc, IL and LHb DBS, using fast scan cyclic voltammetry. 
Results collectively demonstrated that DBS to the NAc, LHb and IL is efficacious in otherwise, 
imipramine resistant animals. In the NAc DBS experiment, a proportion of the ACTH-treated 
animals bilaterally implanted with electrodes (DBS & Sham) exhibited mania-like heightened 
locomotor activity in the open field test, as well as exaggerated escape behaviors in the FST. 
Analyses of mitochondrial function in the prefrontal cortical tissue indicated a functional deficit 
in energy generation in animals pretreated with ACTH. Interestingly, an over-compensative 
mitochondrial efficiency was observed for those animals with a hyperactive phenotype, 
presumably in response to the fluctuating energy demands. 
In Chapter 6, sensors of energy demand, cell division/growth, apoptosis, protein synthesis and 
glucose/glycogen regulation were significantly altered in IL of ACTH treated animals relative to 
naïve controls. A combination of endogenous stress (i.e. ACTH) with environmental stress (FST) 
led to altered gene and protein expression. Phosphorylation of key proteins involved in energy 
regulation were decreased in ACTH/Stress animals compared to the ACTH/naïve group, 
however this was not reversed with IL DBS.  In contrast, mRNA level of genes that respond to 
oxidative stress, hypoxia, ER stress, pro-inflammatory cytokines, nutrient deprivation and DNA 
damage were increased in ACTH/Stress compared with ACTH/naïve, and were restored 
following DBS. Data indicate that DBS may be reversing the maladaptation of genes involved in 
cellular stress rather than those involved in energy/glucose regulation. 
For LHb DBS, the phosphorylation status of LHb Ca2+/calmodulin-dependent protein kinase 
(CaMKIIȽȀȾȌǡ͵ȋ
͵ȽȀȾȌwere significantly correlated with DBS-
induced antidepressant-like behaviors. Concurrent with this, phosphorylated AMP-activated 
protein kinase (AMPK) in the IL was negatively associated with DBS-induced behavioral effects. 
The inverse relationship of CaMKII, GSK3 and AMPK phosphorylation in the LHb and IL, 
respectively, suggest differential roles of these regions in antidepressant processes. The 
distinctive relationships of protein expression found in these targets suggest that LHb DBS 
might engage in structural circuit changes that downregulate metabolic demand in the IL. 
Lastly, an attenuation of stimulation-evoked transient NAc dopamine efflux was observed 
following NAc and IL DBS, whereas LHb DBS uniquely potentiated NAc dopamine release. A 
further examination of the LHb region found that DBS recovered dysregulated dopamine efflux 
in ACTH-treated animals. These findings suggest that animals with ACTH administration are 
unable maintain the DBS-mediated synaptic plasticity and induction of long-term potentiation.   
In conclusion, antidepressant responsive versus resistant animals demonstrate disparate 
responses to stress. DBS was able to reinstate treatment response by modulating cellular stress, 
impaired synaptic plasticity, dysregulated dopamine transmission and energy metabolism.  
Hence, deficits in synaptic plasticity may be involved in the neuroprogression of depression. 
NAc dopamine dysregulation surfaced as another critical modulator of antidepressant 
responsivity. The implications from these results underscore the need for using appropriate 
animal models to gain valuable insight on the neurobiological state of the organism in health 
and disease.  
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Chapter 1. Introduction 
Current hypotheses of mood disorders and antidepressant activity: identifying key signaling 
pathways and molecules mediating treatment responsivity 
 
  According to the American Psychiatric Association (2013), affect reflects a pattern of 
observable behavioral expressions that reflects subjective emotional experience, whereas mood is a 
sustained emotion that influences one’s perception of the environment. Mood disorders are 
differentiated into unipolar depression and bipolar disorders by the type of mood fluctuations, 
severity, and its pattern of progression (Bowden, 2005). Since the publication of DSM-III in 1980, 
bipolar and unipolar depressive disorders have been regarded as a separate phenomenon. The 
position for their true separation –as against simply the presence or absence of manic/hypomanic 
episodes is challenged by differential (i) causes, (ii) episode-related and course of illness 
characteristics, (iii) biological underpinnings (driven by peripheral biomarkers including 
neuroimaging predictors) and (iv) patient-specific responses antidepressants and/or mood 
stabilizing medications. Many argue that limited distinction in the strict sense is a reflection of 
methodological limitations in study selection and clinical assessment (Cuellar, Johnson, & Winters, 
2005). With such controversy around the diagnostic criteria, it has been difficult to deliver targeted 
intervention and establish corresponding mechanisms responsible for treatment response into 
remission. For this reason, it seems necessary to discretely examine the neurobiology of depression 
and antidepressant activity, rather than conflating these two. The given approach may help us to 
understand different pathophysiology’s that may underscore subtypes of depression and 
consequently, develop tailored treatments to those needs. Currently, no biomarkers for predicting 
treatment response in depression have been systematically assessed nor rigorously validated in 
clinical practice (Fu, Steiner, & Costafreda, 2013). The present review will focus on the underlying 
mechanisms of treatment response, namely, the various signaling pathways and their interactions 
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to facilitate or hinder neuronal plasticity, cell survival and growth. Resistance to treatments may 
indicate dysregulation in one or more pathways and/or networks that are not effectively 
modulated by available therapeutic agents.  
Defining unipolar and bipolar depression 
A rather broad range of physiological, neurovegetative, emotional characteristics exist for 
depression, including a prolonged (lasting 2 weeks or longer) depressed mood with changes in 
sleep, appetite, interest or energy. Depressive disorder can present as mild, chronic (captured in the 
definition of dysthymia) or to a more severe state known as treatment resistant depression (TRD). 
While a consensus on the definition is yet to exist for TRD, the field of psychiatric research has 
moved away from simply using a failure to remit after an adequate course of treatment as an 
indication of pure resistance. A staging method proposed by Thase and Rush (1997) has been 
developed for the clarification on treatment resistance, yet several methodological issues exist 
(please see Fava (2003) for details). It is important to recognize that an individuals’ experience of 
depression can be very chronic and debilitating, even when only a few symptoms are present (Fried 
& Nesse, 2014; Gotlib, Lewinsohn, & Seeley, 1995; Solomon, Haaga, & Arnow, 2001). For example, 
anhedonia, a failure to feel pleasure and loss of interest has been described as one of the core 
symptoms of depression. Due to the nature of these symptoms, it has detrimental implications 
when day-to-day activities and quality of life are concerned. Most definitions of treatment 
resistance are symptom and syndrome based where functional outcome is rarely considered. 
Treatment is usually chosen on an empirical basis, informed by clinical characteristics including 
depression severity, subtype, previous treatment responsivity and existing comorbid disorders 
(Levinstein & Samuels, 2014).  
Bipolar disorder (BPD) is characterized by recurrent episodes of disturbed affect including 
mania and depression as well as changes in neurovegetative function, cognitive performance and 
general health. There are several types of BPD based upon specific duration and pattern of manic 
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(hypomania and with or without depressive symptoms) and depressive episodes (American 
Psychiatric Association, 2013). For the purpose of this review, BPD will be discussed broadly, 
encompassing the population as a whole. Criteria used for TRD would apply for BPD, with the 
proviso of a failure to respond to mood stabilizers as well as antidepressants (Gitlin, 2006). Some 
authors (Ghaemi, Sachs, Chiou, Pandurangi, & Goodwin, 1999; Sachs, 1996) additionally argued for 
the absence of antidepressants in defining both acute mania and maintenance stage, due to 
antidepressants possibly exacerbating manic or cycling mood fluctuations. Treatment strategies for 
BPD can also differ between non-compliance precipitated by episodes of mania vs. true 
breakthrough episodes. For example, if a manic episode occurs in the context of non-compliance, it 
is imperative to establish whether the patient discontinued treatment and the episode followed or 
whether the patient became hypomanic, discontinued treatment at that point (of hyped 
impulsivity) and then became even more symptomatic.  
Four relatively consistent, differential symptoms have been reported for the two clinical 
categories of depression (Cuellar et al., 2005). Bipolar depressed patients were more like to report 
anhedonia than those with unipolar depression, with decreased anxiety, activity and somatization. 
In a more recent report examining the most severe lifetime depressive episodes, bipolar patients 
were more likely than those with unipolar depression to have higher rates of psychomotor 
disturbance, impaired concentration, early morning wakening, diurnal variation, psychotic 
symptoms and mixed features (Mitchell et al., 2011). Parker et al. (2012) further noted that bipolar 
depression corresponded closely to unipolar melancholic depression, in terms of its clinical 
features, but not with regards to a number of socio-demographic, illness course and correlate 
variables. Atypical features were common across bipolar and unipolar disorders within the mood-
affected population, but somewhat more prevalent in bipolar disorder. The heterogeneity of the 
depressive syndrome is called to attention by Østergaard, Jensen, and Bech (2011) where 227 
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different combinations with ≥ symptoms fulfilling the DSM-IV criteria. This problem may be 
reflected in outcomes of two significant studies conducted in recent years: 
i) With more than 4000 patients in the STAR*D study, only 30% of the patients 
remitted on treatment with a current first-line antidepressant drug (Citalopram) 
and other 30% failed to remit following four consecutive treatment trials of 
antidepressants from different pharmacological classes, even with rigorous dosing 
method (Gaynes et al., 2009). 
ii) The hypothesis of increased risk and complication for depression caused by gene x 
environment interactions (e.g. the serotonin selective promoter gene polymorphism 
and adverse life events such as childhood maltreatment and medical conditions) has 
been subject to debate over the last few years. A recent meta-analysis by Karg, 
Burmeister, Shedden, and Sen (2011) found gene x environment interaction to 
increase the risk of depression, although it took more than 40,000 participants to 
establish this relationship. Uher (2011) further noted in his review how this 
interaction complicated treatment outcomes, yet the strength and generalizability of 
such influences are not sufficient (with available evidence) to justify personalized 
prescribing.  
Apart from the criticisms on clinical classifications, variables such as treatment intolerance 
and adherence unfortunately inflates the TRD population statistics, although subgroups are 
arguably distinct. Other factors include misdiagnosis, severity of illness, comorbid psychiatric 
conditions, underlying medical condition (e.g. diabetes, cancer etc.), substance abuse, major life 
stressor, ineffective treatment, inadequate treatment duration and dose (Nemeroff, 2007). In terms 
of comorbid psychiatric conditions, BPD mis/under diagnosis is common, with approximately 40% 
of patients with BPD being misdiagnosed with unipolar depression (Ghaemi, Boiman, & Goodwin, 
2000; Singh & Rajput, 2006; Smith & Ghaemi, 2010). The misdiagnosis of bipolar as unipolar 
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depressive disorder is important because of its clinically relevant consequences, including suicide. 
Most suicides in BPD occur during depressive episodes or mixed states with prominent depression 
(Bowden, 2005). In addition, a less obvious consequence of misdiagnosis is that the use of 
antidepressants for BPD patients (not on mood stabilizers) may increase the risk of manic switch, a 
mixed state or accelerate cycling (Bowden, 2005; Ghaemi et al., 2000).   
Why use animal models of mood disorders? 
Considering the degree of heterogeneity among patients with their representations of mood 
disturbances, is it not a major surprise that researchers are struggling to tease out clinically 
relevant effects and treatment and significant interactions between genetic and environment risk 
factors. Due to some of the difficulties aforementioned, rodent models are advantageous to study 
non-responsiveness to an initial line of treatment because molecular parameters such as proteins 
and gene expression can be manipulated and directly compared across multiple brain regions 
between responders and non-responders (Levinstein & Samuels, 2014). One goal of developing 
rodent models of TRD, is to better understand the neurobiological mechanisms that mediate 
treatment response. Naturally, a second goal is to provide a framework where those findings can 
translate to clinical trials. In so far, animal models have utilized three approaches: 1) separation of 
rodents into bimodal subpopulations that respond to or are resistant to traditional antidepressant 
drugs. These include the chronic mild stress (CMS) model (Jayatissa, Bisgaard, Tingström, Papp, & 
Wiborg, 2006), chronic social defeat (Der-Avakian, Mazei-Robison, Kesby, Nestler, & Markou, 2014) 
and the adrenocorticotropic hormone (ACTH) model (Walker et al., 2015); 2) Treatments that 
render rodents resistant to antidepressants (e.g. ACTH model (Kitamura et al., 2008; Walker et al., 
2013) or inflammation (Rizzo et al., 2012)); 3) genetic models that show resistance to available 
pharmacotherapies (e.g. use of genetically modified mice targeting dopamine beta hydroxylase 
(Cryan & Mombereau, 2004), brain derived neurotrophic factor heterozygous null mice (Ibarguen-
Vargas et al., 2009; Saarelainen et al., 2003)). Amongst many preclinical models of behavioral 
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depression, congenital learned helplessness (cLH) is a well-validated model of depression, 
originally developed by Overmier and Seligman (1967). The helplessness animals share symptoms 
of depression as seen in the clinical population including anhedonia, associative-cognitive deficits, 
weight loss, sleep disturbances, libido reduction and hypothalamic pituitary axis (HPA) axis 
disturbances (Enkel, Spanagel, Vollmayr, & Schneider, 2010). Furthermore, they display changes in 
monoamine receptors and respond to pharmacological interventions such as tricyclic 
antidepressants (Henn, Edwards, Anderson, & Vollmayr, 2002; Malberg & Duman, 2003; Sartorius 
et al., 2003). For greater detail on different animal models of depression (including a summary of 
validated antidepressant resistance), please refer to (Caldarone, Zachariou, & King, 2015). 
Animal models using environmental and social context also exist for depression. The 
development of social defeat is accomplished by forcing a mouse to intrude into the space 
territorialized by a larger mouse of a more aggressive genetic strain, leading to an agonistic 
encounter that results in intruder subordination. Inbred population of susceptible mice to social 
defeat show increased social avoidance, anxiety-like behaviors and social hypothermia. These 
behavioral outcomes were accompanied by attenuated a.m. serum of corticosterone (CORT), 
upregulated brain-derived neurotropic factor (BDNF) levels in the nucleus accumbens (NAc) which 
subsequently led to the activation of downstream signaling molecules including glycogen synthase 
kinase 3 (GSK3) beta and mitogen-activated protein kinases (MAPK)/extracellular signal-regulated 
kinases (ERK) 1 and 2 (Krishnan et al., 2007). Specific manipulations of early social environment in 
rats has been shown to foster chronic developmental changes and associated abnormalities in 
depression. Three months of social isolation did not affect animals’ locomotor activity but increased 
depression-like behaviors indicated by the forced swim test (FST). In comparison, environmental 
enrichment showed an antidepressant and anxiolytic-like effect, a potential “protective” role during 
the critical early life (Brenes, Rodríguez, & Fornaguera, 2008). Sáenz, Villagra, and Trías (2006) also 
reported three months of social isolation increased passive coping in rats where this was associated 
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with decrease norepinephrine in the ventral striatum. Conversely, increased serotonin (5-HT) and 
norepinephrine in prefrontal cortex (PFC) and ventral striatum correlated with more time using 
active coping strategies.  
As mentioned in point 3 above, one approach to studying TRD is to use genetic models to 
achieve non-responsiveness to traditional antidepressants. Although these models show promise, 
the contribution of environmental factors to antidepressant resistance, such as stress, are not 
accounted for. Ongoing research of rat and mouse model of TRD exists, which uses the chronic 
administration of ACTH to induce pharmacological resistance to first line antidepressant treatment 
(Caldarone & Brunner, 2009; Kitamura, Araki, & Gomita, 2002; Walker et al., 2013; Walker et al., 
2015). Interestingly, this model reflects and is consistent with human TRD population in terms of 
treatment efficacy. In ACTH pre-treated rats, augmentation of imipramine with carbamazepine and 
electroconvulsive therapy showed efficacy as well as bupropion and rapid acting agent ketamine 
(Kitamura et al., 2008; Li et al., 2006; Walker et al., 2015). The ACTH model is particularly invested 
in the concept that chronic stress conditions dysregulate the HPA axis leading to maladaptive 
responses associated with mood disturbances. Other models for TRD may arise that incorporates 
different physiological, cognitive and/or affective characteristics of depression where risk and 
comorbidity factors can be better studied. At this stage, however, this ACTH model offers a unique 
platform in which underlying biological factors mediating treatment response can be examined on.   
In the upcoming sections, much of what is established on the mechanisms of antidepressant 
action has come from a combination of preclinical experimental designs as well as clinical 
observations and trials using different antidepressant drugs. According to many researchers, the 
lack of efficacy demonstrated by first and second generation antidepressants is partly due to the 
fact that the treatment for depression (especially for TRD) still has not progressed beyond the trial 
and error approach and that the neurobiology underlying how one arrives at remission remain 
largely unknown.  
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Hypotheses of mood regulation 
While dysfunction within the monoaminergic neurotransmitter systems is likely to play an 
important role in the altered mood states, changes in monoamine levels probably represent 
secondary effects to a more primary abnormalities in signal transduction. For example, selective 
serotonin reuptake inhibitors’ (SSRIs) failure to maintain a therapeutic response is evidenced by 
high rates of relapse if those drugs are too rapidly withdrawn following reduction of symptoms 
(Willner, Scheel-Krüger, & Belzung, 2013). Acute accumulation of monoamines following chronic 
antidepressant treatment may necessitate structural and functional changes by modulating 
downstream neurotrophic and neuroplasticity signaling cascades.  
New theories on the pathophysiology of depression and antidepressant action proposes 
that mood disorders are caused by structural and/or functional changes in specific molecules and 
signaling pathways, and that therapeutic measures work by counteracting/compensating one or 
more of these maladaptation. Regional hyper/hypo-activity at different nodes within the network 
have been documented where metabolic disturbances are corrected with effective 
neuromodulation (Giacobbe, Mayberg, & Lozano, 2009). Structural and functional abnormalities in 
patients with mood disorders are associated (not consistently, but frequently) with low levels of 
BDNF, disturbances in HPA axis, activation of inflammatory and cell-mediated immune responses, 
increased oxidative and nitrosative stress, neurodegeneration and altered energy metabolism 
(Fišar & Hroudová, 2010; Gardner & Boles, 2011; Karege et al., 2005; Moylan et al., 2014; Stetler & 
Miller, 2011). Underlying mechanisms of pharmacotherapies and neuromodulatory methods may 
be targeting intermediary proteins or key molecules involved in one or more of the 
abovementioned signaling cascades, all working to facilitate neurogenesis, neuronal remodeling 
and rehabilitation.  
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Monoamines hypothesis 
The classic monoamine hypothesis is an early milestone in the field depression. It argues 
that depressive symptoms are manifested by 5-HT or noradrenaline (NE) deficiency at functionally 
important receptor sites in the brain, i.e. the brain monoamine systems have a primary role in the 
manifestation of mood disturbances. Discovery of the first effective antidepressants –monoamine 
oxidase inhibitors (MAOIs) and tricyclics, uncovered a significant role for 5-HT and NE in the 
ethiopathogenesis of depression symptomatology. Today’s antidepressant agents offer a better 
therapeutic index with lower rates of side effects for most patients, but they are still designed to 
increase monoamine transmission acutely; either by inhibiting neuronal reuptake (e.g. SSRIs) or by 
inhibiting degradation by blocking mitochondrial enzymes (Milano et al., 2004). In one of the 
largest clinical trials, the STAR*D, only about one fourth of the patients achieved remission during 
the first treatment stage (Fried & Nesse, 2014). The ineffectiveness of first line treatments has been 
well-documented over the years, reflecting our limited understanding of the disease and lack of 
progress in novel drug discovery. 
A series of human studies were also conducted to evaluate the effects of monoamine 
depletion on depressive symptoms in patients vs. healthy controls. Relapse following 5-HT 
depletion and catecholamine depletion was found to be specific to the type of antidepressant 
treatment and depletion target (Heninger, Delgado, & Charney, 1996). Interestingly, 5-HT or NE 
depletion did not decrease mood in healthy controls but slightly lowered mood in those with a 
family history of major depressive disorder (MDD) and a moderate mood decrease was found for 
acute tryptophan depletion only (Ruhé, Mason, & Schene, 2007). Acute tryptophan depletion, 
however, induced relapse in remitted patients on serotonergic antidepressants. Overall, depletion 
studies failed to demonstrate a causal relationship between 5-HT and NE with the manifestation as 
well as maintenance of depressive symptoms. Additionally, simultaneous disruption of indoleamine 
and catecholamine systems did not significantly alter mood in non-medicated depressed subjects 
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(Berman et al., 2002). These outcomes may be explained from a sampling perspective where the 
diseased brain is unlike those healthy controls and there are distinctive variability’s in brain 
function and basal brain activity even within the depressed population. An antidepressant treated 
brain has been found to be in a different state from the non-depressed, post-mortem brain in terms 
of receptor densities of the monoamines system in the PFC and reduced grey-matter volume and 
glial density (Krishnan & Nestler, 2008; Muguruza et al., 2014; Rivero et al., 2014). It is important to 
remember that whilst studying mood alterations in healthy controls may be of value, the TRD 
population, due to its severe neuroprogressive state, represents a distinct biological entity. 
Altogether, conflicting preclinical and clinical outcomes led to major revisions on the classic 
monoamine hypothesis of depression.  
Researchers began to investigate dopamine (DA) following the disappointing outcomes (or 
there lack of) of traditional antidepressants and serendipitous discoveries of its prominent role in 
mood in patients suffering from addiction and movement disorders. Supporting reports unveiled 
DA to critically dictate stress responses and core symptoms (e.g. hedonic activity, motivation, 
anticipation, mania) of mood disturbances. The existing body of knowledge is comprised of lesion 
studies (Katarzyna et al., 2011; Winter et al., 2007), delivery of DA agonists and antagonists into 
DA-rich regions of the forebrain, particularly in the striatum and the nucleus accumbens (Cipriani 
et al., 2009; Tohen et al., 2003; Vieta et al., 2005), effects of mood stabilizers (Tohen et al., 2003) 
and antipsychotics administration (Abler, Erk, & Walter, 2007), or measurement of DA metabolism 
in key brain regions (Conway et al., 2014; Martinot et al., 2001). This body of work has consistently 
showed that alterations to DA levels and activation led to reductions in depressive as well as manic 
symptom profiles. The DA system has been identified as a regulator of effort related processes 
(Phillips, Walton, & Jhou, 2007; Salamone, Correa, Mingote, & Weber, 2003). The effort related DA 
function of NAc and its associative forebrain regions are not only important for understanding the 
activational part of motivation, but also for its clinical implications related to natural motivation, 
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addictive behaviors as well as energy-related syndromes including psychomotor slowing, fatigue, 
or anergia in depression, hyperactivity and restlessness in mania (Salamone, Correa, Farrar, & 
Mingote, 2007). 
In recent years, the modulation of ventral tegmental area (VTA)-NAc mesoaccumbens 
pathway has received much attention although the field has often used simplistic localization of 
function approach to examine limbic substrates (e.g. amygdala for fear, NAc for reward). West and 
Weiss (2011) found that chronic administration of antidepressant drugs, except for MAOIs, 
increased the spontaneous firing rate of VTA DA neurons. Moreover, animals receiving five 
electroconvulsive shocks increased both spontaneous firing rates and burst firing of VTA-DA 
neurons. Using chronic social defeat stress model in mice, in vivo firing rates and bursting 
properties of VTA DA neurons are dramatically increased in susceptible mice, but not in resilient 
mice and increased hyperpolarization-activated cation current in VTA DA neurons was normalized 
by chronic treatment with fluoxetine (Cao et al., 2010). It is suggested that these effects are 
consistent with accumulating reports of increased DA release in regions to which VTA neurons 
project after effective antidepressant intervention. One of the possible mechanisms by which the 
mesolimbic DA neurons bring about a positive effect is that they are largely responsible for 
determining adaptive vs. maladaptive responses to chronic stress (Cao et al., 2010). This further 
sensitizes or desensitizes the stress system to future insults on the organism.  
Substantial evidence also indicates that risk for BPD is characterized by elevated activation 
in the fronto-striatal reward neural circuit involving those DA enriched ventral striatum and 
orbitofrontal cortex areas (Strakowski, Delbello, & Adler, 2005). It is proposed that individuals with 
abnormally elevated reward-related neural activation are at risk for experiencing excessive 
increase in approach-related motivation during life events involving rewards or goals attainment 
(Johnson, Ruggero, & Carver, 2005). In the extreme, this increase in motivation is reflected as 
hypomanic/manic behaviors. By contrast, MDD is characterized by decreased reward responsivity, 
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sensitive stress appraisal and decreased reward-related neural activation. Collectively, this 
suggests that risk for BPD and MDD is characterized by distinct and opposite profiles of reward 
processing and reward-related neural activation (Nusslock, Young, & Damme, 2014). The central 
role of DA in both disorders suggest that DA transmission could be a crucial modulator and possible 
pharmacological target for managing both manic and depressive symptoms.   
Despite the progress and advancements made with optogenetics (Lammel, Tye, & Warden, 
2014), the neurochemistry of DA is incompletely understood. The dopaminergic system is complex 
and its differential functioning depends on the neural population, brain region and the expressed 
receptor. Notably, recent evidence suggest that there are also differences in transcriptional 
neuroanatomy across different groups of DA neurons (Berk et al., 2007). Examining these 
differences in DA transcriptional neuroanatomy may be of use for developing a more selective and 
effective therapeutic agents (Nusslock, Young & Damme, 2014). A complex interaction also exists 
for the 5-HT, NE and DA systems where most of the activities exerted on 5-HT and NE affect DA 
release. For example, classic antidepressants have been found to result in phasic activation of DA 
(Friedman, 2007). Acute stress increases the amount of synaptic monoamines induced by 
antidepressants which in return produces secondary and perhaps long lasting neuroplastic changes 
on a transcriptional level affecting molecular and cellular plasticity. Changes that are reflective of 
stress, monoamines and plasticity are believe to be crucial in determining one’s treatment 
response. 
The stress system 
There is a crucial distinction between exposure to stress and the experience of stress. An 
intense stressor may cause little distress if coping mechanisms are adequate, while conversely, if 
coping mechanisms fail (or is maladaptive), a mild stressor may be perceived as highly stressful. 
The proposed neurobiology of stress and mood disorders must recognize that a failure to cope with 
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stress, rather than exposure to stress per se is a critical juncture during the prodromal stage 
(Walker et al., 2014; Willner et al., 2013). Depression diathesis include: early life experiences 
(Walker et al., 2014), genetic factors (Bosch, Seifritz, & Wetter, 2012) as well as personality factors 
(Rosenström et al. (2014), which may reflect early life experiences as well as heritable 
characteristics). The first episode of depression manifests against the level of vulnerability that is 
determined by genetic and experiential factors. It rises more commonly from a major adverse life 
event or from an accumulation of chronic minor stressors. These two types of precipitating events 
respectively form the basis of two of the major animal models of depression (learned helplessness 
and chronic mild stress). A person with a strong depressive diathesis may succumb to minor or 
trivial stressors. Over the course of persistent depressive episodes, the onset of clinically 
diagnosable depression becomes increasingly autonomous. This effect can be described both 
neurobiologically (an episode of depression sensitizes or ‘kindles’ the brain to respond to weaker 
and weaker precipitants); and physiologically (the depressed person relies increasingly on negative 
modes of information processing that come to be activated by increasingly minimal cues).  
While recognizing that stress is a pathogenic factor in mood disorder etiology, it is 
important to remain mindful that the stress response itself is inherenty adaptive and evolutionarily 
conserved to promote survival (Karatsoreos & McEwen, 2013). Appropriate coping mechanisms 
adopted by the individual in response to a stressor functions to coordinate system-wide reactions 
to perceived future threats (Cabib & Puglisi-Allegra, 2012). This process is initially beneficial, but 
can become dangerously pathogenic if followed by prolonged stress system activation and 
maladaptation (Cabib & Puglisi-Allegra, 2012; Krishnan et al., 2007; McEwen, 2007). The resistance 
phase has been suggested to be mediated by the HPA axis and coordinates adaptive stress 
responses over an extended period of time. As the individual’s resources become depleted, they 
enter into a third “exhaustion” stage  wherein the physiologic systems begin to deteriorate, and 
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different stress-associated illnesses can emerge when defense or coping strategies are 
inappropriate (Selye, 1976).  
Major physiological responses to stress occur through the activation of neuroendocrine 
systems –most notably the HPA axis. Hyperactivity of the HPA axis during depression is one of the 
most reliable findings in biological psychiatry (Pariante & Lightman, 2008). Furthermore, a high 
level of activity in the HPA axis has been able to predict treatment resistance (Willner et al., 2013). 
Antidepressants normalize HPA function and part of this effect involves a restoration of 
glucocorticoid receptor (GR) responsiveness. Conversely, chronic stress and long-term 
glucocorticoid treatment lead to the loss of dendritic spines and synaptic contacts in the 
hippocampus and the prefrontal cortex (Cerqueira, Mailliet, Almeida, Jay, & Sousa, 2007; Hajszan, 
MacLusky, & Leranth, 2005; McEwen, 1999). 
In the neuroendocrine system, corticotrophin releasing factor (or hormone: CRF/CRH) is 
released from the paraventricular nucleus of the hypothalamus (PVN) to stimulate the anterior 
pituitary gland to produce ACTH. This in turn stimulates the release of glucocorticoids from the 
adrenal cortex into the blood circulation, which inter alia, exert negative feedback effects on the 
pituitary and hypothalamus that limit the degree of activation of the HPA axis (Willner et al., 2013). 
Signals of homeostatic imbalance in the brainstem leads to the activation of this axis, where 
ascending brain stem pathways project heavily to the parvocellular divisions of the PVN.  
Importantly, there seems to be a reciprocal relationship between reward and stress 
appraisal in the brain. Exposure to natural rewards buffers the effect of stressor on HPA activity 
(Ulrich-Lai et al., 2010), and stress increases reward-seeking behaviors (Weiss, 2005). Experiences 
with rewarding stimuli generally evoke stress-like HPA responses, however the effects may be 
contingent on the type of rewards (Ulrich-Lai & Herman, 2009). The DA reward system 
demonstrates a range of complex responses to stressors, shown to critically mediate one’s adaptive 
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and maladaptive states. A recent study indicates a GR-dependent neuronal dichotomy for the 
regulation of emotional and social behaviors in response to social stress, and clearly implicates 
glucocorticoids as a link between stress resiliency and dopaminergic tone (Barik et al., 2013). In 
turn, the dopamine system affects future appraisals and responses to stress. In support of this view, 
there is evidence that low levels of stress, or controllable stressors have been reported to immunize 
the system to subsequent stressors (Belda, Fuentes, Nadal, & Armario, 2008; Ma & Morilak, 2005).  
All in all, it is well documented that stress interferes with processes responsible for bringing 
about antidepressant effects, namely neurogenesis (cell proliferation), neuronal survival and 
functionality. The cellular effects of stress lead to visible morphological changes (e.g. decrease in 
hippocampal volume –loss of dendrites) as well as functional consequences. The most likely 
mechanism by which stress suppresses adult neurogenesis in the hippocampus is via the activation 
of HPA axis and subsequent elevation of cortisol (glucocorticoids) levels. The hippocampus, in turn, 
provides negative feedback to the HPA axis. Stress also affects PFC functioning, where 
neurodegenerative changes include microglial activation, atrophy of pyramidal neurons, dendritic 
retraction and reduction of synaptic proteins.  Close the PFC, the most stress-sensitive region is 
anterior cingulate cortex (Willner et al., 2013), whose functions are associated with changes in 
cognitive (dorsal) and emotion (ventral) characteristics of depression. While synaptic and 
morphological plasticity have been less extensively examined in the PFC compared to the 
hippocampus, it is clear that stress has similar deleterious effects on the mechanisms of 
neuroplasticity here (Pittenger & Duman, 2008).  
Neuroplasticity  
Stress can have a lasting impact on the structure and function of brain circuitry that 
translates into long lasting behavioral changes. Emerging data suggests that stress not only brings 
about neurochemical alterations, but also impairments of cellular plasticity and resilience (Carlson, 
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Singh, Zarate, Drevets, & Manji, 2006; Manji & Duman, 2000). Plasticity, the ability to undergo and 
sustain change, is essential for adaptive functioning of our nervous system. This capacity for change 
allows organisms to adapt to complex change they face in both their internal and external 
environments. Adaptive mechanisms in learning and memory as well as physiological homeostasis 
–all are dynamic processes that rely on plastic neural circuitry for appropriate regulation of mood 
and affect (Schloesser, Huang, Klein, & Manji, 2008). In recent years, mood disorders have been well 
documented with structural and functional impairments related to neuroplasticity in various 
regions of the CNS (Carlson et al., 2006; Manji & Duman, 2000). Furthermore, commonly prescribed 
psychotropic drugs target molecules and signaling cascades implicated in the regulation of 
neuroplasticity (Carlson et al., 2006). 
Neuroplasticity is a broad term that encapsulates dynamic changes in intracellular signaling 
cascades and gene regulation whereas synaptic plasticity results in long lasting changes in the 
strength and efficacy of neurotransmission. Specifically, synaptic plasticity is the mechanism 
through which information is stored and consolidated within individual synapses, neurons and 
neuronal circuits to guide the behavior of an organism. Long term potentiation (LTP) refers to a 
lasting (hours to days) increase in synaptic strength induced by brief high frequency electrical 
stimulation of afferent fibers or by coincident activation of pre and postsynaptic neurons. Long 
term depression (LTD), on the other hand, is involved in activity-dependent reduction in synaptic 
plasticity at both excitatory and inhibitory synapses (Marsden, 2013). Considering their role in 
learning and memory (e.g. emotional events, aversive stimuli etc.), several independent studies 
show modifications to LTP and LTD in the hippocampus from stressful experiences (Artola et al., 
2006; Diamond, Park, Campbell, & Woodson, 2005; Kim, Foy, & Thompson, 1996). Further, 
restoring the balance of LTP/LTD contribute to maintaining synaptic efficacy that may otherwise 
represent as a factor of vulnerability to the consequences of stress (Popoli, Gennarelli, & Racagni, 
2002). 
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LTP and LTD has been used to study the mechanisms of synaptogenesis where increased 
neuronal activity leads to insertion of glutamate receptors and maturation of spine synapses 
(Kessels & Malinow, 2009). The glutamate hypothesis of depression has recently evolved into a 
larger neuroplasticity hypothesis which proposes that chronic stress disrupts both structural (e.g. 
dendritic spines) and functional glutamatergic synaptic plasticity and that antidepressants at least 
work in part by reversing these disruptions. The formation of spine synapses or synaptogenesis is a 
key form of neuroplasticity, and represents a fundamental characteristic of neurons. 
Synaptogenesis is a structural change at a subcellular level that takes place in response to synaptic 
activity and provides a mechanism for processing and incorporating new information that can be 
used to make appropriate and adaptive responses (Duman & Li, 2012).  
Evidence from animal models of anxiety and depression indicate that neurogenesis is 
necessary but does not occur for all antidepressants (David et al., 2009; Karpova et al., 2011; 
Santarelli et al., 2003). Scopolamine increases synaptic connections and functions in the PFC and 
also increase levels of extracellular glutamate in the PFC (Voleti et al., 2013). Furthermore, a single 
dose of scopolamine stimulates mammalian target of rapamycin complex 1 (mTORC1) signaling 
similar to the rapid antidepressant mechanisms of ketamine. Ketamine alone rapidly increases 
synaptic plasticity, with a primary role of glutamate and mTORC1 modulation synaptic  remodeling, 
plasticity and synchronization  (Duman, 2014). Lithium has been found to enhance this 
synaptogenic and anti-depressive behavioral effects when it is concomitantly administered with 
ketamine (Liu et al., 2013). Tianeptine prevents or reverses stress-associated structural and cellular 
changes and normalizes disrupted glutamatergic transmission in the hippocampus, the amygdala 
and the cortex in animal models of depression (Kasper & McEwen, 2008; McEwen et al., 2010). An 
inhibition of an excessive release of glutamate appears to be important to lamotrigine and riluzole 
mechanisms of action (Zarate et al., 2006). Common to those above mentioned antidepressants 
seem to be the actions of glutamate and an intimate relationship exists between regulation of 
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monoaminergic, glutamatergic systems and treatment response (Krishnan & Nestler, 2008; Paul & 
Skolnick, 2003). Further, these processes have been observed to take place in brain regions heavily 
implicated in antidepressant actions, namely the PFC and the hippocampus.  
The down-regulation of neuroplasticity via neurotrophins pathways account for reduced 
cognitive as well as anxiety strengthening symptomatology of depressive disorders. Under-
expressed neurotrophic factors have been associated with diminished volume of specific brain 
regions in MDD patients and antidepressants work therapeutically by reinstating such imbalance of 
growth factors. Nevertheless, many researchers now argue that this as an oversimplified 
representation on the topic of neurotrophins and their role in antidepressant action (Porcelli, 
Drago, Fabbri, & Serretti, 2011). As an example, the increased function of noradrenergic or 
serotonergic system, activates transcription factor CREB, BDNF and its receptor tropomyosin 
receptor kinase B (TrkB). Consequently, neuronal plasticity is enhanced and leads to a resumption 
of cellular functions. Not only neurotrophic factors facilitate molecular signaling for neuronal 
development earlier in life, they continue to be an essential driver of neuroplasticity in the adult 
brain (Duric & Duman, 2013; Greenberg, Xu, Lu, & Hempstead, 2009; Thoenen, 1995). According to 
the neurotrophic hypothesis, mood abnormalities arise from decreased neurotrophic support, 
leading to neuronal atrophy and decreased neurogenesis (Duman & Li, 2012). Vulnerability to 
depression can escalate as a result of neuronal damage, e.g. after chronic stress, long-term 
increased levels of glucocorticoids, hypoglycemia, ischemia, effects of neurotoxins or certain viral 
infections. This hypothesis links changes in stress-induced vulnerability and the therapeutic actions 
owing to the modification of intracellular mechanisms that modulate neurotropic factors necessary 
for neuronal survival and functioning. Heightened HPA activity and excessive glucocorticoids have 
been found to interfere with neurotrophin signaling. Conversely, neurotrophic factors can stimulate 
the HPA axis (Givalois et al., 2004; Naert, Ixart, Tapia-Arancibia, & Givalois, 2006). These 
observations identify a lack of sufficient neurotrophic support as a key contributor to the 
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neuroprogressive nature of depressive disorders as well as plasticity-induced antidepressant 
effects (Berk et al., 2011; Duman, 2004).  
Energy regulation  
As discussed earlier, chronic stress affects the progression of MDD by reducing synaptic 
plasticity, inducing structural changes in dendrites, activating inflammatory pathways, interfering 
with monoamine transmission and impairing neurogenesis (Pittenger & Duman, 2008). Emerging 
proteomics studies found stress and pharmacotherapies to modulate energy metabolism as well as 
cellular remodeling pathways in animal models of depression (Mallei et al., 2011; Piubelli, Carboni, 
Becchi, Mathe, & Domenici, 2011). Specifically, in a rat gene x environment interaction stress model, 
a number of mitochondrial proteins involved in energy production as well as associative metabolic 
enzymes were dysregulated. In organs demanding most energy (brain, liver and muscles), the 
highest number of mitochondria resides. It is well known that mitochondria strongly affect many 
intracellular processes coupled to signal transduction, neuron survival and plasticity (Hroudová, 
Fišar, & Raboch, 2013). To reiterate, mitochondria may be primary regulators of not only neuronal 
survival and death, but also plasticity (Fišar & Hroudová, 2010). Mitochondrial hypothesis directly 
corresponds to the above mentioned, neurotropic hypothesis because of an important role of 
calcium signaling pathway in both synaptic plasticity regulation. Mitochondrial dysfunctions 
(leading to decreased adenosine triphosphate (ATP) production, oxidative stress and induction of 
apoptosis) occur in the early stages of different neurodegenerative diseases, often being associated 
with mood disorders and antidepressant activity (Carboni et al., 2006; Gardner et al., 2003; 
Madrigal et al., 2001; Quiroz, Gray, Kato, & Manji, 2008; Rezin et al., 2008). 
 The role of mitochondria in BPD is supported both by observation in altered human brain 
metabolism in disease state and by the effects of mood stabilizers (lithium and valproate) on 
mitochondrial functions. Magnetic resonance studies in bipolar patients suggest mitochondrial 
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dysfunction is indicated by impaired oxidative phosphorylation, a resultant shift toward glycolytic 
energy production, attenuated total energy production and/or substrate availability and altered 
phospholipid metabolism (Stork & Renshaw, 2005). These conclusions are drawn from abnormal 
brain metabolism measured by 31P-magnetic resonance spectroscopy (31P MRS), in other words 
decreased intracellular pH, decreased phosphocreatine and enhanced response of phosphocreatine 
(PCr) to photic stimulation. Also other authors (Kato & Kato, 2000) have studied brain phosphorus 
metabolism in autopsied brains in patients with BPD looking at mitochondrial DNA (mtDNA) using 
such a technique. According to bioenergetics hypothesis, mtDNA polymorphisms/mutations or 
mtRNA deletions caused by nuclear gene mutations can cause mitochondrial dysregulation of 
calcium leading to symptoms of cycling mood states that defines BPD. Recently, (Yuksel et al., 2015) 
reported 31P MRS pattern indicative of a disease related failure to replenish ATP from Pcr through 
creatine kinase enzyme catalysis during tissue activation. PCr/ATP ratio is a measure of the 
energetic reserve status of tissues with high energy utilization (including neurons) and lower ratio 
represents diminished energetic reserves at rest. A compensated bioenergetics were observed for 
BPD patients at resting state, possibly due to high-energy requiring processes implicated in BPD, 
such as neuroplasticity and glutamate turnover. 
Effect of mood stabilizers on mitochondria has mostly been conducted in isolated brain 
regions of rodents and larger mammals in vitro. Lithium, the most commonly prescribed drug to 
BPD patients, caused desensitization to calcium, antagonized permeability transition and 
diminished cytochrome c release in isolated brain mitochondria. In isolated rat liver mitochondria, 
valproate inhibited oxidative phosphorylation (OXPHOS). Both lithium and valproate inhibited 
respiratory chain complexes I and IV in larger mammals (Brand & Nicholls, 2011). According to a 
study performed in rats, valproate reversed the inhibited activity of citrate synthase following 
amphetamine administration, whereas lithium prevented the amphetamine induced enzyme 
prevention (Corrêa et al., 2007). Chronic treatment with lithium, valproate and carbamazepine 
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prevented NMDA mediated toxicity. In one recent study performed with children suffering from 
epilepsy, carbamazepine and lamotrigine both influenced respiratory chain complexes and 
significantly affected ATP production (Berger, Segal, Shmueli, & Saada, 2010). These results 
(alongside other investigation in human blastoma and glioma cells, rat brain mitochondria and 
human white blood cells, please refer to Brand and Nicholls (2011) for detail) suggest that mood 
stabilizers exert neuroprotective effects to lessen the existing vulnerability of mitochondria from  
oxidative stress.  
 In contrast to substantial evidence on BPD and mood stabilizers, a small but growing body 
of research from animal studies, muscle biopsy and imaging data supports the role of mitochondria 
in MDD (Chang, Jou, Lin, Lai, & Liu, 2015). In rats, mitochondrial respiratory chain was inhibited 
following 21 days of chronic, repeated stress (Madrigal et al., 2001). Spatial distribution of 
mitochondria is abnormal in depressed patients. This facilitates the neuroprogressive nature of 
MDD by inefficient recruitment and trafficking of mitochondria to meet metabolic requirements 
under certain stress conditions or when their integrity is impaired. Additionally, aged and damaged 
mitochondria is not readily removed, and are thus unable to replenish healthy ones at distal 
terminals (Sheng, 2014). A significant decrease of mitochondrial ATP production rates and 
mitochondrial enzyme ratios in muscle were found in MDD patients compared to healthy controls 
(Gardner et al., 2003). Further, PET studies of cerebral blood flow or glucose metabolism indicates 
reduced blood flow and metabolic rate in PFC, anterior cingulate gyrus and basal ganglia (Videbech, 
2000). Nevertheless, there is no conclusive in vivo outcome on the relationship between mtDNA 
variations and oxidative damage for MDD population.  
There is relatively little data about the effect of antidepressants on mitochondrial functions. 
To date, most examine the influence of antidepressants (imipramine, desimipramine, amitriptyline, 
citalopram and mirtazapine) on activity of both mitochondrial monoamine oxidase and respiratory 
chain complexes in animals. Compared to classic uncouplers, imipramine and clomipramine 
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enhanced ATP synthase activity, hindered ATP synthesis and released respiratory control 
(Weinbach, Costa, & Wieder, 1985). Fluoxetine inhibited oxidative phosphorylation and decreased 
the activity of ATP synthase in the rat brain mitochondria (Curti et al., 1999) whereas 
desimipramine induced apoptosis through the activation of caspases without any changes of 
mitochondrial action potential (Ma et al., 2011). Lastly, nortriptyline was identified as a protector of 
isolated mitochondria against programmed cell death, inhibited release of apoptotic mitochondrial 
factors and caspases, increased Ca2+ retention in mitochondria and delayed the Ca2+ induced loss of 
mitochondrial action potential, ultimately leading to further neuronal cell death (Wang et al., 2007; 
Zhang et al., 2008). With regard to the number and volume of mitochondria in the hippocampus, 
rats genetically susceptible to depressive behavior showed a significant increase in the number of 
mitochondria compared to control group (Chen, Wegener, Madsen, & Nyengaard, 2013). 
Antidepressants may counteract with the structural impairments following changes to 
mitochondrial morphology and number that are a consistent feature of neuroplasticity.  
 Both direct and indirect effects of pharmacotherapies on mitochondrial function have been 
studied. Tricyclic antidepressants have anti-inflammatory and neuroprotective effects by 
modulating glial activation due to decreased production of nitric oxide and proinflammatory 
cytokines (Hwang et al., 2008) and mitochondria are well-known targets of nitric oxide. Recently, 
very different effects of three antidepressants, nefazodone, trazodone, and busiprone, on the 
induction of mitochondrial dysfunction and cytotoxicity were described (Dykens et al., 2008). 
Mitochondrial complex I, and to a lesser amount complex IV, were identified as the targets of 
nefazodone toxicity (a drug that was discontinued for hepatotoxicity). No inhibition to 
mitochondrial respiration was found for trazodone, and buspirone showed much lesser inhibition 
than nefazodone (Fišar & Hroudová, 2010).  
Lastly, recent findings also suggest roles for mitochondria as mediators of at least some 
effects of glutamate and BDNF on synaptic plasticity. BDNF promotes synaptic plasticity, in part, by 
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enhancing mitochondrial energy production. Specifically, it increases glucose utilization and 
increases mitochondrial respiratory coupling at complex (Hroudová et al., 2013). The findings on 
mitochondrial changes to date are mixed and may not be a primary contributor, however is a 
secondary factor that facilitates the neuroprogression of the disease. 
Key molecules underlying treatment response 
The chance of finding sensitive and specific biomarkers for treatment response has 
increased, due to the introduction of new methods of investigating cellular and molecular biology. 
These methods have enabled us to better study the underlying antidepressant activities in different 
brain regions and/or networks. The choice of parameters have been approached from the 
perspective of identifying biological markers of treatment responsivity, derived first of all from 
various signaling pathways involved in the aforementioned hypotheses of mood disorders. In 
consideration of these  parameters, activities of key molecules such as BDNF, glycogen synthase 
kinase 3 (GSK3), mammalian target of rapamycin (mTOR), Ca2+/ calmodulin-dependent kinase II 
(CaMKII) and amp-activated protein kinase (AMPK) can be put forward as principle players in 
mediating responsiveness or resistance to certain pharmacological interventions. Given the 
complexity and intimate connectivity of signaling pathways involved in treatment responsivity, the 
number of chosen molecules discussed herein are not final. 
BDNF 
Among different neurotrophic factors, BDNF is the most widely distributed neurotrophic 
factor in the brain. BDNF is a critical mediator of activity-dependent plasticity in the developing and 
adult CNS (Thoenen, 1995). Recent evidence suggests a complex scenario for BDNF driven neuronal 
plasticity where two active forms of BDNF have been described. Signaling of mature-BDNF through 
TrkB receptor and pro-BDNF through the low affinity p75 neurotrophin receptor (p75NTR), which 
can exert opposing actions on the expression of these factors in limbic regions involved in the 
regulation of mood and cognition (Duman & Monteggia, 2006). 
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Basic research shows that stress decreases the expression of BDNF and causes alterations of 
hippocampal structure and function (Coe et al., 2003; Czéh et al., 2001). Given the functions of 
hippocampal circuitry and its connections to regions that are more directly involved in emotion and 
cognition (amygdala & prefrontal cortex), investigations of BDNF expressions in the hippocampus 
have attracted much attention. Antidepressant treatments increase the activated forms of upstream 
activators (TrkB and CREB) of BDNF in cortical and limbic areas (Saarelainen et al., 2003). 
Alterations of BDNF as well as upstream targets, i.e. TrkB, indicate that stress and appropriate 
treatment results in cellular changes, notably regulation of neurogenesis and synaptogenic 
responses. The formation of spine synapses or synaptogenesis is a key form of neuroplasticity and 
represents structural changes at a subcellular level that enables incorporation of new information 
to be used to make adaptive future responses to stress (Duman & Li, 2012).   
The upregulation of BDNF is observed with different classes of antidepressants, including 
selective SSRI and norepinephrine selective reuptake inhibitors (NESRI), MAOIs, atypical 
antidepressants, and electroconvulsive therapy (Duman & Monteggia, 2006). The induction of 
BDNF is also dependent on chronic antidepressant treatment, consistent with the time course for 
therapeutic action of antidepressants to take place. It is worth noting that other treatments known 
to have antidepressant efficacy also increase the expression of BDNF in the hippocampus. These 
include the administration of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA)kines, NMDA receptor antagonists, transcranial magnetic stimulation and exercise (Duman 
& Monteggia, 2006). In humans, LHb DBS has been related to increased peripheral BDNF (Hoyer et 
al., 2013) whereas in rats, with mPFC DBS, therapeutic behavioral results were correlated to 
partially increased BDNF in the hippocampus (Hamani et al., 2012).  
Interestingly, differential roles of BDNF have been reported, contingent on the brain region 
where it is expressed. Increased BDNF production in the midbrain, hippocampus and the lateral 
ventricles results in an antidepressant effect (Shirayama, Chen, Nakagawa, Russell, & Duman, 
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2002), whereas overexpression of BDNF in the VTA (or NAc, in the mesolimbic DA system) resulted 
in pro-depressive symptoms (Berton & Nestler, 2006; Eisch et al., 2003). Specific deletion or 
knockout of BDNF in mesolimbic DA neurons in the VTA yields antidepressant-like response (Autry 
& Monteggia, 2012). An additional confounding factor is the dependence of BDNF gene expression 
on an enormous number of other genes, and their polymorphisms in the neuroplasticity pathway. 
For example, in rat models, SSRI treatment could not increase BDNF levels and exert an 
antidepressant-like behavioral effect in the absence of the CREB gene expression (Mattson, 
Maudsley, & Martin, 2004). Nonetheless, a large scale mRNA expression study measuring changes 
in SSRI-treated mice found that activation of BDNF-TrkB-CREB1 signaling pathway showed the best 
association with successful SSRI treatment (Kovacs et al., 2014). In stark contrast to the 
antidepressant effects of CREB-BDNF in the hippocampal-prefrontal circuit, activation of CREB-
BDNF cascade in the VTA-NAc pathway results in pro-depressive like behavior (Yu & Chen, 2011). 
While dysfunction of the VTA-NAc circuit is thought to be associated with depression, 
antidepressants have been postulated to reverse this function.  
Although preclinical research demonstrates a substantive evidence on the relationship 
between BDNF, stress and antidepressant activity, it is difficult to extrapolate these findings to 
humans due to the origin and function of serum-derived BDNF being unclear. Analysis of 
postmortem hippocampus tissue demonstrates that the expression of BDNF is decreased in 
depressed suicide patients and increased in patients receiving antidepressant medication at the 
time of death (Chen, Dowlatshahi, MacQueen, Wang, & Young, 2001; Karege et al., 2005). Similarly, 
decreased BDNF and TrkB levels have been correlated with decreased volume of the PFC (Dwivedi 
et al., 2003; Pandey et al., 2008). It is intriguing that similar to preclinical studies, BDNF expression 
is enhanced by MDD in the NAc tissue from patients (Krishnan et al., 2007). There are several 
reports demonstrating the possibility that peripheral BDNF may also influence central nervous 
system function, yet these findings have been dismissed after a meta-analysis. The serum levels of 
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BDNF are significantly decreased in depressed patients whereas successful antidepressant 
treatment has shown to reverse this state (Gonul et al., 2005; Shimizu et al., 2003).  
Together, these findings suggest that behavioral outcome of drug treatment do not appear 
to directly reflect the levels of BDNF, but perhaps the functional role of BDNF within a particular 
network necessitates treatment responses (Pilar-Cuellar et al., 2014). BDNF release is necessary for 
increasing synaptogenesis and reverse the effects of chronic stress on atrophy of pyramidal 
neurons (Hoeffer & Klann, 2010; Jourdi et al., 2009).  
GSK3 
A metabolic enzyme, GSK3, is a serine/threonine kinase known to regulate cellular 
functions such as structure, gene expression, mobility and apoptosis. Recently, it has been linked to 
inflammatory pathways (an important positive regulator) where its activity has been found to be 
necessary for full stimulation of the production of several pro-inflammatory cytokines (e.g. IL6, 
IL1β, TNF). Furthermore, GSK3 is another crucial kinase that acts as an intermediary member of 
many intracellular signaling pathways, specifically in insulin, Wnt and MAPK pathways. 
Additionally, growth factors may exert many of their neurotrophic and neuroprotective effects in 
part by inhibiting GSK3. GSK3 phosphorylates and thereby inactivates many transcription factors 
and further modulates the function of cytoskeletal proteins such as protein tau.  
More recently, an accumulation of reports discovered GSK3 inhibition as a basis for 
lithium’s mood stabilizing effects in BPD. The current concept supposes that lithium-induced 
serine-phosphorylation of GSK3 amplifies the direct inhibitory effect to allow for appropriate 
therapeutic levels of lithium to moderately down-regulate GSK3 activity. In other words, complete 
inhibition of GSK3 would have widespread consequences on many cellular functions, therefore the 
therapeutic action of lithium comes from not completely inhibiting GSK3, but only reducing its 
maximal activity (Jope, Yuskaitis, & Beurel, 2007).  
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Inhibition of GSK3 have been reported to reduce inflammation and apoptosis. Taken in 
conjunction with the evidence that inflammation too, is associated with mood disorders, it raises a 
new possibility that the therapeutic role of lithium-induced inhibition of GSK3 may result from 
reduction of inflammation, as reported to occur in mice treated with a clinically relevant doses of 
lithium (Martin, Rehani, Jope, & Michalek, 2005). Firstly, increased levels of inflammatory cytokines 
in patients with major depression or BPD has been well documented (Brietzke, Stabellini, Grassi-
Oliveira, & Lafer, 2011; Brietzke et al., 2009; Dowlati et al., 2010). Furthermore, administration or 
increased production of cytokines in humans or animals can induce biochemical and behavioral 
changes that mirror those characteristic of deleterious mood states. Although it is not known 
whether the inflammatory condition contributes to the manifestation or is an effect of affective 
disorders, investigators argue that controlling inflammation may contribute to positive results on 
the following grounds: a) the depressive effects that cytokines can produce (Raison, Capuron, & 
Miller, 2006); b) documented results that classical antidepressants have anti-inflammatory effects 
(Hannestad, DellaGioia, & Bloch, 2011) as well as c) deep brain stimulation induced benefits are 
improved by adjunctive anti-inflammatory drugs (Perez-Caballero et al., 2014). Thus, findings of 
anti-inflammatory properties following lithium and other GSK3 inhibitors administration, reinforce 
the possibility where inflammatory processes likely contribute to the therapeutic responses. 
Sodium valproate has recently become widely used as a mood stabilizer to treat BPD (Li, 
Ketter, & Frye, 2002). Although its mechanism of actions has been deemed similar to that of lithium, 
the underlying therapeutics of valproate needs further exploration. It is of considerable interest 
that valproate also shares with lithium the ability to reduce inflammation and ameliorate 
inflammation-associated conditions. Thus, the two most widely used mood stabilizers may have in 
common the capacity to reduce inflammation. However, other anti-inflammatory drugs do not 
share lithium’s mood stabilizing action, so it is clear that reducing inflammation alone is not enough 
to achieve mood stabilization. To demonstrate this, we can turn to studies examining the rapid 
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acting antidepressant effects of ketamine. The mechanisms of this drug has been shown to be 
dependent on mTOR and GSK3, which corresponds to rapid upregulation of structural and 
functional plasticity (Beurel, Song, & Jope, 2011). mTOR inhibition in vivo (TLR-stimulated immune 
cell line) induced a potent adaptive and innate inflammatory response that was abrogated by 
preventing rapamycin from increasing GSK3 activity (Wang et al., 2011). A direct interaction 
between mTOR signaling and GSK3 has been further reported in the regulation of cell growth 
(Buller et al., 2008; Inoki et al., 2006). An inhibition of GSK3 was found sufficient to activate mTOR-
dependent protein translation for axonogenesis (Hur & Zhou, 2010). Nonetheless, reducing 
inflammation by inhibiting GSK3 may contribute some part of lithium’s actions (similar to that of 
ketamine) in controlling mood fluctuations and its long-term prophylactic action in preventing 
recurrences of episodes (Jope et al., 2007).  
Since impaired serotonergic activity has long been implicated in antidepressant 
mechanisms, findings pinpointing enhanced serotonergic activity or antidepressants to 
subsequently inhibit GSK3 in mouse brain in vivo, lends further support to the possibility that 
impaired control of GSK3 is a component of failed treatment response (Li et al., 2004). Interestingly, 
Beaulieu et al. (2004) reported in mice that increases in dopamine-dependent activity are mediated 
via a GSK-dependent mechanism and that lithium plus other inhibitors of GSK3 attenuate the 
hyperactivity in mice that lack the dopamine transporter. Using the forced swim test, a paradigm 
relevant to DA mesolimbic pathway, to assess behavioral despair and the efficacy of novel drugs, 
administration of a peptide inhibitor of GSK3 rapidly induced antidepressant-like behavioral effects 
(Beaulieu et al., 2004; Gould, Einat, Bhat, & Manji, 2004). Together, the normalization of GSK3 and 
monoamines activity seem to attribute to antidepressant mechanisms.  
An integration between GSK3 and an energy signals, AMPK, has been found to regulate cell 
growth in coordination (Inoki, Kim, & Guan, 2012). Disruption in GSK3 function within the AMPK 
complex promotes higher AMPK and cellular catabolic processes even under anabolic conditions 
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indicating GSK3 acts as a critical sensor for anabolic signaling to regulate AMPK. Facilitating GSK3 
dissociation from the AMPK complex may be a novel therapeutic approach for stimulating AMPK 
activity without suppression cellular energy levels (Suzuki et al., 2013). 
mTOR 
 The induction of synaptogenesis, which is crucial for long lasting treatment response, 
requires protein synthesis and the activation of mTOR (Duman & Li, 2012). mTOR, a highly 
conserved nutrient-responsive regulator requires signals from both nutrients (glucose, amino 
acids) and growth factors. Activation occurs via a number of pathways, through GSK3β and most 
notably the release of BDNF, stimulation of its receptor TrkB and downstream signaling cascades 
Akt and MEK-ERK. mTOR signaling regulates local protein synthesis during long-term synaptic 
plasticity (Tang et al., 2002). Recently, the mTOR signaling pathway has been implicated in the 
therapeutic effects of mood stabilizers such as lithium and rapid acting antidepressant, ketamine. It 
has been postulated that the inhibition of mTOR following lithium treatment, has the capacity to 
increase autophagy and is related to one’s ability to withstand a variety of insults following sub-
chronic administration of rapamycin in rats (Cleary et al., 2008). This inhibition of mTOR has been 
corresponded to the antidepressant-like behaviors observed in the FST, induced by lithium 
administration. Activation of mTOR with ketamine in rodent chronic unpredictable stress models 
however, increased synaptogenesis in the prefrontal cortex which is crucial for mediating the 
antidepressant effects of this therapy (Dwyer & Duman, 2013). The synaptic actions of ketamine 
allows for rapid recovery from deleterious effects of repeated stress and prevents further neuronal 
atrophy and loss of synaptic connections. Recent observations highlight the role of N-methyl-D-
aspartate receptors (NMDAR) in the antidepressant action of ketamine. Similar to NMDA receptor 
antagonist Ketamine, the antidepressant actions of scopolamine require mTORC1 signaling and are 
associated with increased glutamate transmission and synaptogenesis (Voleti et al., 2013). In 
contrast to NMDAR antagonists, typical antidepressants (e.g. SSRIs or tricyclics) that requires 
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several weeks to produce antidepressant effects fail to activate mTOR signaling (Li et al., 2010), 
indicating that these agents have differential mechanisms to achieve treatment effects and possibly 
reflect patients with a specific depression symptomatology. 
Preclinical studies were conducted to determine whether behavioral changes brought on by 
ketamine are also dependent on mTOR signaling. Rapamycin pretreatment completely blocked the 
antidepressant effects of ketamine in the FST, learned helplessness and novelty suppressed feeding 
tests (Li et al., 2010). As an example, Duman and Li (2012) demonstrated the rapid antidepressant 
action of ketamine from a single dose which completely reversed the deficits previously seen in 
sucrose consumption test in chronic unpredictable stress (CUS) exposure for three weeks. These 
ketamine induced antidepressant-like behaviors paralleled the rapid reversal of the atrophy of PFC 
pyramidal neuron spine density with CUS exposure (Li et al., 2011). Together, the results provide 
support for the hypothesis that the rapid synaptogenic effects of ketamine underlie the therapeutic 
response to this agent.  
In clinical trials, decreased blood AKT 1 (upstream of mTOR) and mTOR RNA expression 
were observed in BPD patients during episodes, relative to that of healthy controls. Interestingly, 
after lithium treatment, alterations in AKT1 expression were positively correlated with improved 
Hamilton Rating Scale for depression scores, yet these associations were not found for mTOR 
(Machado-Vieira, Soeiro-De-Souza, Richards, Teixeira, & Zarate Jr, 2014). These findings may reflect 
the beginning changes where they are involved in the regulation of many downstream signaling. 
One plausible hypothesis is that the down-regulation of this pathway observed in BPD impacts 
cellular energy production through its action in the mitochondria. (Cunningham et al., 2007) 
demonstrated that the inhibition of mTOR decreases the genetic expression of mitochondrial 
transcriptional regulators, resulting in decreased mitochondrial gene expression and oxygen 
consumption.  
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Typical antidepressants have been reported to influence synaptic plasticity and related 
proteins to achieve a therapeutic response. As an exemplar, chronic fluoxetine administration is 
reported to increase dendritic spine density in the restrosplenial granular and prelimbic cortical 
regions (Ampuero et al., 2010). Chronic treatment with imipramine and fluoxetine can also reverse 
the neuronal atrophy in the hippocampus by typical antidepressants but this effect did not take 
place with atypical antidepressant tianeptine (Bessa et al., 2009). These outcomes highlight the 
unique ability of mTOR signaling (in the PFC) in increasing synaptic protein synthesis and 
synaptogenesis to rapidly reverse the synaptic deficits caused by chronic stress. The site of action is 
important in promoting positive versus negative effects.  
CaMKII 
Mechanisms of neuroplasticity and cellular resilience are involved in complex 
antidepressant drug action. There is overwhelming attention paid to, and evidence mounting for 
antidepressants harnessing signaling pathways related to neuroplasticity through an up-regulation 
of cAMP/PKA/CREB cascade, modulation of CaMKII activity and upregulation of MAPK cascade 
(Pittenger & Duman, 2008). CaMKII is an abundant brain kinase regulating neuronal responses to 
Ca2+ fluxes and represents an essential effector in neuroplasticity. Alpha and beta isoforms are most 
abundant in the brain. Appropriate Ca2+ signals induce autophosphorylation of the kinase at residue 
Thr286, generating a persistently activated form of the kinase that shows Ca2+-independent 
enzymatic activity, which is crucial for various forms of neuroplasticity (Tiraboschi et al., 2004). 
CaMKII has been demonstrated to translocate and potentiate inhibitory synapses in response to 
moderate NMDA receptor activation. Activity-dependent induction, stabilization and expansion of 
spines require NMDA receptor activation and incorporation of AMPA receptor subsets –a direct 
connection to CaMKII activity in both of these processes (Robison, 2014). Once CaMKII is bound to 
the BDNF receptor, it may organize additional anchoring sites for AMPA receptors at the synapse 
(Du, Gray, et al., 2004). It is intriguing that activation of synaptic NMDA receptors versus non-
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synaptic receptors has an opposite effect on cell survival via differential regulation of CREB 
function, a key molecule implicated in antidepressant activity. Calcium enters through synaptic 
NMDA receptors, which in turn induces CREB activity and BDNF gene expression as strongly as did 
stimulation of L-type receptors, triggered by glutamate exposure or hypoxic/ischemic conditions. 
This activates a general and dominant CREB shut-off pathway that blocked induction of BDNF 
expression. Synaptic NMDA receptors have antiapoptotic activity, whereas stimulation of 
extrasynaptic NMDA receptors caused loss of mitochondrial membrane potential (an early marker 
for glutamate-induce neuronal damage) and cell death (Du, Gray, et al., 2004; Hardingham, 
Fukunaga, & Bading, 2002). Most importantly for this present discussion, these processes involving 
CaMKII, NMDA and AMPA receptors are the very same signaling cascades that mood stabilizers and 
antidepressants exert their major effects on (Du et al., 2003; Gould, Chen, & Manji, 2004). These 
observations have led to an extensive series of studies, which have clearly demonstrated that AMPA 
receptor trafficking is highly regulated by antidepressants and mood stabilizers (Gray, Du, Falke, 
Yuan, & Manji, 2003). 
A growing body of literature suggests that CaMKII is regulated by stress and can be a target 
for antidepressant drugs. GR recruit the plasticity and survival pathways activated via CaMKIIα, 
BDNF, TrkB and CREB in the hippocampus (Chen, Bambah-Mukku, Pollonini, & Alberini, 2012).  GRs 
mediate long term memory formation of emotionally important events by recruiting CaMKIIa-
BDNF-CREB dependent neural plasticity pathway in rats (Chen et al., 2012). Acute and repeated, 
but not chronic stress exposure significantly increased phosphorylated CaMKII levels without 
affecting the levels of CaMKII (Suenaga, Morinobu, Kawano, Sawada, & Yamawaki, 2004). The 
increase in the intracellular Ca2+ concentration by the activation of AMPA receptors may play a role 
in the stress-induced phosphorylation seen in the rat hippocampus (Suenaga et al., 2004). Long 
term treatment with SSRIs or a dual inhibitor of 5-HT and NA reuptake increased 
autophosphorylation and activity of CaMKII in hippocampal subcellular fraction enriched with 
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synaptic vesicles and synaptic cytosolic fraction (Consogno, Racagni, & Popoli, 2001; Popoli, 
Vocaturo, Perez, Smeraldi, & Racagni, 1995). Additionally, repeated electroconvulsive seizures or 
imipramine both induced a large increase in the activity of this kinase contained in the total 
particulate fraction, but decreased the activity of soluble kinase. Although concomitant behavioral 
studies were not undertaken, the fact that different types of drugs and electroconvulsive therapy 
resulted in similar effects on CaMKII activity, suggested CaMKII activity to play an important role in 
the process of alleviating depression-related symptoms (Du, Szabo, Gray, & Manji, 2004).  
CaMKII associated changes extend to altered expressions of other plasticity-related 
proteins. CaMKII mediated phosphorylation of CREB in the PFC elicits anti-depressive and cognition 
enhancing effects in olfactory bulbectomized mice (Han et al., 2009). This is of particular interest as 
CREB activity in the PFC following an antidepressant administration is crucial for treatment 
response. Reduced prefrontal cortical expression of CaMKIIα mRNA was found in the postmortem 
brains of individuals suffering from severe bipolar and unipolar depression (Xing et al., 2002). 
These findings highlight and reinforce PFC as a key region of interest, containing antidepressant 
properties in the clinical population, and that CaMKII is involved in the underlying molecular 
mechanisms.  
CaMKII is also associated with and phosphorylates GSK3a/b, another key component in the 
acquisition of treatment efficacy. The pro-survival effect of CaMKII was mediated by GSK3 
phosphorylation and inactivation. This is the first study to identify a novel CaMKII-GSK3 pathway 
that couples depolarization to neuronal survival with implications for the neurodegenerative 
population (Song et al., 2010). Potential substrates of GSK3 that mediate the pro-apoptotic effects of 
potassium withdrawal is likely to include key mitochondrial components of the apoptotic signaling 
pathway.  The novel cellular mechanisms, observed in these studies are not specific to depression. 
Therefore, a direct examination is warranted in animal models of depression to establish these 
activity-dependent cellular processes for their applicability in the treatment of mood disorders.  
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Recently, an evidence of CaMKII activity can be found in learned helplessness animal model 
of depression.  Overexpression of CaMKIIβ in the lateral habenula caused depressive-like behaviors 
in both rats and mice whereas a knockdown of CaMKIIβ yielded antidepressant effects (Li et al., 
2013). It is possible that stress modulation of habenula CaMKII expression increases glutamate 
inputs onto VTA GABAergic interneurons, thereby inhibiting VTA dopaminergic neurons. CaMKII 
expression in NAc also regulates mood and stress responses via the associative reward circuitry 
(Robison, 2014). Chronic exposure to fluoxetine down-regulates NAc expression of CaMKIIα in mice 
and this reduction in CaMKII is both necessary and sufficient for the behavioral effects of the drug 
in a social defeat stress model. There is the possibility that chronic antidepressant treatment leads 
to down-regulation of NAc CaMKII expression to compensate for acute synaptic potentiation. 
Basolateral amygdala CaMKII expression has been suggested to play and important role in mood 
and emotional memory (McReynolds & McIntyre, 2012). A robust up-regulation of kinase activity 
was found in synaptic vesicles from both hippocampus and prefrontal/frontal cortex, following 
therapeutic responses achieved via different antidepressant drugs and electroconvulsive shocks.  
From these findings, CaMKII function in depression and antidepressant action is likely to 
differ across regions, nature of stressors and disease progression. The reported up-regulation of 
CaMKII in cell bodies, as opposed to presynaptic terminals, could lead to other types of synaptic 
plasticity and neuroprotection that also contribute to the actions of antidepressant treatments. 
Thus, future therapeutic approaches involving CaMKII must achieve regional specificity either 
intrinsically or through the targeting of region-specific downstream molecules (Robison, 2014).  
AMPK 
 AMPK is a fuel-sensing enzyme activated by cell’s energy demand, and its activation is 
required for mitochondrial biogenesis and function. AMPK, as well as coordinating cellular 
metabolism, has the ability to trigger stress pathways, regulate cell division, autophagy and 
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apoptosis. Of note, it was shown that AMPK activity is important in maintaining protein synthesis-
dependent forms of synaptic plasticity (Potter et al., 2010). Its activation subsequently leads to an 
up-regulation of ATP producing catabolic pathway and a down-regulation of ATP consuming 
anabolic process (Ruderman et al., 2010). AMPK improves survival under metabolic stress by 
integrating nutritional and hormonal signals in the peripheral tissues and the hypothalamus 
(Marques et al., 2012). AMPK is highly expressed in the hypothalamus and the activation of AMPK 
in vivo has demonstrated complex responses according to the magnitude and type of the stress 
(Pacak, 2000).  Previously described restraint and surgical stress studies purport a notion of 
marked heterogeneity in neuroendocrine stress responses (Gaillet, Lachuer, Malaval, Assenmacher, 
& Szafarczyk, 1991; Reis, Guerra, Reis, & Coimbra, 1995). Likewise, hypothalamic AMPK activity has 
been shown to respond differentially to various stressors (Marques et al., 2012). The PVN has been 
found to be specifically associated with changes in AMPK activity (Kola, 2008). Glucocorticoids, 
among other hormones and its interactions with AMPK has been explored extensively in the PVN 
with regards to appetitive control. Excessive or chronic exposure to glucocorticoids not only results 
in insulin resistance but also increase hypothalamic AMPK activity either directly or via 
endocannabinoid synthesis (Lim, Kola, & Korbonits, 2010; Nakken, Jacobs, Thomson, Fillmore, & 
Winder, 2010). Recently, a pharmacological activator of AMPK was able to acquire positive 
treatment effects in a mice model of depression-like and insulin-resistant state induced by co-
treatment of CORT and high fat diet. Concurrently, significantly higher levels of CORT were 
observed alongside blood glucose (Liu, Zhai, Li, & Ji, 2014). These outcomes, put AMPK forward as a 
potential antidepressant compound targeting CORT-induced HPA dysregulation. These findings, 
together with related studies of the stress system and AMPK introduces AMPK as a putative target 
for enhancing patients’ treatment response. 
 Another important function of AMPK is through the phosphorylation of raptor for the 
inhibition of mTOR and cell-cycle arrest arising from energetic stress (Gwinn et al., 2008). In an 
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inverse manner to AMPK, mTOR is activated when there is abundant energy source and efficiency. 
To add further complexity to mTOR function, mTORC1 is rapidly inactivated by a wide variety of 
cell stress to ensure that cells do not grow under unfavorable conditions (Gwinn et al., 2008). There 
are multiple mechanisms in which AMPK inhibits mTORC1, thereby maintaining cellular energy 
homeostasis. Linear signaling pathway involving the phosphorylation of tuberous sclerosis complex 
2 gene (TSC2) to activate tuberous sclerosis complex (TSC), subsequently attenuates the TORC1 
pathway. Cells can also inhibit mTORC1 through AMPK dependent direct regulation of mTORC1 
involving raptor (Gwinn et al., 2008; Inoki et al., 2012). A third mechanism involves a pathway in 
the down-regulation of Rheb activity through a phosphorylation-dependent mechanism (Zheng et 
al., 2011). In so far, their interactions have been better studied for neurodegenerative disorders 
such as Alzheimer’s disease, diabetes, appetitive control and cancer. Given that the engagement of 
mTORC1 and AMPK mediates cell growth or the induction of autophagy, further research is 
warranted to apply these findings for mood disorders. Appropriate control over cell growth and 
survival is crucial in the context of adaptive responses to and restorative processes after stress.  
Deep brain stimulation and its mechanisms in altering one’s treatment response 
 This review presented current knowledge on mood disorders and factors mediating the 
frontiers of treatment responsivity. All in all, these hypotheses on their own, may not be so relevant 
in looking to deepen our understanding on the mechanisms that moderate resistance to a given 
intervention. More likely, each of them (through interactions) have their unique function in 
enhancing adaptive neuronal remodeling, restructuring and plasticity. It seems probable that an 
effective intervention modulates pathological cellular and molecular networks in severely 
refractory patients, in an attempt to reinstate their responsivity. DBS has emerged as an alternative, 
final method that may exert its antidepressant power by changing the structure (hardware) as well 
as the function of the brain, not only producing a physiologic effect. Constant, chronic and long-term 
stimulation of regions that are heavily implicated in the pathophysiology of depression and 
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antidepressant activity is necessary for reversing resistance in TRD population (Lozano et al., 2008; 
Schlaepfer, 2015). In so far, findings from preclinical and clinical research suggest that different 
DBS targets may be acting upon particular symptom profiles that may be specific to the individuals’ 
depression subtype, severity and progressive stage (Hamani et al., 2014; Schlaepfer, 2015). 
Evidence has been building to expand our limited knowledge on the effects of DBS.  A detailed 
discussion of these findings can be found in the upcoming Chapter 2. To summarize, metabolic 
changes have been reported in the frontostrial, amygdala and the SCG region following DBS on and 
off (Riva-Posse et al., 2014). Early responses to SCG deep brain stimulation in severely depressed 
patients were poorer when they received anti-inflammatory drugs (Perez Caballero et al., 2013). 
Additionally, a role for serotonin and BDNF has been associated to the antidepressant-like 
behaviors following mPFC DBS (Hamani et al., 2012). Findings from subthalamic stimulation for 
Parkinson’s disease support casual changes in human neural plasticity after long-term stimulation 
(Van Hartevelt et al., 2014). Mitochondrial function and antidepressant actions of DBS, however, are 
not known.  
Conclusions 
Stress, allostatic overload and neuroinflammation all impair synaptic plasticity and cellular 
resilience. Disrupted plasticity together with increased cellular vulnerability contribute 
significantly to the pathophysiology of mood disorders and directly accelerate neuroprogression of   
the disease course (Machado-Vieira, 2013; Berk et al., 2007).  Some of the signature characteristics 
of disease progression include oxidative stress, decreased neurotrophic factor expression, reduced 
neurogenesis, impaired regulation of calcium together with alterations in endoplasmic reticulum 
and mitochondrial function, energy metabolism and insulin signaling (For detailed reviews see 
Berk et al., 2011; Brietzke et al., 2011, Machado-Vieira et al., 2013).  This review emphasizes the 
complex processes underlying neuronal plasticity, whereby structural increases, such as 
neurogenesis, neurite aborization and synaptogenesis cannot alone account for plasticity, but these 
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responses need to be balanced by programmed neuronal death, neurite retraction and synaptic 
pruning for healthy, adaptive functioning. Functional activity within the neuronal network 
determines which connections should be maintained and strengthened as opposed to ones 
eliminated (Castren & Rantamaki, 2010; Katz & Shatz, 1996). In other words, the adaptive 
formations are sustained for resilience and the deleterious functions abandoned for optimal 
responses to future threats (i.e. stressors).  
Biological markers and predictors of response to drug administration as well as molecular 
targets of novel antidepressants are searched on the basis of emerging and evolving hypothesis 
around neurogenesis and plasticity. According to these hypothesis, the leading role in the 
pathophysiology of mood disorders and antidepressant efficacy are destined for changes in cellular 
energy metabolism. Mitochondrial dysfunctions and consequently, impaired neuronal metabolism 
can lead to disturbances in neuronal function, plasticity, network circuitry and further systems-
wide degeneration. Together, these ideas highlight the importance and need for preclinical 
research. They can help us to develop a framework for understanding the neurobiology of 
depression and treatment response for targeted, systematic and efficacious antidepressant 
discovery.    
  
39
 
 
 
Fi
gu
re
 1
. 
N
eu
ro
pr
og
re
ss
io
n 
in
 d
ep
re
ss
iv
e 
di
so
rd
er
s.
 P
sy
ch
os
oc
ia
l 
an
d 
ph
ys
ic
al
 s
tr
es
so
rs
 c
om
bi
ne
d 
w
it
h 
pr
e-
ex
is
ti
ng
 
vu
ln
er
ab
ili
ti
es
 p
re
ci
pi
ta
te
 a
 fi
rs
t 
de
pr
es
si
ve
 e
pi
so
de
. B
io
ch
em
ic
al
 fa
ct
or
s 
th
at
 m
ay
 a
cc
el
er
at
e 
th
e 
ne
ur
op
ro
gr
es
si
ve
 n
at
ur
e 
of
 M
D
D
 a
nd
 B
D
P 
in
cl
ud
e 
in
fl
am
m
at
io
n,
 m
on
oa
m
in
e 
al
te
ra
ti
on
s,
 H
PA
 a
xi
s 
dy
sr
eg
ul
at
io
n,
 a
nd
 d
is
tu
rb
an
ce
 t
o 
ne
ur
ot
ro
ph
ic
 
fu
nc
ti
on
, w
hi
ch
 i
nt
er
ac
t 
to
 c
au
se
 c
el
lu
la
r 
da
m
ag
e,
 s
ti
m
ul
at
e 
ap
op
to
si
s 
an
d 
de
cr
ea
se
 n
eu
ro
na
l 
gr
ow
th
 a
nd
 s
ur
vi
va
l. 
T
he
se
 
ef
fe
ct
s 
m
ak
es
 th
e 
in
di
vi
du
al
 m
or
e 
su
sc
ep
ti
bl
e 
to
 fu
rt
he
r 
ep
is
od
es
 a
nd
 p
us
he
s 
th
em
 in
to
 a
n 
in
cr
ea
si
ng
ly
 tr
ea
tm
en
t r
es
is
ta
nt
 
st
at
e.
 E
ac
h 
ep
is
od
e 
co
rr
es
po
nd
s 
to
 p
ro
gr
es
si
ve
 c
og
ni
ti
ve
 a
nd
 f
un
ct
io
na
l 
de
cl
in
e 
an
d 
as
so
ci
at
ed
 s
tr
uc
tu
ra
l 
br
ai
n 
ch
an
ge
s.
 
Im
ag
e 
ad
ap
te
d 
fr
om
 M
oy
la
n,
 M
ae
s,
 W
ra
y,
 a
nd
 B
er
k 
(2
01
3)
 w
it
h 
pe
rm
is
si
on
. 
40 
 
 
References 
Abler, B., Erk, S., & Walter, H. (2007). Human reward system activation is modulated by a single dose 
of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI 
study. Psychopharmacology, 191(3), 823-833.  
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th 
ed.). VA, USA: American Psychiatric Publishing. 
Ampuero, E., Rubio, F., Falcon, R., Sandoval, M., Diaz-Veliz, G., Gonzalez, R., . . . Orrego, F. (2010). 
Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate 
receptor subunits in the rat cerebral cortex. Neuroscience, 169(1), 98-108.  
Artola, A., Von Frijtag, J. C., Fermont, P. C., Gispen, W. H., Schrama, L. H., Kamal, A., & Spruijt, B. M. 
(2006). Long-lasting modulation of the induction of LTD and LTP in rat hippocampal CA1 by 
behavioral stress and environmental enrichment. European Journal of Neuroscience, 23(1), 
261-272.  
Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric 
disorders. Pharmacological reviews, 64(2), 238-258.  
Barik, J., Marti, F., Morel, C., Fernandez, S. P., Lanteri, C., Godeheu, G., . . . Tronche, F. (2013). Chronic 
stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons. 
Science, 339(6117), 332-335.  
Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, 
M. G. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an 
AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of 
Sciences of the United States of America, 101(14), 5099-5104.  
Belda, X., Fuentes, S., Nadal, R., & Armario, A. (2008). A single exposure to immobilization causes long-
lasting pituitary-adrenal and behavioral sensitization to mild stressors. Hormones and 
behavior, 54(5), 654-661.  
41 
 
 
Berger, I., Segal, I., Shmueli, D., & Saada, A. (2010). The effect of antiepileptic drugs on mitochondrial 
activity: a pilot study. Journal of child neurology, 25(5), 541-545.  
Berk, M., Kapczinski, F., Andreazza, A., Dean, O., Giorlando, F., Maes, M., . . . Dean, B. (2011). Pathways 
underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and 
neurotrophic factors. Neuroscience & Biobehavioral Reviews, 35(3), 804-817.  
Berman, R. M., Sanacora, G., Anand, A., Roach, L. M., Fasula, M. K., Finkelstein, C. O., . . . Charney, D. S. 
(2002). Monoamine depletion in unmedicated depressed subjects. Biological psychiatry, 
51(6), 469-473.  
Berton, O., & Nestler, E. J. (2006). New approaches to antidepressant drug discovery: beyond 
monoamines. Nature Reviews Neuroscience, 7(2), 137-151.  
Bessa, J., Ferreira, D., Melo, I., Marques, F., Cerqueira, J., Palha, J., . . . Sousa, N. (2009). The mood-
improving actions of antidepressants do not depend on neurogenesis but are associated with 
neuronal remodeling. Molecular psychiatry, 14(8), 764-773.  
Beurel, E., Song, L., & Jope, R. (2011). Inhibition of glycogen synthase kinase-3 is necessary for the 
rapid antidepressant effect of ketamine in mice. Molecular psychiatry, 16(11), 1068-1070.  
Bosch, O. G., Seifritz, E., & Wetter, T. C. (2012). Stress-related depression: neuroendocrine, genetic, 
and therapeutical aspects. The World Journal of Biological Psychiatry, 13(8), 556-568.  
Bowden, C. L. (2005). A different depression: clinical distinctions between bipolar and unipolar 
depression. Journal of affective disorders, 84(2–3), 117-125. doi: 
http://dx.doi.org/10.1016/S0165-0327(03)00194-0 
Brand, M., & Nicholls, D. (2011). Assessing mitochondrial dysfunction in cells. Biochem. J, 435, 297-
312.  
Brenes, J. C., Rodríguez, O., & Fornaguera, J. (2008). Differential effect of environment enrichment and 
social isolation on depressive-like behavior, spontaneous activity and serotonin and 
42 
 
 
norepinephrine concentration in prefrontal cortex and ventral striatum. Pharmacology 
Biochemistry and Behavior, 89(1), 85-93.  
Brietzke, E., Stabellini, R., Grassi-Oliveira, R., & Lafer, B. (2011). Cytokines in bipolar disorder: recent 
findings, deleterious effects but promise for future therapeutics. CNS spectrums, 16(07), 157-
168.  
Brietzke, E., Stertz, L., Fernandes, B. S., Kauer-Sant’Anna, M., Mascarenhas, M., Vargas, A. E., . . . 
Kapczinski, F. (2009). Comparison of cytokine levels in depressed, manic and euthymic 
patients with bipolar disorder. Journal of affective disorders, 116(3), 214-217.  
Buller, C. L., Loberg, R. D., Fan, M.-H., Zhu, Q., Park, J. L., Vesely, E., . . . Brosius, F. C. (2008). A GSK-
3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter 
expression. American Journal of Physiology-Cell Physiology, 295(3), C836-C843.  
Cabib, S., & Puglisi-Allegra, S. (2012). The mesoaccumbens dopamine in coping with stress. 
Neuroscience & Biobehavioral Reviews, 36(1), 79-89.  
Caldarone, B. J., & Brunner, D. (2009). Preclinical testing in mice for treatment resistant depression. 
Frontiers in Neuroscience, 3, 264-265.  
Caldarone, B. J., Zachariou, V., & King, S. L. (2015). Rodent models of treatment-resistant depression. 
European journal of pharmacology, 753, 51-65.  
Cao, J.-L., Covington, H. E., Friedman, A. K., Wilkinson, M. B., Walsh, J. J., Cooper, D. C., . . . Han, M.-H. 
(2010). Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to 
social defeat and antidepressant action. The Journal of Neuroscience, 30(49), 16453-16458.  
Carboni, L., Vighini, M., Piubelli, C., Castelletti, L., Milli, A., & Domenici, E. (2006). Proteomic analysis 
of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative 
novel antidepressants: CRF1 and NK1 receptor antagonists. European 
Neuropsychopharmacology, 16(7), 521-537.  
43 
 
 
Carlson, P. J., Singh, J. B., Zarate, C. A., Drevets, W. C., & Manji, H. K. (2006). Neural circuitry and 
neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx, 3(1), 22-
41.  
Cerqueira, J. J., Mailliet, F., Almeida, O. F., Jay, T. M., & Sousa, N. (2007). The prefrontal cortex as a key 
target of the maladaptive response to stress. The Journal of Neuroscience, 27(11), 2781-2787.  
Chang, C.-C., Jou, S.-H., Lin, T.-T., Lai, T.-J., & Liu, C.-S. (2015). Mitochondria DNA Change and Oxidative 
Damage in Clinically Stable Patients with Major Depressive Disorder.  
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001). Increased hippocampal 
BDNF immunoreactivity in subjects treated with antidepressant medication. Biological 
psychiatry, 50(4), 260-265.  
Chen, D. Y., Bambah-Mukku, D., Pollonini, G., & Alberini, C. M. (2012). Glucocorticoid receptors recruit 
the CaMKII [alpha]-BDNF-CREB pathways to mediate memory consolidation. Nature 
neuroscience, 15(12), 1707-1714.  
Chen, F., Wegener, G., Madsen, T. M., & Nyengaard, J. R. (2013). Mitochondrial plasticity of the 
hippocampus in a genetic rat model of depression after antidepressant treatment. Synapse, 
67(3), 127-134.  
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., . . . McGuire, H. (2009). 
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-
treatments meta-analysis. The Lancet, 373(9665), 746-758.  
Cleary, C., Linde, J., Hiscock, K., Hadas, I., Belmaker, R., Agam, G., . . . Einat, H. (2008). Antidepressive-
like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target 
for treatment of affective disorders. Brain research bulletin, 76(5), 469-473.  
Coe, C. L., Kramer, M., Czéh, B., Gould, E., Reeves, A. J., Kirschbaum, C., & Fuchs, E. (2003). Prenatal 
stress diminishes neurogenesis in the dentate gyrus of juvenile rhesus monkeys. Biological 
psychiatry, 54(10), 1025-1034.  
44 
 
 
Consogno, E., Racagni, G., & Popoli, M. (2001). Modifications in brain CaM kinase II after long-term 
treatment with desmethylimipramine. Neuropsychopharmacology, 24(1), 21-30.  
Conway, C. R., Chibnall, J. T., Cumming, P., Mintun, M. A., Gebara, M. A. I., Perantie, D. C., . . . Gangwani, 
S. (2014). Antidepressant response to aripiprazole augmentation associated with enhanced 
FDOPA utilization in striatum: a preliminary PET study. Psychiatry Research: Neuroimaging, 
221(3), 231-239.  
Corrêa, C., Amboni, G., Assis, L. C., Martins, M. R., Kapczinski, F., Streck, E. L., & Quevedo, J. (2007). 
Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model 
of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(4), 887-891.  
Cryan, J. F., & Mombereau, C. (2004). In search of a depressed mouse: utility of models for studying 
depression-related behavior in genetically modified mice. Molecular psychiatry, 9(4), 326-
357.  
Cuellar, A. K., Johnson, S. L., & Winters, R. (2005). Distinctions between bipolar and unipolar 
depression. Clinical psychology review, 25(3), 307-339.  
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007). mTOR 
controls mitochondrial oxidative function through a YY1–PGC-1&agr; transcriptional 
complex. Nature, 450(7170), 736-740.  
Curti, C., Mingattao, F. E., Polizello, A. C., Galastri, L. O., Uyemura, S. A., & Santos, A. C. (1999). 
Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain 
mitochondria, inhibiting electron transport and F1F0-ATPase activity. Molecular and cellular 
biochemistry, 199(1-2), 103-109.  
Czéh, B., Michaelis, T., Watanabe, T., Frahm, J., de Biurrun, G., van Kampen, M., . . . Fuchs, E. (2001). 
Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation 
are prevented by antidepressant treatment with tianeptine. Proceedings of the National 
Academy of Sciences, 98(22), 12796-12801.  
45 
 
 
David, D. J., Samuels, B. A., Rainer, Q., Wang, J.-W., Marsteller, D., Mendez, I., . . . Guilloux, J.-P. (2009). 
Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of 
anxiety/depression. Neuron, 62(4), 479-493.  
Der-Avakian, A., Mazei-Robison, M. S., Kesby, J. P., Nestler, E. J., & Markou, A. (2014). Enduring deficits 
in brain reward function after chronic social defeat in rats: Susceptibility, resilience, and 
antidepressant response. Biological psychiatry, 76(7), 542-549.  
Diamond, D. M., Park, C. R., Campbell, A. M., & Woodson, J. C. (2005). Competitive interactions between 
endogenous LTD and LTP in the hippocampus underlie the storage of emotional memories 
and stress-induced amnesia. Hippocampus, 15(8), 1006-1025.  
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010). A meta-
analysis of cytokines in major depression. Biological psychiatry, 67(5), 446-457.  
Du, J., Gray, N. A., Falke, C., Yuan, P., Szabo, S., & Manji, H. K. (2003). Structurally dissimilar antimanic 
agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 
synaptic expression. Annals of the New York Academy of Sciences, 1003(1), 378-380.  
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., . . . Manji, H. K. (2004). Modulation of 
synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 
synaptic expression. The Journal of Neuroscience, 24(29), 6578-6589.  
Du, J., Szabo, S. T., Gray, N. A., & Manji, H. K. (2004). Focus on CaMKII: a molecular switch in the 
pathophysiology and treatment of mood and anxiety disorders. The International Journal of 
Neuropsychopharmacology, 7(03), 243-248.  
Duman, R. S. (2004). Role of neurotrophic factors in the etiology and treatment of mood disorders. 
Neuromolecular medicine, 5(1), 11-25.  
Duman, R. S. (2014). Pathophysiology of depression and innovative treatments: remodeling 
glutamatergic synaptic connections. Dialogues in clinical neuroscience, 16(1), 11.  
46 
 
 
Duman, R. S., & Li, N. (2012). A neurotrophic hypothesis of depression: role of synaptogenesis in the 
actions of NMDA receptor antagonists. Philosophical Transactions of the Royal Society B: 
Biological Sciences, 367(1601), 2475-2484.  
Duman, R. S., & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders. 
Biological psychiatry, 59(12), 1116-1127.  
Duric, V., & Duman, R. S. (2013). Depression and treatment response: dynamic interplay of signaling 
pathways and altered neural processes. Cellular and Molecular Life Sciences, 70(1), 39-53.  
Dwivedi, Y., Rizavi, H. S., Conley, R. R., Roberts, R. C., Tamminga, C. A., & Pandey, G. N. (2003). Altered 
gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in 
postmortem brain of suicide subjects. Archives of general psychiatry, 60(8), 804-815.  
Dwyer, J. M., & Duman, R. S. (2013). Activation of mammalian target of rapamycin and 
synaptogenesis: role in the actions of rapid-acting antidepressants. Biological psychiatry, 
73(12), 1189-1198.  
Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., . . . Will, Y. (2008). In 
vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, 
and buspirone. Toxicological Sciences, 103(2), 335-345.  
Eisch, A. J., Bolaños, C. A., de Wit, J., Simonak, R. D., Pudiak, C. M., Barrot, M., . . . Nestler, E. J. (2003). 
Brain-derived neurotrophic factor in the ventral midbrain–nucleus accumbens pathway: a 
role in depression. Biological psychiatry, 54(10), 994-1005.  
Enkel, T., Spanagel, R., Vollmayr, B., & Schneider, M. (2010). Stress triggers anhedonia in rats bred for 
learned helplessness. Behavioral brain research, 209(1), 183-186.  
Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biological psychiatry, 
53(8), 649-659.  
Fišar, Z., & Hroudová, J. (2010). Intracellular signalling pathways and mood disorders. Folia Biol 
(Praha), 56(4), 135-148.  
47 
 
 
Fried, E. I., & Nesse, R. M. (2014). The impact of individual depressive symptoms on impairment of 
psychosocial functioning. PLoS One, 9(2), e90311.  
Fu, C. H., Steiner, H., & Costafreda, S. G. (2013). Predictive neural biomarkers of clinical response in 
depression: a meta-analysis of functional and structural neuroimaging studies of 
pharmacological and psychological therapies. Neurobiology of disease, 52, 75-83.  
Gaillet, S., Lachuer, J., Malaval, F., Assenmacher, I., & Szafarczyk, A. (1991). The involvement of 
noradrenergic ascending pathways in the stress-induced activation of ACTH and 
corticosterone secretions is dependent on the nature of stressors. Experimental brain 
research, 87(1), 173-180.  
Gardner, A., & Boles, R. G. (2011). Beyond the serotonin hypothesis: mitochondria, inflammation and 
neurodegeneration in major depression and affective spectrum disorders. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 35(3), 730-743.  
Gardner, A., Johansson, A., Wibom, R., Nennesmo, I., von Döbeln, U., Hagenfeldt, L., & Hällström, T. 
(2003). Alterations of mitochondrial function and correlations with personality traits in 
selected major depressive disorder patients. Journal of affective disorders, 76(1), 55-68.  
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009). What did 
STAR* D teach us? Results from a large-scale, practical, clinical trial for patients with 
depression. Psychiatric services, 60(11), 1439-1445.  
Ghaemi, S. N., Boiman, E. E., & Goodwin, F. K. (2000). Diagnosing bipolar disorder and the effect of 
antidepressants: a naturalistic study. J Clin I'svchiatrv, 61(10).  
Ghaemi, S. N., Sachs, G. S., Chiou, A. M., Pandurangi, A. K., & Goodwin, F. K. (1999). Is bipolar disorder 
still underdiagnosed? Are antidepressants overutilized? Journal of affective disorders, 52(1), 
135-144.  
48 
 
 
Giacobbe, P., Mayberg, H. S., & Lozano, A. M. (2009). Treatment resistant depression as a failure of 
brain homeostatic mechanisms: implications for deep brain stimulation. Experimental 
neurology, 219(1), 44-52.  
Gitlin, M. (2006). Treatment-resistant bipolar disorder. Molecular psychiatry, 11(3), 227-240.  
Givalois, L., Naert, G., Rage, F., Ixart, G., Arancibia, S., & Tapia-Arancibia, L. (2004). A single brain-
derived neurotrophic factor injection modifies hypothalamo–pituitary–adrenocortical axis 
activity in adult male rats. Molecular and Cellular Neuroscience, 27(3), 280-295.  
Gonul, A. S., Akdeniz, F., Taneli, F., Donat, O., Eker, Ç., & Vahip, S. (2005). Effect of treatment on serum 
brain–derived neurotrophic factor levels in depressed patients. European archives of 
psychiatry and clinical neuroscience, 255(6), 381-386.  
Gotlib, I. H., Lewinsohn, P. M., & Seeley, J. R. (1995). Symptoms versus a diagnosis of depression: 
differences in psychosocial functioning. Journal of consulting and clinical psychology, 63(1), 
90.  
Gould, T. D., Chen, G., & Manji, H. K. (2004). In vivo evidence in the brain for lithium inhibition of 
glycogen synthase kinase-3. Neuropsychopharmacology: official publication of the American 
College of Neuropsychopharmacology, 29(1), 32-38.  
Gould, T. D., Einat, H., Bhat, R., & Manji, H. K. (2004). AR-A014418, a selective GSK-3 inhibitor, 
produces antidepressant-like effects in the forced swim test. The International Journal of 
Neuropsychopharmacology, 7(04), 387-390.  
Gray, N. A., Du, J., Falke, C. S., Yuan, P., & Manji, H. K. (2003). Lithium regulates total and synaptic 
expression of the AMPA glutamate receptor GluR2 in vitro and in vivo. Annals of the New York 
Academy of Sciences, 1003(1), 402-404.  
Greenberg, M. E., Xu, B., Lu, B., & Hempstead, B. L. (2009). New insights in the biology of BDNF 
synthesis and release: implications in CNS function. The Journal of Neuroscience, 29(41), 
12764-12767.  
49 
 
 
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., . . . Shaw, R. J. 
(2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular cell, 
30(2), 214-226.  
Hajszan, T., MacLusky, N. J., & Leranth, C. (2005). Short-term treatment with the antidepressant 
fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. 
European Journal of Neuroscience, 21(5), 1299-1303.  
Hamani, C., Amorim, B. O., Wheeler, A. L., Diwan, M., Driesslein, K., Covolan, L., . . . Nobrega, J. N. (2014). 
Deep brain stimulation in rats: different targets induce similar antidepressant-like effects but 
influence different circuits. Neurobiology of disease, 71, 205-214.  
Hamani, C., Machado, D. C., Hipólide, D. C., Dubiela, F. P., Suchecki, D., Macedo, C. E., . . . Nobrega, J. N. 
(2012). Deep brain stimulation reverses anhedonic-like behavior in a chronic model of 
depression: role of serotonin and brain derived neurotrophic factor. Biological psychiatry, 
71(1), 30-35.  
Han, F., Nakano, T., Yamamoto, Y., Shioda, N., Lu, Y.-M., & Fukunaga, K. (2009). Improvement of 
depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory 
bulbectomized mice. Brain research, 1265, 205-214.  
Hannestad, J., DellaGioia, N., & Bloch, M. (2011). The effect of antidepressant medication treatment 
on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology, 
36(12), 2452-2459.  
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic 
NMDARs by triggering CREB shut-off and cell death pathways. Nature neuroscience, 5(5), 405-
414.  
Heninger, G., Delgado, P., & Charney, D. (1996). The revised monoamine theory of depression: a 
modulatory role for monoamines, based on new findings from monoamine depletion 
experiments in humans. Pharmacopsychiatry, 29(1), 2-11.  
50 
 
 
Henn, F. A., Edwards, E., Anderson, D., & Vollmayr, B. (2002). Psychotherapy and antidepressant 
treatment of depression: evidence for similar neurobiological mechanisms. World Psychiatry, 
1(2), 115.  
Hoeffer, C. A., & Klann, E. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. 
Trends in neurosciences, 33(2), 67-75.  
Hoyer, C., Sartorius, A., Lecourtier, L., Kiening, K. L., Meyer-Lindenberg, A., & Gass, P. (2013). One ring 
to rule them all?–Temporospatial specificity of deep brain stimulation for treatment-resistant 
depression. Medical hypotheses, 81(4), 611-618.  
Hroudová, J., Fišar, Z., & Raboch, J. (2013). Mitochondrial Functions in Mood Disorders. MOOD 
DISORDERS, 101.  
Hur, E.-M., & Zhou, F.-Q. (2010). GSK3 signalling in neural development. Nature Reviews Neuroscience, 
11(8), 539-551.  
Hwang, J., Zheng, L. T., Ock, J., Lee, M. G., Kim, S.-H., Lee, H.-W., . . . Suk, K. (2008). Inhibition of glial 
inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology, 
55(5), 826-834.  
Ibarguen-Vargas, Y., Surget, A., Vourc’h, P., Leman, S., Andres, C. R., Gardier, A. M., & Belzung, C. (2009). 
Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like 
effects in the unpredictable chronic mild stress. Behavioral brain research, 202(2), 245-251.  
Inoki, K., Kim, J., & Guan, K.-L. (2012). AMPK and mTOR in cellular energy homeostasis and drug 
targets. Annual review of pharmacology and toxicology, 52, 381-400.  
Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., . . . Stankunas, K. (2006). TSC2 integrates 
Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate 
cell growth. Cell, 126(5), 955-968.  
51 
 
 
Jayatissa, M. N., Bisgaard, C., Tingström, A., Papp, M., & Wiborg, O. (2006). Hippocampal cytogenesis 
correlates to escitalopram-mediated recovery in a chronic mild stress rat model of 
depression. Neuropsychopharmacology, 31(11), 2395-2404.  
Johnson, S. L., Ruggero, C. J., & Carver, C. S. (2005). Cognitive, behavioral, and affective responses to 
reward: Links with hypomanic symptoms. Journal of Social and Clinical Psychology, 24(6), 
894-906.  
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007). Glycogen synthase kinase-3 (GSK3): inflammation, 
diseases, and therapeutics. Neurochemical research, 32(4-5), 577-595.  
Jourdi, H., Hsu, Y.-T., Zhou, M., Qin, Q., Bi, X., & Baudry, M. (2009). Positive AMPA receptor modulation 
rapidly stimulates BDNF release and increases dendritic mRNA translation. The Journal of 
Neuroscience, 29(27), 8688-8697.  
Karatsoreos, I. N., & McEwen, B. S. (2013). Resilience and vulnerability: a neurobiological perspective. 
F1000prime reports, 5.  
Karege, F., Bondolfi, G., Gervasoni, N., Schwald, M., Aubry, J.-M., & Bertschy, G. (2005). Low brain-
derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results 
from lowered platelet BDNF release unrelated to platelet reactivity. Biological psychiatry, 
57(9), 1068-1072.  
Karg, K., Burmeister, M., Shedden, K., & Sen, S. (2011). The serotonin transporter promoter variant 
(5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. 
Archives of general psychiatry, 68(5), 444-454.  
Karpova, N. N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Ágústsdóttir, A., . . . 
Sullivan, R. (2011). Fear erasure in mice requires synergy between antidepressant drugs and 
extinction training. Science, 334(6063), 1731-1734.  
Kasper, S., & McEwen, B. S. (2008). Neurobiological and clinical effects of the antidepressant 
tianeptine. CNS drugs, 22(1), 15-26.  
52 
 
 
Katarzyna, K., Wacław, K., Krystyna, G., Anna, D., Gert, S., Klemencja, B., . . . Krystyna, O. (2011). Partial 
lesion of the dopaminergic innervation of the ventral striatum induces “depressive-like” 
behavior of rats. Pharmacological Reports, 63(6), 1383-1392.  
Kato, T., & Kato, N. (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar disorders, 2(3), 
180-190.  
Kessels, H. W., & Malinow, R. (2009). Synaptic AMPA receptor plasticity and behavior. Neuron, 61(3), 
340-350.  
Kim, J. J., Foy, M. R., & Thompson, R. F. (1996). Behavioral stress modifies hippocampal plasticity 
through N-methyl-D-aspartate receptor activation. Proceedings of the National Academy of 
Sciences, 93(10), 4750-4753.  
Kitamura, Y., Araki, H., & Gomita, Y. (2002). Influence of ACTH on the effects of imipramine, 
desipramine and lithium on duration of immobility of rats in the forced swim test. 
Pharmacology Biochemistry and Behavior, 71(1), 63-69.  
Kitamura, Y., Fujitani, Y., Kitagawa, K., Miyazaki, T., Sagara, H., Kawasaki, H., . . . Gomita, Y. (2008). 
Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in 
the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biological 
and Pharmaceutical Bulletin, 31(2), 246-249.  
Kola, B. (2008). Role of AMP-activated protein kinase in the control of appetite. Journal of 
neuroendocrinology, 20(7), 942-951.  
Kovacs, D., Gonda, X., Petschner, P., Edes, A., Eszlari, N., Bagdy, G., & Juhasz, G. (2014). Antidepressant 
treatment response is modulated by genetic and environmental factors and their 
interactions. Ann Gen Psychiatry, 13, 17.  
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., . . . Lagace, D. C. (2007). 
Molecular adaptations underlying susceptibility and resistance to social defeat in brain 
reward regions. Cell, 131(2), 391-404.  
53 
 
 
Krishnan, V., & Nestler, E. J. (2008). The molecular neurobiology of depression. Nature, 455(7215), 
894-902.  
Lammel, S., Tye, K., & Warden, M. (2014). Progress in understanding mood disorders: optogenetic 
dissection of neural circuits. Genes, Brain and Behavior, 13(1), 38-51.  
Levinstein, M. R., & Samuels, B. A. (2014). Mechanisms underlying the antidepressant response and 
treatment resistance. Frontiers in behavioral neuroscience, 8.  
Li, B., Suemaru, K., Cui, R., Kitamura, Y., Gomita, Y., & Araki, H. (2006). Repeated electroconvulsive 
stimuli increase brain-derived neurotrophic factor in ACTH-treated rats. European journal of 
pharmacology, 529(1), 114-121.  
Li, K., Zhou, T., Liao, L., Yang, Z., Wong, C., Henn, F., . . . Hu, H. (2013). βCaMKII in lateral habenula 
mediates core symptoms of depression. Science, 341(6149), 1016-1020.  
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., . . . Duman, R. S. (2010). mTOR-dependent 
synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 
329(5994), 959-964.  
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., . . . Duman, R. S. (2011). Glutamate N-methyl-
D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by 
chronic stress exposure. Biological psychiatry, 69(8), 754-761.  
Li, X., Ketter, T. A., & Frye, M. A. (2002). Synaptic, intracellular, and neuroprotective mechanisms of 
anticonvulsants: are they relevant for the treatment and course of bipolar disorders? Journal 
of affective disorders, 69(1), 1-14.  
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004). In vivo regulation of 
glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. 
Neuropsychopharmacology: official publication of the American College of 
Neuropsychopharmacology, 29(8), 1426.  
54 
 
 
Lim, C. T., Kola, B., & Korbonits, M. (2010). AMPK as a mediator of hormonal signalling. Journal of 
molecular endocrinology, 44(2), 87-97.  
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013). GSK-3 
inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses 
of ketamine. Neuropsychopharmacology, 38(11), 2268-2277.  
Liu, W., Zhai, X., Li, H., & Ji, L. (2014). Depression-like behaviors in mice subjected to co-treatment of 
high-fat diet and corticosterone are ameliorated by AICAR and exercise. Journal of affective 
disorders, 156, 171-177.  
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008). 
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. 
Biological psychiatry, 64(6), 461-467.  
Ma, J., Qiu, Y., Yang, L., Peng, L., Xia, Z., Hou, L.-N., . . . Chen, H.-Z. (2011). Desipramine induces apoptosis 
in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway. Journal of 
neuro-oncology, 101(1), 41-48.  
Ma, S., & Morilak, D. (2005). Norepinephrine Release in Medial Amygdala Facilitates Activation of the 
Hypothalamic-Pituitary-Adrenal Axis in Response to Acute Immobilisation Stress. Journal of 
neuroendocrinology, 17(1), 22-28.  
Machado-Vieira, R., Soeiro-De-Souza, M. G., Richards, E. M., Teixeira, A. L., & Zarate Jr, C. A. (2014). 
Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: 
developing treatments using an integrated translational approach. The World Journal of 
Biological Psychiatry, 15(2), 84-95.  
Madrigal, J. L., Olivenza, R., Moro, M. A., Lizasoain, I., Lorenzo, P., Rodrigo, J., & Leza, J. C. (2001). 
Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by 
chronic stress in rat brain. Neuropsychopharmacology, 24(4), 420-429.  
55 
 
 
Malberg, J. E., & Duman, R. S. (2003). Cell proliferation in adult hippocampus is decreased by 
inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology, 28(9), 1562-
1571.  
Mallei, A., Giambelli, R., Gass, P., Racagni, G., Mathé, A. A., Vollmayr, B., & Popoli, M. (2011). 
Synaptoproteomics of learned helpless rats involve energy metabolism and cellular 
remodeling pathways in depressive-like behavior and antidepressant response. 
Neuropharmacology, 60(7), 1243-1253.  
Manji, H. K., & Duman, R. S. (2000). Impairments of neuroplasticity and cellular resilience in severe 
mood disorders: implications for the development of novel therapeutics. 
Psychopharmacology bulletin, 35(2), 5-49.  
Marques, M. B., Ribeiro-Oliveira Jr, A., Guimarães, J., Nascimento, G. F., Anjos, A. P., Vilas-Boas, W. W., 
. . . Grossman, A. B. (2012). Modifications in basal and stress-induced hypothalamic AMP-
activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II 
receptor blocker. Stress, 15(5), 554-561.  
Marsden, W. (2013). Synaptic plasticity in depression: molecular, cellular and functional correlates. 
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 43, 168-184.  
Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005). Toll-like receptor–mediated cytokine 
production is differentially regulated by glycogen synthase kinase 3. Nature immunology, 
6(8), 777-784.  
Martinot, M.-L. P., Bragulat, V., Artiges, E., Dollé, F., Hinnen, F., Jouvent, R., & Martinot, J.-L. (2001). 
Decreased presynaptic dopamine function in the left caudate of depressed patients with 
affective flattening and psychomotor retardation. American Journal of Psychiatry, 158(2), 
314-316.  
56 
 
 
Mattson, M. P., Maudsley, S., & Martin, B. (2004). BDNF and 5-HT: a dynamic duo in age-related 
neuronal plasticity and neurodegenerative disorders. Trends in neurosciences, 27(10), 589-
594.  
McEwen, B. S. (1999). Stress and hippocampal plasticity. Annual review of neuroscience, 22(1), 105-
122.  
McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. 
Physiological reviews, 87(3), 873-904.  
McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. 
(2010). The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis 
to glutamatergic modulation. Molecular psychiatry, 15(3), 237-249.  
McReynolds, J. R., & McIntyre, C. K. (2012). Emotional modulation of the synapse.  
Milano, G., Bianciardi, P., Corno, A. F., Raddatz, E., Morel, S., von Segesser, L. K., & Samaja, M. (2004). 
Myocardial impairment in chronic hypoxia is abolished by short aeration episodes: 
involvement of K+ ATP channels. Experimental Biology and Medicine, 229(11), 1196-1205.  
Mitchell, P. B., Frankland, A., Hadzi-Pavlovic, D., Roberts, G., Corry, J., Wright, A., . . . Breakspear, M. 
(2011). Comparison of depressive episodes in bipolar disorder and in major depressive 
disorder within bipolar disorder pedigrees. The British Journal of Psychiatry, 199(4), 303-309.  
Moylan, S., Berk, M., Dean, O. M., Samuni, Y., Williams, L. J., O’Neil, A., . . . Jacka, F. N. (2014). Oxidative 
& nitrosative stress in depression: Why so much stress? Neuroscience & Biobehavioral 
Reviews, 45, 46-62.  
Moylan, S., Maes, M., Wray, N., & Berk, M. (2013). The neuroprogressive nature of major depressive 
disorder: pathways to disease evolution and resistance, and therapeutic implications. 
Molecular psychiatry, 18(5), 595-606.  
Muguruza, C., Miranda-Azpiazu, P., Díez-Alarcia, R., Morentin, B., González-Maeso, J., Callado, L. F., & 
Meana, J. J. (2014). Evaluation of 5-HT 2A and mGlu 2/3 receptors in postmortem prefrontal 
57 
 
 
cortex of subjects with major depressive disorder: Effect of antidepressant treatment. 
Neuropharmacology, 86, 311-318.  
Naert, G., Ixart, G., Tapia-Arancibia, L., & Givalois, L. (2006). Continuous icv infusion of brain-derived 
neurotrophic factor modifies hypothalamic–pituitary–adrenal axis activity, locomotor 
activity and body temperature rhythms in adult male rats. Neuroscience, 139(2), 779-789.  
Nakken, G. N., Jacobs, D. L., Thomson, D. M., Fillmore, N., & Winder, W. W. (2010). Effects of excess 
corticosterone on LKB1 and AMPK signaling in rat skeletal muscle. Journal of applied 
physiology, 108(2), 298-305.  
Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of 
Clinical Psychiatry, 68(8), 17.  
Nusslock, R., Young, C. B., & Damme, K. S. (2014). Elevated reward-related neural activation as a 
unique biological marker of bipolar disorder: Assessment and treatment implications. 
Behavior research and therapy, 62, 74-87.  
Østergaard, S. D., Jensen, S., & Bech, P. (2011). The heterogeneity of the depressive syndrome: when 
numbers get serious. Acta Psychiatrica Scandinavica, 124(6), 495-496.  
Overmier, J. B., & Seligman, M. E. (1967). Effects of inescapable shock upon subsequent escape and 
avoidance responding. Journal of comparative and physiological psychology, 63(1), 28.  
Pacak, K. (2000). Stressor-specific activation of the hypothalamic-pituitary adrenocortical axis. 
Physiological Research, 49, S11-S18.  
Pandey, G. N., Ren, X., Rizavi, H. S., Conley, R. R., Roberts, R. C., & Dwivedi, Y. (2008). Brain-derived 
neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of 
teenage suicide victims. International Journal of Neuropsychopharmacology, 11(8), 1047-
1061.  
Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: classical theories and new 
developments. Trends in neurosciences, 31(9), 464-468.  
58 
 
 
Parker, G., Graham, R., Hadzi-Pavlovic, D., Friend, P., Synnott, H., & Barrett, M. (2012). Does testing for 
bimodality clarify whether the bipolar disorders are categorically or dimensionally different 
to unipolar depressive disorders? Journal of affective disorders, 137(1), 135-138.  
Paul, I. A., & Skolnick, P. (2003). Glutamate and depression. Annals of the New York Academy of 
Sciences, 1003(1), 250-272.  
Perez-Caballero, L., Perez-Egea, R., Romero-Grimaldi, C., Puigdemont, D., Molet, J., Caso, J., . . . 
Berrocoso, E. (2014). Early responses to deep brain stimulation in depression are modulated 
by anti-inflammatory drugs. Molecular psychiatry, 19(5), 607-614.  
Phillips, P. E., Walton, M. E., & Jhou, T. C. (2007). Calculating utility: preclinical evidence for cost–
benefit analysis by mesolimbic dopamine. Psychopharmacology, 191(3), 483-495.  
Pilar-Cuellar, F., Vidal, R., Díaz, Á., Castro, E., dos Anjos, S., Vargas, V., . . . M Valdizan, E. (2014). 
Signaling pathways involved in antidepressant-induced cell proliferation and synaptic 
plasticity. Current pharmaceutical design, 20(23), 3776-3794.  
Pittenger, C., & Duman, R. S. (2008). Stress, depression, and neuroplasticity: a convergence of 
mechanisms. Neuropsychopharmacology, 33(1), 88-109.  
Piubelli, C., Carboni, L., Becchi, S., Mathe, A., & Domenici, E. (2011). Regulation of cytoskeleton 
machinery, neurogenesis and energy metabolism pathways in a rat gene-environment model 
of depression revealed by proteomic analysis. Neuroscience, 176, 349-380.  
Popoli, M., Gennarelli, M., & Racagni, G. (2002). Modulation of synaptic plasticity by stress and 
antidepressants. Bipolar disorders, 4(3), 166-182.  
Popoli, M., Vocaturo, C., Perez, J., Smeraldi, E., & Racagni, G. (1995). Presynaptic Ca2+/calmodulin-
dependent protein kinase II: autophosphorylation and activity increase in the hippocampus 
after long-term blockade of serotonin reuptake. Molecular pharmacology, 48(4), 623-629.  
59 
 
 
Porcelli, S., Drago, A., Fabbri, C., & Serretti, A. (2011). Mechanisms of antidepressant action: an 
integrated dopaminergic perspective. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry, 35(7), 1532-1543.  
Potter, W. B., O’riordan, K. J., Barnett, D., Osting, S., Wagoner, M., Burger, C., & Roopra, A. (2010). 
Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One, 5(2), 
e8996.  
Quiroz, J. A., Gray, N. A., Kato, T., & Manji, H. K. (2008). Mitochondrially mediated plasticity in the 
pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 33(11), 
2551-2565.  
Raison, C. L., Capuron, L., & Miller, A. H. (2006). Cytokines sing the blues: inflammation and the 
pathogenesis of depression. Trends in immunology, 27(1), 24-31.  
Reis, F., Guerra, R., Reis, A., & Coimbra, C. (1995). Blood glucose and prolactin in hyperprolactinemic 
rats exposed to restraint and surgical stress. Life sciences, 58(2), 155-161.  
Rezin, G. T., Cardoso, M. R., Gonçalves, C. L., Scaini, G., Fraga, D. B., Riegel, R. E., . . . Streck, E. L. (2008). 
Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental 
model of depression. Neurochemistry international, 53(6), 395-400.  
Riva-Posse, P., Choi, K. S., Holtzheimer, P. E., McIntyre, C. C., Gross, R. E., Chaturvedi, A., . . . Mayberg, 
H. S. (2014). Defining critical white matter pathways mediating successful subcallosal 
cingulate deep brain stimulation for treatment-resistant depression. Biological psychiatry, 
76(12), 963-969.  
Rivero, G., Gabilondo, A. M., García-Sevilla, J. A., La Harpe, R., Callado, L. F., & Meana, J. J. (2014). 
Increased α 2-and β 1-adrenoceptor densities in postmortem brain of subjects with 
depression: Differential effect of antidepressant treatment. Journal of affective disorders, 167, 
343-350.  
60 
 
 
Rizzo, S. S., Neal, S., Hughes, Z., Beyna, M., Rosenzweig-Lipson, S., Moss, S., & Brandon, N. (2012). 
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like 
phenotypes. Translational psychiatry, 2(12), e199.  
Robison, A. (2014). Emerging role of CaMKII in neuropsychiatric disease. Trends in neurosciences, 
37(11), 653-662.  
Rosenström, T., Jylhä, P., Cloninger, C. R., Hintsanen, M., Elovainio, M., Mantere, O., . . . Keltikangas-
Järvinen, L. (2014). Temperament and character traits predict future burden of depression. 
Journal of affective disorders, 158, 139-147.  
Ruderman, N. B., Xu, X. J., Nelson, L., Cacicedo, J. M., Saha, A. K., Lan, F., & Ido, Y. (2010). AMPK and 
SIRT1: a long-standing partnership? American Journal of Physiology-Endocrinology and 
Metabolism, 298(4), E751-E760.  
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007). Mood is indirectly related to serotonin, 
norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion 
studies. Molecular psychiatry, 12(4), 331-359.  
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., . . . Aloyz, R. (2003). 
Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is 
required for antidepressant-induced behavioral effects. The Journal of Neuroscience, 23(1), 
349-357.  
Sachs, G. S. (1996). Treatment-resistant bipolar depression. Psychiatric Clinics of North America, 
19(2), 215-236.  
Sáenz, J. C. B., Villagra, O. R., & Trías, J. F. (2006). Factor analysis of forced swimming test, sucrose 
preference test and open field test on enriched, social and isolated reared rats. Behavioral 
brain research, 169(1), 57-65.  
61 
 
 
Salamone, J. D., Correa, M., Farrar, A., & Mingote, S. M. (2007). Effort-related functions of nucleus 
accumbens dopamine and associated forebrain circuits. Psychopharmacology, 191(3), 461-
482.  
Salamone, J. D., Correa, M., Mingote, S., & Weber, S. M. (2003). Nucleus accumbens dopamine and the 
regulation of effort in food-seeking behavior: implications for studies of natural motivation, 
psychiatry, and drug abuse. Journal of Pharmacology and Experimental Therapeutics, 305(1), 
1-8.  
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., . . . Arancio, O. (2003). Requirement 
of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 
301(5634), 805-809.  
Sartorius, A., Vollmayr, B., Neumann-Haefelin, C., Ende, G., Hoehn, M., & Henn, F. A. (2003). Specific 
creatine rise in learned helplessness induced by electroconvulsive shock treatment. 
Neuroreport, 14(17), 2199-2201.  
Schlaepfer, T. E. (2015). Deep Brain Stimulation for Major Depression—Steps on a Long and Winding 
Road. Biological psychiatry, 78(4), 218-219.  
Schloesser, R. J., Huang, J., Klein, P. S., & Manji, H. K. (2008). Cellular plasticity cascades in the 
pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 33(1), 110-
133.  
Selye, H. (1976). Forty years of stress research: principal remaining problems and misconceptions. 
Canadian Medical Association Journal, 115(1), 53.  
Sheng, Z.-H. (2014). Mitochondrial trafficking and anchoring in neurons: new insight and 
implications. The Journal of cell biology, 204(7), 1087-1098.  
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., . . . Okada, S.-i. (2003). 
Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed 
patients with or without antidepressants. Biological psychiatry, 54(1), 70-75.  
62 
 
 
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002). Brain-derived 
neurotrophic factor produces antidepressant effects in behavioral models of depression. The 
Journal of Neuroscience, 22(8), 3251-3261.  
Singh, T., & Rajput, M. (2006). Misdiagnosis of bipolar disorder. Psychiatry (Edgmont), 3(10), 57.  
Smith, D. J., & Ghaemi, N. (2010). Is underdiagnosis the main pitfall when diagnosing bipolar 
disorder? Yes. BMJ, 340.  
Solomon, A., Haaga, D. A., & Arnow, B. A. (2001). Is clinical depression distinct from subthreshold 
depressive symptoms? A review of the continuity issue in depression research. The Journal of 
nervous and mental disease, 189(8), 498-506.  
Song, B., Lai, B., Zheng, Z., Zhang, Y., Luo, J., Wang, C., . . . Li, M. (2010). Inhibitory phosphorylation of 
GSK-3 by CaMKII couples depolarization to neuronal survival. J Biol Chem, 285(52), 41122-
41134. doi: 10.1074/jbc.M110.130351 
Stetler, C., & Miller, G. E. (2011). Depression and hypothalamic-pituitary-adrenal activation: a 
quantitative summary of four decades of research. Psychosomatic medicine, 73(2), 114-126.  
Stork, C., & Renshaw, P. (2005). Mitochondrial dysfunction in bipolar disorder: evidence from 
magnetic resonance spectroscopy research. Molecular psychiatry, 10(10), 900-919.  
Strakowski, S., Delbello, M., & Adler, C. (2005). The functional neuroanatomy of bipolar disorder: a 
review of neuroimaging findings. Molecular psychiatry, 10(1), 105-116.  
Suenaga, T., Morinobu, S., Kawano, K.-i., Sawada, T., & Yamawaki, S. (2004). Influence of 
immobilization stress on the levels of CaMKII and phospho-CaMKII in the rat hippocampus. 
The International Journal of Neuropsychopharmacology, 7(03), 299-309.  
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002). A rapamycin-
sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. 
Proceedings of the National Academy of Sciences, 99(1), 467-472.  
63 
 
 
Thase, M. E., & Rush, A. J. (1997). When at first you don't succeed: sequential strategies for 
antidepressant nonresponders. Journal of Clinical Psychiatry.  
Thoenen, H. (1995). Neurotrophins and neuronal plasticity. Science, 270(5236), 593-598.  
Tiraboschi, E., Giambelli, R., D'Urso, G., Galietta, A., Barbon, A., de Bartolomeis, A., . . . Popoli, M. (2004). 
Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. 
Neuroreport, 15(15), 2393-2396.  
Tohen, M., Goldberg, J. F., Arrillaga, A. M. G.-P., Azorin, J. M., Vieta, E., Hardy-Bayle, M.-C., . . . Baker, R. 
W. (2003). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment 
of acute mania. Archives of general psychiatry, 60(12), 1218-1226.  
Uher, R. (2011). Genes, environment, and individual differences in responding to treatment for 
depression. Harv Rev Psychiatry, 19(3), 109-124.  
Ulrich-Lai, Y. M., Christiansen, A. M., Ostrander, M. M., Jones, A. A., Jones, K. R., Choi, D. C., . . . Davis, J. 
F. (2010). Pleasurable behaviors reduce stress via brain reward pathways. Proceedings of the 
National Academy of Sciences, 107(47), 20529-20534.  
Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic stress 
responses. Nature Reviews Neuroscience, 10(6), 397-409.  
Van Hartevelt, T. J., Cabral, J., Deco, G., Møller, A., Green, A. L., Aziz, T. Z., & Kringelbach, M. L. (2014). 
Neural Plasticity in Human Brain Connectivity: the effects of long term deep brain stimulation 
of the subthalamic nucleus in Parkinson’s disease. PLoS One, 9(1).  
Videbech, P. (2000). PET measurements of brain glucose metabolism and blood flow in major 
depressive disorder: a critical review. Acta Psychiatrica Scandinavica, 101(1), 11-20.  
Vieta, E., Bourin, M., Sanchez, R., Marcus, R., Stock, E., McQuade, R., . . . Iwamoto, T. (2005). 
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania. The British Journal of 
Psychiatry, 187(3), 235-242.  
64 
 
 
Voleti, B., Navarria, A., Liu, R.-J., Banasr, M., Li, N., Terwilliger, R., . . . Duman, R. S. (2013). Scopolamine 
rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and 
antidepressant behavioral responses. Biological psychiatry, 74(10), 742-749.  
Walker, A. J., Burnett, S. A., Hasebe, K., McGillivray, J. A., Gray, L. J., McGee, S. L., . . . Tye, S. J. (2013). 
Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and 
prefrontal monoamine tissue levels. Behavioral brain research, 242, 76-83.  
Walker, A. J., Foley, B. M., Sutor, S. L., McGillivray, J. A., Frye, M. A., & Tye, S. J. (2015). Peripheral 
proinflammatory markers associated with ketamine response in a preclinical model of 
antidepressant-resistance. Behavioral brain research.  
Walker, A. J., Kim, Y., Price, J. B., Kale, R. P., McGillivray, J. A., Berk, M., & Tye, S. J. (2014). Stress, 
inflammation, and cellular vulnerability during early stages of affective disorders: biomarker 
strategies and opportunities for prevention and intervention. Frontiers in psychiatry, 5.  
Wang, H., Brown, J., Gu, Z., Garcia, C. A., Liang, R., Alard, P., . . . Martin, M. (2011). Convergence of the 
Mammalian Target of Rapamycin Complex 1-and Glycogen Synthase Kinase 3-β–Signaling 
Pathways Regulates the Innate Inflammatory Response. The Journal of Immunology, 186(9), 
5217-5226.  
Wang, H., Guan, Y., Wang, X., Smith, K., Cormier, K., Zhu, S., . . . Kristal, B. S. (2007). Nortriptyline delays 
disease onset in models of chronic neurodegeneration. European Journal of Neuroscience, 
26(3), 633-641.  
Weinbach, E., Costa, J., & Wieder, S. (1985). Antidepressant drugs suppress growth of the human 
pathogenic protozoan Giardia lamblia. Research communications in chemical pathology and 
pharmacology, 47(1), 145-148.  
Weiss, F. (2005). Neurobiology of craving, conditioned reward and relapse. Current opinion in 
pharmacology, 5(1), 9-19.  
65 
 
 
West, C. H., & Weiss, J. M. (2011). Effects of chronic antidepressant drug administration and 
electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. 
International Journal of Neuropsychopharmacology, 14(2), 201-210.  
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013). The neurobiology of depression and 
antidepressant action. Neuroscience & Biobehavioral Reviews, 37(10), 2331-2371.  
Winter, C., von Rumohr, A., Mundt, A., Petrus, D., Klein, J., Lee, T., . . . Juckel, G. (2007). Lesions of 
dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental 
area enhance depressive-like behavior in rats. Behavioral brain research, 184(2), 133-141.  
Xing, G., Russell, S., Hough, C., O'Grady, J., Zhang, L., Yang, S., . . . Post, R. (2002). Decreased prefrontal 
CaMKII α mRNA in bipolar illness. Neuroreport, 13(4), 501-505.  
Yu, H., & Chen, Z.-y. (2011). The role of BDNF in depression on the basis of its location in the neural 
circuitry. Acta Pharmacologica Sinica, 32(1), 3-11.  
Yuksel, C., Du, F., Ravichandran, C., Goldbach, J., Thida, T., Lin, P., . . . Sehovic, S. (2015). Abnormal high-
energy phosphate molecule metabolism during regional brain activation in patients with 
bipolar disorder. Molecular psychiatry.  
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., . . . Manji, H. K. 
(2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant 
major depression. Archives of general psychiatry, 63(8), 856-864.  
Zhang, W.-h., Wang, H., Wang, X., Narayanan, M. V., Stavrovskaya, I. G., Kristal, B. S., & Friedlander, R. 
M. (2008). Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia 
injury. Stroke, 39(2), 455-462.  
Zheng, M., Wang, Y.-H., Wu, X.-N., Wu, S.-Q., Lu, B.-J., Dong, M.-Q., . . . Guan, K.-L. (2011). Inactivation of 
Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced 
suppression of mTORC1. Nature cell biology, 13(3), 263-272.  
  
66 
 
 
 
 
 
 
 
 
 
 
Chapter 2. Deep brain stimulation for treatment resistant depression 
 
Manuscript accepted as: 
Kim Y., O’Connor K. M., Tye S. J. (2015). Deep brain stimulation for treatment resistant depression. 
In Lee, KH, Duffy PS (Eds.), Deep Brain Stimulation. Elsevier.  
  
67 
 
 
CHAPTER 11  
DEEP BRAIN STIMULATION FOR TREATMENT RESISTANT DEPRESSION  
Yesul Kim 1, Katheryn M. O’Connor 2, Susannah J. Tye 3 
1 BA, GdipPsych, PhD Candidate, School of Psychology, Faculty of Health, Deakin University, 
Melbourne, Australia.  
2 BS, Department of Psychiatry & Psychology, Mayo Clinic, Rochester MN, United States 
3 PhD, Department of Psychiatry & Psychology, Mayo Clinic, Rochester MN, United States 
 
INTRODUCTION  
Deep brain stimulation (DBS) has emerged as an alternative, reversible, non-ablative 
neuromodulatory treatment for severely refractory Major Depressive Disorder (MDD) and 
Bipolar Depression (BD). In the past decade, DBS for mood disorders has evolved with clinical 
studies of modest case series, yet it remains largely investigational. For those patients who do not 
receive therapeutic benefit from other available treatment options, including pharmacotherapy, 
psychotherapy and electroconvulsive therapy, DBS holds great promise (Bewernick et al., 2012; 
Fava & Davidson, 1996). In general, DBS is believed to work by modulating the cortico-striato-
thalamo-cortical (CSTC) circuits (see figure 1). The CSTC and its associative limbic and motor 
circuits have been implicated in the pathogenesis of MDD and BD. Various DBS targets have 
been examined for Treatment Resistant Depression (TRD) including the subgenual cingulate 
gyrus, ventral capsule/ventral striatum, nucleus accumbens, inferior thalamic peduncle, lateral 
habenula and the medial forebrain bundle. Still, many important clinical questions remain, 
including: 1) what is the most appropriate, effective and therapeutically consistent target;  2) 
what are the optimal stimulation parameters, and 3) what are the progressive mechanisms of 
action and how can recovery be optimized over time? This chapter will review reported clinical 
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trials of DBS for MDD and BD, describing rationale for target selection, reported efficacy, 
clinical applicability and hypothesized mechanisms of action. 
 
Figure 1. Various DBS targets and modulation of the CSTC circuits 
Abbreviations –vmPFC: ventromedial prefrontal cortex; SCG: subcallosal cingulate gyrus; ITP: inferior 
thalamic peduncle; VTA: ventral tegmental area; dorsal SNR: dorsal substantia nigra pars reticulate; LHb: 
lateral habenula; VP: ventral pallidum; DMmc: dorsomedial motor cortex; GPi: globus pallidus; MFB: 
medial forebrain bundle; NAcc: nucleus accumbens core; NAcsh: nucleus accumbens shell. 
 
DBS TARGETS AND OUTCOMES  
Subcallosal Cingulate Gyrus (SCG): Area 25 
To date, the subcallosal cingulate gyrus (SCG) is the most extensively researched DBS target. 
Reversal of SCG hypermetabolism in TRD is the primary rationale for targeting this region with 
high-frequency stimulation DBS (Lozano et al., 2012; Lozano et al., 2008; Mayberg et al., 1999; 
Mayberg et al., 2005). Clinical trials of SCG stimulation were originally described by Helen 
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Mayberg and colleagues in 2005, in a trial of 6 patients and subsequently in a larger study of 20 
patients (Lozano et al., 2008). Approximately two thirds of patients in these studies showed 
improvement of MDD symptoms, and 35% had complete remission. Blinded, sequential 
intraoperative stimulation at 130Hz was applied to determine the threshold for safe and effective 
stimulation. At final follow-up (3-6 years), 42.9% of patients demonstrated complete resolution 
of symptoms (Kennedy et al., 2011). 
In an effort to replicate and extend these findings, Puigdemont et al. (2012) investigated 
the short and long-term outcomes and safety of SCG in an independent sample of 6 patients. 
Response rates in this group were similar or greater than those reported previously. Seven 
patients displayed marked improvement after 6months of chronic stimulation, and 50% remitted 
after 1 year of DBS. During the follow-ups, antidepressant drugs were not changed but were 
reduced in parallel with signs of clinical improvement. Interestingly, Puigdemont et al. (2012) 
found a significant relationship between long-term response and electrode location. Another 
earlier study, analyzing responders vs. nonresponders in SCG DBS, found robust white matter 
tract connections from the SCG target to the orbitofrontal cortex, amygdala/hippocampus, 
hypothalamus, and NAcc to be critical for mediating therapeutic effects of DBS (Johansen-berg 
et al., 2008). Riva-Posse et al. (2014) further defined the combination and location of specific 
white matter tracts necessary to achieve clinical response. Tractography maps revealed a fiber 
bundle template involving bilateral forceps minor, cingulum, and medial frontal 
striatal/subcortical fibers activation was responsible for response and remission.  
More recently, Holtzheimer et al. (2012) presented an open-label, sham-stimulation study 
of 17 patients with treatment resistant unipolar and bipolar depression undergoing DBS of the 
SCG. In this single-center study, the majority of patients (92%) responded, and over a half (58%) 
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were in remission following two years of stimulation. However, for some patients, improvements 
in depression severity took a longer time course without any clear reasons for the delay. It seems 
likely that premorbid functioning, psychosocial support and temperament/personality contributes 
to the rate of recovery and responsiveness in patients with TRD.  Interestingly, overall these 
findings argued against a clinically significant sham effect over time. Although depression 
severity was significantly lower after 4 weeks of sham stimulation, the mean reduction was not 
clinically significant.  
SCG DBS may work via normalizing CSTC neural networks through a reduction of SCG 
activity. Given the strong reciprocal connectivity between the prefrontal cortex and brainstem 
monoaminergic nuclei, SCG DBS may normalize a putative monoaminergic hypofunction 
secondary to abnormal inputs from the prefrontal cortex (Puigdemont et al., 2011).  
 
Ventral Capsule/ Ventral Striatum  
Stimulation of the ventral capsule/ ventral striatum (VC/VS) was first performed in 
patients with Obsessive Compulsive Disorder (OCD) and it was found that Improvements not 
only occurred in OCD symptoms but also in depression scales. These findings of improved mood 
led to the exploration of this target for TRD (Aouizerate et al., 2004; Greenberg et al., 2006). 
Specifically, Greenberg et al (2006) reported that 50% of the eight patients with comorbid 
depression experienced improved mood and affect. These observations, and the implications they 
had for with the involvement of CSTC circuits, opened up further clinical trials and preclinical 
investigations targeting VC/VS for the treatment of severe MDD patients. 
Malone et al. (2009) presented results of 15 patients with VC/VS stimulation and 
according to the Hamilton Depression Rating Scale (HDRS), patients demonstrated a 20% 
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remission rate after 6 months of treatment and a 40% responder rate at the last follow-up. 
Corresponding remission rates assessed by Montgomery-Asberg Depression Rating Scale 
(MADRS) were 33.3& at 3 months, 26.6% at 6 months and 33.3% at last observation. DBS was 
reported to be well tolerated, with minimal complications. Most notable complications included 
pain at implantation site, lead fracture, transient hypomania, increased depression, transient 
dysphagia and syncopal episodes (Malone et al., 2009). Hypomania was resolved by adjustment 
of stimulation parameters, where one incident of worsening depression was addressed with 
changes in medication and a close monitoring of neurostimulator battery function. Hence, the 
authors stressed the importance of post-operative care as patients felt quite distressed by return of 
depressive symptoms after accidental battery depletion or failure. Relative to cognitive 
functioning, Kubu and colleagues (2013) observed no decline across individuals, and 
neuropsychological improvements were reported on 10 OCD and 11 MDD patients. Similarly, 
Malone et al. (2009) failed to find deleterious effects on measures of general intellectual ability, 
language, processing speed, executive function, learning and memory. 
Taken together, the reported clinical findings VC/VS as a viable target for DBS provide 
encouraging evidence of sustained therapeutic effects. With close postoperative monitoring and 
successful electrode implantation, this region offers therapeutic potential for individuals 
suffering TRD who are unresponsive to conventional treatments.  
Nucleus Accumbens  
The reward circuitry of the nucleus accumbens (NAc) has been associated with 
depression for many years. The NAc is located within the most ventromedial portion of the VS. 
Considering its intimate connections to areas involved in depression phenotypes, NAc emerged 
as a practical candidate for neuromodulation.  
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In a small initial study of three patients undergoing DBS of the NAcc experienced 
improvements in anhedonia (i.e., inability to feel pleasure; Schlaepfer et al., 2008) but did not 
experience complete remission. The changes brought about were also reflective of positive affect 
and metabolic changes in brain networks associated with depression. After one week of DBS, it 
was found that metabolic activity increased in the NAc, amygdala, dorsolateral and dorsomedial 
prefrontal cortex and decreased in the ventral and ventrolateral medial prefrontal cortex, which 
have been described as hypermetabolic in depressed states (Schlaepfer et al., 2008). These 
observations support the hypothesis that NAc DBS can modulate the CSTC circuit.  
Preliminary positive effects of NAc DBS on depression were thus established, yet there 
was limited information on its impact on cognitive functioning. At one year after bilateral NAcc 
DBS, Grubert et al. (2011) found no cognitive decline and a trend towards improved cognitive 
performance, generally improving from below average to average performance in 10 patients. 
These precognitive effects were independent of the antidepressant effects or changes in NAcc 
DBS parameters. This study addresses limited information regarding the impact of NAcc DBS 
on TRD. 
Recently, in a larger scale study, 5 of 11 (45%) patients responded, and the treatment 
effect seen at 12 months was sustained at 4 years (Bewernick et al., 2012). Ratings of both 
depression (HDRS, MARSD) and anxiety (Hamilton Anxiety Scale) were significantly reduced 
from the first month of DBS on. Clinically equally important, improved hedonic activities were 
also reported in those responders. Notably, all 11 patients improved on quality of life measures. 
However one nonresponder committed suicide. The authors judged this suicide as unrelated to 
the DBS. Other than this adverse event, the only adverse effects were weak symptoms of 
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hypomania (elevated mood, fewer hours of sleep), which were observed in two patients after a 
stimulation parameter change and which disappeared within 24 hours.  
In patients who responded well to NAc DBS, the effects have been sustained and have 
not adversely affected cognitive function.  As is true of other DBS at other sites, there is surgical 
risk of the procedure itself.  However, given the NAc role in reward, motivation, aggression and 
impulsivity, there are also psychiatric risks in targeting NAc, including the possibility of 
aggravating depression or generating other adverse effects such as mania and suicide. This is in 
light of the high risk of suicide (approximately 15% in TRD; Wulsin et al., 1999), and compared 
to suicide rate found in SCG DBS (Kennedy et al., 2011).  
 
Inferior Thalamic Peduncle  
The inferior thalamic peduncle (ITP) is a system of fibers that connect the midline and 
intralaminar thalamic nuclei of the nonspecific thalamic system (NSTS) with the orbitofrontal 
cortex, which is involved in the physiopathology of MDD. Subcortical orbitofrontal cortex 
(OFC) connections include the temporal lobe amygdala, ventral striatum, hypothalamus, 
substantia nigra, raphe nuclei and ventral tegmental area. The physiological and anatomical 
significance, together with postmortem imaging observations highlight ITP and its related 
circuits as engaged in mood and behavior control (Jimenez et al., 2005).  
The first and only case to describe targeting the ITP was a 2005 case report by Jimenez et 
al. described a 49 year-old patient with recurrent episodes of unipolar depression of 20 years 
duration. Bilateral 8 contact stimulating electrodes were stereotactically in areas at and around 
the ITP. Depression relapsed partially at the end of first week. Continued electrical stimulation 
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improved depression as measured by the HDRS without antidepressant medication (Jimenez et 
al., 2005).  
Preclinical experiments of the effects of DBS on ITP, present particular challenges. ITP 
is not identified in the rat stereotactic atlas, thus lesions and electrical stimulation of the reticular 
thalamic nucleus and OFC (structures connected by the ITP) have been used as an alternative. 
This may explain the lack of preclinical and clinical research on ITP DBS for TRD. However, 
the ITP remains an interesting exploratory target. Previously mentioned DBS sites in this chapter 
as well as regions implicated in MDD (e.g. temporal lobe amygdala, hypothalamus) all have 
anatomical connections with the OFC. Moreover, the anatomical proximity of the internal 
capsule, NAc and ITP opens up the possibility that the stimulated area may involve more than 
one target. 
 
Lateral Habenula (LHb) 
Studies have reported increased activation of the lateral habenula (LHb) in humans with 
depression (Morris et al., 1999; Smith et al., 1999) as well as in certain animal models of 
depression (Caldecott-Hazard, Mazziotta & Phelps, 1988; Shumake et al., 2003). Increased 
activation of this region leads to the down regulation of the serotonergic, noradrenergic, 
dopaminergic systems and stimulation of the hypothalamic-pituitary-axis.  
Recently, LHb DBS has yielded successful results and is thought to be a mediating 
mechanism for antidepressive actions (Sartorius & Henn, 2007; Sartorius et al., 2010).  The first 
patient showed initial symptom remission, but experienced two full relapses when the 
stimulation device malfunctioned, although the patient was unaware of the malfunction 
(Sartorius et al., 2010). The second improved more than 50% as measured by the Hamilton 
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Depression Scale, but suffered from a comparable relapse during an off period when the 
stimulation device was changed following infection. 
Strikingly, the DBS-OFF relapses in the abovementioned cases were rapid in onset, 
occurring approximately within one week, and the remission times were slow, taking over 8-12 
weeks to occur in the DBS-ON phase. Similar patterns were also noticeable in patients treated 
with DBS of the SCG. Of note, the SCG as well as the medial forebrain bundle is part of the 
midline neurocircuitry that potentially affects the LHb inhibitory projections.  For this reason, 
the investigators suggest that the uneven time course observed in those 2 patients (e.g., rapid 
relapses followed by slow remissions) is likely linked to alterations of neuroplasticity and 
perturbations of monoaminergic systems that are pertinent to theories of depression (Sartorius et 
al., 2010). 
One of the major surgical challenges of DBS in this area is the prevention of intracranial 
bleeding when introducing the electrode. Careful and precise anatomical planning is required. 
Schneider and colleagues (2013) recently conducted a feasibility and safety study of LHb DBS in 
27 patients. They found that a standard frontal trajectory (>40 degrees relative to anterior 
commissure) was safe for bilateral stimulation in 48% of the patients and that a steeper frontal 
trajectory (that is <40 degrees relative to the anterior commissure) was required for bilateral 
stimulation in 96% of the cases.  They concluded that DBS of this small midline structure or 
rather, its major afferent bundle which is adjacent to the third ventricle and thalamus related 
veins, presents predictable, but solvable challenges to neurosurgeons (Schneider et al., 2013).  
Medial Forebrain Bundle 
In 2013 Schlaepfer et al. explored supero-lateral branch of the medial forebrain bundle 
(slMFB) DBS in a pilot study of 6 patients. The modulation of a network of forebrain structures 
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via the medial forebrain bundle (MFB) was inadvertently discovered by activation of myelinated 
fibers descending from the frontal lobe into the ventral tegmentum area (VTA).  It was thought 
that upstream dysfunctional cortical input into the network might thus be ameliorated by 
modulating cortical regions, whereas downstream dopaminergic VTA neurons could be recruited 
and activated directly. As a result, the VTA might exert its activating effects on forebrain 
structures and the prefrontal cortex by way of DBS to the slMFB.  
In a pilot study for the safety and efficacy of slMFB DBS to 7 patients with TRD showed 
similar intraoperative effects of increased appetitive motivation to one another (Schlaepfer et al., 
2013). At last observation in week 12, 6 out of 7 patients were responders; among them, four 
were classified as remitters (MADRS <10). Unexpectedly, the positive effects of slMFB were 
rapid. The mean MADRS was reduced by >50% at day 7 after onset of stimulation, and 6 of the 
7 patients had significant effects over only 2 days of stimulation. Comparable acute and rapid 
effects in depression have only been previously observed in studies with the use of ketamine 
(Zarate et al., 2006) or sleep deprivation (Ibrahim et al., 2011). Nevertheless, clinical studies 
reports the clinical effect of ketamine limited to 2 weeks (Murrough, 2012) and the 
antidepressant effects of sleep deprivation alone are generally reversed after the next recovery 
sleep (Wu & Bunney, 1990). In contrast, the effects of slMFB DBS reported by Schlaepfer et al. 
(2013) seems to be enduring. It is important to note that slMFB stimulation was linked only with 
appetitive motivation, however was not associated with a direct reinforcing, hedonic or liking 
effects.  
This recent data raises questions about the degree to which the various stimulation sites 
can be conceptualized as part of or an entry point into a single dysregulated neurocircuit or 
circuits. Recent preclinical study (Hamani et al., 2014) showed that despite similar 
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antidepressant effects following stimulation to homologous SCG, NAc and MFB regions, they 
induce distinct changes in regional brain activity and functional connectivity. The MFB may act 
as an integrative extension of other associative circuits underlying the pathophysiology of MDD 
to frontal structures (Kiening & Sartorius, 2013). Direct MFB stimulation thus may provide a 
shorter route to the prefrontal cortex and a speed access toward therapeutic reaction. The rapid 
onset of positive MFB DBS effects, if replicated, could not only be of great benefit for patients 
suffering from TRD but may also be a factor in the search for the underlying mechanisms of fast-
working antidepressant strategies (Kiening & Sartorius, 2013).  
 
CONCULSION AND FUTURE DIRECTIONS Each of the various DBS sites studied in the 
treatment of depression have been found to have some positive effects, and each appears to be 
associated with surrounding anatomic regions implicated in psychomotor, cognitive, mood, 
emotional and neurovegetative symptoms of depression (see figure 2). The differences in 
methods used to evaluate DBS efficacy among the studies reported to date prevents a consensus 
on the efficacy of a given target at this time.  Larger controlled, DBS-ON/OFF clinical trials are 
needed to identify optimal targets, patient selection criteria, and the long-term effects of DBS for 
depression, augmentation of social functioning, and normalization of brain metabolism. Such 
studies should also include the effects of DBS on standard measures of attention, learning, and 
memory. The potential for adverse events such as infection, suicide, and hypomania, also should 
be carefully monitored in the post-operative period.  At this point in time, it appears that DBS for 
depression holds great promise for patients with treatment-refractory depression.  
 
78 
 
 
 
Figure 2. DBS sites and its surrounding regions’ function in psychomotor, cognition, mood, emotions and    
neurovegetation  
 
 
Therapeutic mechanisms of DBS 
The therapeutic mechanisms of DBS in TRD are not well understood. Although research 
on the efficacy of DBS for TRD have been underway for approximately 10 years, they are often 
uncontrolled clinical trials and the mechanisms mediating therapeutic effects are only more 
recently becoming apparent.  Unlike movement disorders, therapeutic responses occur via slow, 
progressive improvements in symptoms. While patients will describe an immediate “insertional” 
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effect, this is often followed by a sharp decline before the progressive and enduring improvement 
occurs (Taghva et al., 2013).  Further complicating matters, neuronal effects of DBS vary 
depending not only on the location of stimulation (brain area, cell bodies, or white matter fibers), 
but also on the various parameters of stimulation (voltage, pulse width, and frequency), and the 
overall activity state of the regions to be modulated. (Butson et al., 2007; Holtzheimer and 
Mayberg, 2011; Perlmutter and Mink, 2006). Regardless, patients have reported a common 
reduction of depressive symptoms and restoration of function with all of the aforementioned 
DBS target trials. 
With the exception of several imaging studies conducted during clinical trials, the 
majority of investigations of mechanism of action in high-frequency stimulation research has 
been conducted in small animal models of depression and treatment resistant depression.  The 
main mechanism is thought to facilitate a “resetting” of faulty circuitry in the CTSC pathway 
(Hammond et al., 2007; Kopell and Greenberg, 2008; Taghva et al, 2013).  This requires 
restoration of synaptic plasticity and facilitation of neurogenesis, known to be important 
mechanisms of antidepressant action. In addition to neurotransmitters, cytokines and growth 
actors have been implicated in the DBS-mediated antidepressant effects (Gersner et al., 2010; 
Hamani et al., 2012;Perez-Caballero et al., 3013), occurring via gradual synaptic adaptations 
(plasticity) (Falowski et al., 2011).   
Cytokines 
Inflammation and glial-mediated responses have been shown to play a key role in the therapeutic 
mechanism of DBS in a number of disease states, including Parkinson ’s disease, however little 
is known about their role TRD.  Perez-Cabellero et al. (2013) have shed light on this issue using 
a rodent model of depression, and demonstrating that implantation of the electrode in the 
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infralimbic cortex (homologous to human SGC) was sufficient to induce an antidepressant effect 
in rodents as measured in the forced swim test (FST; a preclinical behavioral screen for 
antidepressant response). This effect was maintained for up to two weeks post-implantation, after 
which active DBS was necessary to sustain a therapeutic response.  These researchers were able 
to effectively block this therapeutic effect with anti-inflammatory pre-treatment and further 
demonstrated that an increase in astrocytes and inflammatory mediators up to two weeks after 
implantation correlated with antidepressant effects. Moreover, this inflammatory- mediated 
response was shown to enhance synaptic efficacy at serotonin synapses through upregulation of 
serotonin receptors and facilitation of serotonin signaling. 
The clinical relevance of this finding is supported by the reported effects of anti-
inflammatories on clinical antidepressant responses to DBS. Perez-Cabellero et al. (2013) also 
reported differences in patient responses to bilateral DBS of SGC, which segregated according to 
anti-inflammatory treatment.  Although early responses to DBS were similar for those patients 
receiving non-steroidal anti-inflammatory drugs (NSAID) and those who were not, 
antidepressant response began deteriorating after ~two weeks and was lost by one month post-
DBS surgery for NSAID-treated patients. This rapid antidepressant response generated by DBS 
has been described as occurring prior to stimulation (Jimenez et al., 2005; Hotzheimer et al., 
2012), and has been attributed to the generation of a microlesion.  However, the Perez-Cabellero 
et al. study was the first to measure an insertional effect, the impact of anti-inflammatories, and 
long-term therapeutic responses to DBS.  
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Growth factors and synaptic plasticity 
Growth factors such as brain derived neurotrophic factor (BDNF) are well established ad 
reduced in patients with depression, a finding similarly documented in rodent models of 
depression (Shimizu et al, 2003; Smith et al, 1995; Nibuya et al., 1995; Kiening and Sartorius, 
2013).  A subsequent increase in BDNF levels, in addition to changes in neuroplasticity, has 
been observed following successful antidepressant treatment and is thought to be a critical 
mechanism through which antidepressants exert their therapeutic effects (Nibuya et al., 1995; 
Alter et al., 2003).  Preclinical data has shown similar results in rodent models of depression 
following therapeutic DBS (Gershner et al., 2010; Hamani et al., 2012; Friedman et al., 2009).  
Not only are levels of BDNF increased, but morphological changes have been observed in the 
dendrites of prefrontal cortex (PFC) pyramidal neurons (Falowski et al., 2011). Interestingly, 
Hamani et al. (2012) found a possible interaction between BDNF and serotonin, demonstrating 
that depletion of serotonin prevented BDNF reduction normally seen in rats undergoing chronic 
mild unpredictable stress to induce depression-like behavior.  This concept has previously been 
suggested and attributed to impairment of stress adaption by the suppression of hippocampal 
glucocorticoid and BDNF responses (Zhou et al., 2008). However, Hamani et al. (2012) also 
demonstrated that an animal’s preference for sucrose, a measure of antidepressant efficacy, did 
not improve following DBS in serotonin-depleted rats with normal hippocampal BDNF.  This 
suggests that although decreases in BDNF are seen in depression, and subsequent increases occur 
following antidepressant treatment, it is the interaction of BDNF with serotonin systems, 
possibly mediated in part by inflammatory responses, that is critical to therapeutic response.  
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Figure 3. Proposed therapeutic mechanisms of DBS action in treatment resistant depression. These 
mechanisms include, inhibition of local neuronal cells, activation of axons of passage and facilitation of 
neurotransmitter efflux, as is well established in the field of DBS for movement disorders. In addition, 
DBS activation of inflammatory responses and upregulation of neurotrophic factors is known to critically 
contribute to the progressive antidepressant actions of DBS for depression. 
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Chapter 3. Methods 
 
General Scope and Aims 
This thesis encompasses various techniques on a molecular and behavioral level in order to 
understand the mechanisms of action of deep brain stimulation (DBS) within the research context 
and resource availability. Clinically relevant DBS targets, the nucleus accumbens (NAc), infralimbic 
(IL) and lateral habenula (LHb) were under examination. These brain regions are not only 
implicated in disease pathophysiology, but modulation of their function and associative circuits 
have been observed to bring about therapeutic treatment response. Our general aim is, therefore, to 
examine the antidepressant properties of different DBS targets. On the other hand, DBS is used as a 
probe to gain insight on cellular, molecular and systematic factors that mediate treatment 
responsivity in tricyclic resistant rats.   
In the first 3 experimental chapters, antidepressant-like behavioral effects of DBS were 
investigated in conjunction with significant molecular adaptations. This approach was taken in the 
hopes to characterize key proteins, signaling pathways and gene expression responsible for 
achieving antidepressant effects in otherwise, treatment resistant animals.  These complex 
biological processes that mediate responsivity include neuroplasticity, mitochondrial function, 
regulation of cell death and growth as well as monoamine transmission. The final chapter explores 
the mesolimbic dopamine (DA) system as a potential common mechanism resulting from DBS.  
Theories and Rationale 
Animals 
The effects of DBS were assessed in the living brain of rats which are standard species 
utilized for determining basic neurochemical mechanisms in mammals. Their neuroanatomy has 
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been extensively studied where stereotactic targeting of specific brain nuclei can be achieved with 
high accuracy. As the structure and function of neuronal systems under investigation are well-
conserved across mammalian species, findings observed herein are translational to higher order 
mammals, including humans.  
In the four upcoming experimental chapters, Wistar or Sprague Dawley rats were used. 
These rodent strains have been consistently and systematically used in preclinical research to 
investigate antidepressant efficacy of novel interventions such as ketamine and electroconvulsive 
therapy (Logan & McClung, 2015). Furthermore, modelling specific phenotypes of depression has 
been valuable in providing insight on the neurobiology of disease. From the viewpoint of animal 
models in helping us to better understand the neurobiology of mood disorders, it has proven useful. 
As an example, stress based models gave insight on the cellular alterations that may contribute to 
reduce hippocampal volume found in severely depressed population (Czéh, Fuchs, Wiborg, & 
Simon, 2015). More recently using Sprague Dawley rats, the inherent issues in the cause-and-effect 
were addressed on the exact role of inflammation as a risk factor in complex and interactive 
pathways of stress to depression (Wood et al., 2014). Advanced techniques such as optogenetics in 
freely moving rats, identified that DA neurons potently alters neural encoding of depression-related 
behaviors in limbic circuitry (Tye et al., 2013).  
Animal Model of Antidepressant Treatment Resistance 
Activation of the hypothalamic pituitary adrenal (HPA) axis is a major 
neuroendocrinological response of the organism to stress. In response to either emotionally salient 
or physiological stress, responsiveness of glucocorticoid production is essential, achieved via 
multiple feedback loops involving the corticotrophin releasing factor (CRF) and vasopressin (AVP) 
from the hypothalamus. In turn, adrenocorticotropic hormone (ACTH) secretion is activated from 
the pituitary, which stimulates the culmination of glucocorticoids (cortisol in humans and 
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corticosterone in rodents) from the adrenal cortex (Pariante & Lightman, 2008). Collectively, HPA 
axis activity is governed by a complex set of feedback interactions among three endocrine glands 
(Figure 1). 
We and others have previously established an animal model of treatment resistant 
depression (TRD) in which chronic ACTH treatment blocks the effects of tricyclic antidepressant 
imipramine and desimipramine (Kitamura, Araki, & Gomita, 2002; Kitamura et al., 2008; Tokita, 
Fujita, Yamaji, & Hashimoto, 2012; Walker et al., 2013). Rats treated with ACTH (100μg/day) for 14 
days exhibited significantly higher plasma corticosterone levels, producing a desensitization of 
somatodendritic serotonin (5-HT) 1A autoreceptors (Kitamura et al., 2007). Our preliminary studies 
have also shown alterations in PFC monoamine levels and irregular proinflammatory cytokines 
(Walker et al., 2013; Walker et al., 2015). 
In clinical settings, a dysfunctional HPA axis has been associated with mood disturbances 
and treatment response (Willner, Scheel-Krüger, & Belzung, 2013). Aberrant activation of the HPA 
axis correlates with treatment resistant depression population. A recent meta-analysis found that 
ACTH levels were elevated to a similar degree during depression and this effect was robust to 
controls for methodological quality (Stetler & Miller, 2011).  
In our animal model, daily doses of ACTH were administered in an attempt to disrupt the 
HPA feedback system, in which a heightened basal activity of HPA will enable us to investigate the 
underlying processes that takes place when the animals are faced with a stressor. Using the above 
mentioned preclinical protocol, we aimed to specifically examine the antidepressant properties of 
chronic and acute high frequency stimulation of clinically relevant neuromodulatory targets. 
Overall, it was of great interest to elucidate the mechanisms by which DBS is restoring adaptive 
brain function and those cellular process that mediates stress and treatment response. 
91 
Figure ͳ. The activation of HPA axis stress system under perceived stressor. Please 
note here that corticosterone (cortisol in humans) applies to rats. ACTH is secreted 
from the pituitary gland, and in turn, stimulates the release of glucocorticoids in the 
adrenal glands. 
Image sourced from Learn.Genetics.Utah.edu (2014). 
Social Isolation 
Early life environmental and social context are not only critical for healthy brain 
development but for reducing vulnerabilities/or strengthening resilience to pathology. It has been 
demonstrated that social isolation produces several long-term adaptations that are phenotypic of 
depressive symptoms. These include increased anxiety in many behavioral paradigms (Weiss, 
Pryce, Jongen-Rêlo, Nanz-Bahr, & Feldon, 2004), impairments in learning and memory tasks 
(Larsson, Winblad, & Mohammed, 2002; Schrijver, Bahr, Weiss, & Würbel, 2002) as well as 
behavioral despair (Brenes, Rodríguez, & Fornaguera, 2008; Lapiz et al., 2003; Sáenz, Villagra, & 
Trías, 2006). Isolation reared rats also have abnormalities in monoamine transmission in the NAc, 
PFC and ventral striatum (Brenes et al., 2008; Lapiz et al., 2003). Given that we wanted to induce 
treatment resistance in rats, complimentary social isolation during acclimatization (during early 
adolescent life ~5 weeks after birth) and throughout the experiment into adulthood was 
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implemented. Studies show social isolation alone can achieve depressive phenotypes and we hope 
to further bring treatment resistance in our animal model.  
Deep Brain Stimulation principles 
DBS first made significant advancements for 1) treating patients suffering from neurological 
motor disorders such as Parkinson’s, essential tremor and dystonia; 2) controlling epileptic 
seizures; and 3) providing relief for people with chronic pain. In the last decade, DBS has been 
operationalized for the treatment of refractory neuropsychiatric disorders including Tourette’s 
syndrome, obsessive compulsive disorder and TRD. More recently, it has been suggested as a 
potential treatment for eating disorders and severe substance abuse addiction. Despite such 
advancements, there remains a gap in the existing experimental data investigating the mechanisms 
of chronic DBS in preclinical research as well as clinical trials. 
The main biological, electrochemical and neurochemical effects of DBS are a result of 
electrical currents that flow into and out of neurological substrates, including cells, axons, dendrites 
and glial cells, leading to polarization of these elements. As it can be seen in Figure 2, the current is 
created by a pulse generator and is delivered to the targeted tissue via electrodes implanted in the 
brain.   
93 
Figure ʹ. An example of DBS device targeting the Thalamus. The pulse generator 
(or Neurostimulator) is similar to a pacemaker device where a battery is connected 
to an extension circuit to generate electrical signals that are delivered by the leads 
to the target regions. The clinician programs and adjusts the settings of the pulse 
generator externally. The lead is made up of a thin, insulated and coiled wires 
(which varies between manufacturer in its composition, size and design) that 
deliver stimulation to DBS regions.  
Image sourced from WebMD, url: http://www.webmd.com/parkinsons-
disease/guide/dbs-parkinsons 
In an electrical circuit, stimulation current is delivered by means of at least one anode 
(positive) and cathode (negative) stimulation electrode. A negative stimulus depolarizes nearby 
neurons, whereas a positive stimulus causes nearby neurons to hyperpolarize (Gielen & Molnar, 
2012). Stimulation current distributions that occur as a result of at least one cathode and at least one 
anode that do not interact physiologically are referred to as “monopolar”. With bipolar stimulating 
electrodes, on the other hand, one tip is the anode and another, cathode, where the electric current is 
passed between the two electrodes that are close together. As a result, a current pathway is 
concentrated between these two electrodes leading to localized stimulation in the tissue immediately 
surrounding the electrodes. In applications designed to target tissue that is located further away, 
larger in size or protected from high-impedance of the dura, monopolar stimulation is implemented to 
94 
increase the stimulation distance (Figure 3.). To date, the field is moving towards optimizing closed-
loop electrodes for personalized care in which the stimulation parameters can be adapted in response 
to physiological changes (Chang et al., 2013). 
Figure ͵. Monopolar and bipolar electrode configuration. Image sourced 
from Hung, Goldberg, and Judy (2010) with permission.  
Despite its history of use, it is still unclear how electrical stimulation works to alleviate 
symptoms of treatment resistant disorders. Traditionally, DBS has been compared to the neural 
mechanism that result from neurosurgical lesions (Kringelbach, Jenkinson, Owen, & Aziz, 2007). Since 
then, the general question has evolved to whether DBS inhibits or excites neurons. Specifically, the 
properties of normal and diseased brain tissue depend on the presence of different types of neurons 
and supporting glial cells that all use different types of ion channels with variable voltage sensitivity 
(Kringelbach et al., 2007). As mentioned previously, many of the known neural processing principles 
are preserved across species and therefore, findings from DBS studies of movement disorders in 
rodents as well as nonhuman primates are highly relevant for elucidating the effects of DBS in 
humans. Altogether, preclinical evidence from neurophysiological/chemical recordings and 
neuroimaging data suggest that DBS helps to modulate oscillatory activity, the activity of postsynaptic 
neurons, neurotransmitter release and elicits changes associated with blood flow, blood oxygenation 
and consumption (Kringelbach et al., 2007).  
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Overall, previous literature pinpoints the most probable mechanistic model of DBS to a 
‘stimulation-induced modulation of pathological network activity’. Results are difficult to interpret, 
given varying experimental circumstances in animal models and between clinical trials, alongside our 
lack of knowledge on the neurobiology of depression. Yet, the weight of evidence suggest that DBS 
works by modulating an existing (dysfunctional) network of interacting brain regions. In other words, 
DBS may start exerting its antidepressant properties through the local effects of the DBS electrode on 
the neural activity in the DBS target, which is passed on to mono-and poly-synaptic network 
connections (Kringelbach et al., 2007). Together, DBS may achieve therapeutic responses through 
different mechanisms, depending on the physiological and geometric properties of the DBS target, the 
stimulation parameters and the connectivity of the affected region of the individual (specified to the 
neuroprogressive state of the patient).  
Fast Scan Cyclic Voltammetry principles 
As mentioned, DBS has been successful in testing a variety of neuropsychiatric disorders 
including TRD and there is a growing body of literature indicating that the therapeutic mechanisms 
of DBS include the regulation of monoamine transmission. Thus, the utilization of tools to measure 
neurotransmitter release in real-time, during DBS, is crucial. Fast scan cyclic voltammetry (FSCV) is 
an electrochemical technique that is used to monitor the release and uptake dynamics of 
endogenous monoamine levels in vitro and in vivo (Figure 4A &B). The background-subtracted 
cyclic voltammogram serves as a chemical signature to identity the neurochemical of interest. More 
recently, FSCV has been used to characterize naturally occurring DA signals. Phasic DA refers to 
transient DA release produced by the activation of DA neuron firing in response to behaviorally 
relevant stimuli. This large amplitude, but brief pulse of DA is proposed to activate postsynaptic DA 
receptors, but is rapidly removed from the synaptic space by fast, low-affinity/ high-capacity re-
uptake systems before it can trigger homeostatic responses (Grace, 1991). These so-called 
“dopamine transients” typically exhibit an amplitude within the nanomolar range with a duration of 
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a few hundred milliseconds and occur with a baseline frequency of ~1 to 2 per minute (Robinson & 
Wightman, 2006). Their signals are considerably more difficult to record. DA oxidizes at + 0.6V 
which can be measured with FSCV by using carbon-fiber microelectrode. In order to mimic 
transient DA efflux in the NAc, we electrically evoked the Ventral Tegmental Area (VTA). Studies in 
animal models of depression have demonstrated that stress (physiologically relevant stimuli) 
potently activates mesoaccumbens DA neurons originating in the VTA and stimulates dopaminergic 
transmission to limbic brain regions.  
Figure 4. A) oxidation and reduction of dopamine; B) quantification of evoked 
dopamine levels and confirmation of neurochemical specificity. 
Wireless instantaneous neurotransmitter concentration sensing system (WINCS) is a small, 
battery-powered, wireless device which supports the electrochemical in vivo recording technique of 
FSCV, which is able to measure dopamine, glutamate, adenosine and serotonin. This device consists 
of 1) front-end analog circuit for FSCV (i.e. current-to-voltage transducer); 2) Bluetooth transceiver; 
3) microprocessor; and 4) direct-current battery (Figure 5 A &B). WINCs is electrically connected to
a brain-implanted microsensor and wireless linked to a home-based computer via Bluetooth. The 
temporal specificity provided by the use of WINCS is highlighted in Figure 5 C-E.  
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Figure 5. A) conceptual view of WINCS principles; B) WINCS circuit board (a: 
microprocessor, b: Bluetooth transceiver, c: leads for working electrode and 
reference electrode) with attached Ultralife battery; C) from top to bottom -applied 
triangle waveform, background current and DA, background-subtracted current ; D) 
colour-plot of DA produced at homebased computer using WINCS analyzer; E) 
background-subtracted cyclic voltammogram and current measured at the peak 
oxidative potential for DA, plotted with time. Image sourced from Bledsoe et al. 
(2009) with permission. 
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Behavioral Paradigms 
Forced Swim Test (FST). FST, also known as the behavioral despair test, was developed 
using rats to test for antidepressant screening. Rodents are forced to swim in a narrow space from 
which there is no escape route – an inescapable stressful condition. After an initial period of 
vigorous activity, a characteristic of immobile posture is evident where the rats move only when 
necessary to keep their heads above the water. As such, the FST has been established to have high 
predictive validity. To date, this behavioral paradigm has become a useful tool for screening novel 
antidepressants as well as alternative treatment methods (e.g. DBS and optogenetics).  
 The animals’ immobility is interpreted as indicating they had learned that escape was 
impossible and had to adopt an immobile position to conserve energy, viewed anthropomorphically 
as hopelessness from escaping this stressful situation (Castagné, Moser, Roux, & Porsolt, 2010). 
This immobile posture was therefore given the name “behavioral despair” and it was subsequently 
found that immobility time could be reduced by a wide range of clinically active antidepressants 
(Porsolt, Bertin, & Jalfre, 1977). However, the validity of this assumption has been heavily criticized. 
For example, a rat swimming in a cylinder is considered a non-ethologically relevant stressor and 
thus it may be inappropriate to relate results from this test to human depressive symptoms. 
Furthermore, considering immobility in terms of a shift from active coping to passivity is 
anthropomorphic. In fact, it has been suggested that energy conservation achieved by immobility 
may actually be a more efficient form of coping (West, 1990) and that immobility represents a 
switch from an active to passive coping strategy. Therefore, the FST may have some face validity 
but low construct validity  (Powell, Fernandes, & Schalkwyk, 2012). Despite these limitations the 
FST has been regarded as an effective screening tool for novel drug discovery. Testing 
antidepressant-like behavioral effects using the FST therefore, gives an opportunity for our 
measures to be comparable to that of pre-existing DBS and pharmacotherapy outcomes.    
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 Open Field Test (OFT). The OFT is a common measure of exploratory behavior and 
general activity in rats, where both the quality and quantity of the activity can be measured. 
Principally, the open field is an enclosure, generally square, rectangular or circular in shape with 
surrounding walls that prevent escape. The most basic and common outcome of interest is 
“movement”; however, this can be influenced by motor output, approach response to novelty, 
exploratory drive, freezing or other fear-related behavior, grooming, sickness, relative time in 
circadian cycle, among many other variables. Distance moved, time spent moving, rearing and 
change in activity over time are among many measures that can be tabulated and reported  (Gould, 
Dao, & Kovacsics, 2009).   
It is important to note that for experiments involving rodents, observers are not measuring 
the effects of treatments on exploration, but the effects on the reaction of the subjects to a stressful 
event. In other words, anxiolytic treatments do not themselves increase exploration in the open 
field but they decrease the stress-induced inhibition of exploration behavior. 
The Open Field Test cannot claim predictive validity for anxiety in general, but this model 
seems to have good face and construct validity. Face validity implies that the anxiety response 
observed in the animal is identical to the one observed in humans (Prut & Belzung, 2003). In the 
open field, the observed behavior is avoidance of threatening places, which can also be observed in 
humans. In rodents, forced confrontation with novelty is stressful (Misslin & Cigrang, 1986). Stress 
induces anxiety-like behaviors, as it does in humans. So the model also fit construct validity (i.e. 
similar etiology). 
Western Blot Analysis 
Western blotting technique has made significant advances in both cell and molecular 
biology in the last three decades. It is used in research to separate and identify specific proteins 
from a complex mixture of proteins extracted from cells/tissues. In this technique, a mixture of 
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protein is separated based on a molecular weight and type through gel electrophoresis. These 
results are then transferred to a membrane producing a band for each protein. This membrane is 
then incubated with labels antibodies specific to the protein of interest. Once detected, the target 
protein will be visualized as a band on a blotting membrane, X-ray fil or and imaging system. The 
aforementioned processes of the western blot technique is summarized in Figure 6. 
Despite its overall simplicity, western blot analysis is a powerful tool that confirms the 
presence of proteins of interest. It can further be used to associate protein expression to 
corresponding behavior of animals in specific brain regions. The results achieved are also easy to 
analysis, interpret and unambiguous.  
Figure 6. Overview of Western Blotting –separation of protein mixtures by 
electrophoresis; transfer to a blotting membrane; and detection of target protein, 
which only becomes visible in the final stage as a band similar to that shown in the 
far right. (‘Introduction of Western Blotting’ from www.abdserotec.com)  
Gene expression –microarray analysis 
Gene expression is a process by which information, the nucleotide sequence, of a gene is 
used in the protein synthesis (genetic transcription and translation). Therefore, gene expression 
analysis determines the pattern of gene expression changes at the level of genetic transcription in 
health and disease. Microarray analysis allow simultaneous measure of the expression level of 
thousands of genes within a particular mRNA sample (Tarca, Romero, & Draghici, 2006). Biological 
interpretations of large gene lists often presents many difficulties, of which, summarizing which 
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genes are associated with specific biological processes and ranking these processes by over-
representation analysis; condensing repetitive or redundant annotation data; identifying functional 
biological modules consisting of related genes and terms; and viewing inter-relationships between 
groups of genes and groups of biologically relevant terms, are some major challenges (Alvord et al., 
2007). 
The database for visualization and annotation, visualization and integrated discovery 
(DAVID) is a clustering tool, providing a module centric approach for functional analysis of large 
gene lists to give relevant biological context. The advantages of this method of classifying groups of 
genes and terms into biological modules are: it largely reduces redundant results into manageable 
size; it is much easier to understand and visualize gene-to-gene, term-to-term where it is much 
easier to relate biological modules of interest to research questions (Alvord et al., 2007). 
Specifically, it adopts kappa statistics, a chance-corrected measure of co-occurrence between two 
sets of categorized data, to statistically measure the annotation profile in a binary categorical scale. 
Kappa is more suitable than Pearson correlation, which is typically used for continuous variables.  
Mitochondrial Function Analysis 
The predominant physiological function of mitochondria is the generation of adenosine 
triphosphate (ATP) by oxidative phosphorylation, but additional functions include the generation 
and detoxification of reactive oxygen species, involvement in some forms of apoptosis, regulation of 
cytoplasmic and mitochondrial matrix calcium, synthesis and catabolism of metabolites and the 
transport of the organelles themselves to correct locations within the cell. Abnormality in any of 
these processes can be termed mitochondrial dysfunction. “Healthy” mitochondria under correctly 
designed incubation conditions show high respiratory control: a large increase in respiration rate 
with adenosine diphosphate (ADP) followed by a return to state 4. Mitochondrial respiratory 
control encapsulates the main function of mitochondria: their ability to idle at a low rate yet 
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respond to ADP by making ATP at a high rate. A lower respiratory control ratio (RCR) would 
indicate some sort of mitochondrial dysfunction that is either impeding ATP production, increasing 
uncoupled respiration, or both. A high RCR implies that the mitochondria have a high capacity for 
substrate oxidation and ATP turnover and a low proton leak. However, there is no absolute RCR 
value that is diagnostic of dysfunctional mitochondria, because values are substrate and tissue-
dependent. Mitochondrial respiratory control is a complex function whose value depends on 
numerous factors, and this complexity is its main strength: a change in almost any aspect of 
oxidative phosphorylation will change RCR (Brand & Nicholls, 2011).  
State 3 respiration refers to peak respiration following addition of excess DP and this is the 
best measure of mitochondrial capacity. State 4 respiration refers to the point where ADP becomes 
exhausted and the residual respiration at this point is largely uncoupled respiration. The 
mitochondrial RCR, defines as the respiration in state 3 ADP divided by that in state 4 (state 3/state 
4). 
The Seahorse XFe24 Extracellular Flux Analyzer simultaneously interrogate the two major 
energy producing pathways of the cell –mitochondrial respiration and glycolysis in a microplate 
and analyzed it real-time. It is able assess oxidative phosphorylation (state 3, state 4 and RCR) by 
determining oxygen consumption rate and extracellular acidification rate in vitro. As XF measures 
cellular bioenergetics on live cells, it enables time-relevant testing of multiple conditions per 
assays. Testing of more conditions with the same amount of sample called for this equipment, with 
increased throughput all the while using less sample compared to conventional respiratory 
techniques, together maximizes the value of the experiment.  
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Materials & Procedure 
Animals 
Male Wistar and Sprague Dawley rats arrived at 5 weeks of age for acclimatization prior to 
experimental procedures. These animals were transported to either the Mayo Clinic animal facility 
(from Harlan rodent colonies) or transported from the Howard Florey Laboratories facility to the 
Mental Health Research Institute (MHRI) Oak Street for subsequent experimental protocols. At both 
facilities animals had ad libitum access to rodent chow and tap water. The 12 hour light period of 
the circadian cycle was from 06:00 a.m. to 06:00 p.m., and all procedures were carried out during 
the light period. Additionally, humidity and temperature were also actively controlled. At the Mayo 
Clinic animal holding facility, rats were housed individually whereas at MHRI, rats were housed in 
groups of 4. 
All experiments were conducted in accordance with the NIH guidelines for the care and use 
of laboratory animals and were approved by the Institutional Animal Care and Use Committee and 
the NHMRC Australian Code of Practice for the Care and Use of Animals for Scientific Purposes for 
Chapter 7.  
Four experimental cohorts were used in studies described in this thesis (Figure 7). The first 
three experimental cohorts were treated and tested at the Mayo Clinic animal facility where as the 
last cohort was treated and tested at the MHRI. The number of rats used in each cohort was based 
on availability of animals at the time of experiments and the number of animals per group required 
to detect significant group differences based on our previous experience with various paradigms, 
with n = 10-12 per group generally considered optimal to sufficiently power the analysis.  
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Figure 7. Experimental timelines of a). Lateral habenula deep brain stimulation (DBS) in 
an animal model of antidepressant resistance: a role for CaMKII, GSK3 and AMPK in 
stress response; b).Global transcriptional profiling of infralimbic deep brain stimulation 
in an animal model of antidepressant treatment resistance; c). Antidepressant and 
mania-like effects of nucleus accumbens deep brain stimulation in an animal model of 
treatment resistance; d). Region-and frequency-specific transient dopamine release as a 
mechanism of deep brain stimulation and Potentiation of accumbens dopamine is a 
therapeutic mechanism of lateral habenula deep brain stimulation in the antidepressant-
resistant brain. 
Acronyms: FST –the Forced Swim Test; OFT –Open Field Test; HF -High Frequency; ACTH –
adenocorticotrophic hormone; FSCV –Fast Scan Cyclic Voltammetry 
ACTH protocol 
The drugs used for ACTH-induced treatment resistance included: ACTH (AnaSpec, San Jose, 
California, USA) 100μg/day dissolved in distilled water and control vehicle consisting of 0.9% 
saline (Fisher Healthcare, Hanover Park, Illinois, USA). Animals were randomly selected to receive 
chronic administration of ACTH or Saline for 14 days (21 for Chapter 4) via intraperitoneal 
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injection. Antidepressant resistance was validated by imipramine hydrochloride (Sigma–Aldrich, St 
Louis, Missouri, USA; 10 mg/kg dissolved in 0.9% saline) administration prior to behavioral tests. 
Antibodies 
List of antibodies used for immunoblotting and in the validation process of the gene 
expression analysis are included in the following Table 1.  
Table 1. Optimised antibody details in rat cerebellum by the Translational Neuroscience 
lab 
Protein Antibody Source 
CaMKII CaMKII (pan) #3362 Cell Signalling, MA, USA 
phosphor-CaMKII 
phosphor-CaMKII (Thr286) 
#3361 
Cell Signalling, MA, USA 
GSK3 GSK3 α/β #5676 Cell Signalling, MA, USA 
phosphor-GSK3 phosphor-GSK3 α/β #9331 Cell Signalling, MA, USA 
AMPK AMPK #2532 Cell Signalling, MA, USA 
phosphor-AMPK phosphor-AMPK #2535 Cell Signalling, MA, USA 
mTOR mTOR #2983 Cell Signalling, MA, USA 
phosphor-mTOR phosphor-mTOR #8238 Cell Signalling, MA, USA 
TrkB TrkB  #sc-8316 Santa Cruz, TX, USA 
phosphor-TrkB phosphor-TrkB #sc8058 Santa Cruz, TX, USA 
AKT AKT (pan) #4685 Cell Signalling, MA, USA 
phosphor-AKT p-AKT (S473) #4060 Cell Signalling, MA, USA 
GAPDH GAPDH #ab9484 Abcam, MA, USA 
b-Actin b-Actin #A5441 Sigma-Aldrich, MO, USA 
Abbreviations include –phosphor: phosphorylated; CaMKII: Ca2+/calmodulin-dependent 
kinase II; GSK3: glycogen synthase kinase 3; AMPK: AMP-activated protein kinase; mTOR: 
mammalian target of rapamycin; BDNF: brain-derived neurotrophic factor; TrkB: 
tropomyosin receptor kinase B; AKT: protein kinase B; CREB: cAMP-response element 
binding protein; GAPDH: glyceraldehyde-3-phospphate dehydrogenase; b-Actin: beta-actin. 
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Anesthesia 
For experimental Chapters 4-6, animals were anesthetized with isoflurane (~1.5%, dosage 
range recommended to be between 0.25-2.5%; Baxter, IL, USA) inhalation via a nose cone that is 
connected to a vaporizer (Harvard Apparatus, MA, USA).  General urethane anesthetic (1.5g/kg) 
given via intraperitoneal injection and local lidocaine analgesia (1cc -20%W/V dissolved in distilled 
water) injected on the scalp were used for long duration FSCV experiments. 
Stereotactic surgery 
Stereotaxic atlases are empirically based on a large group of rats of a specified sex, weight 
and strain. For this reason, we can confidently determine the stereotaxic position of each structure 
of interest. In rodent stereotaxy, this coordinate system originates from the point called the bregma, 
classically defined as the midpoint of the curve of best fit along the coronal suture (Paxinos & 
Watson, 2007). The anteroposterior (AP) axis  is parallel to the midline plane of the skull and 
crosses the point called the lambda, defined as the midpoint of the curve of best fit along the 
lambdoid suture (Paxinos & Watson, 2007; Paxinos, Watson, Pennisi, & Topple, 1985). The 
mediolateral (ML) axis of the coordinate system is parallel to the interaural line, and the 
dorsoventral (DV) axis is perpendicular to the AP and ML axes. Figure 8 illustrates the bregma and 
lambda in rats. 
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Figure 8. Dorsal and sagittal views of the skull of a 290g male Wistar rat from 
Paxinos et al. (1985). Copyright permission obtained from Copyright Clearance. 
The stereotaxic instrument was set up with all the materials needed. The area and 
instruments were clean and sterilized. Animals were weighed for their pre-surgery weight and 
prepared for surgery. Animals were placed on a heating pad to maintain optimal body temperature 
whilst being mounted onto the Kopf stereotaxic frame (Kopf Instruments, CA, USA). An 
anterior/posterior 1.5-2cm incision was made on the scalp with a sterile scalpel extending from the 
lambda to just in-between the eyes of the animal. From bregma, the correct coordinates needed for 
the placement of the probe (i.e. electrodes) was located with the aid of the stereotaxic atlas (Figure 
9). 
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Figure 9. Schematic illustrations of DBS and FSCV targets where red lines outline 
those structures. A) IL: AP +3.0, ML ±0.1, DV – 5.0; B) NAc: AP +1.5, ML ±1.5, DV – 7.0; 
C) LHb: AP -3.7, ML ±0.8, DV -5.4; D) VTA: AP -6.8, ML -0.6, DV -8.6~9.0. All values
represented as mm. 
A pencil mark was made with a sterile pencil at this location on the skull; this is where the 
drill penetrated the skull. Drilling continued until the cannula can clear in a straight path. This step 
was repeated for all other electrode targets. Next, for stereotaxic surgery for deep brain 
stimulation, a drill was required to make three or four surface holes for skull screws using tweezers 
(example shown in Figure 10.). The twisted bipolar platinum iridium electrodes (5.6mm, 7mm or 
10mm long depending on the DBS target, .075mm in diameter; Plastics One, Virginia, USA) were 
lowered according to the calculations made from the bregma. Bipolar electrode configuration was 
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used for the upcoming experimental chapters in order to control for current spread given small rat 
brain regions. A small amount of liquid dental cement (~1ml) was mixed to cover the screws while 
the bottom of the electrodes were held in place. A thicker batch (~2ml) was then made and covered 
the whole area, enough to secure it. Once the dental cement was completely dry, the cannula that 
was holding the electrodes in place were removed and the animal was also freed from the 
apparatus. Antibacterial cream was applied all the way around the cement cap and animal were 
placed in its own cage and monitored until it became conscious. 
Figure 10. Jewelry screws were places on a scalp cap in order to firmly hold the 
dental cement. This is also an example of ‘surgery’ animal conditions where 
animals only undergoes surgery without electrodes placement. 
Deep Brain Stimulation device and application in animals 
Animals received electrical stimulation via either the ISO-Flex Master-8 (AMPI, Jerusalem, 
Israel) or back-mounted DBS device (Deakin University, Geelong, AUS). ISO-Flex, for Chapter 5 and 
6, were used for 3 day (130 Hz; 200μA; 90μSec) where animals were connected to a signal 
generator through a constant current bipolar stimulus isolator unit with a stimulator cable. These 
cables were routed to their home cage with enough room for the animals to move freely during the 
stimulation phase.  
In order to better reflect the longer duration of stimulation applied to the targeted brain 
regions in clinical trials, the laboratory animal should ideally receive this brain stimulation 
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continuously without interruption. The devices that are connected to the implanted electrode 
through long insulated wires that run from the device to the animal’s head can be interrupted at 
times. For example, the stimulator can get disconnected from the electrode over the course of the 
study. To improve the quality of preclinical work and prevent possible mishap during the course of 
the experiment, a back-mountable, battery powered, micro DBS device was developed by (Kouzani, 
Abulseoud, Tye, Hosain, & Berk, 2013). A real-life picture of this device is included in Figure 11, 
alongside an example of animal in DBS group. Micro DBS was only used in Chapter 4 for NAc DBS, as 
it doubled the length in stimulation time (7 days).  
Figure 11. Sample of the single piece, back-mountable micro DBS device and an 
animal with 2 pieces in its backpack. Image sourced from Kouzani et al. (2013) 
with permission (left picture).  
Fast Scan Cyclic Voltammetry experiments 
For the animals in Chapter 7, the same surgical procedure were implemented as described 
for DBS behavioral experiments. Adjustments for FSCV procedure includes, multiple bar holes 
drilled for implantation of the reference, stimulating and the carbon-fiber microelectrodes. 
Furthermore, jewelry screws were unnecessary as the animals were anesthetized and they were 
non-survival surgeries. Similar to DBS stereotaxic surgeries, the coordinates were derived from 
Paxinos and Watson (2007) rat atlas. The stimulating electrodes were inserted in DBS targets, 
whereas the carbon-fiber micro electrode was position in the NAc to obtain DA recordings. The 
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reference electrode was placed into superficial cortical tissue contralateral to the CFM and 
stimulating electrode. Stimulation was delivered via an optical isolator and programmable pulse 
generator (ISO-Flex/Master-8, AMPI). An example experimental set-up of FSCV is included below 
(Figure 12.) 
Figure 12. IL, NAc and LHb DBS is connected to an ISo-Flex device. Carbon-fiber 
microelectrode (red) was placed in the NAc neurochemical dopamine recording.  
Behavioral Tests 
FST. In the FST, rats were placed in a 200 mm diameter, 600 mm high plexiglass cylinder 
(Cleversys Inc, Virginia, USA) filled with 25oC water to a depth of 18 cm for 6 min. The behavior of 
the animals was monitored and recorded with a video camera. The predominant behavior over 
each 2 sec interval was scored over 6 min.  The animals’ behavior was recorded as immobile 
(passive coping) or mobile (active coping including swimming, escape and climbing patterns). 
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Figure 13 captures animals presenting with different coping strategies under this inescapable 
environmental stressor.  
Figure 13. Rats placed in escapable FST apparatus. Example of swimming, 
indicative of mobility and antidepressant-like behaviors as opposed immobility 
which is interpreted as ‘passive’ coping mechanism. Image sourced from Abelaira, 
Reus, and Quevedo (2013) with permission.  
OFT. For the purposes of our experiments, the OFT were used not only to observe animals’ 
anxiolytic behavior but to also remove any possibility of motor deficits that may confound the 
results of FST. The OFT apparatus, represented in Figure 14, consisted of a blue plexiglass box, 
622.3mm x 622.3mm (CleverSys Inc.). Behavior was recorded with a video camera for 6 min where 
time spent in the box, ambulation (number of squares crossed), defecation, rearing and time spent 
grooming provide the measures of depression-related behavior. 
113 
Figure 14. Examples of OFT box plus trace image which tracks animals’ locomotor 
activity. Far right picture represents the OFT apparatus used.   
(Sourced from Cleversys with permission, url: 
http://cleversysinc.com/csi_products/topscan-lite). 
Brain Harvest and Dissection 
For Chapters 4-6, animals were euthanized by using FatalPlus (Vortech Pharmaceuticals, 
Dearborn, Michigan, USA; constituents: pentobarbital sodium 390 mg/ml; propylene glycol 0.01 
mg/ml; ethyl alcohol 0.29 mg/ml; benzyl alcohol (preservative) 0.20 mg/ml) at ~0.70 cc. For 
Chapter 9, animals were culled through urethane overdose, delivered via intra-cardiac injections. 
In the case for LHb and NAc DBS studies, brains were harvested 30 minutes following the 
FST, and slowly frozen on dry ice. Each brain regions of interest were then dissected out on an ice 
plate with dry ice. For NAc study, the medial prefrontal cortex was sliced and prepared for 
mitochondrial analysis at the time of brain harvest procedures. With IL DBS, brains were harvested 
1 hr post FST. Brains were quick frozen by liquid nitrogen.  
Lastly, brains were harvested and stored in formalin for histological verification of 
electrodes for the FSCV study in the last experimental chapter.  
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Western Blot Analysis 
The unbound antibody is washed off leaving only the bound antibody to the protein of 
interest. These bound antibodies (and its corresponding bands) are then detected by developing a 
film or developed by using the ChemiDoc MP system, a full feature instrument for gel or western 
blot imaging. The thickness of the band corresponds to the amount of protein present. 
After the proteins were extracted from different brain regions of interest (obtained from 
dissection and subsequently homogenized), the volume of the protein were prepared to 50 μg in 
each well. The samples are then diluted into a loading buffer with a tracking dye to allow 
identification of separation process. This is then heated in order to denature the higher order 
structure, which ensures that the negative charge of amino acids is not neutralized, enabling the 
protein to move in an electric field during the electrotransfer. Once the sample and gel preparation 
steps are completed, electrophoresis begins. Electrophoresis process allows protein to separate by 
their size through stacking and resolving gel. When proteins are loaded on the gel, they have a 
negative charge but they will travel toward the positive electrode when voltage (30mA/gel) is 
applied. Approximately after an hour of power supply, the dye front runs off to the bottom of the 
gel, leaving defined bands. These bands then need to be transferred to a membrane for 
quantification. The transfer is done using an electric field oriented perpendicular to the surface of 
the gels, causing the gels to migrate and appear on the membrane. Such blotting process includes a 
fiber pad (sponge) at each end and filter papers to protect the gel and the blotting membrane. 
Lastly, before quantification, blocking is a very important step for western blotting as it prevents 
antibodies from binding to the membrane nonspecifically. Blocking with a primary antibody is 
made with 5% skim milk in tri-buffered saline with tween 20 or 5% bovine serum albumin (BSA) 
for 1 hour and incubated overnight on a shaker in 4 degrees. The membrane is then washed and 
blocked with a secondary antibody. In order to visualize the membrane, prepared ECL mix is 
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incubated with the membrane for 1-2 minutes. For quantification, the membranes were visualized 
in the dark room or by using ChemiDocTM touch imaging system (Bio-Rad, CA, USA).  
Microarray Analysis 
RNA extractions and Microarrays. Total RNA was extracted from brain tissue using 
TRIzol reagent (Invitrogen, Melbourne, Australia), and purified using RNeasy-Mini Kit (Qiagen, 
Mannheim, Germany).  RNA quality and quantity was determined using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and RNA6000 NanoAssay Kit (Agilent, 
Melbourne, Australia). Fluorescently-labelled cDNA was prepared from 800ng RNA using Agilent’s 
Quick-Amp Labelling and One-Color RNA Spike-In kits. Cyanine 3-CTP-labelled cDNA was 
hybridized for 17h to Agilent Whole Rat Genome (4x44k) Oligonucleotide Microarray Slides using 
Agilent Gene Expression Hybridization kit. Microarray fluorescent images were acquired using 
GenePix 4000B scanner, with data extraction performed via GenePix 5.1 software (Molecular 
Devices, Melbourne, VIC, Australia). Normalization and primary analysis of microarray data was 
performed using Aquity 4 software (Molecular Devices), as previously described (Carey et al., 
2006). Fluorescent reading for duplicate genes were averaged. Each array dataset sample was 
normalized so that the median expression value in each array was 1.0.  
Gene Set Enrichment Analysis using DAVID. Unpaired t-tests were used to identify genes, 
from the normalized microarray data, with evidence of differential expression between treatment 
groups. The complete gene lists of putative differentially expressed genes were imported into the 
online DAVID software package (version 6.7; National Institute of Allergy and Infectious Diseases, 
MD, USA). Using the functional annotation tools, the data was analyzed to determine enrichment 
values for defined Kyoto Encyclopedia of Genes and Genomes pathways. Pathways were selected 
based upon significant enrichment using Fisher’s exact statistical analysis (p <0.05) and fold 
enrichment score ≥1 .5. 
Gene Validation. Validation of pivotal genes within pathways was performed with 
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alternative sets of treated animals by semi-quantitative real-time PCR and/or immunoblotting. 
RT-PCR. Total RNA was extracted from the dissected brain region using the RNeasy-Plus 
Mini Kit, as per manufacturer’s directions. Amount of RNA was quantified using Nanodrop and 1μg 
was used for cDNA synthesis using iScript reverse transcriptase, as per manufacturer’s instructions. 
cDNA was aliquoted and sealed in plates and frozen at -20°C immediately. iQSYBR Green supermix  
was used for RT-PCR per manufacturer’s directions. For the RT-PCR reaction, 1ml cDNA and 300nM 
final concentration of each of the relevant Forward and Reverse primers were utilized. The PCR 
conditions were 95°C for 3 min and 39 cycles of 95°C for 10 sec and 58°C for 30 sec, followed by 
melt curve 65°C for 5 sec and 95°C for 5 sec. RT-PCR results were normalised to reference gene 
Hprt2.  Relative gene expression was calculated as 2-ΔCt, where Ct is threshold cycle. All sequences 
were designed using Beacon Designer 7.2 (Premier Biosoft International, CA, USA). 
Mitochondrial Function Analysis 
Freezing of tissue for mitochondrial isolation. The PFC tissue was removed immediately 
and immersed into 4mls of cold isolation buffer (Mannitol 200mM, Sucrose 50mM, Potassium 
Phosphate 5mM, EGTA 1mM, MOPS 5mM, and Bovine Serum Albumin 0.10% pH 7.2).  The tissue 
was then minced (while in solution) with a pair of scissors.  The buffer was tipped to decant the 
original buffer and 2mls of fresh cold isolation buffer containing 20% DMSO was added. Samples 
were then frozen on dry ice. Samples were stored at -80C for later isolation of mitochondria. 
Tissue analysis. To isolate mitochondria from PFC samples, the tissue was rapidly thawed 
before being homogenized first with a Teflon homogenizer and then with a handheld homogenizer 
for 2 x 10 sec at the lowest speed setting. Homogenates were then spun in a centrifuge at 800g for 5 
min at 4°C. The supernatants were then spun in a centrifuge at 10,000g for 10 min at 4°C. The 
mitochondrial enriched fraction was then re-suspended in mitochondrial assay solution (MAS; 
70mM sucrose, 220 mM mannitol, 5mM KH2PO4, 5mM MgCl2, 2mM HEPES, 1mM EGTA, 0.2% fatty 
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acid-free BSA) and protein content was determined by the BCA method. 2.5μg of mitochondrial 
protein in 50μL was added to 24-well Seahorse V7 plates in triplicate. Mitochondrial function was 
assessed in MAS supplemented with 5.5mM succinate and 2.2mM rotenone using the Seahorse 
XF24 Analyzer at 37°C. Multiple cycles of 60 sec mix and 4 min measure were used to establish 
state III and state IV respiration following injection of 2mM ADP. Respiration rates were 
determined in point by point mode. 
Statistical Analysis 
All statistics presented herein, were analyzed using IBM SPSS Statistics 22 and illustrated as 
figures using GraphPad Prism 6. An entire animal was removed from analysis when one (or more) 
data point was ± 2 standard deviations. Independent samples t-tests were conducted to examine 
significant differences between 2 variables. For more than 2 means, one-way analysis of variance or 
multivariate analysis of variance were conducted. In order to observe meaning association between 
variables, Pearson correlation was used. Data were tested for normality and homogeneity of 
variance prior to subsequent inferential statistics.  
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Abstract 
Mitochondrial dysfunction plays a critical role in the pathophysiology of mood disorders and 
treatment response.  To investigate this, we established an animal model exhibiting a state of 
antidepressant treatment resistance in male Wistar rats using 21 days of adrenocorticotropic 
hormone (ACTH) administration (100μg /d). Firstly, the effect of ACTH treatment on the efficacy of 
imipramine (10mg/kg) was investigated alongside its effect on prefrontal cortex (PFC) 
mitochondrial function. Secondly, we examined the mood regulatory actions of chronic (7 day) high 
frequency nucleus accumbens (NAc) deep brain stimulation (DBS; 130 Hz, 100μA, 90μSec) and 
concomitant PFC mitochondrial function. Antidepressant-like responses were assessed in the open 
field test (OFT) and forced swim test (FST) for both conditions.  ACTH pre-treatment prevented 
imipramine-mediated improvement in mobility during the FST (p < 0.05).  NAc DBS effectively 
improved FST mobility in ACTH-treated animals (p < 0.05). No improvements in mobility was 
observed for sham control animals (p > 0.05). Analyses of PFC mitochondrial function revealed that 
ACTH-treated animals had decreased capacity for ATP production compared to controls. In 
contrast, ACTH animals following NAc DBS demonstrated greater mitochondrial function relative to 
controls. Interestingly, a proportion (30%) of the ACTH-treated animals exhibited heightened 
locomotor activity in the OFT and exaggerated escape behaviors during the FST, together with 
general hyperactivity in their home-cage settings. More importantly, the induction of this mania-
like phenotype was accompanied by over-compensative increased mitochondrial respiration. 
Manifestation of a DBS induced mania-like phenotype in imipramine resistant animals highlights 
the potential use of this model in elucidating mechanisms of mood dysregulation.  
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Symptomatically, depressive periods are characterized by decreased energy, paralleled by 
reduced brain energy generation (1, 2). This is highlighted by clinical studies examining glucose 
utilization, blood flow and energy metabolites in relevant depressive cohorts (3-5). Mitochondrial 
function plays a central role in energy regulation, where it is directly influenced by glucocorticoids, 
oxidative stress, inflammation and antidepressants (6-9). In turn, mitochondrial function regulates 
not only catabolic processes, but also production of free radicals and apoptotic processes for cellular 
homeostasis (10). Mitochondrial dysfunction may therefore lead to disruption of adaptive neural 
plasticity and an imbalanced cellular response to stressors. Notably, efficacious pharmacotherapies 
including antidepressants, lithium and electroconvulsive therapy all seemingly affect mitochondrial 
function (11-14). One of the most important functions of mitochondria is the generation of adenosine 
triphosphate (ATP), the molecular unit of intracellular energy, which powers numerous cellular 
processes and is needed to recover from insults including oxidative and nitrosative stress. This is 
essential for the maintenance of the above mentioned processes including cellular integrity and 
neural plasticity.  
The link between major depressive disorder (MDD), bipolar disorder (BD) and mitochondrial 
dysfunction has been under-recognized. The brain, as an intensely energy-dependent tissue, is 
particularly vulnerable to the effects of mitochondrial dysfunction  - primary mitochondrial disorders 
are evidenced by neurological symptoms (6). A small but growing body of preclinical and clinical 
research, including proteomic analysis (15, 16), mitochondrial DNA data (17) and imaging 
techniques (5) support a role for mitochondria in neuroprogressive processes that may occur in 
treatment resistant depression (TRD).  
The heterogeneity of MDD and the lack of animal models displaying a treatment resistance 
phenotype is a challenge (18). Our preliminary model of TRD (19, 20) includes typical physiological 
characteristics of the clinical MDD population, namely disturbances in the hypothalamus-pituitary-
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adrenal axis, brain mitochondrial function, dopamine transmission and antidepressant resistance. 
The nucleus accumbens (NAc), a key dopaminergic terminal region of the limbic system, is a 
neurosurgical target for antidepressant modulation (21, 22). In our earlier work, NAc deep brain 
stimulation (DBS) has been shown to increase dopamine efflux in animals resistant to imipramine 
(23-26). Direct electrical stimulation of the NAc region altered depression-related behaviors and 
restored an antidepressant response (21, 24, 27-29). Leveraging off this, investigation of the 
antidepressant and mania inducing effects of NAc DBS in relevant animal models with face validity 
at the levels of neuronal circuitry, biochemistry and phenomenology, has the potential to increase 
our understanding of the role of the underlying neurobiology, particularly mitochondrial function, in 
antidepressant treatment response.  
In this study, we used chronic adrenocorticotropic hormone (ACTH) treatment to investigate 
the efficacy of NAc DBS in a cohort of tricyclic antidepressant-resistant animals with the behavioral 
changes assessed using the forced swim test and open field test. The aim of this study was to 
investigate mitochondrial function in an animal model with face validity and its potential association 
with treatment efficacy.  
Materials and Methods 
All experiments were conducted in accordance with the NIH guidelines for the care and use of 
laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC). 
Animals 
This study utilized male albino Wistar rats weighing 200-400g. Animals were housed individually, in 
controlled temperatures (20-22°C) on a 12h light-dark cycle. Food and water were available ad 
libitum. Animals entered the study at approximately six weeks of age following a week-long 
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acclimatization period, and completed testing in their tenth week, at which point they were 
sacrificed. Animals were randomly assigned into one of 8 groups, under 2 conditions ‘Vehicle’ and 
‘ACTH’ using simple randomization. Group sizes were justified using software G*Power 3.1 for an 
estimated medium effect, with a power of 0.95. Control (CTRL) groups under each condition had n of 
10 whereas surgery groups sized n = 15 to account for potential ‘drop-outs’. Some animals had to be 
removed over the course of study for health reasons (e.g. head-cap failure) and were thus removed 
from the analysis. As a result, final group numbers at the end of phase 2 were as follows: for ‘Vehicle 
(N =41)’ condition including CTRL (n =10), SURG (n =12), SHAM (n =10), DBS (n =9); ‘ACTH (N =44)’ 
including CTRL (n =10), SURG (n=11), SHAM (n =9), DBS (n =14). All procedures were carried out in 
accordance with the National Institute of Health Guide for care and use of laboratory animals (NIH 
publications no.80-23) and were approved by the Institutional Animal Care and Use Committee of 
the Mayo Clinic.  
Drugs 
The drugs used in this experiment included: isoflourane (~1.5%), adrenocorticotropic hormone 
ACTH 1-24 (AnaSpec, San Jose, California, USA), 100μg/day dissolved in distilled water; imipramine 
hydrochloride (Sigma–Aldrich, St Louis, Missouri, USA) 10 mg/kg dissolved in 0.9% saline; control 
vehicle 0.9% saline (Fisher Healthcare, Hanover Park, Illinois, USA); and FatalPlus (Vortech 
Pharmaceuticals, Dearborn, Michigan, USA), (constituents: pentobarbital sodium 390 mg/ml; 
propylene glycol 0.01 mg/ml; ethyl alcohol 0.29 mg/ml; benzyl alcohol (preservative) 0.20 mg/ml) 
0.70 cc. Drugs were all administered via intraperitoneal injection apart from isoflurane which was 
delivered via inhalation. 
Anesthesia and intra-operative monitoring 
The animals were anaesthetized with isoflurane inhalation in an induction chamber and maintained 
with a nose cone (World Precision Instruments, FL). The concentration of isoflurane ranged between 
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1-3% to ensure adequate sedation of the rat during surgery.  Once anaesthetized, the animal was 
placed in a stereotaxic frame (Model 1430, David Kopf Instruments, CA). The skull was secured with 
a nose clamp, incisor bar and ear bars. Constant body temperature (36.50C) was maintained using a 
heat pad, and the animal's body temperature was measured using a digital thermometer placed 
under the abdomen. While under general anesthesia, the animal was monitored by respiratory rate 
and hind-paw pinch. 
Stereotactic Surgery 
A midline 1.5-2cm incision was made starting just caudal to the eyes and ending just rostral to the 
ears to expose the two skull landmarks: bregma and lambda. A 2mm diameter trephine hole was 
broached in the skull at the site corresponding to the targets. The dura matter was opened using a 
fine needle. Then stimulating electrodes (twisted bipolar platinum iridum electrodes, 10mm long, 
.075mm in diameter; Plastics One, Virgnia, USA) were placed bilaterally in the NAc core targets 
(antero-posterior +1.5, medial-lateral ±1.5, dorsal-ventral -7.0 from the bregma) using stereotactic 
coordinates (40). 
The electrodes were secured in place using dental cement. Four small jeweler screws were also 
placed in the skull surface to prevent sliding of the dental cement over the surface of the skull during 
the post-operative period.  
Deep brain stimulation 
The electrodes were connected to a back-mounted DBS device and the battery connected (both the 
device and the battery were secured in a rodent jacket (Harvard Apparatus; Massachusetts, USA)) so 
that the animals could not disturb the device. Animals remained awake throughout the course of DBS 
and were closely observed for the first hour of stimulation. We had not previously observed any 
adverse effects of DBS of the NAc using the currents applied in this study (130 Hz, 90 μS, 100 μA). 
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DBS was continuously delivered for 7 days via the back-mounted DBS device. This occurred in the 
animal’s homecage and the animal was free to move about the cage without any restriction.  
Behavioral Testing 
Open field test (OFT). The arenas used were 622.3mm x 622.3mm (CleverSys Inc., Virginia, USA). 
Animals were each placed in the central zone of the arena, and allowed to move freely for 6 minutes. 
Their behavior was recorded by video camera. Data was then analyzed ‘blind’ using the behavioral 
analysis package CleverSys TopScan. Open field test was used to quantify locomotor and exploratory 
activities by observing the animals. 
Porsolt forced swim test (FST). The forced swim apparatus (CleverSys Inc., Virginia, USA) was used in 
this experiment (dimensions: 600 mm height x 200 mm diameter) and filled with tap water (25±1 
◦C) to a depth of 25 cm. Animals were exposed to a 15 minutes learning trial, conducted two hours 
after the OFT. A 6 minutes test session was then conducted on the subsequent day. Sessions were 
recorded by a video camera, and then analyzed ‘blind’ using the behavioral analysis package 
CleverSys ForcedSwimScan CleverSys Inc., Virginia, USA) and validated with hand scoring. The 
behaviors of interest included ‘immobility’ (passive coping behavior), ‘swimming’ and ‘climbing’ 
(active coping behavior). 
Experimental procedure 
After 7 days of acclimatization, electrodes were implanted bilaterally into the NAc using stereotactic 
surgical procedures. Following recovery from surgery (3 days) animals first received 14 days of 
injections of either saline (0.9%) or ACTH-(1-24) (100μg/d). In order to test for antidepressant 
efficacy in the ACTH model, animals were challenged with imipramine (10mg/kg) on the 14th day for 
the OFT. Two hours post-test, animals received their initial forced swim stress exposure for 15 
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minutes. Then a FST was conducted on day 15 (6 minutes), 30 minutes after the second imipramine 
administration (Figure 1a). 
DBS Animals received high-frequency NAc DBS (130Hz, 100μA, 90μs) after another 7 days of ACTH 
or saline treatment, using a back mounted DBS device (devices were off during behavior). Behavioral 
tests were recorded for subsequent analysis. Final OFT, FST training and FST were conducted on day 
21 and 22 to investigate the efficacy of DBS (Figure 1a).  Animals were sacrificed 30 minutes after 
FST, and brains were harvested and cardiac blood samples were collected. Isolated plasma aliquots 
of cardiac blood (centrifuged at 3300g for 10 minutes) were taken, and stored at -80°C.    
Euthanasia and Dissection 
Rats were euthanized by an IP overdose of pentobarbital (20mg/kg).  The brain was then dissected 
out of the skull. The prefrontal cortex (PFC) was removed and prepared for mitochondrial isolation. 
The remaining portion of the brain was frozen by placing on dry ice, followed by storage at -80C.    
Immunohistochemistry 
The remaining portion of brain was embedding using Cryo-M-Bed (A-M Systems 527738). 6mm 
coronal plane sections were taken of the NAc.  The sections were fixed using ice-cold acetone for 10 
minutes, followed by 10 minutes of drying time.  
Hematoxylin and Eosin Staining. After fixation and drying, the slides were then incubated in 
phosphate buffered saline for 10 minutes, followed by 30-second incubation in hematoxylin stain, 
then rinsed under running water for 5 minutes.  The following dips were done:  Blueing 4 dips, water 
10 dips, water 10 dips, 95% Ethanol 4 dips, Eosin 6 dips, 50% Ethanol 12 dips, 70% Ethanol 12 dips, 
95% Ethanol 12 dips, Absolute Ethanol 12 dips, Xylene 12 dips.  Slides were allowed to completely 
dry before preserving in Vecta-mount (Vector Laboratories LTD, CA, USA) and coverslipping. Refer 
to Figure 1b for electrode tract images. 
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Freezing of tissue for mitochondrial isolation 
The PFC tissue was removed immediately and immersed into 4 ml of 4°C isolation buffer (Mannitol 
200mM, Sucrose 50mM, Potassium Phosphate 5mM, EGTA 1mM, MOPS 5mM, and Bovine Serum 
Albumin 0.10% pH 7.2).  The tissue was then minced (while in solution) with a pair of scissors.  The 
buffer was tipped to decant the original buffer and 2 ml of 4°C isolation buffer containing 20% DMSO 
was added. Samples were then frozen on dry ice. Samples were stored at -80C for later isolation of 
mitochondria.  
Mitochondrial function analysis 
To isolate mitochondria from PFC samples, the tissue was rapidly thawed before being homogenized 
first with a Teflon homogenizer and then with a handheld homogenizer for 2 x 10 sec at the lowest 
speed setting. Homogenates were then spun in a centrifuge at 800g for 5 min at 4°C. The supernatants 
were then spun in a centrifuge at 10,000g for 10 min at 4°C. The mitochondrial enriched fraction was 
then re-suspended in mitochondrial assay solution (MAS; 70mM sucrose, 220 mM mannitol, 5mM 
KH2PO4, 5mM MgCl2, 2mM HEPES, 1mM EGTA, 0.2% fatty acid-free BSA) and protein content was 
determined by the BCA method. 2.5μg of mitochondrial protein in 50μL MAS was added to 24-well 
Seahorse V7 plates in triplicate. Mitochondrial function was assessed in MAS supplemented with 
5.5mM succinate and 2.2mM rotenone using the Seahorse XF24 Analyzer at 37°C. Multiple cycles of 
60 sec mix and 4 min measure were used to establish state III and state IV respiration following 
injection of 2mM ADP. Respiration rates were determined in point by point mode. 
Statistical analyses  
In all instances, the Shapiro-Wilk test of normality and Levene’s test for homogeneity of variance 
were utilized. Data points more than 2 standard deviations from the mean, were deemed ‘extreme’ 
outliers and were excluded from the analysis. When data were normally distributed, one-way 
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analysis of variance (ANOVA) was conducted, where it was followed by Sidak’s post-hoc tests. When 
these assumptions were violated however, the data were then analyzed by non-parametric Kruskal-
Wallis one-way tests. For experimental questions with only two specific groups of interest, an 
independent t test was used. Statistical significance was set at α = 0.05. Analyses were performed 
using GraphPad Prism 6.0 and IBM SPSS package 22.0. 
[Figure 1] 
Results and Discussions 
1 a). Validation of Antidepressant Resistance 
The first phase of the experiment (Figure 1a) started with 2 groups of animals (with no surgery) 
receiving daily administration for 14 days of either ACTH (100μg/d, n =12) or vehicle (water, n =8). 
These animals were then further randomly allocated into 4 groups (2 under each condition where n 
= 4-6) for imipramine (10 μg/kg/d) or saline treatment in order to measure response to this tricyclic 
antidepressant.  
Antidepressant resistance to imipramine was demonstrated in our ACTH-treated animal model. No 
differences in locomotor activity were detected between groups, precluding a motor component in 
the observed effects in the FST (S1 Figure 1).  
With respect to immobility time in the FST, one way ANOVA revealed a statistically significant 
difference between the 4 treatment conditions (p < 0.05). ACTH treatment increased immobility time 
in the FST and this was not reversed by treatment with imipramine (Figure 2a). Therefore, 
administration of ACTH induced a model of treatment resistant depression in these rats. 
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1 b). Reduced mitochondrial function in ACTH treated animals 
In order to quantify mitochondrial function, respiration analyses were performed on mitochondria 
isolated from the prefrontal cortex (PFC) using a Seahorse XF Analyzer.  
State 3 respiration, the peak respiration achieved following addition of excess adenosine 
diphosphate, is a widely accepted measure of mitochondrial capacity. An unpaired t-test revealed a 
statistically significant difference in state 3 respiration, indicating that ACTH treatment reduced the 
capacity for ATP production (p < 0.05; Figure 2b). 
 
[Figure 2] 
 
2 a). NAc DBS efficacy in imipramine resistant animals 
The second phase of the experiment included animals selected to receive continuous DBS stimulation 
for 7 days. The SHAM group denotes animals with electrode placement in the NAc with no electrical 
stimulation, whereas animals within the DBS group had active stimulation to the NAc. The SURG 
group indicates animals with 4 jewelry screws placed on the skull cap. CTRL condition refers to 
animals with no surgical procedures and only receiving the drug (or vehicle) administration. In total, 
this phase included 8 groups, 4 (DBS, SHAM, SURG, CTRL) each belonging to either ACTH or vehicle 
treatment condition (n = 6-12).  
No differences in locomotion during the OFT between groups suggests that there was no motor 
impairment or damage to confound findings in the FST analyses (p > 0.05; S2).   
The FST was used to investigate the antidepressant efficacy of NAc DBS after 7 days of uninterrupted 
stimulation in animals presumed non-responsive to imipramine treatment.  When compared to the 
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ACTH group’s phase 1 immobility scores following imipramine administration, there was a 76% 
reduction in their immobility time after continuous high frequency stimulation. A one way ANOVA 
revealed a statistically significant difference between ACTH treated groups in their final FST (p < 
0.05; Figure 3a). In ACTH treated rats, NAc DBS decreased immobility time in FST by 54% compared 
with controls (p < 0.05).  
In contrast, saline animals with DBS did not display significant reductions in their immobility time 
compared with that of the saline control group (Figure 3a). 
[Figure 3] 
2 b). Mitochondrial function and antidepressant response 
Respiratory control ratio (RCR) is the ratio of state 3 to state 4 respiration and measures the coupling 
efficiency of mitochondria. A lower RCR would indicate mitcohondrial dysfuncion that is either 
impeding ATP production, increasing uncoupled respiration, or both. NAc DBS increased RCR in 
ACTH treated rats compared with the SHAM and control groups (p < 0.05; Figure 3b). No differences 
were seen in the vehicle treated rats. 
3. Heightened locomotor activity in ACTH treated animals following DBS electrode placement
When analyzing OFT data, it was evident that there was a bimodal distribution, with a subset of rats 
(in the DBS and SHAM groups, n =7) exhibiting markedly increased activity levels in terms of distance 
travelled. We selected this subset based on the distance travelled greater than mean + 1 standard 
deviation of the control (vehicle) animals (M = 29014, SD = 5372). Any animals with OFT trial 
performance beyond this point were considered hyperactive.  
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Given violations to a test of normality (W =0.701, p < 0.05) and tests of homogeneity of variance (F8,71 
= 4.838, p < 0.05), a Kruskal-Wallis test was used to confirm a significant group effect where 
hyperactive animals travelled the furthest during the OFT  (p < 0.05; Figure 4a).  
The OFT results together with representative trace image (Figure 4b) clearly distinguish animals 
with heightened locomotor behavioral patterns that were followed by extreme application of models 
of active coping strategies in the FST including persistent diving and escape actions (p < 0.05, Figure 
4b). These behaviors persisted and were recognizable in their home-cage setting (see SI Video 1 & 
2). 
Interestingly, when examining the RCR (state3/state4), we observed an increase in mitochondrial 
function in the hyperactive rats relative to other groups pre-treated with ACTH (p < 0.05; Figure 4c).  
 
[Figure 4] 
 
This study aimed to examine the mechanisms underlying TRD and antidepressant activity in 
terms of mitochondrial function. Firstly, the data provide evidence for treatment resistance to 
imipramine, induced by a chronic administration of ACTH. Secondly, our current findings show 
reduced mitochondrial capacity in treatment resistant ACTH-treated animals which was restored by 
continuous NAc DBS for 7 days. Concurrently, NAc DBS reduced immobility time in the FST. Lastly, a 
subgroup of ACTH animals developed a mania-like phenotype, suggested by their adoption of 
increased behavioral patterns alongside heightened mitochondrial function. Together, these results 
support a biphasic role for mitochondrial function in regulation of both depressive and manic mood 
states and additionally reflecting treatment response.  
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Chronic administration of ACTH interfered with the treatment response to a tricyclic 
antidepressant and lowered mitochondrial state 3 respiration rate, indicative of reduced ATP 
production capacity. One possible mechanism whereby ACTH contributes to this dysfunction may be 
through adaptations of the HPA axis, which has consistently been shown to be hyperactive in patients 
suffering from depression (30). Daily administration of ACTH blocks antidepressant efficacy and 
alters key PFC monoamine concentration following stress, and down-regulates glucocorticoid 
responses (19). Mitochondria participate in stress responses in part by sensing levels of 
glucocorticoids. Receptors for glucocorticoids exist within the mitochondria, or translocate from the 
cytoplasm into mitochondria in the presence of their ligand, endowing these organelles with the 
ability to sense and readily respond during acute stress (31).  
We were secondly able to reverse the imipramine resistant effects of ACTH using bilateral 
NAc DBS. The efficacy of NAc DBS in a model of treatment resistance was observed using well 
validated behavioral paradigms. These findings corroborate with previous literature on the potential 
therapeutic effects of NAc DBS for TRD (27, 29, 32). Following 1 week of DBS, animals previously 
resistant to tricyclic antidepressant responded, indicated by reduced utilization of passive coping 
strategies during the FST. The FST is established as a valid tool for screening antidepressant effects, 
specifically observing the animals’ behavioral despair and helplessness under stress.  
Mitochondrial dysfunction can be regarded as the inability of mitochondria to appropriately 
produce ATP in response to energy demands. ‘Healthy’ mitochondria under standard conditions have 
a high RCR; in other words, a large increase in respiration rate with ADP administration followed by 
a return to state 4. Mitochondrial respiratory control encapsulates one of the main functions of 
mitochondria, which is their ability to idle at a low rate yet respond to ADP triggered demand by 
generating ATP at a high rate. ACTH-treated rats had significantly lower RCR, suggestive of 
mitochondrial dysfunction. Notably, a high RCR was found in ACTH pretreated animals following DBS 
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treatment compared to ACTH SHAM and ACTH CTRL, suggesting that mitochondrial efficiency is 
increased with NAc DBS. As values are substrate and tissue dependent, there is no absolute RCR value 
that is diagnostic of dysfunctional mitochondria. Mitochondrial respiratory control is a complex 
function whose values respond to numerous factors and this complexity is its main strength: a change 
in almost any aspect of oxidative phosphorylation will change RCR (33). 
Additional physiological functions of mitochondria include the generation and detoxification 
of reactive oxygen species, involvement in apoptosis, regulation of cytoplasmic and mitochondrial 
matrix calcium, synthesis and catabolism of metabolites and the transport of the organelles 
themselves to the correct location within the cell (33). Notably, many of these functions are altered 
in mood disorders, including dysregulated intracellular calcium, increased oxidative stress and 
apoptosis (34, 35). From these results, it seems likely that mitochondria play a role in the 
neuroprogression of MDD and in antidepressant treatment response.  
Increasingly, emerging data show an inextricable interconnection between oxidative stress 
and inflammatory responses (Morris & Berk, 2015). Recent meta-analysis indicated globally 
increased cell mediated immunity and macrophage activities (Dowlati et al., 2010; Liu et al., 2010; 
Maes et al., 2012). In light of converging findings, the activation of immuno-inflammatory pathways, 
and oxidative stress coupled with mitochondrial dysfunction may be strong contributors to the 
progression and persistence of TRD.  
Finally, following NAc DBS, we observed a subgroup of animals with markedly higher 
locomotor activity, exemplified by increased rates of active climbing and frequent diving. These 
animals firstly exhibited such a phenotype with electrode implantation and ACTH administration, 
which was further exacerbated by active DBS stimulation. Animals not receiving NAc DBS 
preferentially implemented passive coping strategies in the FST. Mania-like activity included 
persistent interest in novel stimuli and areas outside their provided enclosure as well as erratic 
140 
motor movements. In addition, these home cage behavioral patterns were also evident in their 
performance during behavioral tests. Notably, a high RCR was found for these animals, offering a 
possible over-compensatory mechanism where increased mitochondrial function is responsive to 
the great energy demands.  Overall these observations, together with resistance to imipramine, are 
indicative of induction of a mania-like phenotype in a vulnerable subset of animals following HPA 
stimulation and a physical disruption to the dopaminergic mesoaccumbens pathway. Future studies 
will need to further quantify these mania-like characteristics, investigate the fine grained biological 
mechanisms mediating such an effect and determine factors predisposing to vulnerability for this 
behavioral phenotype. But this paradigm does suggest a putative animal model of mania with face 
validity from the perspective of neurocircuitry and neurochemistry.  
It is important to emphasize that neither unipolar nor bipolar depression are necessarily 
classic (or primary) mitochondrial disorders. While noting that some people with primary 
mitochondrial disorders like MELAS have very high rates of bipolar like symptoms (36), by and large 
those with bipolar disorder do not exhibit the symptoms of classic mitochondrial disorders. Instead, 
emerging data suggest that upstream abnormalities (likely encoded in the nucleus) converge at 
mitochondrial function (37), leading to altered synaptic plasticity and impaired cellular resilience 
(38). Given the biphasic nature of bipolar disorder, it is hypothesized that the disorder represents a 
bi-directional state dependent alteration in mitochondrial regulation (39). Our data presented here 
suggest that it may be possible to develop a new model of bipolar disorder with a biphasic 
mitochondrial and behavioral response to ACTH administration.  
The results of this study should be considered in light of limitations shared by many 
translational models of psychiatric disorders. Firstly, the models such as the FST alone may not be 
sufficient to provide strong predictive validity of antidepressant-like effects of DBS. Secondly, 
animals do not have genotype/phenotype features that may resemble all clinical depression-like and 
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bipolar states before testing, apart from their resistance to imipramine and heightened locomotor 
activities. Despite these aforementioned caveats, preclinical models are integral for the study of DBS 
efficacy, and offer mechanistic contributions to our understanding in the field not available in human 
studies. In humans, the appraisal of clinical effects of DBS to date is primarily carried out through the 
use of subjective measures. Hence, placebo/sham effects are difficult to incorporate and measure in 
clinical trials. Preclinical research can help characterize the biological mechanisms of DBS and DBS 
induced mania, as well as to further isolate the unique effects of chronic stimulation in antidepressant 
mechanisms.  
All in all, mitochondrial dysfunction seems to play a role in the impairments of cellular 
plasticity and resilience manifested in the context of mood-related disorders. DBS of the NAc was 
effective in reducing immobility time in antidepressant resistant animals. Bearing in mind that PFC 
regions heavily project to the accumbens and some of the projections from the PFC to subcortical 
areas run through white matter fibers of the frontal cortex, these findings suggest that mitochondrial 
function within the PFC may impact motivated behaviors associated with NAc involvement. Possible 
factors that may underlie the altered bioenergetic phenotype observed in this preclinical model of 
tricyclic antidepressant-resistance include: dopamine dysregulation, mitochondrial dysfunction, 
oxidative stress, inflammation and glial cell abnormalities.  
In the future, the field of neuromodulation must look to basic research to establish key factors 
influencing different sub-populations, driving mood states and affecting treatment responsivity. The 
challenges of developing an animal model of treatment resistant depression and/or mania are many, 
however, the potential benefits of such a feat are no doubt worthwhile to help unlock the 
neurobiology of these illness states.  
 
Supplementary information is available at Translational Psychiatry’s website.  
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Figure legends 
Figure 1. (a) A detailed outline of experimental timeline (b) H&E staining validation of electrode 
tracts in DBS animals treated with ACTH. 
Figure 2. (a) Differential effects of imipramine on FST immobility time between ACTH pre-treated 
and vehicle animals (n = 8-12). Saline treated animals responded to the antidepressant-like effects 
following imipramine administration. Treatment resistance induced with a chronic treatment of 
ACTH for 14 days; (b) ACTH animals show lower capacity to generate ATP in response to the 
energy demand relative to the vehicle group. State 3 respiration point represents a maximal ADP 
stimulation respiration. The values are displayed as means and ±SEM. * p < 0.05 † p = 0.07 
Figure 3. (a) Effects of DBS on the forced swim test in ACTH treated animals (n = 7-12). NAc DBS 
significantly decreased time spent immobile in animals previously shown to resist imipramine. In 
comparison, DBS did not yield significant antidepressant-like effects on vehicle animals; (b) 
Mitochondrial function in the PFC, represented as the respiratory control ratio (RCR). Animals 
following NAc DBS show greater mitochondrial function as opposed to attenuated ratio in ACTH-
treated animals.  The values are displayed as means and ±SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Figure 4. (a) A subset of animals developed hyperactive motor activity over the course of ACTH 
treatment (only evident in DBS or sham surgery animals with ACTH on board). No such effects were 
observed in vehicle animals. Animals in this heightened locomotor activity  subgroup significantly 
differed in their distance traveled compared to other ACTH groups (b) Representative trace image 
of control ACTH vs. hyperactive animal & Percentage of time engaged in each coping style during 
FST –Representation of coping behaviors for control ACTH and manic-like phenotype animals 
during the FST-training. Persistent dive, escape and active climbing behaviors indicate these 
animals had an exaggerated drive to escape the FST apparatus compared to controls. (c) Animals 
exhibiting mania-like behaviors (HYP) show heightened RCR relative to other ACTH pre-treated 
groups. The values are displayed as means and ±SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
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Abstract 
High frequency deep brain stimulation (DBS) of the lateral habenula (LHb) reduces symptoms of 
depression in severely treatment-resistant individuals. Despite the observed therapeutic effects, the 
molecular underpinnings of DBS are poorly understood. This study investigated the efficacy of high 
frequency LHb DBS (130 Hz; 200μA; 90μSec) in an animal model of tricyclic antidepressant 
resistance. Further, we reported DBS mediated changes in Ca2+/calmodulin-dependent protein 
kinase (CaMKIIα/β), glycogen synthase kinase 3 (GSK3α/β) and AMP-activated protein kinase 
(AMPK) both locally and in the infralimbic cortex (IL). Protein expressions were then correlated to 
immobility time during the forced swim test (FST). Antidepressant actions were quantified via FST. 
Treatment groups comprised of animals treated with adrenocorticotropic hormone alone (ACTH; 
100μg/day, 14 days, n =7), ACTH with DBS, sham, surg or control (n =7, n =8, n =8 and: n =8 
respectively). DBS significantly reduced immobility in ACTH-treated animals (p < 0.05), an effect that 
required active stimulation rather than electrode implnataions. For DBS group, western blot results 
demonstrated phosphorylation status of LHb CaMKIIα/β and GSK3α/β significantly correlated to 
immobility time in the FST. Concurrently, we observed phosphorylation status of CaMKIIα/β, 
GSK3α/β, and AMPK in the IL to be positively associated with antidepressant actions of DBS.  These 
findings suggest that activity dependent phosphorylation of CaMKIIα/β, and GSK3α/β in the LHb 
together with the downregulation of AMPK in the IL, contribute to the antidepressant actions of DBS.   
 
Key words Lateral Habenula, Deep Brain Stimulation, Treatment Resistant Depression, CaMKII, 
GSK3, AMPK  
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Introduction 
The lateral habenula (LHb) plays a critical role in mood, reward, incentive motivation and 
stress responses [1-5]. Patients suffering from severe depression [6] and animal depression models 
of alpha-methyl-para-tyrosine administration, amphetamine withdrawal, stress exposures, genetic 
manipulation or selective breeding [5, 7-10], show elevated activity in this region. Local deactivation 
of the LHb via lesioning elicits antidepressant responses, promoting escape behavior in the 
congenital learned helplessness (cLH) rats during inescapable paradigm [11]. These behavioral 
changes were mediated, in part, by the regulation of dorsal raphe serotonin levels and ventral 
tegmentum dopamine transmission [11-14]. Recently, deep brain stimulation (DBS) of the LHb has 
been trialed for treatment resistant depression (TRD), with therapeutic effects reported to coincide 
with periods of active stimulation [15]. Similarly, LHb DBS effectively achieved an antidepressant 
response in the cLH model of depression [16, 17]. Nevertheless, the mechanisms through which LHb 
activity is up- or downregulated and whether it yields pro- or antidepressant actions, respectively, 
are not well understood.  
Stress-induced molecular adaptations in the LHb region have important implications for 
modulating associative networks and depression-like behaviors [17-20]. In particular, recent 
attention has been given to the role calcium/calmodulin-dependent protein kinase type II (CaMKII) 
in learning and synaptic plasticity. Both exposure to stress and administration of the antidepressant 
escitalopram altere the expression of CaMKII in the LHb [19]. In cLH model, CaMKIIα and CaMKIIβ 
levels were shown to be significantly up-regulated in this region, prior to receiving effective 
antidepressant treatment [17]. Conversely, the down-regulation or blockade of CaMKIIβ activity 
reversed the depressive phenotype in these animals in standardized behavioral paradigms [17]. 
CaMKII is involved in many signaling cascades critical to cellular homeostasis, growth and plasticity, 
and functions together with glycogen synthase kinase 3 (GSK3) to regulate synaptic vesicle recycling 
in mature synapses [21, 22]. This activity-dependent interaction poses a possible mechanistic link 
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between high frequency DBS and local CaMKII/GSK3 modulation. GSK3 also serves as a mediator in 
cellular metabolism and plasticity. Upstream of this, AMP-activated protein kinase (AMPK), a cellular 
energy sensor, is activated when cellular energy reserves are low and coordinates intracellular 
functions mediating plasticity [23]. Stress-induced changes in energy metabolism and substrate 
utilization via this cell signaling system is implicated in the pathophysiology of depression [24, 25]. 
Plasticity within this intracellular pathway may be an important contributor to the 
pathophysiological underpinnings of TRD.  
Like the LHb, hypermetabolism of the subgenual cingulate gyrus (SCG) is well documented in 
the TRD population also, and the down regulation of this activity follows a successful antidepressant 
response, regardless of treatment method [26-30]. The LHb and SCG regulate affective and cognitive 
aspects of depressive symptoms [31-34]. The link between their hyperactivity and depressive states 
has been well-documented in patients [27, 35, 36]. Based on the existing literature, LHb function is 
important for alleviating depression symptomatology. Therefore, the present study further aims to 
validate this using LHb DBS in an animal model of antidepressant resistance, induced via chronic 
adrenocorticotropic hormone (ACTH) treatment [37-43].  In addition, we aimed to quantify 
antidepressant-like behavioral effects and its associated metabolic signaling in LHb and IL. DBS 
effects on CaMKIIα/β, GSK3α/β, and AMPK expressions locally as well as in the infralimbic cortex (IL; 
rodent homologue of SCG) specifically, will be examined in terms of the correlative relationship 
between behavior x protein signal. 
Materials and Methods 
All experiments were approved by Mayo Clinic Institutional Animal Care and Use Committee 
and conducted in accordance with The Code of Ethics of the EU Directive 2010/63/EU for animal 
experiments. All animals were housed individually, with food and water available ad libitum. 
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Surgical procedures and post-operative care 
Male Wistar rats (190-230g) were anesthetized with isoflurane (1-3%) for stereotactic 
surgery. A 1.5-2cm incision was made and small holes were broached in the skull at the site 
corresponding to the targets. Twisted bipolar platinum iridum electrodes (5.6mm long, .075mm in 
diameter; Plastics One, Virginia, USA) were bilaterally implanted into the LHb (from bregma: antero-
posterior (AP) -3.7mm, medial-lateral (ML), ±0.8mm, dorsal-ventral (DV) -5.4mm; Paxinos & Watson, 
2007). Stimulating electrodes and screws were mounted with dental cement. Animals in the sham-
surgery group were anesthetized and had four screws placed in the skull and secured with dental 
cement. Control animals did not undergo any surgical procedures.   
 
Experimental procedure  
After 3 days of acclimatization, rats received 14 days of either saline (0.9%) or ACTH 
(100μg/day) treatment as described previously (38). On day 7, DBS electrodes were implanted as 
described above. Continuous high frequency DBS stimulation (130 Hz, 90 μS, 200 μA) was delivered 
for 3 days prior to the FST (Iso-Flex /Master-8; AMPI, Jerusalem, Israel).  
 
Behavioral testing 
Open field test (OFT) was used to quantify animals’ general locomotor activity in a novel 
environment. A plexiglass box with a 622.3mm x 622.3mm base, and camera oriented with a top-
down view was used for this test (CleverSys Inc., Virginia, USA). Animals were each placed in the 
central zone of the arena, and allowed to move freely for 6 min and behavior recorded by a video 
camera unit. 
Porsolt forced swim test (FST) was used to quantify antidepressant response. Animals 
were placed into a narrow cylinder filled with water on the training day and consecutive test day. 
The apparatus consisted of clear plexiglass cylindrical tanks (60 cm height x 20 cm diameter; 
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CleverSys Inc., Virginia, USA) filled with tap water (23-25°C) to a depth of 25 cm. Animals were 
initially exposed to 15 min learning trial on day 14, conducted 2 hr after the OFT. A 6 min test session 
was then conducted on the subsequent day. For this test, the animals’ behavior was quantified to 
assess either active (swim, climb, escape) vs. passive (immobility, pass-dives) coping mechanisms. 
Behavioral data were analyzed using the cleversys topscan and forced swim software (CleverSys Inc., 
Virginia, USA) and validated by hand scoring.  
Tissue collection and western blot analysis 
Animals were injected with 100mg/kg of Fatal Plus (Vortech, Michigan, USA) 30 min 
following the FST test. Brains were rapidly removed and frozen on dry ice. Tissue samples were 
dissected over dry ice and homogenized in lysis RIPA buffer. Electrode location was confirmed during 
dissections. Samples containing equivalent amounts of protein were applied to 15% acrylaminde 
denaturing gels and transferred to an Immobulin P for 1.5hrs at 90V. Each membrane was blocked 
for 15 min with 10mL of tris-buffered saline with tween 20 buffer (TBST), +5% milk to block (5% 
bovine serum albumin (BSA)+TBST for phosphor-antibodies). After washing, membranes were 
incubated with primary antibodies: CaMKII (pan) antibody (1:1000) #3362, phospho-CaMKII 
(Thr286, 1:3000) antibody #3361, GSK3α/β (1:2000) #5676, phospho-GSK3α/β (Ser21/9, 1:1000) 
#9331, AMPK (1:1000) #2532, phospho-AMPK (1:2000) #2535, (all from Cell Signaling Technology, 
Beverley, MA) for overnight with 1x phosphate buffered saline (PBST) + 5% milk (5%BSA+TBST for 
phospho-antibodies). Membranes were washed and incubated the following day with the 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody (1:2000-4000). 
Immunoreactive proteins were visualized using the enhanced chemiluminescence detection system 
(Biorad; location). Images were scanned and analyzed using Bio-Rad Chemi Doc (Hercules, CA). β-
actin antibody #A5441 (Sigma, St Louis, MO) was quantified as loading control for each gel.  
157 
Statistical analyses 
Firstly, the Shapiro-Wilk test of normality and Levene’s test for homogeneity of variance were 
also conducted. One-way multivariate analysis of variance (MANOVA), followed by Tukey’s test for 
multiple comparisons were used where appropriate for statistical analyses on behavioral and 
molecular observations. Statistical significance was set at p = 0.05. When assumptions for normality 
and homogeneity of variances were violated, the data were then analyzed by non-parametric 
Kruskal-Wallis one-way tests. Correlations between antidepressant-like effects in the FST and 
protein expressions were assessed using linear regression analyses. Calculations were performed 
using the IBM SPSS Statistics 22.0 software package and graphically represented using GraphPad 
Prism 6.0.  
Results
Electrode localization 
Electrode location was confirmed during tissue dissections and representative traces 
recorded diagrammatically (39). Bipolar stimulating electrode tips were localized to the LHb (in the 
range of -3.7mm posterior to bregma, ±3.7mm lateral to midline, and -5.7 mm ventral from dura; fig 
1). No histological damage was observed for animals receiving DBS treatment. 
[Insert Figure 1] 
OFT & FST behavioral outcomes following LHb DBS 
No statistically significant differences were found for distance nor ambulation across 
treatment groups (p > 0.05); and in the number of bouts taken, (p > 0.05; fig 2a-c). These behaviors 
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during the OFT indicate that findings in the FST are not due to any motor impairment or 
hyperactivity.  
Animals when faced with an inescapable forced swim paradigm differed in their coping 
strategies, specifically the duration of immobile posture, F (4, 32) = 17.92, p < 0.0001, ηp2 = 0.69 (fig 
2d). LHb DBS animals, overall, displayed 75% reduction in immobility time compared to ACTH 
pretreated animals (p = 0.02). Further, DBS animals displayed attenuated immobility when 
compared to the surg group, indicative of distinct treatment effect (p = 0.07; fig 2d). 
In terms of active coping strategies, animals demonstrated differences in climbing behavior, 
F (4, 32) = 87.06, p < 0.0001, ηp2 = 0.91. Specifically, animals receiving active stimulation of the LHb 
used climbing significantly more than ACTH (p = 0.001) and sham (p = 0.0001; fig 2d) groups. 
Significant differences were found for time spent swimming (F (4, 32) = 26.36, p < 0.0001, ηp2 = 0.76, 
fig 2e, f), prominent in ACTH sham animals.. 
[Insert Figure 2] 
Western blots 
i) Protein expression in the lateral habenula
Changes in p/CaMKIIα levels were observed between treatment groups, χ2 (3) =8.81, p =.032, 
with a mean rank of 18.17 for ACTH, 13.50 for ACTH DBS, 8.08 for ACTH SURG and 8.50 for CTRL. A 
trend was observed in p/CaMKIIβ, χ2 (3) =7.01, p =.076 (with a mean rank of 17.33 for ACTH, 13.70 
for ACTH DBS, 8.42 for ACTH SURG, 8.83 for CTRL) and in p/AMPK, χ2 (3) =7.44, p =.059 (with a mean 
rank of 18.00 for ACTH, 11.80 for ACTH DBS, 7.67 for ACTH SURG and 10.50 for CTRL). 
Phosphorylated GSK3α and GSK3β changed in parallel, but in short exposure to stress (or relay time 
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between stress and decapitation), the signals of other phosphorylated proteins were too weak to be 
detected.  
The most interesting and significant findings lie in the relationship between immobility time 
during the FST and protein expression (fig 3 a-e). Negative and moderate to strong correlations were 
observed for phosphorylated/total protein levels of CaMKIIα/β, GSK3α/β and AMPK in DBS ACTH 
animals. No significant correlations were observed for other groups. A table containing the results of 
linear regressions for all conditions is presented in Supplementary Materials. 
[Insert Figure 3] 
ii) Protein expression in the infralimbic cortex.
Protein expression in the IL region did not significantly differ across treatment groups 
following an inescapable stress exposure. Nevertheless, trends were observed for CaMKIIα, F (3, 27) 
=2.75, p =.06 and CaMKIIβ, F (3, 27) =2.57, p =.07.  
More importantly, significant correlations were similarly observed for immobility in the FST 
and phosphorylated/total protein levels in the IL, however in an inverse direction to that observed 
in the LHb region. Linear regression analyses identified significant positive and moderate to strong 
relationships between immobility time and phosphorylated proteins and/or phosphorylated/total 
protein levels. CaMKIIα, CaMKIIβ, GSK3α, GSK3β, and AMPK were consistently found to be 
phosphorylated 30 min post stress exposure in for DBS treated animals (fig 4a-e). A linear regression 
results table for all conditions can be found in the Supplementary Materials. 
[Insert Figure 4] 
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Discussion 
This study demonstrated antidepressant-like effects of LHb DBS in animals pretreated with 
ACTH and further presents data to suggest these behavioral responses relate to local as well as IL 
CaMKIIα/β, GSK3α/β and/or AMPK activity. The DBS group showed significantly reduced immobility 
behavior during the FST following active stimulation, compared to other conditions. With ACTH sham 
animals gaining no therapeutic benefit from electrodes insertion, it seems that active stimulation is 
necessary to bringing about antidepressant-like effects. These results corroborate with other animal 
models of depression where LHb DBS has also reduced immobility in the FST [9, 17, 44]. This study 
further aimed to quantify the effects of ACTH and DBS treatment x inescapable stress on the 
expressions of CaMKIIα/β, GSK3α/β, and AMPK in the LHb and IL. Significantly higher levels of LHb 
p/CaMKIIα were observed for ACTH-treated animals relative to other groups. A similar, near 
significant, increase was observed for ACTH-treated animals in p/CaMKIIβ and p/AMPK. Linear 
regression analyses further demonstrated that DBS-mediated reductions in immobility negatively 
correlated with phosphorylated CaMKII, GSK3 and AMPK in the LHb. Conversely, phosphorylation of 
these proteins in the IL, positively correlated with DBS-induced antidepressant response quantified 
as time spent immobile.   
The outcomes of this study suggest the antidepressant action of LHb DBS may involve local 
activation of CaMKII, GSK3 and AMPK signaling, concurrent with opposing effects in the IL. It is 
possible that high frequency stimulation triggered activity dependent activation of this pathway in 
the LHb, which in turn facilitated a correlative downregulation of activity and energy demand in the 
IL supportive of increased active/reduced passive coping responses in the FST. As mentioned, a 
reversal of SCG hypermetabolism has been observed for patients in remission following efficacious 
antidepressant treatments [29, 45]. Decreased IL metabolism following fluoxetine administration 
has been reported by preclinical studies using optogenetic manipulation [31, 32, 46, 47]. CaMKII has 
been found to phosphorylate GSK3 during chronic depolarization and is the best possible candidate 
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for mediating acute activity-dependent phosphorylation of GSK3 activity [21]. Activity-dependent 
consumption of ATP, likewise, is associated with phosphorylation of AMPK and mediates structural 
plasticity as well as mitochondrial transport [48]. Taken together, the phosphorylation status of these 
proteins couples depolarization to encourage neuronal survival and synaptic plasticity [22, 49], a 
necessary process in achieving antidepressant responses [50].  
Existing literature uses deficits in energy metabolism to explain the cellular damage, atrophy 
and reduced capacity for synaptic plasticity observed in mood disorders [51]. We have previously 
shown that mitochondrial function is reduced in ACTH-treated animals (Kim et al, under review). 
This work demonstrated that mitochondrial capacity to create ATP was significantly attenuated by 
pretreatment with ACTH. This metabolic deficit may contribute to the neuroprogressive nature of 
depression [52], and contribute to the antidepressant resistance observed in these animals [43]. 
AMPK functions as an energy checkpoint within a cell, coordinating cellular functions for survival 
when reserves run low. This includes limiting cell cycle and growth processes as well as long-term 
plasticity responses to high frequency stimulation [53]. A role for efficacious antidepressant 
treatments in mediating these cellular growth and plasticity processes in TRD is emerging. Inhibition 
of GSK3 via lithium treatment has long been an established augmentation therapy in TRD, believed 
to exert neuroprotective actions and increase neuroplasticity, neurogenesis and cell resilience [54]. 
Ketamine has also been shown to recruit mTOR and GSK3 to exert its rapid antidepressant actions, 
which coincides with rapid upregulation of structural and functional plasticity [55]. Further work is 
needed to better understand the role of cellular metabolism in treatment resistance and responsivity, 
particularly to DBS. 
Based on our results, one of many antidepressant actions of LHb stimulation may arise from 
an inverse relationship between DBS-mediated alterations in the metabolic function of local cells as 
well as those in the IL region, together coordinating therapeutic behavioral responses to stress. 
Chronic DBS stimulation has been found to promote structural and synaptic plasticity, changes in 
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metabolic activity, whereas acute stimulation results in antidromic and/or orthodromic activation 
[56]. The differential association of phosphorylated protein status of CaMKIIα/β, GSK3α/β, and 
AMPK in these two regions suggest LHb DBS may downregulate metabolic demand in the IL. 
Functional activation of LHb and IL are necessary for different processes involved in stress appraisal, 
response and antidepressant activity [57, 58]. Moreover, they both play a key role in mediating the 
psychological as well as physiological reactions to emotionally negative or stressful events [35, 59]. 
The interplay between local DBS effects and functional changes needs to be better understood, 
particularly with respect to the effects of chronic stimulation. The present study provides interesting 
new data to suggest DBS of the LHb directly modulates metabolic cell signaling cascades, both locally 
and in the IL region in ACTH pretreated animals. It will be important for future work to further 
investigate these mechanisms within the specific context of the neurobiological underpinnings of 
disease progression, and antidepressant-resistance.  DBS therapeutics holds much potential for the 
treatment of severe, refractory depression. To do so, it is important that we elucidate its disease 
specific mechanisms so that we can reliably extend this promising neuromodulation therapy to those 
patients most in need.  
 
There are two major limitations that were beyond the scope of the present paper. Firstly, 
further investigation on downstream or upstream targets and intermediary proteins would be of 
great value. Our exploratory approach placed particular interest on studying the role of specific 
proteins known to be abundant in the LHb (CaMKII), antidepressant response (GSK3) and energy 
regulation (AMPK). Future studies may be able to provide a more comprehensive picture of the 
molecular mehanisms mediating LHb antidepressant processes. In addition, given the size of LHb 
structure, the surrounding structures may have been modulated by DBS intervention, thereby 
possibly contributing to the observed antidepressant-like effects. Best efforts were made in order to 
reduce such confounding variables by implementing optimal DBS parameter setting (see Hamani et 
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al., 2010), as well as including two positive controls. Future studies may want to explore different 
frequency, current intensity and stimulated hemisphere to further investigate the relationship 
between the LHb and IL.  
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Figure legends
Figure 1. Schematic illustration of the anatomical placement of stimulating electrodes in the LHb. 
Figure 2a, b &c. Animals’ locomotor activity during the 6 minutes OFT for speed and total distance 
travelled (n = 7-8). No apparent differences in motor ability is observed across the treatment groups; 
d. Animals who received DBS show reduced immobility time compared to that of ACTH and saline
controls (n = 7-8); e &f. For active coping strategies, including climbing and swimming, significant 
differences were only exhibited in animals’ climbing behavior (n = 7-8). All values are represented as 
means and standard error of mean. 
Figure 3. Activation of three proteins of interest in the LHb region of DBS animals (n =5) where they 
received active high frequency stimulation. Higher expression of CaMKII, GSK3 an AMPK was 
associated with lower immobility time. Linear regression results are displayed with corresponding p 
and r2 values. 
Figure 4.   Phosphorylated/expression proteins for IL region in DBS animals (n =7). Lower 
phosphorylation and activation was moderate to strongly correlated with reduced time spent 
immobile following 3 days of chronic stimulation. Linear regression results are displayed with 
corresponding p and r2 values.
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Chapter 6. Global transcriptional profiling of infralimbic deep brain stimulation in an animal 
model of antidepressant treatment resistance 
Manuscript prepared for submission in Molecular Psychiatry. 
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Abstract 
Treatment resistant depression is a major unmet need for which deep brain stimulation (DBS) is an 
emerging therapy. However, the physiological mechanisms giving rise to antidepressant treatment 
resistance in depressive illness and the mechanisms underlying responses to DBS remain poorly 
understood. Using a genome-wide transcriptomics approach, we aimed to identify molecular 
pathways contributing to both antidepressant resistance and DBS efficacy in a preclinical model of 
antidepressant-resistance induced via chronic adrenocorticotropic hormone (ACTH; 100μg; i.p.; 14 
days). Animals were allocated to stress-naïve or forced swim test (FST) stress conditions and 
received either ACTH or saline (0.9%) control treatments. Additional groups received either 
imipramine (to validate antidepressant treatment non-response) or infralimbic (IL) DBS (n=7-8 per 
group). The infralimbic area was dissected and global gene expression profiles obtained for saline, 
ACTH and ACTH-DBS groups (Agilent).  Gene set enrichment analysis (DAVID) was performed 
following Bonferroni correction and KEGG pathways were identified (Fisher exact score p<0.05).  
Differential expression of pivotal genes and proteins were confirmed in independent groups (n=4-5) 
by RT-PCR and/or immunoblotting. Significant alterations were observed in key sensors of energy 
demand, cell division/growth, apoptosis, inflammation, protein synthesis and glucose/glycogen 
regulation following stress.  Cellular distress molecular patterns indicative of oxidative stress, 
hypoxia, endoplasmic reticulum stress, pro-inflammatory cytokines, nutrient deprivation and DNA 
damage, such as Gadd45E, Gadd45J, HIF1D, CHOP and p53, were increased in the treatment-resistant 
group and attenuated by DBS (p<0.05). This suggests that development of antidepressant resistance 
may relate to reduced capacity for cellular adaptation to stress, and that DBS helps to restore this 
capacity and overcome mechanisms contributing to cellular distress. Such actions may be critical in 
initiating longer-term neural adaptations that contribute to treatment efficacy in DBS therapeutics 
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for depression. This has potential for augmentation to further optimize DBS mechanism(s) of action 
and identifies novel specific therapeutic targets.  
 
KEYWORDS: Deep Brain Stimulation, depression, treatment resistance, antidepressant,  
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Introduction 
Depression is a heterogeneous disorder with some forms of the disease highly resistant to available 
treatments. For these most severe and refractory manifestations of the disease, emerging 
neuromodulation therapeutic strategies such as deep brain stimulation (DBS) hold promise. 
However, the therapeutic mechanisms remain poorly understood. This is especially true of the 
molecular mechanisms, and this gap may contribute to the limited success of multisite studies, while 
uncovering these may identify new treatment targets.  Preclinical rodent studies provide a unique 
opportunity for elucidating these molecular mechanisms.  Given the inherent paucity of data in this 
area, we have utilized a ‘hypothesis generating’ genome-wide transcriptomics approach to systems 
biology in order to identify molecular mechanisms of DBS in a preclinical model of antidepressant 
treatment-resistance (Wang et al., 2015). The first and most thoroughly studied DBS target for 
treatment resistant depression (TRD) is subcallosal cingulate (SCC) white matter (Riva-Posse, et al., 
2014; Holtzheimer et al., 2012; Lozano et al., 2008; Mayberg et al., 2005). Through careful, blinded 
investigational studies, this work has identified critical neural tracts that mediate SCC DBS 
antidepressant responses (Riva-Posse, et al., 2014). This work has demonstrated that there is an 
acute ‘reset’ response following initiation of DBS, followed by a more chronic recovery suggestive of 
longer-term adaptations mediated by synaptic plasticity. This concept was first put forward to 
conceptualize drug-induced neural plasticity occurring in response to antidepressant and other 
psychotropic drug (Hyman & Nestler, 1996), however may have relevance to the mechanism(s) of 
DBS action. Currently, we understand so little about the neurobiological mechanisms mediating acute 
and progressive responses to DBS in the treatment of depression, and why some patients respond 
quickly, while others take much longer to achieve the same level of therapeutic response. Elucidation 
of early phase molecular responses of neural tissue to DBS in antidepressant-resistant brains may 
help to uncover molecular mechanism and systems critical to initiation of synaptic plasticity 
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processes underlying longer term adaptive responses; and in turn, targets for optimization and 
enhanced responsivity.  
One approach for studying the molecular mechanisms of MDD is through animal models with chronic 
stress diathesis. Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis during depression 
is a reliable clinical finding (Pariante & Lightman, 2008) and has been found to predict treatment 
resistance (Willner et al., 2013). In rodents, chronic administration of ACTH blocks the 
antidepressant effects of many pharmacologic interventions (Kitamura et al., 2002; Kitamura et al., 
2008; Tokita et al., 2012; Walker et al., 2013; 2015). This model, although not as robust in its face 
validity for certain aspect of depressive illness as other chronic stress models is inherently more 
powerful for elucidation of mechanisms mediating treatment response and non-response. The 
simplicity of its design – chronic ACTH treatment – provides a consistent and standardized approach 
to modulating physiological processes that are critical to facilitation or blockade of antidepressant 
response. What’s more, it addresses an important and often undiscussed factor contributing to 
antidepressant resistance in TRD, the progressive loss of response over time (Moylan et al., 2013). 
This is not an uncommon phenomenon and is often observed in patients at the extreme end of the 
‘TRD’ spectrum who present for DBS. These patients may have been responsive to a particular 
treatment and then over time their therapeutic responsivity is lost. We need to better understand 
both this neuroprogressive phenomenon, and the mechanisms of DBS that might reverse it. Several 
studies demonstrated the advantage of using animal models of disease to inform clinical research by 
providing hypothesis free candidate gene selection that are affected in MDD and altered consequent 
to treatment response (Barreto et al., 2012; Malki et al., 2011; Molteni, Macchi & Riva., 2013). DBS 
can also serve as an effective tool for probing mechanisms of antidepressant response in TRD, 
thought to have a distinct pathophysiology compared with more treatment responsive forms of 
depressive illness. 
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Based on anatomical connections and cytoarchitectural features, the ventral aspect of the medial 
prefrontal cortex, particularly the infralimbic (IL) cortex, is the region most commonly suggested as 
the anatomical correlate of the SCC.  In rodents, the IL has been implicated in mechanisms of stress 
coping (Diorio, 1993; Ostrander, 2003; Amat, 2005,), autonomic (Hardy, 1988; Resstel, 2004, 
Tavares, 2004), and conditioned response extinction (Milad, 2002; Milad, 2004; Quirk, 2000). Due to 
the complexity of clinical depression and somatic symptoms that cannot be reproduced in animal 
model, an endophenotype assay in response to antidepressant-like behavior can be a useful tool for 
elucidating mechanisms of response and non-response. The stress coping forced swim test (FST) 
assay, first introduced by Porsolt et al. (1977), has been implemented as an effective tool for 
screening antidepressant responses and better understanding the underlying mechanisms (Nestler 
et al. 2002). The present study utilized this behavioral screening assay, and aimed to interpret 
changes in endogenous gene expression induced by this test in treatment resistant and responsive 
rodents. Further, it assessed the impact of IL DBS on gene expression responses in ACTH-treated 
antidepressant-resistant animals, which may provide clues on acute local neural responses to DBS in 
antidepressant-resistant and DBS responsive animals. Findings from our study suggest the ACTH 
pretreatment has reduced the capacity of cells in the IL region to ‘cope’ with the supplementary stress 
of the FST. Cellular distress molecular patterns were identified, together with differential expression 
of critical cellular metabolism and growth/plasticity pathways in ACTH-treated animals post-stress 
relative to saline-treated control. DBS was effective in reducing cellular distress patterns within the 
IL and we propose such cellular effects contribute to the early cellular responses that function to 
initiate longer term adaptations that confer plasticity and treatment response clinically.  
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Methods 
We first confirmed the antidepressant actions of IL DBS in ACTH-treated animals non-responsive to 
the tricyclic antidepressant imipramine, indexed by the forced swim test. In brief, male Sprague-
Dawley rats were treated with daily injections of either saline (0.9%) or ACTH-(1-24) (100μg/d) for 
14 days and randomly assigned to the stress-naïve or forced swim test (FST) groups. Imipramine 
(10mg/kg), high frequency IL DBS (1 hour, 130 Hz) or sham IL DBS (no stimulation) were 
administered to assess treatment efficacy. We then investigated how chronic ACTH treatment affects 
gene expression in the rodent IL following FST stress, relative to saline treated controls, as well as 
effects of IL DBS on local gene expression in ACTH-treated animals.  
Animal experiments: 
Male Sprague-Dawley rats (ARC, Australia and Harlan Laboratories, USA) were housed in pairs in a 
temperature controlled room. Food and water were available ad libitum. Room temperature was 
maintained at 21±2°C, humidity 40-70%, with a 12h light/dark cycle.  Animals, weighing 200-350g 
at the time of testing, were treated with daily injections of saline (0.9%) or ACTH (100 μg) for 14 days 
and randomly allocated to the stress-naïve or forced swim test (FST) groups.  Experimental groups 
included: saline/stress naïve, saline/FST, saline-imipramine/FST, ACTH/naïve, ACTH/FST, ACTH-
imipramine/FST and ACTH-DBS/FST (n=7-8 per group).  The open-field test (OFT) was used to 
assess locomotor, anxiety and exploratory behaviors and FST was used to assess antidepressant 
response (reduced immobility).  Application of DBS was stopped immediately prior to the forced 
swim test and animals were euthanized 1 hour following FST. Brains were snap frozen in liquid 
nitrogen and stored at -80°C.  All procedures were carried out in accordance to institutional 
guidelines for ethical animal care and use.  
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Drugs 
The drugs used in this study were: ACTH-(1-24) (AnaSpec, California, USA), 100μg/day dissolved in 
distilled water; imipramine hydrochloride (Sigma-Aldrich, New South Wales, Australia), 10mg/kg 
dissolved in 0.9% saline; Saline (Baxter, New South Wales, Australia), 0.9%.  Drugs were all delivered 
via intraperitoneal (i.p.) injection at ~10am each day. 
Stereotactic Surgery 
Animals were anaesthetized with isoflurane inhalation in an induction chamber (World Precision 
Instruments). Once anaesthetized, the animal was placed in a stereotaxic frame (David Kopf 
Instruments, CA) and maintained with isoflurane. The skull was secured with a nose clamp, incisor 
bar and ear bars. Constant body temperature (36.50C) was maintained using an isothermal heat pad 
(Braintree Scientific). A midline 1.5cm incision was made in the skin overlying the skull to expose 
bregma. A 2mm diameter trephine hole was broached in the skull at the site corresponding to the 
target. The dura matter was opened using a fine needle and a stimulating electrode (Plastics One) 
was placed in the IL target (stereotactic coordinates: AP: +3.0; ML: ±0.4; DV: -5.6) (Paxinos & Watson, 
2007). Three small jewelry screws were also placed in the skull surface and stimulating electrodes 
were secured in place with dental cement.  
Porsolt Forced Swim Test (FST). The FST is a well-established screening tool for antidepressant 
efficacy, with strong predictive validity (Nestler & Hyman, 2010). The apparatus consisted of a clear 
plexiglass cylindrical tank (60 cm height × 20 cm diameter) filled with tap water (23–25 ◦C) to a 
height of 25 cm. Animals were exposed to 10 min learning trial, conducted two hours after the OFT. 
A 6 min test session was then conducted on the subsequent day. Sessions were recorded by video 
camera, and then reviewed for analyses. On completion of the FST, each test session was de-
identified, and then manually scored in 2 s intervals using the criteria outlined by Porsolt et al. 
(1977). The behaviors of interest included ‘immobility’ (passive behavior), ‘swimming’ and 
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‘climbing’ (active behaviors).  The effect of treatment on behavior was compared using separate 
one-way analysis of variance (ANOVA) (GraphPad Prism 6.0).   
Open Field Test (OFT). The OFT was used to quantify locomotor, exploratory and anxiety-like 
behavior. The apparatus comprised a clear plexiglass box (36 cm × 50 cm × 50 cm) with 16 
homologous squares marked on the base. Animals were each placed in the central zone of the 
arena, and allowed to move freely for 6 min and behavior was recorded by video camera. Each test 
session was de-identified, and then manually scored in 2 s intervals. The primary behavior of 
interest was ‘ambulation’, an indication of locomotor activity. Other behaviors of interest included 
‘rearing’, time spent in central regions of the arena, and ‘grooming’ counts. These behaviors were 
used as indications of exploratory and anxious behavior. The effect of treatment on behavior was 
compared using separate one-way analysis of variance (ANOVA) (GraphPad Prism 6.0).   
Tissue Collection 
Following behavioral testing on day 15, animals were humanely euthanized by anaesthetic overdose 
1 h after completion of the FST (sodium pentobarbitone ‘Lethabarb’0.4cc, Virbac, New South Wales, 
Australia). Animals in the stress naïve groups were euthanized at the same time of day via identical 
methodology. Brain samples were extracted and flash frozen in liquid nitrogen and stored at −80°C 
for later analysis of tissue. 
RNA Extractions and Microarrays: 
Total RNA was extracted from IL PFC using TRIzol reagent (Invitrogen, Melbourne, Australia), and 
purified using RNeasy-Mini Kit (Qiagen, Mannheim, Germany).  RNA quality and quantity was 
determined using the Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA) and 
RNA6000 NanoAssay Kit (Agilent, Melbourne, Australia).  Fluorescently-labelled cDNA was 
prepared from 800ng RNA using Agilent’s Quick-Amp Labelling and One-Color RNA Spike-In kits. 
Cyanine 3-CTP-labelled cDNA was hybridized for 17h to Agilent Whole Rat Genome (4x44k) 
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Oligonucleotide Microarray Slides using Agilent Gene Expression Hybridization kit.  Microarray 
fluorescent images were acquired using GenePix 4000B scanner, with data extraction performed 
via GenePix 5.1 software (Molecular Devices, Melbourne, VIC, Australia).  Normalization and 
primary analysis of microarray data was performed using Aquity 4 software (Molecular Devices), as 
previously described (Carey KA, Segal D, Klein R, Sanigorski A, Walder K, Collier GR, and Cameron-
Smith D. Identification of novel genes expressed during rhabdomyosarcoma differentiation using 
cDNA microarrays. Pathology International 56: 246-255, 2006.).  Fluorescent reading for duplicate 
genes were averaged.  Each array dataset sample was normalized so that the median expression 
value in each array was 1.0.  The microarray dataset generated conforms to MIAME guidelines and 
is available at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi) series 
record GSEXXXX. 
Gene Set Enrichment Analysis (GSEA) using DAVID: 
Unpaired t-tests were used to identify genes, from the normalized microarray data, with evidence 
of differential expression between treatment groups (nominal p<0.05) (refer to Error! Reference 
source not found.).  The complete gene lists of putative differentially expressed genes were 
imported into the online Database for Annotation, Visualization and Integrated Discovery (DAVID) 
software package (version 6.7) (Huang et al., 2009).  Using the functional annotation tools, the data 
was analyzed to determine enrichment values for defined Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathways.  Pathways were selected based upon significant enrichment using 
Fisher’s exact statistical analysis (p<0.05) and fold enrichment score ≥1 .5. 
Gene Validation: 
Validation of pivotal genes and proteins within pathways was performed with alternative sets of 
treated animals by semi-quantitative real-time PCR (RT-PCR) and/or immunoblotting (n=4-5 per 
treatment group). 
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RT-PCR - Total RNA was extracted from the dissected brain region using the RNeasy-Plus Mini Kit 
(Qiagen, Valencia, CA), as per the manufacturer’s directions.  RNA was quantified using Nanodrop 
2000 (Thermoscientific, Wilmington, DE) and 1μg was used for cDNA synthesis using iScript 
reverse transcriptase (BioRad), as per the manufacturer’s instructions.  cDNA was aliquoted and 
sealed in plates and frozen at -20°C immediately.  iQSYBR Green supermix (BioRad) was used for 
RT-PCR as per the manufacturer’s directions.  For the RT-PCR reaction, 1ml cDNA and 300nM final 
concentration of each of the relevant Forward and Reverse primers were utilized.  The PCR 
conditions were 95°C for 3 min and 39 cycles of 95°C for 10 sec and 58°C for 30 sec, followed by 
melt curve 65°C for 5 sec and 95°C for 5 sec. RT-PCR results were normalized to the reference gene 
Hprt1 (expression of Hprt1 did not differ significantly between treatment groups).  Relative gene 
expression was calculated as 2-ΔCt, where Ct is threshold cycle. Supplementary Table 1 displays 
the list of primer sequences.  All sequences were designed using The National Center for 
Biotechnology Information (NCBI) Primer-Blast and oligos were ordered from Integrated DNA 
Technologies (IDT; Coralville, IA) 
Western Blotting- Each dissected brain region was solubilized on ice by homogenization in ice-cold 
RIPA lysis buffer (50mM Tris at pH 7.4 containing 150mM NaCl, 1mM EDTA, 0.5% Deoxycholic Acid 
(SDC), 1% Triton X-100 and 0.1% SDS) with freshly added phosphatase and protease inhibitors 
(1mM Na3VO4, 2mM PMSF, 10Pg/ml leupeptin, 10Pg/ml aprotinin and 10Pg/ml pepstatin A) using 
individually wrapped sterile 1.5ml pestles (Argos #P7339-901).  After solubilization, lysates were 
incubated on ice for 15 min and were then cleared of cellular debris by centrifugation at 930xg for 
20 min at 4°C.  Supernatants were collected into pre-chilled 1.5ml microfuge tubes.  Protein 
quantification was determined using BioRad’s Bradford assay kit with BSA as the standard.  
Samples were denatured in Reducing Sample buffer followed by incubation at 100°C for 5 min 
before being loaded onto and resolved by either 7.5 or 15% SDS-PAGE at 20Pg per lane.  Proteins 
were separated at140 V for ~45 min and subsequently transferred onto polyvinylidine diflouride 
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(PVDF) membranes (Millipore) using 1x transfer buffer (25 mM Tris, pH 8.2 containing 192 mM 
glycine, 20% methanol, 0.1% SDS) at 4°C, 100 V for 100 min.  PVDF membranes were blocked in 1x 
Tris-buffered saline, pH 7.4 and 0.1% (v/v) Tween20 (TBST) containing either 5% (w/v) BSA or 
5% (w/v) skim milk for 1 h on a rocking platform at room temperature (22°C).  The membranes 
were then incubated with the relevant primary antibody (Trkb; truncated and full length), Santa 
Cruz;, p-Trk, Cell Signaling; AMPK, Cell Signaling; p-AMPK, Cell Signaling; GSK3, Cell Signaling; p-
GSK3, Cell Signaling; p21, Santa Cruz; p-53, R&D Systems; mTOR, Cell Signaling and p-mTOR, Cell 
Signaling) as per the manufacturer’s methods for each antibody.  Protein bands were visualised 
using enhanced chemiluminescent (ECL) detection system reagents (Invitrogen, USA) and exposed to 
X-ray film (Kodac, Ultra blue sensitive).  The films were then scanned on to the Chemidoc MP Imaging 
System (BioRad) and quantitated using Analysis Software Image Lab version 4.0 (Bio-Rad, Hercules, 
CA). 
Statistical Analysis - Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS version 20.0, Fullerton, CA, USA).  Normality of data distribution was determined 
using a one-sample Kolmogorov-Smirnov test, and then analyzed using independent samples T-test 
or one-way ANOVA.  Homogeneity of variance of group mean differences was determined using 
Levene’s Test, and post-hoc analysis of ANOVA used either Fisher’s least significant difference (LSD, 
homogeneous variance) or Games-Howell (non-homogeneous variance).  For data not normally 
distributed, group mean differences were determined using the Kruskal-Wallis test followed by 
post-hoc analysis with Dunn’s multiple comparison test using GraphPad statistical software 
(version 6.0).  Data were considered statistically different at p<0.05 and each data point presented 
as the mean of ≥4 animals ± SE unless otherwise stated. 
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Results 
Tricyclic antidepressant resistance and response to DBS 
We established antidepressant resistance in male Sprague-Dawley rats utilizing chronic 
pretreatment with ACTH that was sufficient to alter behavioral response to the tricyclic 
antidepressant imipramine, as measured by the forced swim test. Imipramine (10mg/kg) 
significantly reduced immobility time in saline-treated rats only (p<0.05). In contrast, high 
frequency IL DBS effectively reduced immobility time in ACTH-treated animals (p<0.05) (Figure 1). 
No differences were observed for locomotor activity (Figure 1). 
Differential gene expression profile in the infralimbic cortex following forced swim stress 
Differential gene expression (P < 0.05 and fold enrichment score ≥1 .5) in the in the IL was 
determined as outlined in Table 1  The complete data set is shown in Supplementary Table S2.  Our 
primary comparisons of interest focussed on stress naïve versus stress exposure states for saline- 
and ACTH-treated animals. Additionally, we assessed the impact of DBS on these differential 
expression patterns for ACTH-treated animals. 
Table 2  Number of genes and pathways with evidence of differential expression between 
treatment groups. 
Number of 
Saline v 
ACTH 
Saline v 
Saline/FST 
Saline/FST v 
ACTH/FST 
ACTH v 
ACTH/FST 
ACTH/FST v 
ACTH-
DBS/FST 
Genes with 
differential 
expression (p<0.05) 
5376 4590 381 1390 1245 
Genes with mapped 
IDs to rat genome 
2039 1969 148 519 473 
Genes that could 
not be mapped 
3337 2621 218 738 627 
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Molecular pathways differentially expressed under forced swim stress in the IL of saline-treated 
antidepressant-responsive animals. 
The lists of genes with evidence of differential expression were subjected to functional enrichment 
analysis using the KEGG and PANTHER systems.  We found 43 pathways in which differentially 
expressed genes were overrepresented in the IL of saline pretreated animals under conditions of 
forced swim stress relative to the stress naïve state.  24 such pathways were identified using 
Panther software.  
Molecular pathways differentially expressed under forced swim stress in the IL of ACTH-treated 
antidepressant-resistant animals. 
The list of differentially expressed genes in the IL of ACTH-treated stress-naïve and ACTH-treated 
forced swim test stress exposed was subjected to functional enrichment analysis using the KEGG 
and PANTHER systems.  Using KEGG software, we found 17 pathways in which differentially 
expressed genes were overrepresented (Table 2), while only 4 pathways were identified using 
Panther software (Table 3).  
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Table 2 KEGG pathways identified as significantly overrepresented in the differentially expressed 
genes between ACTH and ACTH-FST rat IL. 
KEGG Pathway Number of 
differentially 
expressed genes 
in pathway 
Fold 
Enrichment 
Fisher Exact 
p-value 
Type I diabetes mellitus 8/ 4.8 2.0E-4 
p53 signaling pathway 9/ 4.4 1.7E-4 
Graft-versus-host disease 7/ 5.3 2.8E-4 
Allograft rejection 7/ 4.9 4.5E-4 
Antigen processing and presentation 10/ 4.2 1.1E-4 
Endocytosis 15/ 2.4 1.2E-3 
Autoimmune thyroid disease 7/ 4.1 1.3E-3 
Adipocyte signaling pathway 8/ 3.6 1.5E-3 
mTOR signaling pathway 6/ 3.6 6.3E-3 
MAPK signaling pathway 16/ 1.9 1.2E-2 
Cell cycle 9/ 2.3 1.6E-2 
Pathways in cancer 17/ 1.7 2.2E-2 
Viral myocarditis 7/ 2.7 1.3E-2 
Insulin signaling pathway 9/ 2.2 2.3E-2 
Prostate cancer 7/ 2.6 1.8E-2 
ErbB signaling pathway 7/ 2.6 1.8E-2 
Chronic myeloid leukemia 6/ 2.6 2.7E-2 
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Table 3 PANTHER pathways identified as significantly overrepresented in the differentially 
expressed genes between ACTH  and ACTH-FST rat IL. 
Molecular pathways differentially expressed in the IL of antidepressant-resistant animals with 
efficacious DBS. 
The differentially expressed IL gene list of ACTH-treated forced swim test stress exposed animals 
with and without DBS was subjected to functional enrichment analysis using the KEGG and 
PANTHER systems.  We found 21 pathways in which differentially expressed genes were 
overrepresented using KEGG (Table 4), and 4 pathways using Panther software (Table 5).  
PANTHER Pathway Number of 
differentially 
expressed genes in 
pathway 
Fold 
Enrichment 
Fisher Exact 
p-value 
p53 pathway 8/ 2.2 2.8E-2 
Insulin/IGF pathway-mitogen activated 
protein kinase kinase/MAP kinase cascade 
5/ 3.5 1.3E-2 
Interleukin signaling pathway 11/ 2.2 8.9E-3 
PDGF signaling pathway 11/ 1.9 2.4E-2 
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Table 4 KEGG pathways identified as significantly overrepresented in the differentially expressed 
genes between ACTH-FST and ACTH-FST-DBS rat IL. 
KEGG Pathway Number of 
differentially 
expressed genes 
in pathway 
Fold 
Enrichment 
Fisher Exact 
p-value 
Pathways in cancer 19/ 2.0 3.3E-3 
Oocyte meiosis 10/ 3.0 1.8E-3 
Thyroid cancer 6/ 6.8 2.0E-4 
Bladder cancer 6/ 5.3 8.3E-4 
Cell cycle 11/ 2.9 1.3E-3 
Progesterone-mediated oocyte maturation 8/ 3.2 3.6E-3 
Acute myeloid leukemia 6/ 3.6 6.2E-3 
Chronic myeloid leukemia 7/ 3.2 6.4E-3 
Melanoma 7/ 3.2 5.4E-3 
Chemokine signalling pathway 10/ 1.9 3.5E-2 
Gap junction 7/ 2.8 1.2E-2 
Type I diabetes mellitus 5/ 3.2 2.0E-2 
Endocytosis 11/ 1.9 3.5E-2 
Natural killer cell mediated cytotoxicity 7/ 2.4 2.6E-2 
Melanogenesis 7/ 2.5 2.1E-2 
Regulation of actin cytoskeleton 12/ 1.9 2.4E-2 
T cell receptor signaling pathway 8/ 2.4 1.8E-2 
Complement and coagulation cascades 6/ 2.7 2.3E-2 
Cell adhesion molecules 9/ 2.1 2.5E-2 
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Table 5 PANTHER pathways identified as significantly overrepresented in the differentially 
expressed genes between ACTH-FST and ACTH-FST-DBS rat IL. 
Validation of IL molecular pathways differentially regulated under stress in treatment resistance 
and DBS treatment response 
Significant alterations were observed in key pathways of energy demand, cell division/growth, 
apoptosis, protein synthesis and glucose/glycogen regulation across groups. 
PANTHER Pathway Number of 
differentially 
expressed genes 
in pathway 
Fold 
Enrichment 
Fisher Exact 
p-value 
p53 pathway feedback loops 2 6/ 2.7 2.3E-2 
PDGF signaling pathway 11/ 1.7 5.0E-2 
Inflammation mediated by chemokine and 
cytokine signaling pathway 
17/ 1.6 3.8E-2 
Ras pathway 8/ 2.5 1.4E-2 
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Figure 2 – Cellular metabolism pathway genes and proteins 
Figure 3 – Cellular stress pathway genes and proteins 
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Figure 4 – Cell survival pathway genes and proteins 
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Discussion: 
Novel molecular signatures of resistance and response were identified in the IL of TCA treatment 
resistant and responsive animals. Additionally, the impact of the IL DBS on these local molecular 
mechanisms in TCA-resistant animals was determined. The IL, as the rodent homologue of the 
human subgenual cingulate, is an area of particular interest for elucidating mechanisms associated 
with treatment response and non-response (Mayberg ref). It is now well established that this 
region is hyperactive in depressive states and that activity is consistently reduced by efficacious 
treatment response, regardless of mechanism. This is true for response to placebo, cognitive 
behavioral therapy, pharmacotherapies such as SSRI, ECT as well as DBS therapeutics in the most 
treatment resistant of patients (McCormick et al., 2009; Mayberg, Henn).  
This study demonstrated that induction of treatment resistance with chronic ACTH treatments 
results in a substantially distinct gene expression profile in many pathways and systems in the IL of 
ACTH and saline-treated animals exposed to the FST stress relative to their stress naïve 
counterparts. Functional pathway analysis revealed that inflammatory, metabolic, cell stress and 
cell survival molecular pathways were differentially up- or down –regulated in the IL of these 
animals that foundationally distinguished these treatment-resistant and responsive groups. 
Moreover, application of IL DBS served to partially reverse the metabolic gene expression profile 
and nearly fully reversed the cellular stress signaling profile of the ACTH treated TCA-resistant 
animals. 
Exposure to the forced swim behavioral stressor significantly elevated p53 expression in the IL of 
ACTH-treated TCA-resistant animals. p53 is a critical molecular mediator of cellular stress and 
survival, and for this reason, plays a critical role in cancer proliferation.  p53 interacts with other 
regulatory components of cellular metabolism, growth and survival, including Akt1, Wnt, and 
GSK3β. Akt signaling plays a critical role in cellular growth and metabolism via interaction with 
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JNK, MAPK, mTOR and GSK3β. An important functional outcome of this is regulation of 
glucose/glycogen production, cell growth and neural plasticity. These changes in term alter 
downstream pathways associated with cell stress including β-oxidation and proteasomal 
degradation. This finding highlights a potentially compensatory mechanism occurring with the IL 
under stress – upregulation of cellular metabolism as a potentially compensatory mechanism for 
the elevated energetic demands on this region under duress. As noted above, the IL and subgenual 
cingulate are well established to be metabolically hyperactive during depressive states, with this 
metabolic overactivity normalized with efficacious treatment. Collectively, our data suggests this 
metabolic shift (upregulation in depression) may functionally occur as cells in this region attempt 
to keep up with demand and counter the damaging and potentially lethal effects of cellular stress, to 
in turn support cellular survival and growth processes.  That is, ACTH-treated animals have 
significant demand on this region due to chronic stimulation of the HPA-axis. In turn, with 
supplemental forced swim stress, this region has limited capacity to respond to additional demands 
and cells in the region demonstrate a molecular profile reflective of allostatic overload / cellular 
stress (Walker et al., 2014). It is interesting to note that DBS reverses this profile in ACTH-treated 
animals, with differential signaling identified for the p53 feedback loop in these animals. 
Hypoxia is also induced under states of cellular stress, and this was observed in our ACTH-treated 
stressed animals. An increase in HIF gene expression levels, observed herein, has been associated 
with oxygen deprivation. Increased hypoxia due to stress, decreases VEGF and activates tight 
junction and vesicular transport by activating SNAP and SNARES, an important mechanism to 
compensate for energy deficits.  Exposure to the stress of the FST activated caspase, WNT, insulin 
and HIF, may serve to compensate for glucose and oxygen deprivation. 
The role of inflammatory signaling in this model is of particular interest, particularly given recent 
data emerging in the field as to the effects of acute inflammation in chronically stressed animals and 
the potential of anti-inflammatory antidepressive strategies (Kim et al., 2015; Köhler et al., 2014). 
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Herein we demonstrate that inflammatory signaling cascades were upregulated in the IL of 
treatment-responsive saline pretreated animals following exposure to the FST. Conversely, these 
same pathways were downregulated in the IL following forced swim exposure in the ACTH-treated 
antidepressant resistant animals. This differential expression profile may reflect the impact of 
chronic ACTH-pretreatment on inflammation in the brains of these animals, such that subsequent 
stress exposure attenuated rather than enhanced these responses. DBS, not surprisingly, resulted in 
upregulation of these inflammatory pathways relative to ACTH-FST animals not receiving DBS. Of 
note, levels of monocyte chemoattractant protein-1 (MCP-1), a potent chemokine synthesized by 
several cell types, were 400 fold elevated in DBS animals relative to all other groups. This was the 
most robust difference observed across groups for all genes and proteins quantified, and may 
reflect and important initiating or contributing factor to the other molecular responses observed 
with DBS.  Altering the microglial milieu within the brain may be an important contributing factor 
to other observed metabolic and cellular stress and cell growth adaptations occurring therein. 
Given glial cells play a particularly important role in maintaining neuronal energetic capacity at the 
tripartite synapse, this potential interaction warrants further investigation as a potentially 
important mechanism in both antidepressant treatment resistance and response. Specifically, its 
potential to impact response to DBS in the most refractory of patients needs to be explored. 
Overall, treatment with DBS in the IL cortex has a mechanism of action which reverses or stops the 
cellular cascade initiated by stress. IL DBs decreases GADD45B, GADD45G and Hifα, which were all 
increased in our ACTH stress model. Moreover, HSP27 activity is increased with DBS, this could be 
due to the introduction of a foreign substance such as electrode. A higher level of p53 and CHOP is 
associated with DNA damage and apoptosis. In our ACTH stress model, levels of p53, p21 and CHOP 
were elevated, whereas the IL DBS group showed a reduction in the expression of these genes. 
Inflammatory markers such as MCP-1 show increased activity with DBS treatment. MCP-1 is the 
primary response to any foreign substance that could be elevated due to electrode placement. 
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However, this inflammatory response seems to revert to baseline indexed by other inflammatory 
markers such as TNFα and interleukins (IL). Moreover, cell check cycle is another critical cycle that 
is regulated with DBS treatment, shown by decreased levels of CREB2/ATF4 and cyclin B levels. 
Lastly, IL DBS suppresses major contributors involved in growth hormone and cell signaling, which 
is correlated with suppression of apoptotic markers.  
Identifying the unique and independent pathway responsible in subtypes of depression could be 
beneficial to diagnose patient’s depression subtype. This supports systems biology based 
approaches and can also lead to further research into depression drug therapy to better assist the 
patients.   
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Figures for discussion 
1. 
2.
196 
Acknowledgements: 
MB is supported by a NHMRC Senior Principal Research Fellowship 1059660. 
Conflicts of Interest: 
MB and has received Grant/Research Support from Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, 
Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a 
speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, 
Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and  Wyeth, and served as a consultant to Astra 
Zeneca, Bioadvantex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck 
and Servier. 
197 
 
 
References 
 
Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF (2005): Medial prefrontal cortex 
determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 
8:365–371. 
 
Diorio D, Viau V, Meaney MJ (1993): The role of the medial prefrontal  cortex (cingulate gyrus) in the 
regulation of hypothalamic-pituitaryadrenal responses to stress. J Neurosci 13:3839 –3847. 
 
Gabbott PL, Warner TA, Jays PR, Bacon SJ (2003): Areal and synaptic interconnectivity of prelimbic 
(area 32), infralimbic (area 25) and insular cortices in the rat. Brain Res 993:59 –71. 
 
Hardy SG, Holmes DE (1988): Prefrontal stimulus-produced hypotension in rat. Exp Brain Res 73:249 
–255. 
 
Holtzheimer PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A et al. (2012): Subcallosal 
cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression Arch Gen 
Psychiatry 69: 150–158. 
 
Kim SW, Bae KY, Kim JM, Shin IS, Hong YJ, Ahn Y, Jeong MH, Berk M, Yoon JS (2015): The use of statins 
for the treatment of depression in patients with acute coronary syndrome. Transl Psychiatry 5: e620 
 
Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014): Effect of anti-
inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic 
review and meta-analysis of randomized clinical trials JAMA Psychiatry 71:1381-91. 
Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH (2008): Subcallosal 
cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 64 :461–
467 
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C et al. (2005): Deep brain 
stimulation for treatment-resistant depression. Neuron, 45: 651–660. 
McCormick LM, Yamada T, Yeh M, Brumm MC, Thatcher RW (2009): Antipsychotic effect of 
electroconvulsive therapy is related to normalization of subgenual cingulate theta activity in 
psychotic depression. J Psychiatr Res. 43:553-60. 
Milad MR, Quirk GJ (2002): Neurons in medial prefrontal cortex signal memory for fear extinction. 
Nature 420:70 –74. 
 
Milad MR, Vidal-Gonzalez I, Quirk GJ (2004): Electrical stimulation of medial prefrontal cortex 
reduces conditioned fear in a temporally specific manner. Behav Neurosci 118:389 –394. 
 
Moylan S, Maes M, Wray NR, Berk M (2013): The neuroprogressive nature of major depressive 
disorder: pathways to disease evolution and resistance, and therapeutic implications Mol Psychiatry 
18:595-606.  
Ostrander MM, Richtand NM, Herman JP (2003): Stress and amphetamine induce Fos expression in 
medial prefrontal cortex neurons containing glucocorticoid receptors. Brain Res 990:209 –214. 
 
198 
Quirk GJ, Russo GK, Barron JL, Lebron K (2000): The role of ventromedial prefrontal cotex in the 
recovery of extinguished fear. J Nerosci 20:6225-6231 
Resstel LB, Correa FM (2005): Pressor and tachycardic responses evoked by microinjections of L-
glutamate into the medial prefrontal cortex of unanaesthetized rats. Eur J Neurosci 21:2513–2520. 
Takagishi M, Chiba T (1991): Efferent projections of the infralimbic (area 25) region of the medial 
prefrontal cortex in the rat: An anterograde tracer PHA-L study. Brain Res 566:26 –39. 
Tavares RF, Antunes-Rodrigues J, de Aguiar Correa FM (2004): Pressor effects of electrical 
stimulation of medial prefrontal cortex in unanesthetized rats. J Neurosci Res 77:613– 620. 
Walker AJ, Kim Y, Price JB, Kale RP, McGillivray JA, Berk M, Tye SJ (2014): Stress, Inflammation, and 
Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and 
Opportunities for Prevention and Intervention. Front Psychiatry  9:5-34.  
Wang RS, Maron BA, Loscalzo J (2015): Systems medicine: evolution of systems biology from bench 
to bedside. Wiley Interdiscip Rev Syst Biol Med 7:141-61.  
199 
Chapter 7. Region- and frequency-specific transient dopamine release as a mechanism of 
deep brain stimulation in anesthetized rats 
Yesul Kim 
Deakin University 
Contributing authors: Rodney J. Anderson1, Kyoko Hasebe2, Kevin Bennet3, Kendall H. Lee4, Mark A. 
Frye5 and Susannah J. Tye5 
1 Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia. 
2 Faculty of Health, Deakin University, Australia. 
3 Division of Engineering, Mayo Clinic, USA. 
4 Department of Neurosurgery, Mayo Clinic, USA. 
5 Department of Psychology and Psychiatry, Mayo Clinic, USA. 
Manuscript prepared for the Journal of Neuroscience. 
200 
 
 
Abstract 
Over the last decade, deep brain stimulation (DBS) has demonstrated potential as a therapeutic 
intervention for treatment resistance depression (TRD). However, its mechanisms of action remain 
unknown and further experimental and clinical studies are needed to determine the central actions 
of DBS. Each of the clinical targets for DBS modulate the mesoaccumbens dopamine (DA) system; a 
system extensively studied for its involvement in normal reward-related function. Dysfunction of 
the mesoaccumbens dopamine system also plays a critical role in depressive pathophysiology. The 
influence of DBS at neurologic targets used to treat TRD on mesoaccumbens dopamine 
neurotransmission has not been investigated. We have addressed this issue by quantifying the 
effects of DBS of the nucleus accumbens (NAc), infralimbic cortex (IL) and lateral habenula (LHb) 
on transient NAc DA release in urethane-anesthetized male Sprague Dawley rats. Real-time ventral 
tegmental area-evoked (125μA, 60Hz, 2ms pulse width for 23 pulses) NAc DA efflux was measured 
with fast-scan cyclic voltammetry during the pre-DBS phase (baseline; 60 min), high (130Hz) or 
low (10 Hz) frequency (both at 100μA, 90μs pulse width) DBS phase (90 min) and post-DBS phase 
(120 min).  Data demonstrated that low frequency DBS elicited a negligible response in all three 
regions, while high frequency DBS to IL and NAc significantly attenuated DA release in the NAc. In 
contrast, LHb high frequency DBS induced a significantly potentiated DA-efflux in the NAc. The IL- 
and LHb-DBS-induced effects were sustained for >2hrs post-DSB, indicative of long-term 
depression and potentiation, respectively. These findings demonstrate a regional- and frequency-
specific effect of DBS on NAc DA release and long-term plasticity, therefore suggesting that 
modulation of synaptic plasticity may be a possible mechanisms of action.  
Keywords: dopamine, nucleus accumbens, infralimbic, lateral habenula, deep brain 
stimulation  
201 
Deep brain stimulation (DBS) for treatment resistant depression (TRD) is a promising 
clinical neuromodulation intervention (Bewernick et al., 2010; Holtzheimer et al., 2012; Lozano et 
al., 2008; Mayberg et al., 2005; Puigdemont et al., 2012; Sartorius et al., 2010; Schlaepfer et al., 
2007). Neuromodulatory targets include the subgenual cingulate gyrus (SCG), nucleus accumbens 
(NAc) and lateral habenula (LHb) for patients with TRD (Holtzheimer et al., 2012; Sartorius et al., 
2010; Schlaepfer et al., 2007). These regions were targeted due to converging evidence that shows 
their prominent role in stress appraisal (Amat et al., 2005), emotion regulation (Damasio et al., 
2000; Liotti et al., 2000; Mayberg et al., 2014), dysfunction in emotion processing (Drevets, Bogers, 
& Raichle, 2002; Mayberg et al., 2005; Wu et al., 1999) and involvement in the successful 
amelioration of depressive symptomatology via various treatment modalities (Dougherty et al., 
2003; Goldapple et al., 2004; Kennedy, Foy, Sherazi, McDonough, & McKeon, 2007; Mayberg, 2002; 
Mayberg et al., 2000; Mottaghy et al., 2002). Despite encouraging results from early single site 
trials, where a large number of patients experienced relief and remitted from TRD, the mechanisms 
of action underlying the therapeutic effects are unresolved. Our lack of understanding of these 
mechanisms may have contributed to the failure or discontinuation of larger, randomized, double-
blind studies that have attempted to extend these techniques (Cavuoto, 2013; Dougherty et al., 
2014; Morishita, Fayad, Higuchi, Nestor, & Foote, 2014). It is therefore, imperative that we 
investigate the antidepressant actions of DBS so that the translation of early clinical success is not 
stalled unnecessarily. 
The goal of this paper is to quantify the effects of high frequency (HF) and low frequency 
(LF) DBS on transient stimulation-evoked NAc dopamine (DA) efflux in the rodent homologue of 
the human SCG, the infralimbic (IL) cortex (Gabbott, Warner, Jays, & Bacon, 2003; Shumake & 
Gonzalez-Lima, 2003; Takagishi & Chiba, 1991), NAc and LHb. Norepinephrine and serotonin have 
traditionally been the focus of treatment efficacy and disease pathophysiology in major depressive 
disorder (MDD). However, an increasing body of literature indicates the involvement of mesolimbic 
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DA pathway in mood regulation and its dysfunction in MDD symptomatology, which is particularly 
more pronounced in the treatment resistant population (Dunlop & Nemeroff, 2007; Malhi & Berk, 
2007; Nestler & Carlezon, 2006; Tremblay et al., 2005). Transient DA is a critical gating mechanism 
for glutamatergic information flow through the NAc (See Figure 1.) wherein it effectively selects 
whether cortical or limbic inputs activate GABAergic output to subcortical regions (Chaudhury et 
al., 2013; Goto & Grace, 2005). Recent findings from diffusion tensor magnetic resonance imaging 
tractography (Coenen, Schlaepfer, Allert, & Mädler, 2012; Schoene-Bake et al., 2010), optogenetics 
(Lammel, Tye, & Warden, 2014; Warden et al., 2012) and fast scan cyclic voltammetry (Stuber, 
Roitman, Phillips, Carelli, & Wightman, 2005) further reinforce the important role of the reward-
related system in TRD. These studies conceptualize depressive symptoms as arising from 
dysregulated networks that are responsible for stimulus appraisal, reward/aversion processing 
and reward/punishment anticipation. Consequently, patients suffering from TRD may achieve 
therapeutic effects by manipulating these systems via pharmacological or DBS intervention 
(Schlaepfer, Bewernick, Kayser, Hurlemann, & Coenen, 2014). DA neurotransmission in the NAc, 
which arises from DA producing neurons in the ventral tegmental area (VTA), plays an important 
neuromodulatory role in regulation of plasticity thought to be a key mechanism of antidepressant 
response (Bonci & Malenka, 1999; Friedman, Friedman, Dremencov, & Yadid, 2008). 
203 
Figure ͳ. Major dopaminergic, glutamatergic and GABAergic connections to and from 
the VTA and NAc in the rodent brain. Dopaminergic projections from the VTA to the 
NAc releases DA in response to reward-related (or aversion-related) stimuli. The NAc 
also receives densely innervated glutamatergic circuits from the medial prefrontal 
cortex (mPFC), hippocampus (HIP) and the amygdala (Amyg). Lastly, there are 
GABAergic projections from the NAc to the lateral hypothalamus (LH) and the VTA. 
These circuits control aspects reward-related perception, memory and learning. 
Neuroplasticity within the mesolimbic DA pathway has been shown to be involved in the 
maintenance of emotional homeostasis (Krishnan et al., 2007), with disruption of neuroplasticity 
potentially contributing to the neuroprogressive stage of treatment resistance (Pittenger & Duman, 
2008). The requirement of DA for the induction of striatal long term potentiation (LTP) and long 
term depression (LTD) makes these two forms of synaptic plasticity unique in comparison to long 
term synaptic plasticity changes in other brain regions (Calabresi, Picconi, Tozzi, & Di Filippo, 
2007). Dysregulation of DA signaling may thus negatively impact long-term plasticity and an 
individual’s capacity for adaptive responses to antidepressant action over time. 
Here, we examined VTA stimulation-evoked transient NAc DA neurotransmission during 
DBS of the IL, NAc or LHb regions of male wistar rats. We hypothesized that HF stimulation but not 
LF stimulation, would modulate phasic DA neurotransmission. Further, given that Walker et al. 
(2013) observed attenuation of transient DA levels in the ACTH preclinical model, we hypothesized 
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that DBS may function to recover this signal. Correcting the altered DA transmission, together with 
disrupted hypothalamic pituitary axis stress system may be potential pharmacological and/or 
neuromodulatory targets for reinstating treatment response. We also monitored DA 
neurotransmission after discontinuing stimulation to these regions in order to evaluate 
neuroplasticity as a possible mechanism underlying the therapeutic effects of DBS. Lastly, we 
hypothesized that HF stimulation would induce lasting effects on neurotransmitter efflux, 
consistent with long term plasticity observed in animals’ response to tetanic (i.e. HF) stimulation. 
Methods 
Animals 
Male Sprague-Dawley rats were purchased through Deakin University Animal House 
(Geelong, Victoria, Australia) and Animal Resources Centre (Perth, WA, Australia). Experiments 
were carried out between 9:00 a.m. and 6:00 p.m. on animals weighing 200-350g. Animals were 
housed in pairs, in a temperature controlled environment with 12-hour light/dark cycles and 
access to food and water ad libitum. Animal care and experimental procedures were conducted in 
accordance with the Prevention of Cruelty to Animals Act 1986 (2009), and the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (2004). Ethics approval was 
received for the project from the Animal Welfare Committee, Deakin University (Geelong, Australia) 
and the Florey Institute of Neuroscience and Mental Health Animal Experimental Ethics committee, 
University of Melbourne (Melbourne, Australia). 
Surgical Procedure 
Rats were anaesthetized with urethane (1.5g/kg) intraperitoneally, placed in a stereotaxic 
frame (David Kopf Instruments, Tujunga, California, USA) and body temperature maintained at 
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37°C with an isothermal heat pad (Delta Phase Isothermal Pad, Braintree Scientific, Braintree, 
Massachusetts). An incision was made along the midline of the scalp and the skin retracted to 
expose the skull. Four burr holes were drilled in the skull for placement of the reference, recording, 
and two stimulating electrodes. Concentric bipolar stimulating electrodes (SNE-100, d = 0.25mm, 
exposed surface = 0.75mm; Rhodes Medical Instruments, Summerland, CA, USA) were placed in the 
VTA or DBS target region (IL, NAc or LHb). A recording electrode (carbon-fiber microelectrode) was 
placed in the core of the NAc. Both the stimulating and recording electrodes were placed in the left 
hemisphere, with the reference electrode positioned in superficial cortex in the contralateral 
hemisphere. A chloridized silver wire (Ag/AgCl) was used as a reference electrode. Coordinates for 
all electrodes were calculated using the atlas of Paxinos and Watson (2007). Coordinates for the 
recording electrode in the NAc, in millimetres, (referenced to bregma) were: anteroposterior (AP) = 
+1.2, mediolateral (ML) = +1.5, dorsoventral (DV) = -6.5 to 8.0; the stimulating electrode in the IL 
(referenced to bregma) AP= +3.0, ML=0.1, DV= -5.8, NAc AP +1.5, ML ±1.5, DV -7.0 or LHb AP -3.7, 
ML, ±0.8, DV -5.4 and the stimulating electrode in the VTA (interaural coordinates) AP= -2.16, ML= -
0.6, DV= -2.0 to 1.2. Due to space constraints, the stimulating electrode in the IL was lowered at an 
angle of 60° from the contralateral hemisphere to its final coordinates. Once a robust voltammetric 
response was obtained (determined by the size of the current at the peak oxidation potential of DA) 
the electrodes were maintained at these coordinates throughout the experiment. 
Electrochemistry 
Fast scan cyclic voltammetry was performed using 5μm-diameter carbon fiber electrodes. 
Voltammetric scans, stimulus waveform generation and timing, data collection were performed 
using Wireless Instantaneous Neurotransmitter Concentration System (Bledsoe et al., 2009). All 
carbon fiber electrodes were tested for stable background currents and responsiveness prior to 
each experiment sitting. Voltammetric scans from -0.4V to 1.3V and from 1.3V to -0.4 were 
performed at 300V/s in a triangle waveform which was repeated every 100ms, with the potential 
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held at -0.4V between scans. The high scan-rates used produce a large background current (Heien & 
Wightman, 2006), which is removed by subtracting a series of cyclic voltammograms prior to 
stimulation. The resultant background-subtracted voltammogram provides a signature for the 
species oxidised or reduced at the CFM. DA at the carbon-fiber surface is oxidised (at ~ +0.6V 
versus Ag/AgCl) and the electroformed DA-o-quinone is then reduced back to DA (at ~ -0.3V versus 
Ag/AgCl). Changes in the resulting oxidative current are proportional to changes in DA 
concentration at the carbon fiber surface (Robinson & Wightman, 2006). 
Electrical Stimulation 
DA release was evoked with monophasic stimulation pulses at 125μA, 60Hz, 2ms pulse 
width for 23 pulses, (Master 9 Pulse Stimulator and Iso-Flex Stimulation Pulse Isolator; AMPI, 
Israel). These parameters were chosen to mimic endogenous transient DA release (Heien & 
Wightman, 2006). During the DBS phase of the experiments the brain regions were stimulated for 
90 minutes at 100μA, 90μs pulse width, and 130Hz for the HF DBS condition and 10Hz for the LF 
DBS condition. The stimulation parameters for the HF condition were chosen to approximate the 
charge density of that experienced by patients receiving DBS for TRD (Hamani, Diwan, Isabella, 
Lozano, & Nobrega, 2010) that takes into account the smaller volume of the rat brain and the size of 
the electrodes. 
Histological Verification of Electrode Placement 
At the conclusion of each experiment, while all electrodes were still in place, lesions were 
created by applying a DC current to the stimulating electrodes (100μA for 5sec). Animals were 
euthanized using a 1.0 ml urethane intracardial injection, the brain removed immediately and fixed 
in a 10% formalin solution. Brain slices were prepared (40μm coronal sections) using a cryostat 
microtome (Cryostat HM500 Series) at -23°C, mounted on glass slides and viewed under a light 
207 
microscope. The location of the recording electrode in the NAc was determined from the tract left 
by the electrode shaft (see Figure 2 for histology schematics). 
Figure 2. Target locations of stimulating electrodes and recording carbon-fiber 
electrode (left to right). A, B &C is in reference to IL DBS; D, E &F is a schematic 
representation of NAc DBS; LHb electrodes tracts are G, H &I. Specifically, first column 
represents VTA-evoked stimulation sites, second column indicates HF DBS sites and 
lastly, the third column shows recording sites. Green dots refer to LF DBS whereas HF 
is illustrated with red dots. Figures adapted from Paxinos and Watson (2007). 
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DBS Experimental Design and Statistical Analysis 
Each DBS experiment consisted of three phases: a baseline phase, DBS phase, and a post-
DBS phase. For each experiment, baseline was calculated by averaging all responses subsequent to 
final coordinates being reached. Each animal was assigned to either a HF condition (n = 5) or a LF 
condition (n = 4-5). DA release, measured as current at the maximum oxidation potential of DA, was 
the measured variable. An independent samples t-test was used to compare the mean change in DA 
release from baseline during HF to that of LF stimulation. The statistical significance level was set at 
p < .05. The homogeneity of variance assumption was confirmed using Levene’s test for equality of 
variance. 
Results 
Differential DA efflux with NAc, IL or LHb DBS in healthy control animals 
Results show differential changes to VTA-evoked DA release in the NAc, depending on the 
DBS target. Further, HF stimulation brought on greater attenuation of DA following IL (Figure 3.) 
and NAc DBS, whereas HF LHb DBS potentiated DA release in the NAc. Table 1 summarizes the 
associated percent change in DA efflux prior to stimulation (baseline), during stimulation and 
following DBS. Mean percentage changes from baseline to the effects of HF or LF is graphically 
represented for all targets in Figure 5. 
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Figure 3. A decrease in DA efflux from baseline levels recorded in the NAc following 
HF stimulation to the IL. Representative current time plots for baseline (top left) 
versus during HF stimulation (top right). Note that the colorplot corresponds to the 
above current representative figure. The purple spots represent VTA evoked DA 
release.  
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Table 1. A summary table of percentage change observed for VTA-evoked DA release in the NAc 
prior to, following and post NAc, IL and LHb DBS. 
Percent Change 
PreDBS vs. DBS 
PreDBS vs. 
LateDBS 
PostDBS vs. 
LateDBS 
EndPostDBS vs. 
LateDBS 
LHb HF M 33.09 40.05 -0.17 -14.10 
SD 12.40 21.89 14.26 8.40 
SEM 5.54 9.79 6.38 3.76 
LHb LF M -1.98 -4.36 -13.42 -24.81 
SD 2.32 29.74 12.37 15.08 
SEM 1.16 14.87 6.18 7.54 
IL HF M -27.60 -37.75 -8.49 -11.21 
SD 10.77 7.46 6.21 1.92 
SEM 6.22 4.30 3.59 1.11 
IL LF M 6.08 -0.73 -16.39 -17.87 
SD 11.78 6.92 20.34 19.10 
SEM 5.89 3.46 10.17 9.55 
NAc HF M -10.30 -22.95 -23.22 -20.25 
SD 20.89 12.87 16.81 23.96 
SEM 9.34 5.76 7.52 10.72 
NAc LF M -2.26 -9.32 -18.68 -26.30 
SD 19.77 21.65 10.45 10.30 
SEM 8.84 9.68 4.67 4.61 
LHb –lateral habenula; NAc –nucleus accumbens, IL –infralimbic, DBS –deep 
brain stimulation, HF –high frequency, LF –low frequency; n =3-6 for each 
group. Late DBS refers to second half of active DBS whereas Post DBS refers 
to recordings made with no active DBS (once stimulation stopped).  
IL region. During 90 min of HF DBS of the infralimbic cortex DA release in the core of the 
NAc decreased by a mean of -27.60% of baseline (SEM = 6.22) to a significantly greater degree than 
the low frequency stimulation group that showed a mean decrease of 5.61% of baseline (SEM = 
3.96), t(10) = 5.87, p < .01, d = 4.48 (the homogeneity of variance assumption was satisfied, with 
Levene’s test showing no significant difference between variances). Note the gradual decrease in 
the relative concentration of DA over time in both the HF and LF conditions; this may be due to 
decreasing sensitivity of the recording electrode. DA release did no return to baseline levels after 
stimulation was discontinued for period of at least 2 hr. 
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NAc region. An independent samples t-test showed that the magnitude of DA signal during 
HF DBS was significantly attenuated in comparison to pre HF DBS DA signal evoked by VTA 23 
pulses stimulation, t(4) = 6.58, p < .01. A Cohen’s d (d = 5.37) indicated that the magnitude of 
transient DA release between pre HF DBS and HF DBS was considerably differed by 5.37 standard 
deviations. Also, the magnitude of phasic DA release after HF DBS was significantly smaller than 
those before HF DBS, t(4) = 6.20, p < .01, and the effect size (d= 5.07) revealed the substantial mean 
difference (approximately 5 SD) in the amount of phasic DA release between pre and post HF DBS 
(Figure 4.). The magnitude of post HF DBS DA signal did not significantly differ from those of during 
HF DBS, t(4) = 1.81, p > .05. 
Figure 4. A comparison of VTA-evoked transient DA release between baseline (left) 
and post HF DBS (right).  
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LHb region. An independent samples t-test was conducted to examine differences in mean 
percentage changes between HF and LF condition in rats. This analysis revealed that only HF DBS 
potentiates VTA- evokes NAc DA efflux in control animals, t(9) =6.917, p < 0.001. Interestingly, in 
the LHb, HF DBS potentiates NAc DA release in controls (pre-DBS vs. DBS), t(10) =1.288, p > 0.05. 
VTA-evoked NAc DA efflux 2 hours post-DBS relative to during DBS in control animals show long 
term plasticity evident for healthy controls, t(10) = 4.331, p < .01. 
Figure 5. Mean percent change (± SEM) in evoked dopamine efflux from baseline in 
the NAc after 90 minutes of high-frequency stimulation (n = 3-6) and low-frequency 
stimulation (n = 4-6). Error bars represent the standard error of the mean. Dopamine 
was evoked with 23 pulses, 60Hz, 125μA, 2ms pulse width, monophasic stimulation of 
the VTA. 
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Discussion 
We found that HF stimulation of the IL and NAc in the rat attenuated VTA evoked phasic DA 
neurotransmission in the core of the NAc, whereas LF stimulation elicited a negligible response. 
Clinically, HF stimulation is necessary for the induction of antidepressant properties of DBS in the 
TRD population. Consistent with these clinical findings, we demonstrated that HF stimulation, but 
not LF stimulation, of these regions modulated DA transmission. Interestingly, a potentiation NAc 
DA was observed for animals with LHb HF DBS. Mechanisms underlying changes of phasic DA efflux 
in the NAc with DBS may have occurred via direct (monosynaptic) and indirect (multisynaptic) 
pathways. 
The monosynaptic pathway for IL DBS involves excitation of glutamatergic efferents via 
orthodromic activation from DBS, which projects directly to the NAc (Takagishi & Chiba, 1991; 
Vertes, 2004). In the NAc, the excitation of GABAergic medium spiny neurons may inhibit DA 
neurotransmission. It has been shown experimentally that glutamate input to the NAc can affect DA 
neurotransmission independent of the action on DA neurons in the VTA (Howland, Taepavarapruk, 
& Phillips, 2002). A number of indirect pathways may be involved in the attenuation of phasic DA in 
the NAc glutamatergic neurons project to the VTA (Carr & Sesack, 2000; Geisler, Derst, Veh, & 
Zahm, 2007; Geisler & Zahm, 2005; Takagishi & Chiba, 1991; Vertes, 2004)  and form synapses with 
GABAergic interneurons (Adell & Artigas, 2004; Carr & Sesack, 2000) as well as forming minor 
connections with GABAergic neurons of the ventral pallidum (Takagishi & Chiba, 1991; Vertes, 
2004). Importantly, both of these regions project to and synapse with DA neurons within the VTA 
(Adell & Artigas, 2004; Bayer & Pickel, 1991; Geisler & Zahm, 2005; Kalivas, 1993). This is 
remarkable as excitation of GABAergic neurons from both these sources can lead to inhibition of the 
DA neurons in the VTA which project to NAc (Adell & Artigas, 2004; Björklund & Dunnett, 2007; 
Carr & Sesack, 2000; Ikemoto & Panksepp, 1999; Moore & Bloom, 1978; Swanson, 1982). IL 
glutamatergic neurons also synapse with GABAergic projection neurons in the VTA that project 
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directly to the NAc (Carr & Sesack, 2000). Support for an indirect route in modulating NAc DA, 
comes from studies that use pharmacological manipulation of the rat mPFC to increase or decrease 
VTA DA neuron firing rates, depending on the drug administered, which subsequently increase or 
decrease DA concentration in the NAc (Murase, Grenhoff, Chouvet, Gonon, & Svensson, 1993). 
Cellular mechanisms underlying DBS of the accumbens, or the nearby structure ventral 
capsule/ventral striatum, have not been as extensively studied (Veerakumar & Berton, 2015). The 
attenuating DA efflux observed herein may arise from the innervation of local DA cell bodies and 
astrocytic adenosine triphosphate release. Furthermore, NAc receives strong serotonergic and 
dopaminergic input from the dorsal raphe nucleus and VTA respectively, whose axons all travel via 
the medial forebrain bundle (Lammel et al., 2014). This is important as the dorsal raphe nucleus is 
an important source of serotonergic and glutamatergic synaptic inputs to the VTA (Qi et al., 2014). 
Entrainment of these local and distal circuits to stimulation frequency may also explain the 
alterations in DA efflux via NAc DBS.  
Given that NAc receives inputs from both cortical and limbic regions which in turn sends 
outputs to relevant motor regions, the NAc is in an ideal position to translate cognitive and 
emotional input to behavioral responses (Floresco, 2007).  Here, DA neurotransmission acts a key 
facilitator of information processing, selecting which neural input will successfully activate post-
synaptic outputs to the basal ganglia (Goto & Grace, 2005). It follows that dysfunction of DA 
neurotransmission in the NAc critically influences the anhedonic and amotivational symptom 
characteristics of MDD and that appropriate modulation of the mesolimbic DA pathway may be 
involved in the amelioration of depressive symptoms using DBS. 
Striatal dependent learning and memory consolidation has been linked to anhedonia and 
other cognitive impairments in MDD (Bressan & Crippa, 2005; Dunlop & Nemeroff, 2007; Nestler & 
Carlezon, 2006). LTD, a form of synaptic plasticity, of phasic DA release in the NAc was observed for 
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two hours following the discontinuation of HF stimulation of the IL. After LHb HF stimulation, LTP 
was observed, whereas NAc HF stimulation produced mixed results. The mechanisms underlying 
LTD in the NAc involve interactions between the neurotransmitters DA and primarily glutamate 
(Calabresi et al., 2007). N-methyl-D-aspartate receptors (NMDARs) are glutamatergic receptors 
critical to NAc LTD induction (Thomas, Malenka, & Bonci, 2000) where NMDAR activation enables 
calcium influx to the neuron, triggering intracellular CaMKII- dependent mechanism (Huang & Hsu, 
2012). Our findings in Chapter 5 show the modulation of CaMKII expression in the NAc to be 
associated with antidepressant actions in treatment resistance animals. These findings provide a 
potential link between DA transmission and CaMKII dependent NMDAR function.  
In terms of IL DBS, the fact that LTD was induced following HF stimulation rather than LTP, 
could indicate the presence of tonic concentration levels of DA prior to stimulation, which is 
thought to be critical in determining the polarity of long term synaptic plasticity (Goto & Grace, 
2005). It has been previously suggested that the bi-directional (increases or decreases) modulation 
of DA release can have markedly different effects on brain function dependent on the state of the 
organism. Goto, Otani, and Grace (2007), using in vitro slice preparations of PFC, found HF tetanic 
stimulation that is normally sufficient to induce LTP in vivo, instead resulted in the induction of 
LTD. However, when a low concentration of DA was applied into the bath solution to mimic tonic 
background, HF stimulation instead resulted in the induction of LTP, suggesting that the level or 
tonic DA could determine transient DA release in the PFC. Our differential LTP and LTD findings in 
the LHb and IL, respectively, may be due to differential influence of tonic DA levels on these 
projections.  
Considering the gating influence hypothesized to be a critical function of phasic NAc DA in 
the regulation of cortical and limbic processes, DBS may function to restore balance to a 
dysregulated mesolimbic DA pathway in TRD. In other words, restoring adaptive appraisal and 
behavioral responses dependent on optimal responsivity of the mesocorticolimbic DA system. 
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Unfortunately, a major caveat of this study is that we did not examine DA function in our animal 
model of antidepressant resistance for all DBS regions due to availability of resources. Uniquely, 
LHb DBS findings herein show LTP in comparison to LTD in NAc and IL. Previous literature on LHb 
stimulation, both clinical and preclinical, suggests a likely inhibitory effect of DA. As LHb is largely 
glutamatergic, an inhibition of excitatory synapses to the VTA may explain the increase of DA 
release in the NAc in response to VTA-evoked transients. Therefore, we have decided to pursue our 
interest in LHb further and use this site to compare the effects DBS on NAc DA transmission in 
adrenocorticotrophic treated animals vs. controls in the next Chapter 8. 
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Abstract 
Impaired synaptic plasticity has been implicated in major depressive disorder. Recently, several 
studies examining the therapeutic effects of DBS postulates the possibility of plasticity as an 
important mechanism of this neuromodulatory treatment. In order to investigate this, 
adrenocorticotropic hormone (ACTH)-induced antidepressant resistant animals were subjected to 
high frequency lateral habenula (LHb) deep brain stimulation (DBS; 90 minutes at 100μA, 90μs 
pulse width, and 130Hz). The experiment involved real-time measurements of ventral tegmental 
area-evoked (125μA, 60Hz, 2ms pulse width for 23 pulses) dopamine (DA) efflux in the nucleus 
accumbens for induction of striatal-dependent plasticity. Results show that ACTH-treated animals 
failed to maintain recovered DA release once DBS was discontinued. Saline control animals, 
however, was able to induct long term potentiation of DA transmission. Together, current findings 
suggest a role for synaptic plasticity in treatment resistance and response in major depression.  
Keywords: dopamine, lateral habenula, deep brain stimulation, synaptic plasticity 
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The habenula is uniquely positioned to regulate many of the deficits in emotion, motivation, 
reward and cognitive processing implicated in mood disorders. Interest in the lateral habenula 
(LHb) has recently demonstrated that such behaviors are mediated by LHb regulation of dopamine 
(DA) and serotonin systems. Within the brainstem, LHb efferents mainly target the nuclei 
containing monoamine neurons: the dopaminergic ventral tegmental area (VTA) and substantia 
nigra pars compacta, serotonergic dorsal and median raphe, and cholinergic laterodorsal 
tegmentum (Hikosaka, Sesack, Lecourtier, & Shepard, 2008). The LHb forms a node of connection 
between the cortex and brainstem monoamine neurons that operates in parallel to the medial 
forebrain bundle. As a result, the LHb is known to be involved in a variety of physiological 
responses like reward (Hong & Hikosaka, 2008), reward error processing (Matsumoto & Hikosaka, 
2009), suppression of escape related behavior (Nieh, Kim, Namburi, & Tye, 2013) and stress (Kazi, 
Mori, Kuchiiwa, & Nakagawa, 2004). LHb cells exert a relatively short latency and potent inhibitory 
influence (Hikosaka et al., 2008) where the LHb neurons are heterogeneous in their neurochemical 
expression patterns at rest (Kim & Chang, 2005). Studies using electrophysiology and anatomical 
tools indicate the majority to have an excitatory, glutamatergic phenotype (Geisler & Trimble, 2008; 
Kalén, Karlson, & Wiklund, 1985; Weiss & Veh, 2011; Yang, Hu, Xia, Zhang, & Zhao, 2008).  
The inhibition of dopaminergic neurons in the VTA is less well understood. Accumulating 
evidence suggests that the LHb is a promising candidate to exert an inhibitory control over the VTA 
dopaminergic system. Supporting information dates back to observations that lesions of the 
habenula complexes result in activation (Nishikawa, Fage, & Scatton, 1986) and that electrical 
stimulation of the LHb provoked inhibition of mesencephalic DA neurons (Christoph, Leonzio, & 
Wilcox, 1986). In fact, in a more recent study on primates (Matsumoto & Hikosaka, 2009), it was 
demonstrated that the inhibitory input from the LHb, elicited by weak electrical stimulation, plays 
an important role in determining the reward-related activity of DA neurons. Ji and Shepard (2007) 
found that single pulse stimulation of the LHb completely suppressed the dopaminergic activity in 
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the VTA for close to 100 ms. More importantly, their findings suggest that LHb-induced suppression 
of DA cell activity is mediated indirectly by orthodromic activation of putative GABAergic neurons 
in the ventral midbrain.  
The infralimbic (IL; subgenual cingulate gyrus homologous) and LHb have significantly 
increased metabolism in a genetic rat model of depression (Mirrione et al., 2014; Shumake, 
Poremba, Edwards, & Gonzalez-Lima, 2000) and this  is  also  consistently  observed  in  the  clinical  
population (Mayberg et al., 2014).  Such hyperactivity is then reversed with effective 
antidepressant, including DBS, treatment. Previously, stimulation in rats under animal models of 
depression show that DBS to the IL, nucleus accumbens (NAc) and LHb decreases depressive-like 
phenotype in various behavioral assays (Hamani et al., 2014). Our preliminary studies using the 
adrenocorticotropic hormone (ACTH) model have also shown effectiveness of LHb (Kim et al., 2015, 
under review), NAc (Kim et al., 2015 under review) and IL (Tye et al., 2015; Reker et al., 2015 –both 
manuscripts in preparation) DBS in imipramine resistant animals.  
The aim of this chapter is to examine the VTA stimulation-evoked transient DA 
neurotransmission in NAc during high frequency DBS of the LHb in ACTH-treated animals 
compared to that of healthy controls. Similar to the previous chapter, we monitored DA release 
after discontinuing the stimulation of LHb in order to evaluate neuroplasticity as a possible 
mechanism underlying the therapeutic effects of DBS. We hypothesize that high frequency 
stimulation would induce lasting changes on neurotransmitter efflux in healthy rats whereas this 
function would be impaired in treatment resistant animals.  
Methods 
Animals 
Male Sprague-Dawley rats were purchased through Deakin University Animal House 
(Geelong, Victoria, Australia) and Animal Resources Centre (Perth, WA, Australia). Animals were 
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housed in pairs, in a temperature controlled environment with 12-hour light/dark cycles and 
access to food and water ad libitum. Fast Scan Cyclic Voltammetry recordings were conducted 
between 9:00 a.m. and 6:00 p.m. on animals weighing between 200-350g.  Animal care and 
experimental procedures were carried out in accordance with the Prevention of Cruelty to Animals 
Act 1986 (2009), and the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (2004). Ethics approval was received for the project from the Animal Welfare Committee, 
Deakin University (Geelong, Australia) and the Florey Institute of Neuroscience and Mental Health 
Animal Experimental Ethics committee, University of Melbourne (Melbourne, Australia). 
Animal model of tricycle-resistance 
Similar to that of published papers (Walker et al., 2013; Walker et al., 2015), a separate 
cohort of animals were administered either 14 days of adrenocorticotrophic hormone (ACTH, 
100μg/day, n = 6) or saline (0.9%, n = 7) intraperitoneally, prior to FSCV experiments.  
Surgical Procedure 
Rats were anaesthetized with urethane (1.5g/kg) via an intraperitoneal injection, then 
placed in a stereotaxic frame (David Kopf Instruments, Tujunga, California, USA) where body 
temperature was maintained at 37°C with an isothermal heat pad (Delta Phase Isothermal Pad, 
Braintree Scientific, Braintree, Massachusetts). An incision was made along the midline of the scalp 
and the skin was retracted to expose the skull surface. Four burr holes were drilled in the skull for 
placement of the reference, recording, and two stimulating electrodes. Concentric bipolar 
stimulating electrodes (SNE-100, d = 0.25mm, exposed surface = 0.75mm; Rhodes Medical 
Instruments, Summerland, CA, USA) were placed in the VTA or LHb. A recording electrode (carbon-
fiber microelectrode) was placed in the core of the NAc. Both the stimulating and recording 
electrodes were placed in the left hemisphere, with the reference electrode positioned in superficial 
cortex in the contralateral hemisphere. A chloridized silver wire (Ag/AgCl) was used as a reference 
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electrode. Coordinates for all electrodes were calculated using the atlas of Paxinos and Watson 
(2007). Coordinates for the carbon-fiber recording electrode in the NAc, in millimetres, (referenced 
to bregma) were: anteroposterior (AP) = +1.2, mediolateral (ML) = +1.5, dorsoventral (DV) = -6.5 to 
8.0; the stimulating electrode in the LHb AP -3.7, ML, ±0.8, DV -5.4 and the stimulating electrode in 
the VTA (interaural coordinates) AP= -2.2, ML= -0.6, DV= -2.0 to 1.2. Once a robust voltammetric 
response was obtained (determined by the size of the current at the peak oxidation potential of DA) 
the electrodes were maintained at these coordinates throughout the experiment. 
Electrochemistry 
Fast scan cyclic voltammetry was performed using 5μm-diameter carbon fiber electrodes. 
Voltammetric scans, stimulus waveform generation and timing, data collection were performed 
using Wireless Instantaneous Neurotransmitter Concentration System (Bledsoe et al., 2009). All 
carbon fiber electrodes were tested for stable background currents and responsiveness prior to 
each experiment sitting. Voltammetric scans from -0.4V to 1.3V and from 1.3V to -0.4 were 
performed at 300V/s in a triangle waveform which was repeated every 100ms, with the potential 
held at -0.4V between scans. The high scan-rates used produce a large background current (Heien & 
Wightman, 2006), which is removed by subtracting a series of cyclic voltammograms prior to 
stimulation. The resultant background-subtracted voltammogram provides a signature for the 
species oxidised or reduced at the CFM. DA at the carbon-fiber surface is oxidised (at ~ +0.6V 
versus Ag/AgCl) and the electroformed DA-o-quinone is then reduced back to DA (at ~ -0.3V versus 
Ag/AgCl). Changes in the resulting oxidative current are proportional to changes in DA 
concentration at the carbon fiber surface (Robinson & Wightman, 2006). 
Electrical Stimulation 
DA release was evoked with monophasic stimulation pulses at 125μA, 60Hz, 2ms pulse 
width for 23 pulses (Master 9 Pulse Stimulator and Iso-Flex Stimulation Pulse Isolator; AMPI, 
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Israel). These parameters were chosen to mimic endogenous transient DA release (Heien & 
Wightman, 2006). During the DBS phase of the experiments the brain regions were stimulated for 
90 minutes at 100μA, 90μs pulse width, and 130Hz for the HF DBS. The stimulation parameters for 
the HF condition were chosen to approximate the charge density of that experienced by patients 
receiving DBS for TRD (Hamani, Diwan, Isabella, Lozano, & Nobrega, 2010) that takes into account 
the smaller volume of the rat brain and the size of the electrodes. 
Histological Verification of Electrode Placement 
Lesions were delivered with all electrodes still in place, by applying a DC current to the 
stimulating electrodes (100μA for 5sec) for histological verification (see Figure 1 for histology 
schematics). Animals were euthanized using a 1.0 ml urethane intracardial injection and the brains 
were removed immediately then fixed in a 10% formalin solution. Brain slices were prepared 
(40μm coronal sections) using a cryostat microtome (Cryostat HM500 Series) at -23°C, mounted on 
glass slides and viewed under a light microscope.  
 
Figure 1. Schematic representations of A: VTA stimulating electrode; B: HF LHb DBS; 
C: voltammetric recording electrode in the NAc. Red dotes signify saline treated 
animals and yellow dots for ACTH-treated animals. 
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Results 
Attenuated DA release and potentiation in ACTH treated animals with LHb DBS 
Independent sample t-tests were conducted to examine meaningful differences in mean percent 
change of DA release in ACTH- vs. saline- treated animals. As hypothesized, these analyses revealed 
a restoration of DA function with DBS in animals with chronic ACTH administration, yet these 
effects did not translate into long-term synaptic plasticity. Table 1 summarizes the mean percent 
change and corresponding SD and SEM for control saline and ACTH groups. 
Table 1. A summary table of percentage change observed for VTA-evoked DA release in 
the NAc prior to, following and post NAc, IL and LHb DBS. 
LHb –lateral habenula; DBS –deep brain stimulation; ACTH –adrenocorticotropic hormone; HF –
high frequency; n =6-7 for each group. 
 
An independent samples t-test revealed in the LHb, HF DBS potentiates NAc DA release in 
both control and ACTH-treatment groups (pre-DBS vs. DBS), t(10) =1.288, p > 0.05. VTA-evoked 
NAc DA efflux post-DBS relative to during DBS in control and ACTH pre-treated animals where 
the effects of DA signal was not sustained in ACTH animals, t(10) = 3.244, p < 0.01. VTA-evoked NAc 
DA efflux which was recorded 2 hours post-DBS, compared to during active DBS in control and ACTH 
pre-treated animals indicate evidence of long term plasticity only for healthy controls, t(10) = 4.331, 
p < 0.01 (Figure 2.).   
  Percent Change 
  Pre-DBS vs. 
DBS 
Pre-DBS vs. 
Late-DBS 
Post-DBS vs. 
Late-DBS 
End-DBS vs. 
Late-DBS 
LHb HF M 33.09 40.05 -0.17 -14.10 
(Saline) SD 12.40 21.89 14.26 8.40 
 SEM 5.54 9.79 6.38 3.76 
LHb HF M 23.59 28.14 -21.23 -29.42 
(ACTH) SD 12.37 12.77 10.62 4.83 
 SEM 5.53 5.71 4.75 2.16 
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Figure 2. Representative DA release and reuptake in healthy (saline treated) vs. 
antidepressant resistant animals. The ability for DA reuptake in ACTH-treated animals is 
possibly impaired, as signified by the decaying tail. 
234 
 
Below, Figure 3 represents an averaged time course of LHb DBS-induced long-term potentiation 
of NAc DA in healthy controls, whereas a recovered transient DA efflux in ACTH animals is decaying after 
the discontinuation of DBS.  
Figure 3. Averaged data points showing percent change in transient VTA stimulation-
evoked NAc dopamine efflux prior to, during and following 90 minutes of high 
frequneyc (HF) LHb DBS in control and ACTH-treated animals. 
 
 
Discussion 
In support of previous DBS success in clinical practice, we show that high frequency 
stimulation is necessary to restore attenuated DA function in rats treated with chronic ACTH. The 
therapeutic effects of DBS, however, were not sustained once active stimulation of LHb has been 
stopped. These findings suggest that deficits in synaptic plasticity may be implicated in TRD, 
possibly inhibiting the capacity of enduring therapeutic responses to be induced and maintained. 
The results of this study indicate that modulating of DA neurotransmission in the NAc via LHb DBS 
may be involved in the therapeutic effects of DBS for TRD, possibly in the amelioration of the 
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anhedonic and amotivational symptoms of the depressive syndrome based on the function of these 
circuits.  
With no active stimulation, ACTH animals’ capacity for long term potentiation was absent. 
Plastic changes in the mesolimbic DA pathway may be how DBS reinstates treatment response in 
TRD patients. Neuroplasticity has been shown to be disrupted in patients suffering from MDD 
(Duman, 2002; Pittenger & Duman, 2008) and in animal models of stress (Goto & Grace, 2006). 
Long-term biochemical and neuroplastic changes in the mesolimbic DA pathway have been found to 
occur following acute and chronic stress in rats (Ortiz, Fitzgerald, Lane, Terwilliger, & Nestler, 
1996; Saal, Dong, Bonci, & Malenka, 2003). Effectively, antidepressant treatment promotes 
neuroplasticity, possibly reversing the disruption during the pathological state (Duman, 2002; 
Pittenger & Duman, 2008).  
Authors of clinical case report interpret their findings as  likely resulting from inhibitory 
effects of LHb DBS, the suppression of LHb hyperactivity, which corresponds to the remission of 
depressive symptoms (Sartorius et al., 2010). LHb hyperactivity has been hypothesized as an 
etiologic factor in MDD, based on imaging studies. Relevant to current findings, decreased LHb 
metabolism was associated with increases in midbrain DA activity, established from amphetamine 
and apomorphine based rodent studies (Shumake & Gonzalez-Lima, 2013). This largely 
glutamatergic structure projects to the VTA, thereby exerting critical influence over VTA-NAc 
mesolimbic pathway. LHb has typically been found to have an inhibitory dopaminergic function 
over the NAc. Hence, an overactive LHb, observed in MDD patients and in the learned helplessness 
rodent model of depression, represses the activity of VTA and DRN. By depleting afferents from the 
basal ganglia which drives LHb hyperactivity, LHb DBS disinhibits the VTA and DRN (Veerakumar & 
Berton, 2015). Present findings of increase DA efflux following LHb DBS are consistent with existing 
data demonstrating that pharmacological inhibition of LHb increases DA release in the forebrain 
(Lecourtier, DeFrancesco, & Moghaddam, 2008). 
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Conversely, Stamatakis et al. (2013) suggest that the phasic DA release seen in the NAc in 
response to motivationally relevant stimuli, at least in part, could require activation of inhibitory 
afferents to LHb, thus disinhibiting midbrain dopaminergic neurons. Findings presented by this 
group, derived from optically evoked DA release and characterized by voltammetric methods, show 
that hybrid population of VTA neurons expressing dopaminergic and GABAergic markers send an 
inhibitory projection to the LHb and thus are able to directly inhibit LHb neurons, resulting in 
profound downstream effects on midbrain circuitry. In terms of our outcomes, phasic DA release, 
evoked by VTA in order to mimic those naturally occurring reward stimuli, may also work via 
similar mechanisms. VTA stimulation to evoke accumbal DA release could also provide inhibitory 
output to the LHb (thus further disinhibiting the VTA) where an overactive LHb (a largely 
excitatory structure) causes inhibition of phasic accumbal DA release. To make this concept clearer, 
LHb may be targeting midbrain GABAergic cells that normally inhibit the VTA DA neurons (and 
~30% of cells in the VTA are GABAergic, and act as interneurons capable of suppressing adjacent 
DA neurons, see Creed et al. 2014 for a recent review). This also provide support for why 
pharmacological inhibition of the LHb would cause disinhibition of DA release in the forebrain. 
Mechanistic framework underscores the flexibility and complexity of the circuitry that impinges 
upon VTA dopaminergic neurons to promote motivated behavior, one of the core symptoms of 
depression (Stamatakis et al., 2013). Altogether, our results corroborating with previous literature 
highlights the bi-directional function of DA, depending on the target neurons and the state of the 
organism. Many support the diverse and differential role of DA which is sensitive to energy 
metabolism, stress and DA availability.   
Firing patterns of mesolimbic dopamine neurons mediate an individual’s responses to 
chronic stress and antidepressant action. Similar to present findings, studies using a chronic social 
defeat model found abnormalities in the in vivo firing properties of VTA DA neurons which were 
tightly correlated with stress-induced behavioral abnormalities (Cao et al., 2010). Greater interest 
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of the mesolimbic DA system in the pathophysiology and treatment of depression have been gained, 
given the accumulating evidence of its role in hedonia and motivation (Friedman et al., 2007; 
Lammel et al., 2012; Nestler & Carlezon, 2006; Salamone & Correa, 2012). Future research should 
expand on the differential role of DA and corresponding behavioral adaptations.
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Chapter 9. General Discussion 
 
As introduced in earlier chapters, deep brain stimulation (DBS) has emerged as an 
alternative method for the treatment of refractory patients with depression and continues to hold 
great promise. Yet, our lack of understanding on its mechanisms of action are likely limiting our 
capacity to optimize this neuromodulation advancement for clinical practice, as illustrated by two 
recently failed clinical trials (Dougherty et al., 2015; Malone et al., 2009; Mayberg, Personal 
Communication, 2007). The series of papers presented in this thesis includes preclinical works 
aimed at providing insight into the therapeutic mechanisms of action of DBS in treatment resistant 
depression (TRD). Additionally, experiments were designed to model the neurobiology of 
antidepressant resistance, providing an opportunity to understand its distinct disease 
pathophysiology and how biological adaptations can reverse drug resistance.  
From an experimental perspective, DBS can be used as an excellent probe to modulate 
neuronal activity in key regions and associative networks implicated in stress, stress response and 
antidepressant action (Benabid, 2015). The works presented here adopted this approach in 
combination with a number of complementary laboratory techniques such as gene expression 
profiling, immunoblotting, mitochondrial analysis and fast scan cyclic voltammetry (FSCV) to 
investigate biological mechanisms associated with treatment responsivity. Standardized behavioral 
assays were used throughout the chapters as an indicator of antidepressant-like response to 
various DBS targets. Our aims for each chapter were as follows: Chapter 4) to evaluate the effects of 
nucleus accumbens (NAc) DBS and adrenocorticotrophic hormone (ACTH) treatment on 
mitochondrial function and to characterize corresponding antidepressant-like and mania-like 
behaviors; Chapter 5) to establish lateral habenula (LHb) DBS efficacy in an animal model of 
tricyclic resistance and to quantify treatment modifications on calcium/calmodulin-dependent 
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protein kinase II alpha/beta (CaMKIIα/β), glycogen synthase kinase 3 alpha/beta (GSK3α/β), and 
AMP-activated protein kinase (AMPK) expression locally, and in the infralimbic (IL) cortex; Chapter 
6) to interpret changes in endogenous gene expression modulated by IL DBS following forced swim 
test (FST) to identify acute, local neural responses to DBS in antidepressant-resistant vs. naïve 
animals; and Chapter 7) to examine phasic dopamine (DA) neurotransmission in the core of the 
NAc during high frequency (HF) stimulation of the IL, NAc and LHb, consistent with the role DA 
plays in emotion, motivation and TRD. Further, we monitored DA neurotransmission after 
discontinuing stimulation of these regions to observe neuroplastic processes in therapeutic 
responses of DBS. These studies have provided insight into the region- and/or network-specific 
mechanisms of DBS associated with induction of a therapeutic response in the antidepressant 
resistant state.  
Stress and the HPA axis 
Cellular and systemic responses to stress are plastic and continue to adapt with the 
organism over time in response to changing environmental demands (Belda et al., 2008). How the 
system deals with the first stress exposure is particularly important as it instigates cellular 
adaptations evolutionarily pre-programmed to facilitate effective neurohormonal responses to 
future insults. For example, memory consolidation following an emotionally stressful event can 
prepare an organism for an adaptive response in the face of apparent threat, however, under 
certain circumstances, it also has the ability to trigger multiple pathological states (Valenti, Gill, & 
Grace, 2012). Long lasting effects of stress not only depend on stress type and chronicity, but also 
on the developmental stage of an organism (Lupien, McEwen, Gunnar, & Heim, 2009). Incidentally, 
the stress system plays both adaptive and maladaptive roles, either strengthening resilience or 
accelerating psychopathological processes (i.e. neuroprogression). Given that the hypothalamic 
pituitary adrenal (HPA) axis functions to promulgate stress and fine-tunes the metabolic 
requirements at the system and cellular level, animal models, such as the ACTH model of 
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antidepressant resistance, can help us to better understand biological characteristics of TRD. The 
HPA axis is a major participant in optimal stress reaction for survival (Gold, 2015) as well as 
treatment responsivity (Stetler & Miller, 2011), where it receives constraining inputs from the 
subgenual prefrontal cortex, a site implicated in stress appraisal and antidepressant action. To date, 
studies on the functional integrity of the HPA axis under various therapeutic interventions report 
conflicting results (Flores, Kenna, Keller, Solvason, & Schatzberg, 2006; Nemeroff & Owens, 2004; 
Papiol et al., 2007) and therefore, its involvement with antidepressant processes is incompletely 
understood. The model utilized in this series of experiments, chronic ACTH administration, 
however, indicates the HPA axis plays a critical role in the development of antidepressant non-
response and in so doing, helps to fill this gap in clinical research. 
Overall Behavioral Outcomes 
The biological and behavioral reactions of an organism to stress, its stress coping responses, 
occur in the face of perceived environmental or systemic stressors and are thought to critically 
influence risk for and resilience against ill health.  Our results of ACTH-induced tricyclic 
antidepressant resistance, replicated previous studies by Caldarone and Brunner (2009), Kitamura 
et al. (2008) and Walker et al. (2015). Depending on stress reactivity, recovery and the availability 
of adaptive coping resources, overcoming threatening or benign stimuli (through appraisal 
processes) may be indicative of the organism’s resiliency or susceptibility to mood disturbances. 
Brain regions such as the amygdala, hippocampus, prefrontal cortex, NAc and LHb are primary 
mediators of stress resiliency and vulnerability because of their roles in cognitive appraisal, and the 
regulation of behavioral, emotional and physiological responses to a given stressor. The 
aforementioned FST is a well validated tool, with a strong predictive validity for screening 
antidepressant effectivity, through the assessment of animals’ behavioral coping response 
(climbing, swimming, and immobility). It utilizes anthropomorphic concepts of different coping 
styles to identify animals that actively respond to a perceived stressor and those that demonstrate 
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passivity, previously referred to as ‘behavioral despair’.  The robust active FST behavioral profile of 
animals receiving NAc, LHb and IL DBS indicates that these treatments are efficacious in otherwise 
tricyclic resistant animals. The outcomes further corroborate findings obtained in other preclinical 
depression models and clinical reports documenting the efficacy of DBS (Hamani et al., 2014; Meng 
et al., 2011; Riva-Posse et al., 2014). In these studies, animals receiving active stimulation in each 
brain region demonstrated clear antidepressant (active coping) responses relative to sham or 
surgery only animals under inescapable FST stress. These findings are promising; nevertheless FST 
results should be interpreted in light of its ability to evaluate antidepressant activity based on the 
reduction of immobility time (a test with predictive validity), rather than through a demonstrated 
reduction of anhedonia (i.e. sucrose preference test, considered strong face validity for depression, 
Nestler and Hyman (2010)). Of course, whether the differences in FST responses is due to the 
severity of the given stressor that it perceives or the inescapable nature, is impossible to discern.  
Key findings from each experiment 
Chapter 4: NAc DBS. There were two major findings in chapter 4. Firstly, mitochondrial 
function was associated with treatment resistant state vs. antidepressant action. Stress induces 
robust inhibition of mitochondrial energy generation (Gong, Chai, Ding, Sun, & Hu, 2011) and 
damages the mitochondrial ultrastructure. Changes in mitochondrial size, distribution and function 
are also observed in major depressive disorder (MDD) patients (Gardner & Boles, 2011). ACTH-
treated animals’ capacity to create adenosine triphosphate (ATP) in response to the increased 
energy demand during inescapable situation was deficient. To our knowledge, this is the first 
preclinical study that directly implicates mitochondrial function in the underlying mechanisms of 
DBS. Secondly, NAc DBS obtained interesting behavioral results where both antidepressant-like and 
mania-like phenotypes were developed only in those with ACTH treatment and DBS electrode 
implantation. We observed that in ACTH-treated animals, electrode implantation prior to active 
DBS, elicited a mania-like phenotype in a sub-set of ACTH-treated animals. This was not observed in 
247 
 
the vehicle treated group. Here, the presentations of hyper-locomotor behavior, a failed response to 
imipramine and increased appetitive behaviors were accompanied by heighted mitochondrial 
efficiency. This contrasts the attenuated efficiency found in ACTH-treated animals and may reflect a 
biological overcompensation for this deficit. In other words, the ACTH-treated animals may have 
lacked the metabolic resources to meet the metabolic demands necessary to engage in an active 
behavioral response considered predictive of antidepressant response. In contrast, the hyperactive 
‘mania-like’ animals demonstrated enhanced mitochondrial respiration activity. This was 
determined with the seahorse XP24 analyzer, which interrogates major energy producing pathways 
of the cell in brain tissue.  
The current findings provide a crucial link between NAc DBS induced alterations in the 
medial prefrontal cortex (mPFC) mitochondrial function and the dysregulated HPA axis followed by 
chronic ACTH administration. Notably, DA and mitochondrial dysfunction are both implicated in 
neurodegeneration, established predominantly based on the Parkinsonism, schizophrenic and 
bipolar population data. It is widely thought that hyperactive DA levels underlie mania where 
increasing synaptic levels of DA (following amphetamine administration) correspond to defining 
manic-like features of bipolar disorder (BPD) in both humans and mice (Berk et al., 2007). Free 
radicals are produced during the metabolism of monoamines including DA, by monoamine oxidase 
A and B, both of which are located on the outer mitochondrial membrane (Manji et al., 2012). 
Mitochondria use several protective antioxidant molecules to interrupt or minimize this oxidative 
process, thereby reducing cytotoxicity from high levels of DA. Previously, increased oxidation has 
been observed in the DA enriched area of PFC in BPD patients (Kim, Andreazza, Yeung, Isaacs-
Trepanier, & Young, 2014) and amphetamine increased markers of this oxidation in animals (Frey 
et al., 2006). Consequently, blocking DA receptors are among the most effective treatments for BPD 
patients (Cipriani et al., 2009). DA inhibits mitochondrial mobility through D2R agonist which 
subsequently decreased Akt-GSK3β signaling (Chen, Owens, & Edelman, 2008). A disturbance of 
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energy metabolism evidenced by behavioral and molecular results herein, may also reflect those 
changes in DA that have been previously observed in the clinical population. Levels of PFC DA have 
also been shown to be reduced with chronic ACTH administration (Walker et al. (2013). This was 
also demonstrated for transient NAc dopamine in the current series of studies (see Chapter 7). 
Additionally, the socially isolating conditions, as utilized herein, have been found to alter 
presynaptic DA transmission in rats (Lapiz et al 2003). Mitochondrial and dopamine dysfunction 
may therefore be an important mediator of cycling mood states, with uncorrected metabolic deficits 
contributing to the neuroprogressive nature of MDD and BPD, eventuating in refractory depression 
states.  
As an aside, a point should be made on possible pro-inflammatory reactions that likely 
occurred following electrode implantation and may have contributed to the observed mania-like 
behavioral phenotype. Others have shown that the electrode implantation surgery procedure alone 
can induce an antidepressant response in the chronic mild stress animal model of 
depression(Perez-Caballero et al., 2014). These authors further suggest that clinical treatment 
outcomes may be confounded by use of anti-inflammatories. Reduction in immobility time 
(attenuation observed with NAc electrode placement, although not statistically significant) 
observed for our ACTH animals, may be explained by acute pro-inflammatory reactions also. 
Inflammatory processes have been associated with treatment response where rats implanted with 
electrodes, irrespective of whether they received active stimulation, showed antidepressant-like 
behaviors (Perez-Caballero et al., 2014). This effect was due to regional inflammation, where it was 
temporally correlated with an increase of glial-fibrillary-acidic-protein immunoreactivity which 
was blocked by anti-inflammatory drugs. Furthermore, a retrospective study by the same group 
indicated that the early responses of MDD patients subjected to DBS was poorer when they 
received anti-inflammatory drugs in conjunction.  
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Chapter 5: LHb DBS. The critical role of energy regulation in our animal model of stress 
was further illustrated by the therapeutic mechanisms of LHb DBS. Immunoblotting quantified total 
protein expression, phosphorylated and total, 30 min post FST. Protein responses were expected to 
be distinctive, conditional upon ACTH vs. Saline administration separate to DBS treatment. DBS-
facilitated local phosphorylation of CaMKIIα/β and GSK3α/β, with the normalization of AMPK 
activity in the IL was found. These effects were correlated with the adoption of active coping 
strategies in the FST. In clinical and preclinical trials of pharmacological and neuromodulatory 
interventions, decreased metabolic activity of the IL (or SCG in human trials) has consistently been 
associated with antidepressant efficacy (Mayberg et al., 2014; Riva-Posse et al., 2014). Similar to 
these previous findings, our results provide further support for attenuated metabolism of SCG and 
treatment response. This was indicated by reduced expression of AMPK in the IL following active 
stimulation, simultaneous to the activity-dependent phosphorylation of GSK3 and CAMKII in LHb.  
The actions of these proteins also include management of cellular growth and survival. 
AMPK, where its activity is governed by cell’s energy demand, mitigates dopamine dysfunction and 
is involved in maintaining mitochondrial homeostasis (Ng et al., 2012). As mentioned in the 
introduction, GSK3 mediates responses to lithium and affects dopamine activity. Furthermore, 
inhibitory phosphorylation of GSK3 and CaMKII coupled depolarization protects neurons from 
apoptosis (Song et al., 2010). To detail, the pro-survival effects of CaMKII has been found to be 
mediated by GSK3 phosphorylation and thus leading to inactivation. It has been well reported that 
depolarizing conditions sustain neuronal survival by causing influx of Ca2+ via L-type Ca2+ channels 
(Ghosh & Greenberg, 1995; West, Griffith, & Greenberg, 2002), which implicates Ca2+ as a necessary 
second messenger for survival signaling. When activated by elevated Ca2+, CaMKII has been 
documented to mediate this depolarization for neuronal survival. Therapeutic effects observed in 
our animal model of TRD correlated with the modifications in the phosphorylated and overall 
expression of these molecules.  
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Cellular mediators of calcium signaling, energy regulation and plasticity were identified as 
potential underlying mechanisms of LHb DBS in reinstating one’s treatment response. The 
differential role of LHb (which is activity dependent) and IL highlights distinctive network effects of 
DBS and provide interesting avenues for future application of these brain regions. The LHb has 
been reported to selectively target mPFC-projecting dopaminergic VTA neurons that produce 
aversion/avoidance in rodents (Lammel et al., 2012) and this LHb-mPFC-VTA may further be 
involved in stress-related cognitive disturbances in MDD (Mizoguchi et al., 2000). Present findings 
reinforce the importance of obtaining antidepressant actions via normalizing cellular and metabolic 
processes in the IL region of rats (SCG homologous) exerted by LHb stimulation.  
Chapter 6: IL DBS. In Chapter 6, the investigation of gene expression proved a valuable tool 
for identifying candidate genes and altered molecular pathways in this stress diathesis model of 
treatment resistance and the restoration process. This study aimed to interpret changes in local 
gene expression modulated by IL DBS and after an exposure to the FST. Investigating the IL cortex 
is particularly significant due to its role in HPA axis regulation, cellular energetics (McKlveen, 
Myers, & Herman, 2015) as well as its connections to other depression relevant regions such as bed 
nucleus of the stria terminalis, NAc and LHb. Key sensors of energy demand, cell division/growth, 
protein synthesis and glucose/glycogen regulation were significantly altered in both ACTH and 
Saline-treated animals. Introducing an exogenous stressor, the FST, to ACTH animals resulted in 
decreased p53, yet activated glucose production pathways, possibly to compensate for the 
increasing energy demand and protecting against the deleterious effects of stress. Environmental 
stressors further altered WNT and B-catenin signal transductions leading to the inhibition of cell 
proliferation. This process is another major compensatory action in controlling for maladaptation’s 
that may contribute to presentation of depressive symptoms. Endogenous systematic stress on the 
other hand, induced up-regulation of metabolic pathways implicated in hypoxia, suggestive of 
oxygen deprivation within that region. Finally, a combination of endogenous (ACTH) and exogenous 
251 
 
(FST) stress led to altered gene and protein expressions in regulators of cell proliferation and 
apoptosis. Initiation of apoptosis is necessary to lessen the chances of senesce and DNA mismatch. 
Absence of appropriate apoptotic processes, therefore, facilitates the neuroprogression of mood 
disorders and prevents possible correction of maladaptations on a cellular level.  
The manipulation of inescapable environmental stressor together with the administration 
of ACTH uncovered differential cellular/molecular mechanisms that the animals adopt, providing a 
snapshot of the molecular mechanisms contributing to antidepressant-resistance in this model. 
These molecular mechanisms, in turn, will inform important information in developing basic animal 
models for target discovery. Thereafter, target discovery should be based on casual relations, not 
phenomena, for translational and predictive treatment outcomes.  
Chapter 7 & 8: FSCV recording of DA transmission following high frequency NAc, IL 
and LHb DBS. FSCV, given its temporal specificity, was an important tool for studying ventral 
tegmentum area (VTA) evoked NAc DA release and plasticity in chapter 7. Plasticity and stress is 
intimately linked and as discussed in Chapter 1, their relationship is crucial in either accelerating or 
slowing the onset of disease progression. High frequency DBS of each region modulated transient 
NAc DA efflux.  DBS at these targets may thus serve to regulate the availability of DA release in 
response to stimuli. In healthy controls, an attenuation and long term depression (LTD) of phasic 
DA were observed following NAc and IL DBS. Uniquely, LHb DBS induced long term potentiation 
(LTP). As hypothesized, this DBS-induced long-term plasticity of VTA-evoked NAc DA efflux in 
ACTH animals was absent. Moreover, the ACTH-induced reduction of VTA-evoked phasic DA release 
was restored with LHb DBS. However, as LTP was absent, the signal recovered to its pre-DBS 
baseline levels soon after cessation of DBS. The findings from this study, thus suggest that the 
mesoaccumbens circuit is dysregulated in ACTH animals and that this may be a contributing factor 
for their resistance to antidepressants.  
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The deficit in synaptic plasticity induced by chronic pre-treatment with ACTH suggests 
inhibition of long-term plasticity may contribute to the progression of treatment resistance in 
depression. The DA system is not only modulated by stress and metabolic mediators on a cellular 
level, but at the systems level the output of DA release is contingent upon the interplay between 
metabolic hormones and the experience of stress. DA neurons are particularly sensitive to 
physiologic energy demands, changing the responsivity to stimuli, with important implications for 
psychological well-being and stress appraisal (Schellekens, Finger, Dinan, & Cryan, 2012).  
Dysregulation of DA system function has been proposed to partially underlie the delayed 
responses to antidepressants (Dunlop & Nemeroff, 2007).  A role for DA in antidepressant 
treatment non-response is suggested from data demonstrating that responders to SSRIs exhibit 
increased DA binding to striatal D2 receptors –with the degree of increased D2 receptor binding 
correlated with improvement in depressive symptoms (Moylan, Maes, Wray, & Berk, 2013). 
Repeated stress may lead to sensitization of the mesolimbic DA system via increased 
glucocorticoids (GR), as GR themselves may selectively facilitate DA transmission in NAc (Oswald et 
al., 2005). The DA system has been found to demonstrate complex responses to stressors and likely 
plays a major role in adaptive as well as maladaptive responses, particularly as they influence 
effort-related motivation and psychopathology (Salamone, Correa, Farrar, & Mingote, 2007; Valenti 
et al., 2012).  
In addition, the FSCV outcomes suggest that pathway-specific dopaminergic output of the 
VTA is intricately regulated by long-range inputs to drive reward or aversion. Salamone and 
colleagues, through their works looking at DA (Salamone & Correa, 2012; Salamone et al., 2007), 
also emphasize this neurotransmitter as selective and dissociative where it acts on activational 
aspects of motivation. In other words, not only it is closely linked to motivation and reward, but it 
plays a crucial role in effort-related decision making and hedonic sensitivity. Previous findings, 
together with our results, reinforce the role of DA in emotional, behavioral and attentional aspects 
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of depressive phenotype. It underscores important therapeutic implications for DA, as the DA 
system is interlaced with stress and is implicated in the neuroprogressive nature of mood disorders 
(Berk et al., 2007).  
Potential DBS mechanisms and its implications as an alternative treatment 
DBS may be reinstating or reversing the cellular, molecular and system adaptations 
following stress by modulating: 1) activity dependent local cellular functions; 2) orthodromic vs 
antidromic inhibition or excitation of afferent regions; 3) inhibitory action; and lastly 4) modulating 
local and distal networks. The most plausible model of DBS mechanisms is stimulation-induced 
modulation of pathological network activity reflecting one or more of those actions listed above. Dr 
Paul Holtzheimer recently presented an important perspective, suggesting that DBS may help the 
brain to reinstate to a normal dynamic state (where this does not equate to a state of a ‘healthy’ 
brain), but enables patients to rehabilitate via a progressive process of recovery (SOBP 2015 
conference). This rehabilitation may require a combination of adjunctive psychotherapy, social 
support and healthy lifestyle changes. In order to effectively treat these severely refractory 
patients, the field of psychiatric research needs to move away from circuit replacement theory but 
instead, towards fostering plasticity and neuronal remodeling (Bessa et al., 2009). Findings herein, 
together with the existing literature, demonstrate significant therapeutic responses by influencing 
inter-connected intermediary nodes and molecules that mediate plasticity, neuronal growth and 
energy regulation. Given the extreme treatment resistant forms of MDD the patients had, it is not 
surprising that these effects may only take place after a considerable time of active stimulation that 
may also differ from individual to individual.  
A need for understanding different etiologies  
As depression is heterogeneous, subpopulations of TRD exist. In Chapter 1, these concerns 
were raised and a subsequent review of previous literature made clear of their impact on diagnosis, 
254 
 
treatment effectivity and population statistics. The manner in which patients may enter a 
depressive episode changes across developmental trajectory and disease progression, which could 
incidentally account for much of the inconsistency in the neurobiological literature, in relation to, 
for example, the HPA activity, peripheral BDNF or the changes reported in structural and functional 
imaging data. It is also a distinct possibility that if the neurobiological mechanisms change across 
episodes and depression severity, then different antidepressant strategies might be necessary at 
these stages, and this might account largely for the clinical failure in TRD population (apart from 
treatment adherence, tolerability etc.).  
Foremost factors behind individual variability in disease trajectory may be explained by 
genetic x environmental interactions, types of stressors, early life stress and comorbidities with 
medical or other psychological conditions. A short discussion of stress is important here given that 
our animal model utilizes disturbances in the stress axis as a basis for studying the antidepressant 
effects of DBS. Overlapping constitutional and experiential factors promote both vulnerability to 
depression and resistance to treatment (Willner, Scheel-Krüger, & Belzung, 2013). Differentiation 
exists for the effects of intense stressor vs. a combination of low levels of stress with a variety of 
factors that confer vulnerability to depression (Valenti et al., 2012). These differences accordingly 
cause cellular damages, dysregulated monoamines transmission to regional hyper/hypo-activity. 
Currently available antidepressants targeting monoamines, primarily repair a damaged 
hippocampus and are therefore ineffective in depression subtypes where it is assumed that stress 
has had only a minor precipitating role (perhaps vulnerability due to genetics). Antidepressants 
promote hippocampal neurogenesis but this is not a critical event for their mood-rectifying actions 
(Anacker & Pariante, 2011). Demonstrated by the present findings, the mesoaccumbens pathway 
and its associative regions play a crucial role in treatment responsivity that cannot be all accounted 
for by hippocampal processes. 
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All parts of the system can be narrowed down to specific symptoms of depression, with 
corresponding network activity (e.g. rumination and negative self-referential attributions reflect 
hyperactivity in amygdala and ventral prefrontal cortex regions whereas anhedonia has been 
linked to hypoactivity of NAc and dorsal prefrontal cortex). Current findings suggest that complex 
networks and interactions between signaling pathways will generate a wide variety of symptoms 
and severity, contingent upon the degree of dysfunction in each region (and their major molecular 
function), which in turn, depends upon the patients’ profile of vulnerability, precipitants and 
manner in which they are affected. It is also apparent that traditional ways of thinking about 
depression, based around a single brain region or a neurotransmitter are no longer adequate and 
the field of translational neuroscience and biological psychiatry are moving away from it. 
Hippocampal function, for example has been heavily focused in studying the neurobiology of 
depression and antidepressant properties. As shown in our findings, a broader focus is essential 
because, according to our current understanding, the hippocampus may almost be incidental to the 
symptomatology of depression. Neurogenesis maintains an efficient level of functioning within the 
hippocampus (Airan et al., 2007), which is concerned primarily with contextual learning (Rudy, 
2009). In the mPFC, synaptic remodeling and plasticity may underlie the action of antidepressant 
drugs. More direct involvement in the psychological (via bed nucleus of the stria terminalis, PFC, 
NAc and LHb) and physiological (PVN –stress axis) areas characterize the multifaceted depressive 
symptomatology and severity. 
A new understanding could adopt a perspective that different routes can be taken in order 
to achieve the same therapeutic outcome –via correcting for an abnormality either critical in its 
physiological function or of several functions that are not critical (primary) in itself. Again, this 
highlights the notion that DBS or any other drug intervention may exert its antidepressant effects 
by modulating pathological network activity. In light of recent negative results (Dougherty et al., 
2015), a lower response rate may be due to a systematic issue where individual DBS parameters 
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were established using a complicated process quickly within days and then left unchanged for the 
4-months controlled period (Schlaepfer, 2015). This approach, which is often similar to 
administering first-line pharmacotherapies, is counterintuitive because MDD patients take lengthy 
(often years) treatment course to reach optimal antidepressant efficacy. It would be of great 
interest in the future to examine how antidepressants could promote recovery of key symptoms 
with or without the reversal of the original etiology of the disease. Other psychopharmacological 
and neuromodulatory methods (e.g. TMS) could also be formulated to encounter these tracts on a 
signaling to systems level.  
An interaction between strong expectation of DBS effect x implantation of electrodes may 
explain no distinct separation on therapeutic outcomes between treatment and placebo. Previously, 
anticipation of treatment benefit in placebo groups have been found to affect outcomes with 
various antidepressants (Benedetti, Carlino, & Pollo, 2011). On the other hand, HDMRS or other 
depression scores used in clinical trials may not adequately represent the functional outcomes or 
emotional differences these patients experience. Changes in our expectations and/or addition of 
other measures could more appropriately investigate the results of DBS efficacy.  
Also, the development of mechanistic/mathematical models could capture the inter-
relationships that are so many and far too great for our minds to comprehend as to defy accurate 
predictions of the effects of any perturbation. Previously, Belzung and de Villemeur (2010) have 
presented such formal computational model of the hippocampal control of the HPA axis. Our gene 
expression data portrays a number of interrelated pathways that differentially or similarly respond 
to stress that are unique to the state of organism. Such models may help us better converge 
different cellular cascades and molecular interactions to use them for clinically meaningful, 
personalized and optimal treatment deliverance. These models could provide predictive outcomes 
that links specific depression etiologies to treatment options. 
257 
 
Finally, a concept that demands attention is a suggestion that what is important about 
depression is not so much its symptomatology as its chronicity: that is, the phenomenology of 
depression is a frequent natural response to adversity and what distinguishes people who become 
clinically diagnosable from those who do not, is that they become “stuck in a rut” and are unable to 
recover (Holtzheimer & Mayberg, 2011). The progressive nature of MDD consequently increases 
vulnerabilities to future depressive episodes, relapses and precipitates illness course leading to 
functional deterioration (Moylan, Maes, Wray & Berk, 2013).   
Limitations 
The work represented here should be interpreted in light of several limitations. First of all, a 
diverse set of behavioral paradigms could have been implemented to better characterize 
antidepressant-like effects and neuroplastic processes (novelty suppressed feeding, morris water 
maze etc.). Nevertheless, the experiments were carried out within the given time and available 
resources. More importantly, we were particularly interested in characterizing a treatment 
resistance phenotype where the FST was deemed sufficient in such a case. There is a no perfect 
animal model for depression. However, each animal model offers a unique insight into a specific 
feature of this heterogeneous disorder.  
Secondly, rats were housed in isolation from arrival to testing in chapters 4 & 5 to promote 
a depressive-like phenotype that should, in theory, enhance the appearance of TRD in combination 
with ACTH treatment. In experiments where socially-housed rats were used (chapters 6-8), the 
observed effects could have differed from the earlier experiments as those animals were not 
exposed to the social isolation paradigm. Nevertheless, the reader should take a note that there is 
an emphasis on the possible antidepressant-like effects of DBS using the ACTH model in chapters 4 
& 5; whereas chapter 6 explored gene x environmental interactions in a broader sense. Chapters 7 
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& 8 on the other hand, specifically investigated the region of interest-, frequency of stimulation and 
treatment on accumbal DA release. 
A deep, inherent issue that lies with preclinical research, and with the perspective of a 
diathesis/stress model, is that animal models of depression are mostly models of a first depressive 
episode. Animal models of depression have not addressed the progressive vulnerability that 
develops over successive episodes of depression. Consequently, the preclinical literature has almost 
nothing to say about the mechanisms by which depression becomes progressively more 
autonomous to stress (Willner et al., 2013). Animal models of repeated depressive episodes may be 
the next step in preclinical research. Our experimental design presented a novel method in 
incorporating chronic ACTH administration (an endogenous stressor) over time to observe its 
continual effects. Corticosterone administration, could be a useful way of identifying systems of 
interest but preempts investigation of important elements to the stress system. Whereas, our 
exploratory approach (especially in LHb and IL DBS chapters) allowed us to capture novel 
therapeutic targets and corroborated with previous findings to build a more integrative picture on 
the roles of key molecules and brain regions to necessitate antidepressant effects.  
Conclusions/Future directions 
The experiments within this thesis have significant implications for studying behaviors that 
are relevant to both health and disease. We further need to study native patterns of cellular 
function or circuit projections. By doing so, we should be able to distinguish the mechanisms that 
‘flip’ an individual from healthy to mental illness and what exacerbates that condition. At large, 
current experimental designs involve focusing on recreating or reflecting a disease state. It would 
be of great value to understand natural cell dynamics and mammalian behavior to identify factors 
that speeds up the transition from adaptive to maladaptive system. A problem with studying 
mechanisms and corresponding behavior by turning systems up or down is that we have 
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preconceived expectations and ‘chosen’ pathways that we think are involved for certain stress 
responses. Conversely, teasing out the intimately interconnected systems and studying them one by 
one, enables us to put together a whole picture. By separating the phenomena of interest from 
subjective emotional states, we may be able to better understand the complexity of the systems 
(see Figure 1).  
Figure ͳ. We need to carefully redefine subjective human emotion state to animal 
behavior. Technical advances in the last decade has expanded our capacity to map 
neural pathways that are relevant across species. Implementation of appropriate 
animal models may provide us with new possibilities for establishing individualized, 
stage specific treatment options. Diagram included with permission from Hendriksen 
and Groenink (2015). 
Stimulus and conditioned experience are not factors that fundamentally make us feel 
emotional. It is our capacity to have a conscious awareness of this experience and a cognitive 
processing that this is happening to ‘us’ that makes an event an emotionally relevant one. Such 
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higher executive functioning processes require cognition and language, which is also culturally 
bound and environmentally driven, rather than made up of innate survival responses –these innate 
autonomic reactions are only temporary. 
In conclusion, current antidepressant and neuromodulatory methods improve abnormal 
mood states through multidimensional mechanisms that are themselves incompletely understood. 
Presented works in this thesis demonstrates that each pathway (bioenergetics, synaptic plasticity, 
dopamine, mitochondrial function and stress) represents valuable pieces that provide a more 
comprehensive and converging picture on factors mediating treatment responsivity. Not all have to 
be dysregulated or be severe in order to cause enough of a deficit to ultimately bring about 
treatment resistance in an individual. Furthermore, it may be that these cellular and molecular 
systems work in intricate orchestration which ultimately disturbs cellular patterns on a systems-
wide level. We need to understand whether primary and/or secondary causes need to be targeted 
for effective treatment outcome. The initial etiology may not correctly represent the necessary 
target for recovery as the patients move through different stages in the neuroprogression of mood 
disorders.   
Overall, the outcomes underscore the significance in understanding the underlying 
antidepressant properties that achieves treatment response in individuals of refractory state in 
TRD, using DBS to manipulate and probe different systems. Such an approach gave us insight into 
the consequences of serious neuroprogressive nature of this disorder, which not only contributes to 
the economic and societal burden but may lead to fatal consequences for its sufferers. Armed with 
this knowledge, we must work on preventative strategies and interventions that could take place 
during one’s ultra-risk prodromal stages. The following chapter, titled “Stress, inflammation, and 
cellular vulnerability during early stages of affective disorders: Biomarker strategies and 
opportunities for prevention and intervention” (Walker et al., 2014), highlights how some of the 
mechanisms identified in this thesis may also be relevant targets for prevention and intervention 
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during the prodromal (not yet clinically diagnosable) stage of mood disorders. With successful 
intervention and earlier modulation of these systems during the critical neurodevelopmental 
stages, the neuroprogression of these illnesses may be hindered or even prevent the onset. Apart 
from many other factors that contributes to the makeup of TRD population, early intervention may 
be a fundamental, long lasting step to reduce the growth of susceptible individuals falling into such 
a debilitating stage of the disease. Shifting the way we typically think of mental disorder as stages of 
neurodevelopment provides an optimum foundation for prevention-driven research.  
 
 
  
262 
 
References 
Airan, R. D., Hu, E. S., Vijaykumar, R., Roy, M., Meltzer, L. A., & Deisseroth, K. (2007). Integration of 
light-controlled neuronal firing and fast circuit imaging. Current opinion in neurobiology, 
17(5), 587-592.  
Anacker, C., & Pariante, C. (2011). Can adult neurogenesis buffer stress responses and depressive 
behavior&quest. Molecular psychiatry.  
Belda, X., Rotllant, D., Fuentes, S., Delgado, R., Nadal, R., & Armario, A. (2008). Exposure to Severe 
Stressors Causes Long-lasting Dysregulation of Resting and Stress-induced Activation of the 
Hypothalamic-Pituitary-Adrenal Axis. Annals of the New York Academy of Sciences, 1148(1), 
165-173.  
Belzung, C., & de Villemeur, E. B. (2010). The design of new antidepressants: can formal models help? 
A first attempt using a model of the hippocampal control over the HPA-axis based on a review 
from the literature. Behavioral pharmacology, 21(8), 677-689.  
Benabid, A. L. (2015). Neuroscience: Spotlight on deep-brain stimulation. Nature, 519(7543), 299-
300.  
Benedetti, F., Carlino, E., & Pollo, A. (2011). How placebos change the patient's brain. 
Neuropsychopharmacology, 36(1), 339.  
Berk, M., Dodd, S., Kauer-Sant’Anna, M., Malhi, G., Bourin, M., Kapczinski, F., & Norman, T. (2007). 
Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar 
disorder. Acta Psychiatrica Scandinavica, 116(s434), 41-49.  
Bessa, J., Ferreira, D., Melo, I., Marques, F., Cerqueira, J., Palha, J., . . . Sousa, N. (2009). The mood-
improving actions of antidepressants do not depend on neurogenesis but are associated with 
neuronal remodeling. Molecular psychiatry, 14(8), 764-773.  
Caldarone, B. J., & Brunner, D. (2009). Preclinical testing in mice for treatment resistant depression. 
Frontiers in Neuroscience, 3, 264-265.  
263 
 
Chen, S., Owens, G. C., & Edelman, D. B. (2008). Dopamine inhibits mitochondrial motility in 
hippocampal neurons. PLoS One, 3(7), e2804.  
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., . . . McGuire, H. (2009). 
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-
treatments meta-analysis. The Lancet, 373(9665), 746-758.  
Dunlop, B. W., & Nemeroff, C. B. (2007). The role of dopamine in the pathophysiology of depression. 
Archives of general psychiatry, 64(3), 327-337.  
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006). Clinical and biological 
effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology, 31(3), 
628-636.  
Frey, B. N., Valvassori, S. S., Réus, G. Z., Martins, M. R., Petronilho, F. C., Bardini, K., . . . Quevedo, J. 
(2006). Effects of lithium and valproate on amphetamine-induced oxidative stress generation 
in an animal model of mania. Journal of Psychiatry and Neuroscience, 31(5), 326.  
Gardner, A., & Boles, R. G. (2011). Beyond the serotonin hypothesis: mitochondria, inflammation and 
neurodegeneration in major depression and affective spectrum disorders. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 35(3), 730-743.  
Ghosh, A., & Greenberg, M. E. (1995). Calcium signaling in neurons: molecular mechanisms and 
cellular consequences. Science, 268(5208), 239-247.  
Gold, P. (2015). The organization of the stress system and its dysregulation in depressive illness. 
Molecular psychiatry, 20(1), 32-47.  
Gong, Y., Chai, Y., Ding, J.-H., Sun, X.-L., & Hu, G. (2011). Chronic mild stress damages mitochondrial 
ultrastructure and function in mouse brain. Neuroscience letters, 488(1), 76-80.  
Hamani, C., Amorim, B. O., Wheeler, A. L., Diwan, M., Driesslein, K., Covolan, L., . . . Nobrega, J. N. (2014). 
Deep brain stimulation in rats: different targets induce similar antidepressant-like effects but 
influence different circuits. Neurobiology of disease, 71, 205-214.  
264 
 
Hendriksen, H., & Groenink, L. (2015). Back to the future of psychopharmacology: A perspective on 
animal models in drug discovery. European journal of pharmacology, 759, 30-41.  
Holtzheimer, P. E., & Mayberg, H. S. (2011). Stuck in a rut: rethinking depression and its treatment. 
Trends in neurosciences, 34(1), 1-9.  
Kim, H. K., Andreazza, A. C., Yeung, P. Y., Isaacs-Trepanier, C., & Young, L. T. (2014). Oxidation and 
nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder 
and schizophrenia. Journal of psychiatry & neuroscience: JPN, 39(4), 276-285.  
Kitamura, Y., Fujitani, Y., Kitagawa, K., Miyazaki, T., Sagara, H., Kawasaki, H., . . . Gomita, Y. (2008). 
Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in 
the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biological 
and Pharmaceutical Bulletin, 31(2), 246-249.  
Lammel, S., Lim, B. K., Ran, C., Huang, K. W., Betley, M. J., Tye, K. M., . . . Malenka, R. C. (2012). Input-
specific control of reward and aversion in the ventral tegmental area. Nature, 491(7423), 212-
217.  
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009). Effects of stress throughout the lifespan 
on the brain, behavior and cognition. Nature Reviews Neuroscience, 10(6), 434-445.  
Manji, H., Kato, T., Di Prospero, N. A., Ness, S., Beal, M. F., Krams, M., & Chen, G. (2012). Impaired 
mitochondrial function in psychiatric disorders. Nature Reviews Neuroscience, 13(5), 293-
307.  
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., . . . Lancaster, J. L. 
(2014). Reciprocal limbic-cortical function and negative mood: converging PET findings in 
depression and normal sadness.  
McKlveen, J. M., Myers, B., & Herman, J. P. (2015). The Medial Prefrontal Cortex: Coordinator of 
Autonomic, Neuroendocrine and Behavioral Responses to Stress. Journal of 
neuroendocrinology, 27(6), 446-456.  
265 
 
Meng, H., Wang, Y., Huang, M., Lin, W., Wang, S., & Zhang, B. (2011). Chronic deep brain stimulation 
of the lateral habenula nucleus in a rat model of depression. Brain research, 1422, 32-38.  
Mizoguchi, K., Yuzurihara, M., Ishige, A., Sasaki, H., Chui, D.-H., & Tabira, T. (2000). Chronic stress 
induces impairment of spatial working memory because of prefrontal dopaminergic 
dysfunction. The Journal of Neuroscience, 20(4), 1568-1574.  
Moylan, S., Maes, M., Wray, N., & Berk, M. (2013). The neuroprogressive nature of major depressive 
disorder: pathways to disease evolution and resistance, and therapeutic implications. 
Molecular psychiatry, 18(5), 595-606.  
Nemeroff, C. B., & Owens, M. J. (2004). Pharmacologic differences among the SSRIs: focus on 
monoamine transporters and the HPA axis. CNS spectrums, 9(S4), 23-31.  
Nestler, E. J., & Hyman, S. E. (2010). Animal models of neuropsychiatric disorders. Nature 
neuroscience, 13(10), 1161-1169.  
Ng, C.-H., Guan, M. S., Koh, C., Ouyang, X., Yu, F., Tan, E.-K., . . . Lim, K.-L. (2012). AMP kinase activation 
mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models 
of Parkinson's disease. The Journal of Neuroscience, 32(41), 14311-14317.  
Oswald, L. M., Wong, D. F., McCaul, M., Zhou, Y., Kuwabara, H., Choi, L., . . . Wand, G. S. (2005). 
Relationships among ventral striatal dopamine release, cortisol secretion, and subjective 
responses to amphetamine. Neuropsychopharmacology, 30(4), 821-832.  
Papiol, S., Arias, B., Gastó, C., Gutiérrez, B., Catalán, R., & Fañanás, L. (2007). Genetic variability at HPA 
axis in major depression and clinical response to antidepressant treatment. Journal of 
affective disorders, 104(1), 83-90.  
Perez-Caballero, L., Perez-Egea, R., Romero-Grimaldi, C., Puigdemont, D., Molet, J., Caso, J., . . . 
Berrocoso, E. (2014). Early responses to deep brain stimulation in depression are modulated 
by anti-inflammatory drugs. Molecular psychiatry, 19(5), 607-614.  
266 
 
Riva-Posse, P., Choi, K. S., Holtzheimer, P. E., McIntyre, C. C., Gross, R. E., Chaturvedi, A., . . . Mayberg, 
H. S. (2014). Defining critical white matter pathways mediating successful subcallosal 
cingulate deep brain stimulation for treatment-resistant depression. Biological psychiatry, 
76(12), 963-969.  
Rudy, J. W. (2009). Context representations, context functions, and the parahippocampal–
hippocampal system. Learning & memory, 16(10), 573-585.  
Salamone, J. D., & Correa, M. (2012). The mysterious motivational functions of mesolimbic dopamine. 
Neuron, 76(3), 470-485.  
Salamone, J. D., Correa, M., Farrar, A., & Mingote, S. M. (2007). Effort-related functions of nucleus 
accumbens dopamine and associated forebrain circuits. Psychopharmacology, 191(3), 461-
482.  
Schellekens, H., Finger, B. C., Dinan, T. G., & Cryan, J. F. (2012). Ghrelin signalling and obesity: at the 
interface of stress, mood and food reward. Pharmacology & therapeutics, 135(3), 316-326.  
Song, B., Lai, B., Zheng, Z., Zhang, Y., Luo, J., Wang, C., . . . Li, M. (2010). Inhibitory phosphorylation of 
GSK-3 by CaMKII couples depolarization to neuronal survival. J Biol Chem, 285(52), 41122-
41134. doi: 10.1074/jbc.M110.130351 
Valenti, O., Gill, K. M., & Grace, A. A. (2012). Different stressors produce excitation or inhibition of 
mesolimbic dopamine neuron activity: response alteration by stress pre-exposure. European 
Journal of Neuroscience, 35(8), 1312-1321.  
Walker, A. J., Burnett, S. A., Hasebe, K., McGillivray, J. A., Gray, L. J., McGee, S. L., . . . Tye, S. J. (2013). 
Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and 
prefrontal monoamine tissue levels. Behavioral brain research, 242, 76-83.  
Walker, A. J., Foley, B. M., Sutor, S. L., McGillivray, J. A., Frye, M. A., & Tye, S. J. (2015). Peripheral 
proinflammatory markers associated with ketamine response in a preclinical model of 
antidepressant-resistance. Behavioral brain research.  
267 
 
Walker, A. J., Kim, Y., Price, J. B., Kale, R. P., McGillivray, J. A., Berk, M., & Tye, S. J. (2014). Stress, 
inflammation, and cellular vulnerability during early stages of affective disorders: biomarker 
strategies and opportunities for prevention and intervention. Frontiers in psychiatry, 5.  
West, A. E., Griffith, E. C., & Greenberg, M. E. (2002). Regulation of transcription factors by neuronal 
activity. Nature Reviews Neuroscience, 3(12), 921-931.  
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013). The neurobiology of depression and 
antidepressant action. Neuroscience & Biobehavioral Reviews, 37(10), 2331-2371.  
 
  
268 
 
 
 
 
 
 
 
 
 
 
Chapter 10. Stress, inflammation, and cellular vulnerability during early stages of affective 
disorders: biomarker strategies and opportunities for prevention and intervention 
 
Manuscript published as: 
Walker A.J., Kim Y., Price J.B., Kale R.P., McGillivray J.A., Berk M., Tye S.J. (2014). Stress, 
inflammation and cellular vulnerability during early stages of affective disorders: Biomarker 
strategies and opportunities for prevention and intervention. Frontiers in Psychiatry, 5, 1-8. 
 
 
 
 
 
 
PSYCHIATRY
MINI REVIEW ARTICLE
published: 09 April 2014
doi: 10.3389/fpsyt.2014.00034
Stress, inﬂammation, and cellular vulnerability during
early stages of affective disorders: biomarker strategies
and opportunities for prevention and intervention
Adam J.Walker 1,2,Yesul Kim1,2, J. Blair Price1, Rajas P. Kale1,3, Jane A. McGillivray 2, Michael Berk 4,5,6,7 and
Susannah J.Tye1,2,8*
1 Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
2 School of Psychology, Deakin University, Melbourne, VIC, Australia
3 School of Engineering, Deakin University, Geelong, VIC, Australia
4 School of Medicine, Deakin University, Geelong, VIC, Australia
5 Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia
6 OrygenYouth Health Research Centre, Melbourne, VIC, Australia
7 The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
8 Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
Edited by:
Stephanie Ameis, University of
Toronto, Canada
Reviewed by:
Vilma Gabbay, Mount Sinai School of
Medicine, USA
Ellen Grishman, University of Texas
Southwestern Medical Center, USA
*Correspondence:
Susannah J. Tye, Department of
Psychiatry and Psychology, Mayo
Clinic, 200 First Street SW,
Rochester, MN 55905, USA
e-mail: tye.susannah@mayo.edu
The mood disorder prodrome is conceptualized as a symptomatic, but not yet clinically diag-
nosable stage of an affective disorder. Although a growing area, more focused research
is needed in the pediatric population to better characterize psychopathological symptoms
and biological markers that can reliably identify this very early stage in the evolution of
mood disorder pathology. Such information will facilitate early prevention and intervention,
which has the potential to affect a person’s disease course.This review focuses on the pro-
dromal characteristics, risk factors, and neurobiological mechanisms of mood disorders.
In particular, we consider the inﬂuence of early-life stress, inﬂammation, and allostatic
load in mediating neural mechanisms of neuroprogression. These inherently modiﬁable
factors have known neuroadaptive and neurodegenerative implications, and consequently
may provide useful biomarker targets. Identiﬁcation of these factors early in the course
of the disease will accordingly allow for the introduction of early interventions which aug-
ment an individual’s capacity for psychological resilience through maintenance of synaptic
integrity and cellular resilience. A targeted and complementary approach to boosting both
psychological and physiological resilience simultaneously during the prodromal stage of
mood disorder pathology has the greatest promise for optimizing the neurodevelopmental
potential of those individuals at risk of disabling mood disorders.
Keywords: prodrome, depression, bipolar, biomarker, stress, inﬂammation, cellular resilience, plasticity
INTRODUCTION
There is increasing appreciation for the need to both identify and
treat mood disorders during their earliest stages (1). Although
some dispute remains,maladaptive changes inmood and behavior
ﬁrst become evident during the prodromal period (2). However,
the low speciﬁcity of these changes makes the prodromal stage
difﬁcult to deﬁnitively characterize prior to disease onset (3).
Observable changes in mood and general physiologic function-
ing can include increases in sadness, anhedonia, irritability, anger,
and anxiety, together with alterations in sleep and energy (4).
Correlating these symptoms with prodromal biomarkers offers an
exciting juncture whereby targeted interventions could be oppor-
tunistically employed to prevent neurodegenerative changes from
accruing as the disease progresses (5). The potential to inter-
vene during the prodromal stage of psychiatric illness through the
detection and remediation of novel biomarkers has perhaps been
best studied in schizophrenia, wherein most individuals experi-
ence a lengthy prodromal period prior to the full emergence of
diagnosable psychotic symptoms (6). As an exemplar, low levels
of nervonic acid appear to be a risk factor for conversion from
high-risk to frank psychosis (7), and this risk of conversion may
be reduced by targeted omega-3 fatty acid supplementation (8).
Encouraging results from this work have renewed interest in the
early detection of affective disorders, particularly bipolar disorder,
with the hope that earlier and more targeted interventions might
slow disease progression (3, 9–12). This can signiﬁcantly impact
neuroprogression and subsequent disease course for the individual
(13). This concept of “neuroprogression” refers to the cumulative
restructuring of the central nervous system which in turn medi-
ates the development and persistence of psychiatric illness (14, 15).
This process results fromdisturbances in inﬂammatorymediators,
neurotrophins, oxidative stress, and energy regulation (14, 15).
BIOMARKER STRATEGIES FOR PRODROMAL MOOD
DISORDERS
STRESS AND ALLOSTATIC LOAD
Stress sensitization and early detection
Stress is one of the best-studied mediators by which genetic vul-
nerabilities are translated into mood disorder pathology through
the process of neuroprogression (16–18). Numerous studies have
www.frontiersin.org April 2014 | Volume 5 | Article 34 | 1
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demonstrated that both depression and bipolar disorder are more
prevalent in individuals who have experienced adverse early-life
events. This is partly because such experiences prime future phys-
iologic and neural responses to stress, elicit a state of chronic
inﬂammation (19), alter cellularmediators of plasticity and energy
metabolism, and increase cellular “wear and tear” (20–22). Early-
life stress (2) can be particularly deleterious because of its poten-
tial to inﬂuence the programing of the hypothalamic–pituitary–
adrenal (HPA) axis (23) to induce persistent sensitization of
neuroendocrine, autonomic, oxidative, and immune responses to
stress. Over time these sensitized systems cumulatively contribute
to the cellular and synaptic alterations underlying neuroprogres-
sion (21, 24–26). Speciﬁc examples include changes in reactivity
of inﬂammatory cytokines [e.g., interleukin 6 (IL-6)] (25), alter-
ations in markers for lipid peroxidation [e.g., 8-iso-prostaglandin
F (2α)],oxidative damage toDNA(8-hydroxy-2′-deoxyguanosine)
and RNA (8-hydroxyguanosine) (24), as well as altered cortisol,
adrenocorticotropic hormone, and corticotrophin releasing fac-
tor responses (26). Identiﬁcation of the state of physiologic and
cellular resilience or sensitivity to stress may provide an important
indicator of the level of neuroprogression and stress-mediated dis-
ease pathology for affective disorders,potentially prior to the initial
manifestation of the mood episode (22).
One mechanism whereby HPA axis sensitization is likely to
occur is through epigenetic regulation of stress response processes
(21, 27). Evidence shows that exposure to various forms of stress
result in multiple epigenetic changes in limbic regions as well as
the HPA axis (21, 27). Interestingly, a recent study by Klendel
and colleagues (18) found that only individuals who exhibited
allele-speciﬁc DNA demethylation in functional glucocorticoid
response elements of FK506 binding protein 5 (FKBP5), were
prone to developing persistent cortisol dysregulation (18, 21).
Further, this association was found to be dependent on an inter-
action effect with trauma in early life, suggesting that key devel-
opmental stages are directly related to stability of the observed
effects across time (18). In another study, signiﬁcant interactions
between peripheral FKBP5 mRNAexpression and disease progres-
sion were reported, suggesting that polymorphisms in the gene
directly impact the extent of neuroendocrine dysregulation, and
corresponding neuroprogression (28). The FKBP5 risk allele and
corresponding levels of mRNA expression may represent useful
biomarkers. These markers could be employed to identify individ-
uals in the prodromal stages of stress-sensitive psychiatric disor-
ders, such as major depression or bipolar disorder. Such detection
would facilitate early intervention and could improve resilience
and alleviate allostatic load in the prodromal individual.
Early-life stress and accumulation of allostatic load
Accumulation of allostatic load is a keymechanism throughwhich
early-life stress is thought to result in psychopathology (29). This
ismediated via a series of enduring adaptive changes across a range
of systems primed both to respond rapidly to challenge, as well as
to restore homeostatic equilibrium (30). Adaptive allostatic mech-
anisms may fail when chronically challenged or when regulatory
systems falter. This leads to a state of allostatic overload, which
is thought to considerably impact the clinical course of mood
disorders (31–33). Without sufﬁcient opportunity for recovery,
the brain and body are repeatedly exposed to molecular media-
tors of stress that can increase the level of cellular “wear and tear”
(33). Thesemediators,which includemetabolic factors, inﬂamma-
tory cytokines, neurotrophins, and oxidative species, collectively
impact an individual’s mental and physical resilience as outlined
below [for more detailed reviews see Ref. (6, 34, 35)]. Both phys-
iological (i.e., immune and/or metabolic) and psychological (i.e.,
bullying) stressors contribute signiﬁcantly to allostatic load, and
thus need to be considered together when assessing both risk and
relative staging of mood disorder pathology (6, 34).
Enhancing an individual’s capacity to buffer the physiologic
toll that accumulates through allostatic overload should be con-
sidered an important early intervention strategy. As allostatic load
accumulates and attempts to maintain cellular homeostasis fail,
cell danger signals are propagated and pro-apoptotic cell signaling
pathways become increasingly engaged (36–39). This may play a
role in medical comorbidities such as heart disease (40), as well
as interfere with the therapeutic mechanisms of antidepressants
and mood stabilizers to impair treatment efﬁcacy (41–43). Inter-
nal stressors that activate the HPA axis and associated allostatic
systems can limit an individual’s capacity for allostasis even prior
to the onset of external stressors (36). For example, an endogenous
load can build through the expression of homocysteine or inﬂam-
matory cytokines, limiting the capacity of adaptive responses in the
face of subsequent stressors. Interventions that counter this load
and reduce levels of proinﬂammatory mediators or interfere with
their neuromodulatory actions could limit neuroprogression in
both bipolar and unipolar depression, as well as enhance capacity
for antidepressant efﬁcacy (44–46).
INFLAMMATORY PROFILE
Stress during earlier life is not only associated with disruption of
the HPA axis, but may also serve to sensitize proinﬂammatory
responses to future insults (47–49). Inﬂammatory mechanisms
are increasingly appreciated for their critical role in mood disor-
der pathophysiology, in particular via their regulation of neuronal
excitability, synaptic transmission, synaptic plasticity and neu-
ronal survival (41,50, 51).Of speciﬁc interest are proinﬂammatory
mediators, such as cytokines [i.e., interleukin 1, IL-6, and tumor
necrosis factor alpha (TNF-α)] andC-reactive protein (CRP). CRP
is often used as a biomarker for inﬂammation in studies due to
its relationship with proinﬂammatory cytokines and role in the
immune response.As demonstrated by Slopen and colleagues (49),
individuals at ages 10 and 15 who reported adverse life events at
critical stages between the ages of 1.5 and 8 years were found to
have signiﬁcantly increased levels of CRP and IL-6. These height-
ened concentrations were correlated with immune activation and
depressive-like symptoms.Notably, increasedCRP levels have been
used previously to predict depression severity and recurrence rates
in males (48, 52).
There is a growing literature supporting the use of inﬂam-
matory biomarkers as predictors of ensuing mood disorder
pathology (22). Research to date has been focused on inves-
tigating the relationship between inﬂammatory cytokines and
affective disorders in adults; however, their speciﬁc role in early
onset/adolescent psychopathology is less well explored (53).
Cytokines are thought to inﬂuence neurodevelopment during key
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stages, such as adolescence, interacting with biological systems
including those of stress hormones and gonadal hormones (53).
As such, perturbation of inﬂammatory balance in adolescents may
signiﬁcantly contribute to neuroprogression and development of
psychiatric illness (19, 53, 54). For example, elevated serum lev-
els of TNF-α, IL-6, and interleukin-10 (IL-10) have been reported
during the early stages of bipolar disorder (55), and CRP appears
to be a biomarker of de novo depression risk (56).
As themooddisorder pathology progresses, an increasing num-
ber of proinﬂammatory cytokines are observed, including elevated
levels of interferon gamma (IFN-γ) (22, 54, 55). Notably, increases
in IFN-γ are associated with dysregulation of the tryptophan
metabolite pathway via direct role in indoleamine 2,3-dioxygenase
(IDO) activation. Activation of IDO is commonly found in later
stages of mood disorders, and is a biomarker of depression-like
behavior mediated by neural inﬂammation in animal models
(48). Proinﬂammatory cytokines activate IDO, resulting in deple-
tion of serotonin and augmentation of quinolinic acid (QUIN)
metabolism over kynurenic acid (KYNA). Tryptophan metabo-
lites (kynurenine, KYNA, 3-hydroxykynurenine, and QUIN) act
as neuromodulators to inﬂuence behavioral, neuroendocrine, and
neurochemical aspects of depression (57–60). Consequently, this
accumulation of QUIN facilitates neurodegeneration over neu-
roprotection, impacting mood disorder neuroprogression and
resultant disability (61).
It is noteworthy to mention several other ﬁndings regard-
ing altered inﬂammation in youth with psychiatric pathology.
Increased mRNA and protein expression levels of IL-1β, IL-6, and
TNF-α were reported in the anterior prefrontal cortex of adoles-
cent suicide victims compared with normal control subjects (62).
Elevated levels of inﬂammatory cytokines (among others: TNF-α,
IL-1β, IL-6, and IFN-γ) were also observed in the serum of pedi-
atric patients who experienced ﬁrst-episode psychosis, in addition
to increased leukocyte counts and evidence of blood–brain barrier
damage (63). Quantiﬁcation of inﬂammatory biomarkers (e.g.,
TNF-α, IL-6, IL-10, or CRP) may thus prove useful for detecting
individuals at risk for developing a mood disorder. A recent study
by Byrne and colleagues (64) suggests that levels of peripheral
cytokines (e.g., IFN-γ) and CRP in salivary samples may correlate
with serum samples in young people. Salivary assay may prove to
be a simpler, less invasive method of estimating peripheral lev-
els of inﬂammatory markers in adolescents (64). This provides
one avenue whereby prodromal individuals could potentially be
identiﬁed and their disease onset delayed.
DIMINISHED SYNAPTIC INTEGRITY
Homeostatic control of synaptic connections within key mood-
related circuits plays a critical role in the etiology of mood dis-
orders (65). Stress and inﬂammation as discussed in previous
sections are implicated in disruption of synaptic signaling and
integrity during the early stages of mood disorder pathogenesis.
This is mediated in part through the inhibition of neurotrophin
function, of which brain derived neurotrophic factor (BDNF) is
the most thoroughly characterized. BDNF plays an important
role in neuronal development, survival, and function, including
activity-dependent synaptic plasticity (66). Synaptic plasticity is
characterized by various processes, including synaptic remodeling,
synaptogenesis, long-term potentiation, and long-term depres-
sion, all of which critically mediate the ﬂow of electrochemical
information throughout the central nervous system (67, 68).
Stress, allostatic load, inﬂammation, antidepressants, and mood
stabilizers exert major effects on signaling pathways that regu-
late cellular plasticity, suggesting these are critical neurobiologi-
cal mediators of mood dysfunction and therapeutic intervention
(69–72).
Glycogen synthase kinase-3 (GSK-3), part of the signaling cas-
cade regulated byBDNF,plays an important role in synaptic home-
ostasis through regulation of synaptic deconsolidation (pruning)
and glutamate receptor cycling (73). Increased GSK-3-mediated
synaptic deconsolidation has been suggested to be an important
factor contributing to reduced spine density in mood disorders
(74). Additionally, levels of activated GSK-3 are increased in post-
mortem brain tissue from individuals with unipolar and bipolar
depression (74). In addition to BDNF,GSK-3 is deactivated by sig-
nals originating from numerous signaling pathways demonstrated
to be dysregulated in mood disorders (e.g., Wnt and PI3K path-
ways), and is either the direct or downstream target of manymood
stabilizer and antidepressant medications (75). GSK-3 activity is
modulated by serotonin and dopamine, and is a critical node at
the intersection of multiple neurotransmitter and cell signaling
cascades (68). As a result,GSK-3modulates not only synaptic plas-
ticity but also apoptotic mechanisms and, in turn, plays a critical
role in mediating cellular resilience (75). For this reason, GSK-3
has received much attention for its potential to be targeted as an
early intervention strategy during the prodrome period.
IDENTIFYING IMPAIRED CELLULAR RESILIENCE
Stress, allostatic overload, and neuroinﬂammation function
together to impair synaptic plasticity and cellular resilience. Dis-
rupted plasticity along with increased cellular vulnerability con-
tributes signiﬁcantly to the pathophysiology of mood disorders
anddirectly to the neuroprogressive nature of the disease course (3,
76). Some of the key mechanisms of disease progression affecting
cellular resilience include: oxidative stress, decreased neurotrophic
factor expression, reduced neurogenesis, impaired regulation of
calcium, altered endoplasmic reticulum and mitochondrial func-
tion, together with dysregulated energy metabolism and insulin
signaling. Each of these mechanisms are mediated by allostatic
overload and neuroinﬂammation [for detailed reviews see Ref. (3,
36, 76–78)]. Together, these processes demonstrate that in addition
to synaptic integrity,maintenance of cellular homeostasis is critical
for facilitating cellular resilience and attenuating mood disorder
pathogenesis (79), which is also likely to enhance the capacity for
treatment response during later stages of the disorder (80).
Cellular vulnerability and resilience are mediated by apop-
totic and anti-apoptotic intracellular signaling cascades, respec-
tively. Apoptosis is important for the regulation of develop-
mental processes and prevention of cancerous growths. Exces-
sive apoptosis in neuronal systems, however, leads to neurode-
generation and certain cell populations are at increased risk
of stress-mediated apoptotic cell death (80). Apoptosis is a
tightly regulated and energy-dependent process, which coordi-
nates programed cell death in response to different stimuli (81).
This can occur through stimulation of death receptor proteins
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[i.e., tumor necrosis factor (TNF) receptor] by cytokines of the
TNF superfamily or in response to mitochondrial degradation.
These stimuli result in activation of executioner caspases that
function to coordinate cellular process necessary for apoptosis,
including cessation of cell repair processes and cell cycle pro-
gression, cytoskeletal and nuclear disassembly, and ﬂagging the
cell for phagocytosis (82). Distinct classes of antidepressants
and mood stabilizers have been demonstrated to facilitate cellu-
lar resilience to prevent progression of pro-apoptotic processes,
and novel treatments are currently being developed to target
these speciﬁc mechanisms (83). Biomarkers that characterize the
level of neuronal vulnerability relative to resilience may prove
useful as biomarkers of prodromal mood disorder pathology.
This has been demonstrated for later stages of bipolar disorder
(84), however more studies are needed to determine the util-
ity of such cell danger biomarkers during the mood disorder
prodrome (22).
OPPORTUNITIES FOR PREVENTION AND INTERVENTION
IDENTIFYING VULNERABILITIES AND BUILDING RESILIENCE AT THE
CELLULAR LEVEL
Identiﬁcation of individuals at risk of developing amood disorder,
or those in the prodromal stage, provides a potential opportunity
to target these mechanisms for neuroprotective interventions that
enhance cellular resilience, maintain synaptic plasticity and boost
psychological resilience (Figure 1) (85). One of the longest held
notions of brain plasticity is that certain critical periods or win-
dows exist in development, during which circuitry is consolidated
for lifetime functionality. Recently, there is a rising consensus that
developmentally induced plasticity can, to an extent, be reversed
by “re-opening” those windows of plasticity (86). Hyman and
Nestler (87) have underscored the importance of shifting the brain
into an “adaptive state” to necessitate the antidepressant response.
Their theory of “initiation and adaption” is exempliﬁed by psy-
chotropic drugs wherein primary molecular targets that initiate
alterations in brain function activate homeostatic mechanisms
that return the system to an adaptive and treatment responsive
state (87). Plasticity and cellular resilience are thus necessary for
the efﬁcacy of antidepressants and mood stabilizing treatments.
McGorry and colleagues (6, 88) and others (89) have demon-
strated this concept with pre-psychotic interventions, and repeat-
edly emphasized the need to take advantage of the “windows of
opportunity” present within the prodromal stages of psychiatric
disease (6, 88, 89). During this stage, the course of the disease
remains theoretically plastic and amenable to intervention (90).
Previous literature indicates that once risk or prodromal symp-
toms of mood disorders are identiﬁed, there is some (91), but not
unequivocal (92) evidence that early intervention in adolescents
can signiﬁcantly reduce mood-related symptoms and incidence
of fully diagnosable psychiatric disorders such as depression (93–
95). Neuroprotective pharmacotherapies together with appropri-
ate psychotherapy may reduce the risk of neuropsychiatric disease
progression in young people which, together with allostatic load
reducing behavioral interventions, may signiﬁcantly slow the tra-
jectory of the disease course into adulthood (6, 36, 96). Such
interventionsmay include reducing lifestylemediators of allostatic
load (19, 97).
FIGURE 1 | A representation of the conceptual balance between
vulnerability and resilience in prodromal individuals. The scale’s balance
beam teeters between vulnerability and resilience as scale pans are loaded
with different positive and negative biological, psychological and social
factors. The presence or absence of these factors inﬂuence the ability of
the individual to cope with stressors, and maintain allostasis. (A) Prodromal
individuals are somewhat predisposed to vulnerability; but with intervention
(B) an individual may adopt more adaptive environmental coping strategies,
support mechanisms, general healthy lifestyle choices, and/or receive
pharmacological interventions that collectively enhance physiological and
psychological resilience.
COGNITIVE AND BEHAVIORAL INTERVENTIONS TO BUFFER STRESS
AND BUILD RESILIENCE
Individuals provided with effective social and emotional sup-
port to help cope with stressors that are adverse and potentially
taxing will be much better placed to limit associated biological
costs and maintain allostasis (98). The absence of emotional or
social support and the implementation of maladaptive coping
strategies can enhance the toxic effects of stress and contribute
to allostatic overload (98). Exposure to regular and controllable
stressors over the course of childhood and adolescence is essen-
tial for the development of effective coping strategies. Through
such exposure, an individual can develop a repertoire of these
coping strategies. Mathew and Nanoo (99) found that adaptive
coping strategies (e.g., employing self-control, accepting respon-
sibilities, problem solving, seeking social support, or positive re-
appraisal) are protective for suicide risk in adolescents. Conversely,
maladaptive coping strategies, such as confrontation, distancing,
and escape-avoidance were reported to be signiﬁcant risk factors
associated with adolescent suicide attempts (99). These ﬁndings
provide evidence to support the notion that coping strategies
can act as protective factors against both the development and
progression of mood disorders. Importantly, educating children
and adolescents in protective coping skills may be a promising
intervention that could be implemented as early as elementary
school. In recent years, patterns of threat perception such as opti-
mism have attracted much attention in relation to later mood,
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coping, and immune change in response to stress (100,101).More-
over, it has been found to be protective against the development
of depressive symptoms in later life (102). Its potential role in
buffering against the negative emotional consequence of adverse
events has led to a view of optimism as an index of resilience
(103). Optimists may also choose lifestyles that promote phys-
ical as well as mental health, thereby reducing other aspects of
allostatic load.
Healthy lifestyle, similar to optimism, provides a solid founda-
tion for adaptation, and increases available resources for buffering
the neurodegenerative effects of stress. Speciﬁcally, previous lit-
erature highlights the importance of healthy diet, adequate sleep,
avoidance of smoking, and sufﬁcient exercise (104). A population-
based study reported higher emotional well-being among physi-
cally active youths, independent of social class and health status
(105). Across a 2-year period, Motl and colleagues (106) found
changes in physical activity were inversely related to a change
in depressive symptoms. Levels of physical activity in childhood
can modulate the risk of adult depression (107). Exercise modu-
lates many of the core biomarkers of neuroprogression, including
inﬂammation, oxidative stress, and neurotrophins (108). Poor
eating habits and sleep have been linked to the manifestation
of toxic stress and unhealthy growth in pediatrics by disrupt-
ing the architecture of the plastic, adaptive brain (109). There is
now extensive evidence that poor diet quality is a risk for ado-
lescent depression (110), and new data suggests that maternal
diet inﬂuences the mental health of offspring (111). Similarly,
smoking increases the risk of mood and anxiety disorders, and
appears to inﬂuence similar biological pathways (112, 113). Par-
ents and care givers of younger children need to be informed of
the potential impact that a healthy lifestyle can have in mitigat-
ingmood-related symptoms and problematic behaviors. Low-risk
interventions such as those aforementioned are critical for enhanc-
ing both psychological and biological resilience to stress. When
such perspectives and lifestyle health behaviors are consolidated
early in childhood and adolescence, the cumulative effect may be
meaningful (103).
CONCLUSION
Early intervention offers the possibility of altering the trajec-
tory of mood disorder pathology. In so doing, we may curtail
the progressive nature of the illness, both through neuropro-
tection and maintenance of peripheral health. Prevention and
intervention treatments should go beyond stabilizing mood to
include various and complementary strategies for reducing allo-
static load, perhaps through psychoeducation and lifestyle-related
interventions, including effective stress management. The com-
bination of these techniques with speciﬁc pharmacotherapies
may signiﬁcantly improve functional outcomes by both reduc-
ing cellular insults and enhancing resilience. In so doing, this
optimizes the capacity for maintenance of synaptic integrity
and cellular resilience, which must be aggressively targeted as a
therapeutic strategy during the prodromal stage of mood dis-
order pathology (90). This neuroprotective approach not only
slows neuroprogression associated with the disease, but lays
a foundation for more treatment-responsive outcomes during
later stages.
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Table 3 
Linear regression analyses for the LHb region 
CaMKIIα phospho-CaMKIIα p/CaMKIIα
F p r2 F p r2 F p r2
DBS 3.49 0.12 0.41 9.64 0.05 0.76 9.64 0.05 0.76
ACTH 0.2 0.66 0.03 0.17 0.7 0.04 0.22 0.66 0.05
SURG 0.16 0.7 0.02 1.41 0.3 0.26 0.16 0.71 0.04
SALINE 0.003 0.95 0.0005 0.57 0.49 0.12 0.13 0.73 0.03
CaMKIIβ phospho-CaMKIIβ p/CaMKIIβ
F p r2 F p r2 F p r2
DBS 0.92 0.38 0.16 1.98 0.25 0.39 4.28 0.13 0.59
ACTH 0.01 0.92 0.002 0.1 0.76 0.02 0.24 0.65 0.06
SURG 0.56 0.82 0.009 2.04 0.23 0.34 0.06 0.81 0.01
SALINE 0.5 0.5 0.08 0.33 0.6 0.76 0.09 0.78 0.02
GSK3α phospho-GSK3α p/GSK3α
F p r2 F p r2 F p r2
DBS 0.06 0.81 0.01 7.56 0.07 0.72 33.13 0.01 0.91
ACTH 0.02 0.9 0.003 0.57 0.82 0.01 0.08 0.78 0.02
SURG 0.3 0.6 0.05 1.64 0.27 0.29 0.03 0.87 0.007
SALINE 2.5 0.16 0.29 2.19 0.21 0.35 0.06 0.81 0.02
GSK3β phospho-GSK3β p/GSK3β
F p r2 F p r2 F p r2
DBS 0.94 0.37 0.16 6.3 0.08 0.68 15.1 0.03 0.83
ACTH 0.53 0.49 0.08 0.06 0.82 0.01 0.24 0.65 0.06
SURG 0.33 0.58 0.53 1.75 0.26 0.3 0.35 0.58 0.08
SALINE 1.3 0.28 0.18 0.77 0.43 0.16 0.01 0.91 0.003
AMPK phospho-AMPK p/AMPK
F p r2 F p r2 F p r2
DBS 0.68 0.45 0.12 7 0.07 0.7 6.9 0.07 0.7
ACTH 0.51 0.5 0.08 0.09 0.77 0.02 0.15 0.72 0.03
SURG 0.06 0.81 0.009 2.23 0.2 0.36 0.2 0.67 0.05
SALINE 0.12 0.74 0.02 0.3 0.62 0.65 0.91 0.39 0.19
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Table 4 
Linear regression analyses for the IL region 
CaMKIIα phospho-CaMKIIα p/CaMKIIα
F p r2 F p r2 F p r2
DBS 1.29 0.31 0.2 14.86 0.01 0.75 13.08 0.01 0.72
ACTH 0.09 0.77 0.01 3.46 0.11 0.36 5.29 0.06 0.47
SURG 1.47 0.27 0.19 2.76 0.15 0.31 0.48 0.51 0.07
SALINE 0.34 0.58 0.05 0.03 0.86 0.0005 0.02 0.9 0.003
CaMKIIβ phospho-CaMKIIβ p/CaMKIIβ
F p r2 F p r2 F p r2
DBS 0.79 0.41 0.14 11.74 0.02 0.7 18.63 0.007 0.79
ACTH 0.47 0.52 0.07 2.45 0.17 0.29 4.56 0.07 0.43
SURG 3.85 0.09 0.39 2.94 0.13 0.33 0.39 0.55 0.06
SALINE 0.33 0.58 0.05 0.2 0.66 0.03 0.04 0.84 0.007
GSK3α phospho-GSK3α p/GSK3α
F p r2 F p r2 F p r2
DBS 7.74 0.04 0.61 10.86 0.02 0.68 18.09 0.008 0.78
ACTH 4.25 0.08 0.41 0.99 0.36 0.14 1.55 0.26 0.2
SURG 1.5 0.27 0.2 1.84 0.22 0.23 2.26 0.18 0.27
SALINE 0.06 0.8 0.02 0.05 0.84 0.007 0.05 0.82 0.008
GSK3β phospho-GSK3β p/GSK3β
F p r2 F p r2 F p r2
DBS 4.92 0.07 0.49 0.65 0.45 0.11 9.45 0.03 0.65
ACTH 1.49 0.27 0.19 1.14 0.33 0.16 2.55 0.16 0.3
SURG 2.7 0.15 0.31 0.004 0.95 0.0007 1.03 0.35 0.15
SALINE 0.007 0.93 0.001 0.11 0.75 0.02 0.34 0.58 0.05
AMPK phospho-AMPK p/AMPK
F p r2 F p r2 F p r2
DBS 0.55 0.49 0.09 13.74 0.01 0.73 13.65 0.01 0.73
ACTH 0.15 0.71 0.03 2.67 0.15 0.31 4.46 0.08 0.42
SURG 0.22 0.65 0.03 0.94 0.37 0.13 0.21 0.66 0.03
SALINE 0.19 0.67 0.03 0.01 0.9 0.002 0.35 0.58 0.05
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Supplementary Table 1:   
Primer sequences for RT-PCR analysis of the target genes identified through functional gene enrichment. 
Gene Name NCBI Forward Primer Reverse Primer
Pomt1 NM_053406 TGT ATG GTC CTT ACG CCT GC CTC CCA TGG CAG TAC AGT GG
Hes5 NM_024383 CGT CAG CTA CCT GAA GCA CA CCG CTG GAA GTG GTA AAG CA
Scrn2 NM_001012142 TGG AAC AGG TGT GGA AGA CG CAA AGT CAA AGA CGC CCT GC
Cpta1 AM237458 CCT ACC ACG GCT GGA TGT TT TAC AAC ATG GGC TTC CGA CC
Abra NM_175844 AGG TGA CCA GAA CGG TTG TC TGT CAC TCT TCC ACT TGG GC
Ftcd NM_053567 TCA CTG CGT GCT TTT GTT CG GCA TGG AAG GGT GGG ATC AA
Rps6ka1 NM_031107 GAC TTT CTG CGT GGT GGA GA TACA ATG GCC TCC TTG CTC AG
Accn2 NM_024154 CTG CAT GGT CTT GCC CAC AT AAG CTT GGT GAC GTG GTG AT
Acot3 NM_031315 ATG CAC GCA TTT ACC ACC CA ATA AGC CAG AGC CAT GAC GG
Mrap NM_001135834 AGG CAT ACT CCC CAA GCC TA CCC TAG GAC ACC CAT CCT GA
Mrps2 NM_001108576 TTG TGA GCC GGA ATC GTC AA TGG GGT GAG TCA TCA TTG CC
PEPCK2 NM_198780 GGG CTC AGG GTT AGA ACT GG TTT CTA CCC GTG CCA CAT CC
GADD45g NM_001077640 GGG TTC CCT CTG CAC TCT TC TTC AGG ACT TTG GCG GAC TC
GADD45b NM_001008321 CGG ATC TGG ACG AGT GCT TT TCG CAG CAG AAC GAT TGG AT
CHOP/GADD15
3
NM_00110998
6 AGG AGA GAG AAA CCG GTC CA CTT CAT GCG CTG TTT CCC AG
Hif1a NM_024359 GTA CTC ACA GTC GGA CAG CC CAT AGT AGG GGC ACG GTC AC
Atf4/CREB2 NM_024403 CTG AAC AGC GAA GTG TTG GC TCT GTC CCG GAA AAG GCA TC
Jund/AP-1 NM_138875 TCT GTA CCC CCA GTC CTA CG ACC AAC GTT TGT TCC CGA GT
Insulin NM_017071 GTG TGT GGG GAA CGT GGT TT GTG CCA AGG TCT GAA GAT CCC
TNFa NM_012675 ATC CGA GAT GTG GAA CTG GC AAA TGG CAA ATC GGC TGA CG
MCP1 NM_031530 CTG TAG CAT CCA CGT GCT GT GGT GCT GAA GTC CTT AGG GT
IFNg NM_138880 GGA ACT GGC AAA AGG ACG GT TGG GTT GTT CAC CTC GAA CT
IL1b NM_031512 AGG CTT CCT TGT GCA AGT GT TCC TGG GGA AGG CAT TAG GA
IL6 NM_012589 CCA GTT GCC TTC TTG GGA CT TCT GAC AGT GCA TCA TCG CT
Akt1 NM_033230 CGA CGT AGC CAT TGT GAA GG CTC CTG CCG TTT GAG TCC AT
mTOR NM_019906 CGT CAC AAT GCA GCC AAC AA AAC AAA CTC GTG CCC ATT GC
BDNF NM_001270637 CAG GGA AAT CTC CTG AGC CG TCG TCA GAC CTC TCG AAC CT
GDNF NM_019139 CAG AGG GAA AGG TCG CAG AG CAC ACC GTT TAG CGG AAT GC
VEGFa NM_001287110 ACT CAT CAG CCA GGG AGT CT GAG CCC AGA AGT TGG ACG AA
TGFb-1 NM_021578 AGG AGA CGG AAT ACA GGG CT CCA CGT AGT AGA CGA TGG GC
TGFb-2 NM_031131 CAG GTA TCG ATG GCA CCT CC GCA ATA GGC GGC ATC CAA AG
HSP27 NM_031970 GTC AAC CAC TTC GCT CCT GA CGA CTC TGG GCC TCC AAT TT
HSP70 NM_153629 AGG TCT TGT CTG CCT CCG AT TCA CTG CTA GCT CCG TGT TG
Cyclin B X64589 GGG TGT CTT CTC AGA TCG GC GTT CTC GAT CTC AGC AGG GG
Cyclin D NC_005102 ACC TTT GCG ATG TAC CCT CC TGT GAG GGG AAA AAG AGC CC
 & 2
GSK3B NM_032080 GAC ACA CCT GCC CTC TTC AA CCA AAC GTG ACC AGT GTT GC
p53 NM_030989 TAC TTC CCA GCA GGG TGT CA GGT GGA AGC CAT AGT TGC CT
AMPKa NM_023991 CCC CTT GAA GCG AGC AAC TA TGG AGG CGA GGT AGA ACT CA
NGFR NM_012610 GGC TGA TGC TGA ATG CGA AG AGC AGC CAA GAT GGA GCA AT
p21 U09793 ATG TCC GAC CTG TTC CAC AC ATC GGC GCT TGG AGT GAT AG
c-fos NM_022197 TAC TAC CAT TCC CCA GCC GA GCG TAT CTG TCA GCT CCC TC
Caspase 9 NM_031632 GAC AAG GCC TTC GAC AGT GA GCT TCA CGG GAC AGT TCT GA
GYS2 NM_013089 AAT GAG CTG AGC CCA AGT CC GTG ACA CAT GTC GGT GGC TA
Phk XM_008773194 TGC GCT TGC GCG GTA AC GCT CAC TCC TCT GCC AAT GA
Hprt1 NM_012583 GTC AAG CAG TAC AGC CCC AA TGG CCA CAT CAA CAG GAC TC
 & 2
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